Severe Mental Illness — MCQs

Q: A 58-year-old man presents with progressive memory loss and behavioral changes over 10 months. MRI shows asymmetric frontotemporal atrophy. What is the most appropriate symptomatic treatment?

Supportive care only. ***Supportive care only*** - Frontotemporal dementia (FTD), characterized by **progressive memory loss**, **behavioral changes**, and **asymmetric frontotemporal atrophy** on MRI, currently lacks disease-modifying treatments. - Management focuses on **supportive care**, including symptom management for agitation, sleep disturbances, and nutritional needs, alongside comprehensive caregiver support. *Cholinesterase inhibitors* - These medications, like donepezil or rivastigmine, are primarily used in **Alzheimer's disease** to enhance cholinergic neurotransmission. - They are generally **ineffective** in FTD and can potentially worsen behavioral symptoms in some patients. *Memantine* - Memantine is an **NMDA receptor antagonist** approved for moderate to severe **Alzheimer's disease**. - Its efficacy in FTD has **not been established**, and it is typically not recommended as a primary symptomatic treatment. *Antipsychotics for behavior* - While **antipsychotics** can be used cautiously to manage severe behavioral disturbances like aggression or psychosis in FTD, they are not a primary symptomatic treatment for the core disease process. - Their use carries **significant risks**, including increased mortality in elderly dementia patients, and should be reserved for severe, refractory symptoms. *Antidepressants* - **Antidepressants** may be used to address co-occurring **mood symptoms** such as depression or anxiety, which can be present in FTD. - They do not directly treat the core cognitive or behavioral aspects of FTD and are not considered a primary symptomatic treatment for the dementia itself.

Q: A 53-year-old woman presents with progressive memory loss and personality changes over 8 months. MRI shows frontotemporal atrophy. CSF shows elevated tau but normal amyloid-β42. What is the most likely diagnosis?

Frontotemporal dementia. ***Frontotemporal dementia***- The clinical presentation of progressive **personality changes** and prominent **frontotemporal atrophy** on MRI is highly specific for FTD, particularly the behavioral variant (bvFTD).- The CSF profile of **elevated tau** with **normal amyloid-β42** is consistent with FTD, as amyloid-β42 is typically normal, unlike in Alzheimer's disease.*Alzheimer's disease*- AD typically begins with profound **episodic memory loss**, and early atrophy is usually centered in the **medial temporal lobes** (hippocampi), not primarily frontotemporal.- The CSF profile for established AD usually shows **low amyloid-β42** (due to amyloid plaque deposition) and high tau/phospho-tau; this patient's *normal* amyloid-β42 makes typical AD pathology less likely.*Lewy body dementia*- This diagnosis requires at least two of the following core features: **fluctuating cognition**, recurrent detailed **visual hallucinations**, or spontaneous **parkinsonism**, none of which are detailed here.- While atrophy can occur, profound frontotemporal atrophy and primary personality change are less characteristic of LBD compared to FTD.*Vascular dementia*- Vascular dementia is strongly associated with cerebrovascular risk factors and typically demonstrates **stepwise decline** or imaging evidence of multiple **infarcts** or extensive white matter disease.- The smooth progression over 8 months, coupled with atrophy focused specifically on the frontal lobes rather than diffuse vascular damage, argues against this diagnosis.*Creutzfeldt-Jakob disease*- CJD usually presents with very **rapid progression** (weeks to a few months) leading quickly to death, often accompanied by **myoclonus** (involuntary jerking).- Although CJD can present atypically, the 8-month course is too protracted for classic CJD, and the lack of characteristic MRI findings (e.g., DWI hyperintensities) makes it improbable.

Q: A 59-year-old man presents with progressive memory loss and behavioral changes. MRI shows frontotemporal atrophy. What is the most likely diagnosis?

Frontotemporal dementia. ***Frontotemporal dementia***- This diagnosis is strongly supported by the combination of **behavioral changes** (often presenting as apathy or disinhibition) and the specific radiographic finding of predominant **frontotemporal atrophy** on MRI.- FTD typically affects individuals under 65 (like this 59-year-old man) and is characterized by early decline in **personality**, social conduct, or **language abilities**, often before severe memory impairment.*Alzheimer's disease*- While memory loss is present, AD typically presents with early and predominant decline in **episodic memory** (new learning and recalling recent events).- The classic MRI finding in AD is atrophy primarily affecting the **medial temporal lobes** and **hippocampi**, not the anterior frontal and temporal lobes.*Vascular dementia*- This condition is typically associated with a history of **cerebrovascular disease** and imaging evidence of **multiple infarcts** or significant **ischemic white matter lesions**.- The course of decline is often abrupt or **stepwise**, corresponding to specific vascular events, rather than the gradual, smooth progression seen in primary neurodegenerative diseases.*Lewy body dementia*- Core features differentiating LBD include recurrent **well-formed visual hallucinations**, profound **fluctuations** in attention and alertness, and spontaneous **Parkinsonism**.- While memory and behavior are affected, the absence of these three hallmark symptoms makes **Lewy body dementia** less likely than FTD given the frontotemporal atrophy.*Normal pressure hydrocephalus*- NPH is characterized by the classic triad of **gait disturbance** (ataxia), **urinary incontinence**, and dementia, which is not fully described here.- MRI shows **ventriculomegaly** (enlarged ventricles) with often minimal or normal sulcal atrophy, a distinct finding from localized cortical atrophy.

Q: A 70-year-old man presents with confusion, agitation, and visual hallucinations that fluctuate throughout the day. He has a shuffling gait and mild tremor. His daughter reports he often falls asleep during conversations. What is the most likely diagnosis?

Lewy body dementia. ***Lewy body dementia***- The combination of **fluctuating cognition** (confusion, agitation, falling asleep during conversations), recurrent, well-formed **visual hallucinations**, and spontaneous **parkinsonism** (shuffling gait, mild tremor) is the classic diagnostic triad for Lewy body dementia.- It is characterized by the accumulation of **alpha-synuclein** protein deposits (Lewy bodies) in neurons, affecting both cognitive and motor functions.*Alzheimer's disease*- Typically presents with **insidious onset** of **progressive memory impairment** as the predominant symptom, rather than prominent fluctuations or early hallucinations.- Motor symptoms like parkinsonism appear very late, if at all, and are not core diagnostic features of early Alzheimer's.*Vascular dementia*- Cognitive decline often occurs in a **stepwise** fashion, frequently associated with a history of **cerebral vascular events** (strokes) or risk factors.- While gait disturbance is common, florid visual hallucinations and dramatic cognitive fluctuations are not typical or primary features of pure vascular dementia.*Frontotemporal dementia*- Primarily involves early changes in **personality**, **behavior** (e.g., disinhibition, apathy), or **language deficits**, often with executive dysfunction.- Lacks the characteristic combination of prominent visual hallucinations, rapid cognitive fluctuations, and parkinsonism seen in this patient.*Delirium*- Delirium is an **acute** and usually reversible disturbance in attention and consciousness, often triggered by underlying medical illness, infection, or medication.- While fluctuations and agitation are present, the patient's history describes chronic, progressive features consistent with a **dementia syndrome**, not an acute confusional state.

Q: A 60-year-old man presents with progressive memory loss and behavioral changes over 8 months. MRI shows frontotemporal atrophy. What is the most likely diagnosis?

Frontotemporal dementia. ***Frontotemporal dementia*** - The clinical presentation of **progressive memory loss** and prominent **behavioral changes** over 8 months, coupled with specific **frontotemporal atrophy** on MRI, is highly characteristic of frontotemporal dementia. - This condition is characterized by early and prominent changes in personality, behavior, or language, often preceding significant memory deficits, which aligns with the described behavioral changes. *Alzheimer's disease* - While memory loss is a primary feature, Alzheimer's typically presents with **medial temporal lobe atrophy** (e.g., hippocampus) rather than predominantly frontotemporal atrophy on MRI. - Behavioral changes usually emerge later in the course of Alzheimer's, whereas they are often a presenting and prominent symptom in frontotemporal dementia. *Vascular dementia* - This type of dementia often presents with a **step-wise cognitive decline** and is associated with cerebrovascular disease and focal neurological signs. - MRI would typically show evidence of **infarcts** or **ischemic changes**, not specific frontotemporal atrophy in isolation, making it less likely. *Lewy body dementia* - Key features include **fluctuating cognition**, **recurrent visual hallucinations**, and **parkinsonism**. - While memory loss and behavioral changes occur, the absence of these characteristic features and the specific finding of frontotemporal atrophy do not support this diagnosis. *Normal pressure hydrocephalus* - This condition presents with a classic triad of **gait disturbance**, **urinary incontinence**, and **dementia** (often executive dysfunction). - MRI would reveal **ventriculomegaly** with normal or mildly increased CSF pressure, not selective frontotemporal atrophy.

Q: A 27-year-old woman presents with amenorrhea, weight loss, and excessive exercise. She has fine lanugo hair and her BMI is 16 kg/m². She denies having an eating disorder. What is the most likely diagnosis?

Anorexia nervosa. ***Anorexia nervosa***- The triad of significantly **low BMI** (<17.5 kg/m² indicating severe restriction), **amenorrhea** due to HPO axis suppression, and **lanugo hair** (a compensatory mechanism for body temperature regulation in starvation) is highly specific for anorexia nervosa.- The presence of excessive exercise alongside severe weight loss strongly indicates the behavioral pathology of this disorder, even with the patient's denial, which is common.*Hyperthyroidism*- Although hyperthyroidism causes weight loss, it is typically accompanied by symptoms like **tachycardia**, **tremors**, goiter, and heat intolerance, which are absent here.- Hyperthyroidism does not cause the development of **lanugo hair**, which is a sign of chronic severe malnutrition.*Depression*- Depression can cause weight change and sometimes secondary amenorrhea, but it lacks the specific combination of the **low BMI**, excessive exercise, and physiological signs of starvation like **lanugo hair**.- The focus on weight-related behaviors (excessive exercise) points primarily toward an **eating disorder** rather than an isolated mood disorder.*Celiac disease*- Celiac disease leads to weight loss primarily through **malabsorption**, often associated with GI symptoms like chronic diarrhea or abdominal pain.- It does not explain the behavioral feature of **excessive exercise** or the dermatological finding of **lanugo hair** due strictly to gluten intolerance.*Addison's disease*- Addison's disease causes weight loss and fatigue but is classically characterized by **hyperpigmentation** (primary adrenal insufficiency) and volume depletion.- It does not typically present with the specific severe **malnutrition** signs (BMI 16, lanugo hair) or the core psychopathology of restricted intake and **excessive exercise** seen in this patient.

Q: A 52-year-old woman presents with progressive memory loss and personality changes over 8 months. MRI shows frontotemporal atrophy. CSF shows elevated tau but normal amyloid-β. What is the most likely diagnosis?

Frontotemporal dementia. ***Frontotemporal dementia***- The combination of progressive **personality changes** and memory loss, particularly with **frontotemporal atrophy** on MRI, is highly characteristic of Frontotemporal Dementia (FTD).- CSF showing **elevated tau** but **normal amyloid-β** further supports FTD (specifically tauopathies), as low amyloid-β is typically seen in Alzheimer's disease.*Alzheimer's disease*- While memory loss is prominent, **personality changes** are usually not the initial or most prominent symptom in early Alzheimer's compared to FTD.- **CSF amyloid-β** is typically **low** in Alzheimer's disease due to its deposition in plaques, which contradicts the normal amyloid-β finding in this patient.*Lewy body dementia*- This condition presents with a classic triad of **fluctuating cognition**, **recurrent visual hallucinations**, and **parkinsonism**, none of which are described.- MRI in LBD typically shows less specific atrophy, and CSF markers alone are not usually sufficient for differentiation without the characteristic clinical features.*Vascular dementia*- Vascular dementia is characterized by a **step-wise decline** in cognitive function, often associated with stroke or cerebrovascular disease, not typically a progressive decline over 8 months with frontotemporal atrophy.- Imaging would show evidence of **infarcts** or **white matter lesions**, which are not mentioned.*Normal pressure hydrocephalus*- The classic triad for NPH includes **gait disturbance**, **urinary incontinence**, and **dementia**, with MRI showing **ventriculomegaly**.- The patient's presentation of prominent personality changes and frontotemporal atrophy does not align with NPH.

Severe Mental Illness UK Medical PG Practice Questions and MCQs

Question 1: A 58-year-old man presents with progressive memory loss and behavioral changes over 10 months. MRI shows asymmetric frontotemporal atrophy. What is the most appropriate symptomatic treatment?

A. Cholinesterase inhibitors
B. Memantine
C. Antipsychotics for behavior
D. Supportive care only (Correct Answer)
E. Antidepressants

Explanation: ***Supportive care only*** - Frontotemporal dementia (FTD), characterized by **progressive memory loss**, **behavioral changes**, and **asymmetric frontotemporal atrophy** on MRI, currently lacks disease-modifying treatments. - Management focuses on **supportive care**, including symptom management for agitation, sleep disturbances, and nutritional needs, alongside comprehensive caregiver support. *Cholinesterase inhibitors* - These medications, like donepezil or rivastigmine, are primarily used in **Alzheimer's disease** to enhance cholinergic neurotransmission. - They are generally **ineffective** in FTD and can potentially worsen behavioral symptoms in some patients. *Memantine* - Memantine is an **NMDA receptor antagonist** approved for moderate to severe **Alzheimer's disease**. - Its efficacy in FTD has **not been established**, and it is typically not recommended as a primary symptomatic treatment. *Antipsychotics for behavior* - While **antipsychotics** can be used cautiously to manage severe behavioral disturbances like aggression or psychosis in FTD, they are not a primary symptomatic treatment for the core disease process. - Their use carries **significant risks**, including increased mortality in elderly dementia patients, and should be reserved for severe, refractory symptoms. *Antidepressants* - **Antidepressants** may be used to address co-occurring **mood symptoms** such as depression or anxiety, which can be present in FTD. - They do not directly treat the core cognitive or behavioral aspects of FTD and are not considered a primary symptomatic treatment for the dementia itself.

Question 2: A 53-year-old woman presents with progressive memory loss and personality changes over 8 months. MRI shows frontotemporal atrophy. CSF shows elevated tau but normal amyloid-β42. What is the most likely diagnosis?

A. Alzheimer's disease
B. Frontotemporal dementia (Correct Answer)
C. Lewy body dementia
D. Vascular dementia
E. Creutzfeldt-Jakob disease

Explanation: ***Frontotemporal dementia***- The clinical presentation of progressive **personality changes** and prominent **frontotemporal atrophy** on MRI is highly specific for FTD, particularly the behavioral variant (bvFTD).- The CSF profile of **elevated tau** with **normal amyloid-β42** is consistent with FTD, as amyloid-β42 is typically normal, unlike in Alzheimer's disease.*Alzheimer's disease*- AD typically begins with profound **episodic memory loss**, and early atrophy is usually centered in the **medial temporal lobes** (hippocampi), not primarily frontotemporal.- The CSF profile for established AD usually shows **low amyloid-β42** (due to amyloid plaque deposition) and high tau/phospho-tau; this patient's *normal* amyloid-β42 makes typical AD pathology less likely.*Lewy body dementia*- This diagnosis requires at least two of the following core features: **fluctuating cognition**, recurrent detailed **visual hallucinations**, or spontaneous **parkinsonism**, none of which are detailed here.- While atrophy can occur, profound frontotemporal atrophy and primary personality change are less characteristic of LBD compared to FTD.*Vascular dementia*- Vascular dementia is strongly associated with cerebrovascular risk factors and typically demonstrates **stepwise decline** or imaging evidence of multiple **infarcts** or extensive white matter disease.- The smooth progression over 8 months, coupled with atrophy focused specifically on the frontal lobes rather than diffuse vascular damage, argues against this diagnosis.*Creutzfeldt-Jakob disease*- CJD usually presents with very **rapid progression** (weeks to a few months) leading quickly to death, often accompanied by **myoclonus** (involuntary jerking).- Although CJD can present atypically, the 8-month course is too protracted for classic CJD, and the lack of characteristic MRI findings (e.g., DWI hyperintensities) makes it improbable.

Question 3: A 59-year-old man presents with progressive memory loss and behavioral changes. MRI shows frontotemporal atrophy. What is the most likely diagnosis?

A. Alzheimer's disease
B. Frontotemporal dementia (Correct Answer)
C. Vascular dementia
D. Lewy body dementia
E. Normal pressure hydrocephalus

Explanation: ***Frontotemporal dementia***- This diagnosis is strongly supported by the combination of **behavioral changes** (often presenting as apathy or disinhibition) and the specific radiographic finding of predominant **frontotemporal atrophy** on MRI.- FTD typically affects individuals under 65 (like this 59-year-old man) and is characterized by early decline in **personality**, social conduct, or **language abilities**, often before severe memory impairment.*Alzheimer's disease*- While memory loss is present, AD typically presents with early and predominant decline in **episodic memory** (new learning and recalling recent events).- The classic MRI finding in AD is atrophy primarily affecting the **medial temporal lobes** and **hippocampi**, not the anterior frontal and temporal lobes.*Vascular dementia*- This condition is typically associated with a history of **cerebrovascular disease** and imaging evidence of **multiple infarcts** or significant **ischemic white matter lesions**.- The course of decline is often abrupt or **stepwise**, corresponding to specific vascular events, rather than the gradual, smooth progression seen in primary neurodegenerative diseases.*Lewy body dementia*- Core features differentiating LBD include recurrent **well-formed visual hallucinations**, profound **fluctuations** in attention and alertness, and spontaneous **Parkinsonism**.- While memory and behavior are affected, the absence of these three hallmark symptoms makes **Lewy body dementia** less likely than FTD given the frontotemporal atrophy.*Normal pressure hydrocephalus*- NPH is characterized by the classic triad of **gait disturbance** (ataxia), **urinary incontinence**, and dementia, which is not fully described here.- MRI shows **ventriculomegaly** (enlarged ventricles) with often minimal or normal sulcal atrophy, a distinct finding from localized cortical atrophy.

Question 4: A 68-year-old man presents with progressive memory loss and parkinsonism. He has visual hallucinations and fluctuating cognition. What is the most likely diagnosis?

A. Alzheimer's disease
B. Parkinson's disease dementia
C. Lewy body dementia (Correct Answer)
D. Vascular dementia
E. Frontotemporal dementia

Explanation: ***Lewy body dementia*** - The classic triad of **progressive memory loss** (dementia), **parkinsonism**, and **recurrent visual hallucinations**, along with **fluctuating cognition**, are hallmark diagnostic features of Lewy body dementia. - This condition is characterized by the presence of **Lewy bodies** in the brainstem and cortex, leading to a combination of cognitive and motor symptoms. *Alzheimer's disease* - While memory loss is prominent, **Alzheimer's disease** typically does not present with early or significant **parkinsonism** or prominent **visual hallucinations**. - Cognitive fluctuations are also not a primary distinguishing feature of Alzheimer's, which is more characterized by a gradual, progressive decline in memory and other cognitive domains. *Parkinson's disease dementia* - In **Parkinson's disease dementia (PDD)**, the **dementia** typically develops at least **one year after** the onset of well-established **parkinsonism**. - Although PDD can also feature visual hallucinations and cognitive fluctuations, the **temporal relationship** (parkinsonism preceding dementia by a significant period) is crucial for its diagnosis, unlike in LBD where symptoms often emerge concurrently or dementia precedes parkinsonism by less than a year. *Vascular dementia* - This condition is characterized by a **step-wise cognitive decline**, often associated with a history of stroke or cerebrovascular disease, and typically presents with **focal neurological deficits**. - **Parkinsonism** and **visual hallucinations** are not typical primary features of vascular dementia; cognitive decline is usually related to specific brain lesions. *Frontotemporal dementia* - **Frontotemporal dementia (FTD)** typically presents with prominent early changes in **behavior** (e.g., disinhibition, apathy) or **language difficulties**, rather than primary memory loss. - **Parkinsonism** and **visual hallucinations** are not characteristic features of FTD and would make this diagnosis less likely.

Question 5: A 70-year-old man presents with confusion, agitation, and visual hallucinations that fluctuate throughout the day. He has a shuffling gait and mild tremor. His daughter reports he often falls asleep during conversations. What is the most likely diagnosis?

A. Alzheimer's disease
B. Vascular dementia
C. Lewy body dementia (Correct Answer)
D. Frontotemporal dementia
E. Delirium

Explanation: ***Lewy body dementia***- The combination of **fluctuating cognition** (confusion, agitation, falling asleep during conversations), recurrent, well-formed **visual hallucinations**, and spontaneous **parkinsonism** (shuffling gait, mild tremor) is the classic diagnostic triad for Lewy body dementia.- It is characterized by the accumulation of **alpha-synuclein** protein deposits (Lewy bodies) in neurons, affecting both cognitive and motor functions.*Alzheimer's disease*- Typically presents with **insidious onset** of **progressive memory impairment** as the predominant symptom, rather than prominent fluctuations or early hallucinations.- Motor symptoms like parkinsonism appear very late, if at all, and are not core diagnostic features of early Alzheimer's.*Vascular dementia*- Cognitive decline often occurs in a **stepwise** fashion, frequently associated with a history of **cerebral vascular events** (strokes) or risk factors.- While gait disturbance is common, florid visual hallucinations and dramatic cognitive fluctuations are not typical or primary features of pure vascular dementia.*Frontotemporal dementia*- Primarily involves early changes in **personality**, **behavior** (e.g., disinhibition, apathy), or **language deficits**, often with executive dysfunction.- Lacks the characteristic combination of prominent visual hallucinations, rapid cognitive fluctuations, and parkinsonism seen in this patient.*Delirium*- Delirium is an **acute** and usually reversible disturbance in attention and consciousness, often triggered by underlying medical illness, infection, or medication.- While fluctuations and agitation are present, the patient's history describes chronic, progressive features consistent with a **dementia syndrome**, not an acute confusional state.

Question 6: A 60-year-old man presents with progressive memory loss and behavioral changes over 8 months. MRI shows frontotemporal atrophy. What is the most likely diagnosis?

A. Alzheimer's disease
B. Vascular dementia
C. Frontotemporal dementia (Correct Answer)
D. Lewy body dementia
E. Normal pressure hydrocephalus

Explanation: ***Frontotemporal dementia*** - The clinical presentation of **progressive memory loss** and prominent **behavioral changes** over 8 months, coupled with specific **frontotemporal atrophy** on MRI, is highly characteristic of frontotemporal dementia. - This condition is characterized by early and prominent changes in personality, behavior, or language, often preceding significant memory deficits, which aligns with the described behavioral changes. *Alzheimer's disease* - While memory loss is a primary feature, Alzheimer's typically presents with **medial temporal lobe atrophy** (e.g., hippocampus) rather than predominantly frontotemporal atrophy on MRI. - Behavioral changes usually emerge later in the course of Alzheimer's, whereas they are often a presenting and prominent symptom in frontotemporal dementia. *Vascular dementia* - This type of dementia often presents with a **step-wise cognitive decline** and is associated with cerebrovascular disease and focal neurological signs. - MRI would typically show evidence of **infarcts** or **ischemic changes**, not specific frontotemporal atrophy in isolation, making it less likely. *Lewy body dementia* - Key features include **fluctuating cognition**, **recurrent visual hallucinations**, and **parkinsonism**. - While memory loss and behavioral changes occur, the absence of these characteristic features and the specific finding of frontotemporal atrophy do not support this diagnosis. *Normal pressure hydrocephalus* - This condition presents with a classic triad of **gait disturbance**, **urinary incontinence**, and **dementia** (often executive dysfunction). - MRI would reveal **ventriculomegaly** with normal or mildly increased CSF pressure, not selective frontotemporal atrophy.

Question 7: A 78-year-old man presents with confusion and falls. His wife reports he has been increasingly forgetful over the past year. MMSE score is 18/30. What is the most appropriate initial investigation?

A. CT head (Correct Answer)
B. MRI brain
C. Lumbar puncture
D. EEG
E. PET scan

Explanation: ***CT head*** - Given the patient's age (78 years), confusion, falls, and cognitive decline (MMSE 18/30), an initial **CT head** is crucial to rapidly rule out **reversible causes** of dementia and acute structural pathologies. - It efficiently identifies conditions like **subdural hematoma**, **normal pressure hydrocephalus (NPH)**, or **mass lesions** (e.g., tumors, large strokes) that require urgent management and can present with cognitive symptoms and falls. *MRI brain* - While **MRI brain** provides superior resolution for detecting subtle structural changes, such as **vascular disease**, **small infarcts**, or **white matter lesions**, it is often reserved for a more detailed evaluation after initial screening. - It is less available, more time-consuming, and not the primary initial choice when urgent exclusion of acute, potentially life-threatening causes is paramount. *Lumbar puncture* - This invasive procedure is typically indicated for the investigation of **rapidly progressive dementia**, suspected **infectious causes** (e.g., neurosyphilis, chronic meningitis), or **inflammatory conditions**. - It is not a routine initial investigation for gradual cognitive decline unless there are specific clinical features suggestive of these conditions. *EEG* - **Electroencephalography (EEG)** assesses brain electrical activity and is primarily used to investigate **seizure disorders** (e.g., non-convulsive status epilepticus mimicking confusion) or specific types of dementia like **Creutzfeldt-Jakob disease (CJD)**. - It does not provide the structural information needed to identify lesions or hydrocephalus that can cause acute confusion and falls. *PET scan* - **Positron Emission Tomography (PET)** scans (e.g., FDG-PET or amyloid-PET) are specialized functional imaging modalities used later in the diagnostic process to help differentiate specific types of dementia (e.g., **Alzheimer’s disease** from **frontotemporal dementia**). - It is a costly, advanced investigation and is not appropriate as the initial screening tool for structural brain pathology or reversible causes of cognitive impairment.

Question 8: A 27-year-old woman presents with amenorrhea, weight loss, and excessive exercise. She has fine lanugo hair and her BMI is 16 kg/m². She denies having an eating disorder. What is the most likely diagnosis?

A. Hyperthyroidism
B. Anorexia nervosa (Correct Answer)
C. Depression
D. Celiac disease
E. Addison's disease

Explanation: ***Anorexia nervosa***- The triad of significantly **low BMI** (<17.5 kg/m² indicating severe restriction), **amenorrhea** due to HPO axis suppression, and **lanugo hair** (a compensatory mechanism for body temperature regulation in starvation) is highly specific for anorexia nervosa.- The presence of excessive exercise alongside severe weight loss strongly indicates the behavioral pathology of this disorder, even with the patient's denial, which is common.*Hyperthyroidism*- Although hyperthyroidism causes weight loss, it is typically accompanied by symptoms like **tachycardia**, **tremors**, goiter, and heat intolerance, which are absent here.- Hyperthyroidism does not cause the development of **lanugo hair**, which is a sign of chronic severe malnutrition.*Depression*- Depression can cause weight change and sometimes secondary amenorrhea, but it lacks the specific combination of the **low BMI**, excessive exercise, and physiological signs of starvation like **lanugo hair**.- The focus on weight-related behaviors (excessive exercise) points primarily toward an **eating disorder** rather than an isolated mood disorder.*Celiac disease*- Celiac disease leads to weight loss primarily through **malabsorption**, often associated with GI symptoms like chronic diarrhea or abdominal pain.- It does not explain the behavioral feature of **excessive exercise** or the dermatological finding of **lanugo hair** due strictly to gluten intolerance.*Addison's disease*- Addison's disease causes weight loss and fatigue but is classically characterized by **hyperpigmentation** (primary adrenal insufficiency) and volume depletion.- It does not typically present with the specific severe **malnutrition** signs (BMI 16, lanugo hair) or the core psychopathology of restricted intake and **excessive exercise** seen in this patient.

Question 9: A 52-year-old woman presents with progressive memory loss and personality changes over 8 months. MRI shows frontotemporal atrophy. CSF shows elevated tau but normal amyloid-β. What is the most likely diagnosis?

A. Alzheimer's disease
B. Frontotemporal dementia (Correct Answer)
C. Lewy body dementia
D. Vascular dementia
E. Normal pressure hydrocephalus

Explanation: ***Frontotemporal dementia***- The combination of progressive **personality changes** and memory loss, particularly with **frontotemporal atrophy** on MRI, is highly characteristic of Frontotemporal Dementia (FTD).- CSF showing **elevated tau** but **normal amyloid-β** further supports FTD (specifically tauopathies), as low amyloid-β is typically seen in Alzheimer's disease.*Alzheimer's disease*- While memory loss is prominent, **personality changes** are usually not the initial or most prominent symptom in early Alzheimer's compared to FTD.- **CSF amyloid-β** is typically **low** in Alzheimer's disease due to its deposition in plaques, which contradicts the normal amyloid-β finding in this patient.*Lewy body dementia*- This condition presents with a classic triad of **fluctuating cognition**, **recurrent visual hallucinations**, and **parkinsonism**, none of which are described.- MRI in LBD typically shows less specific atrophy, and CSF markers alone are not usually sufficient for differentiation without the characteristic clinical features.*Vascular dementia*- Vascular dementia is characterized by a **step-wise decline** in cognitive function, often associated with stroke or cerebrovascular disease, not typically a progressive decline over 8 months with frontotemporal atrophy.- Imaging would show evidence of **infarcts** or **white matter lesions**, which are not mentioned.*Normal pressure hydrocephalus*- The classic triad for NPH includes **gait disturbance**, **urinary incontinence**, and **dementia**, with MRI showing **ventriculomegaly**.- The patient's presentation of prominent personality changes and frontotemporal atrophy does not align with NPH.

Question 10: A 68-year-old man presents with progressive memory loss and behavioral changes. He has difficulty with language and shows disinhibited behavior. MRI shows frontotemporal atrophy. What is the most likely diagnosis?

A. Alzheimer's disease
B. Frontotemporal dementia (Correct Answer)
C. Vascular dementia
D. Lewy body dementia
E. Normal pressure hydrocephalus

Explanation: ***Frontotemporal dementia*** - The combination of **progressive memory loss** along with significant **behavioral changes** (specifically **disinhibited behavior**), **difficulty with language**, and **frontotemporal atrophy** on MRI, is highly indicative of frontotemporal dementia (FTD). - FTD is characterized by early and prominent alterations in personality, behavior, and/or language, often preceding significant memory deficits, unlike Alzheimer's. *Alzheimer's disease* - While memory loss is a primary feature of Alzheimer's, it typically presents with early and predominant **episodic memory impairment** and often involves **hippocampal/medial temporal atrophy** first. - Severe social disinhibition and early language difficulties (non-amnestic presentation) are less typical initial features of AD compared to FTD, which directly affects these frontal and temporal functions. *Vascular dementia* - This diagnosis is characterized by a **stepwise decline** in cognitive function and is associated with evidence of **cerebrovascular disease** (e.g., infarcts, white matter lesions) on imaging. - The case description does not mention a stepwise decline or history of strokes, nor does the MRI show classic vascular lesions but rather frontotemporal atrophy. *Lewy body dementia* - Key features of Lewy body dementia (LBD) include **fluctuating cognition**, recurrent detailed **visual hallucinations**, and spontaneous **parkinsonism**. - While behavioral changes and cognitive deficits occur, the specific presentation of prominent language difficulty and disinhibition, without the classic LBD triad, makes it less likely. *Normal pressure hydrocephalus* - Normal pressure hydrocephalus (NPH) is characterized by the classic triad of **gait disturbance**, **urinary incontinence**, and dementia. - MRI in NPH typically shows **ventriculomegaly** disproportionate to sulcal atrophy, not focal frontotemporal cortical atrophy as described in the patient's MRI.

Question 11: A 67-year-old man presents with progressive memory loss and parkinsonian features. He has visual hallucinations and fluctuating consciousness. His wife reports he acts out his dreams. What is the most likely diagnosis?

A. Alzheimer's disease
B. Parkinson's disease with dementia
C. Lewy body dementia (Correct Answer)
D. Vascular dementia
E. Frontotemporal dementia

Explanation: ***Lewy body dementia***- The combination of **progressive memory loss**, **parkinsonian features**, recurrent **visual hallucinations**, and marked **fluctuating consciousness** are the core diagnostic features of Lewy body dementia (LBD).- The history of **acting out dreams** indicates **REM sleep behavior disorder (RBD)**, which is highly characteristic of LBD and often precedes other symptoms.*Alzheimer's disease*- Primary deficit in Alzheimer's disease is typically **episodic memory loss** in the early stages, without prominent movement disorders or complex visual hallucinations.- **Fluctuating cognition** and severe **parkinsonism** are not characteristic core features of pure Alzheimer's disease.*Parkinson's disease with dementia*- PDD is diagnosed when **motor symptoms (parkinsonism)** precede the onset of dementia by **more than one year**.- In this patient, the memory loss and parkinsonian features are presenting closer together, making LBD more likely given the other symptoms.*Vascular dementia*- This type of dementia is caused by **cerebrovascular disease** and typically presents with a **step-wise decline** in cognitive function.- **Visual hallucinations**, **fluctuating consciousness**, and **REM sleep behavior disorder** are not typical features of vascular dementia.*Frontotemporal dementia*- Characterized by early changes in **personality, behavior**, or **language (aphasia)**, with relative preservation of memory in early stages.- It does not typically present with prominent **parkinsonian features**, **visual hallucinations**, or **fluctuating consciousness**.

Question 12: A 67-year-old man presents with progressive memory loss and personality changes over 12 months. His wife reports he has become disinhibited and uses inappropriate language. MR shows asymmetric frontotemporal atrophy. What is the most likely diagnosis?

A. Alzheimer's disease
B. Vascular dementia
C. Frontotemporal dementia (Correct Answer)
D. Lewy body dementia
E. Normal pressure hydrocephalus

Explanation: ***Frontotemporal dementia*** - The combination of **progressive personality changes**, **disinhibition**, and **inappropriate language** with **asymmetric frontotemporal atrophy** on MRI is highly characteristic. - This presentation points to the **behavioral variant of FTD**, where changes in social conduct and executive function precede significant memory loss. *Alzheimer's disease* - Typically presents with **prominent early episodic memory loss** and difficulties with learning new information, which are not the primary features here. - MRI usually shows **medial temporal lobe atrophy** (e.g., hippocampus), not predominantly frontotemporal atrophy. *Vascular dementia* - Often presents with a **step-wise decline** in cognitive function, focal neurological deficits, and evidence of cerebrovascular disease on imaging. - The described gradual, progressive personality changes and specific atrophy pattern are less consistent with this diagnosis. *Lewy body dementia* - Key features include **fluctuating cognition**, **recurrent visual hallucinations**, and **spontaneous parkinsonism**. - While cognitive decline is present, the prominent disinhibition and specific atrophy pattern are not typical for Lewy body dementia. *Normal pressure hydrocephalus* - Characterized by a **classic triad of gait disturbance**, **urinary incontinence**, and **dementia** (often executive dysfunction). - MRI would show **enlarged ventricles** out of proportion to sulcal atrophy, rather than asymmetric frontotemporal atrophy.

Question 13: A 52-year-old woman presents with progressive memory loss and language difficulties over 10 months. MRI shows asymmetric frontotemporal atrophy. CSF shows elevated tau but normal amyloid-β42. What is the most likely diagnosis?

A. Alzheimer's disease
B. Frontotemporal dementia (Correct Answer)
C. Lewy body dementia
D. Vascular dementia
E. Creutzfeldt-Jakob disease

Explanation: ***Frontotemporal dementia***

Question 14: A 67-year-old man presents with progressive memory loss and behavioral changes. He has difficulty with language and shows disinhibited behavior. MRI shows frontotemporal atrophy. What is the most likely diagnosis?

A. Alzheimer's disease
B. Frontotemporal dementia (Correct Answer)
C. Vascular dementia
D. Lewy body dementia
E. Normal pressure hydrocephalus

Explanation: ***Frontotemporal dementia***- This diagnosis is strongly supported by the patient's prominent **progressive behavioral changes**, including disinhibition, alongside difficulty with language (aphasia) and memory loss. The MRI finding of **frontotemporal atrophy** is the characteristic neuroradiological feature defining this group of dementias, particularly the behavioral variant (bvFTD).- It involves the primary atrophy of the frontal and temporal lobes, associated with accumulation of abnormal proteins like **tau** or **TDP-43**.*Alzheimer's disease*- AD typically begins with profound impairment of **episodic memory** (hippocampal system involvement), preceding severe personality or behavioral changes.- Radiologically, AD is characterized by early **hippocampal or medial temporal lobe atrophy**, followed by parietotemporal involvement, rather than selective **frontotemporal atrophy**. *Vascular dementia*- This dementia usually presents with a **stepwise decline** in cognitive function, and patients often have a history of strokes or significant cardiovascular risk factors.- Imaging findings typically include evidence of multiple **cortical or subcortical infarcts** or significant **ischemic white matter lesions**. *Lewy body dementia*- Characteristic features include **fluctuating cognition**, **recurrent visual hallucinations**, and spontaneous **Parkinsonism** (rigidity, tremor), none of which are detailed here.- While memory is affected, the initial presentation is often distinct, and the primary cognitive deficit is typically in **visual and spatial function** rather than **disinhibition** and language. *Normal pressure hydrocephalus*- NPH presents with a distinct triad: **gait ataxia**, urinary incontinence, and subcortical dementia (poor executive function, slowness).- The MRI hallmark is **ventricular enlargement** (hydrocephalus) out of proportion to the degree of cerebral atrophy, which contrasts with the significant cortical shrinkage described as frontotemporal atrophy.

Question 15: A 63-year-old man presents with progressive memory loss and parkinsonian features. He has visual hallucinations and fluctuating consciousness. His wife reports he acts out his dreams. What is the most likely diagnosis?

A. Alzheimer's disease with agitation
B. Lewy body dementia (Correct Answer)
C. Parkinson's disease with dementia
D. Vascular dementia
E. Frontotemporal dementia

Explanation: ***Lewy body dementia*** - **Progressive memory loss**, **parkinsonian features**, **visual hallucinations**, and **fluctuating consciousness** are the cardinal clinical features of Lewy body dementia. - **Acting out dreams** (REM sleep behavior disorder) is a highly characteristic and often early symptom that strongly supports this diagnosis. *Alzheimer's disease with agitation* - While **memory loss** is prominent, **parkinsonian features**, **visual hallucinations**, and **fluctuating consciousness** are not typical core diagnostic criteria for Alzheimer's disease. - **REM sleep behavior disorder** is much less common in Alzheimer's disease compared to Lewy body dementia, even if agitation can be present. *Parkinson's disease with dementia* - In **Parkinson's disease with dementia**, motor symptoms (**parkinsonian features**) must precede the onset of dementia by at least **one year**. - The concurrent presentation of memory loss and parkinsonian features, along with other symptoms like visual hallucinations, points away from PDD and towards LBD. *Vascular dementia* - Characterized by a **stepwise cognitive decline**, often associated with **focal neurological deficits** and evidence of cerebrovascular disease. - **Visual hallucinations**, **fluctuating consciousness**, and **REM sleep behavior disorder** are not typical features of vascular dementia. *Frontotemporal dementia* - Primarily affects **personality**, **behavior**, and **language**, with memory often relatively preserved in the early stages. - The presence of prominent **parkinsonian features**, **visual hallucinations**, **fluctuating consciousness**, and **REM sleep behavior disorder** is inconsistent with frontotemporal dementia.

Question 16: A 62-year-old woman presents with progressive memory loss and personality changes over 8 months. MRI shows frontotemporal atrophy. CSF tau is elevated but amyloid-β is normal. What is the most likely diagnosis?

A. Alzheimer's disease
B. Frontotemporal dementia (Correct Answer)
C. Lewy body dementia
D. Vascular dementia
E. Normal pressure hydrocephalus

Explanation: ***Frontotemporal dementia***- The combination of progressive personality changes and **frontotemporal atrophy** on MRI is highly characteristic of **Frontotemporal Dementia (FTD)**.- While tau may be elevated (indicating neuronal injury), FTD is generally associated with relatively **normal CSF amyloid-β (Aβ42)**, which distinguishes it from Alzheimer's disease.*Alzheimer's disease*- AD typically presents with prominent **early memory loss** (amnesia) and posterior/medial temporal lobe atrophy, rather than early personality changes and frontotemporal atrophy.- CSF findings in AD typically show **low levels of amyloid-β42** (due to cerebral plaque deposition) and very high levels of phosphorylated tau.*Lewy body dementia*- The defining clinical features often include recurrent **visual hallucinations**, **Parkinsonism**, and severe cognitive fluctuations, none of which are detailed in this presentation.- Imaging may show relatively preserved medial temporal lobes, unlike the pronounced atrophy seen in this patient.*Vascular dementia*- This diagnosis is usually supported by a history of stroke or cardiac risk factors and imaging evidence of multiple **infarcts** or white matter lesions.- Cognitive decline is often characterized by an abrupt onset or a **stepwise progression**, rather than the smooth, progressive decline described.*Normal pressure hydrocephalus*- NPH is characterized by the classic triad of gait disturbance (**wobbly**), urinary incontinence (**wet**), and dementia (**wacky**).- MRI would typically show marked **ventriculomegaly** without significant cortical atrophy, which contrasts with the finding of frontotemporal atrophy.

Question 17: A 24-year-old woman presents with amenorrhea, weight loss, and exercise intolerance. She has bradycardia and hypotension. Her BMI is 15 kg/m². What is the most serious immediate complication?

A. Osteoporosis
B. Cardiac arrhythmias (Correct Answer)
C. Renal failure
D. Liver dysfunction
E. Hypothermia

Explanation: ***Cardiac arrhythmias***- Severe malnutrition causes myocardial atrophy and significant electrolyte disturbances, particularly **hypokalemia** and **hypophosphatemia**, which prolong the **QT interval**.- These changes create an unstable electrical environment, leading to a high risk of lethal ventricular rhythms and **sudden cardiac death**, making it the most critical immediate complication.*Osteoporosis*- This is a chronic consequence of anorexia nervosa stemming from low **estrogen** levels, poor nutrition (calcium/vitamin D), and increased cortisol.- Osteoporosis significantly increases the risk of **pathological fractures** but is not an acute, life-threatening complication in the immediate term.*Renal failure*- Patients often develop **prerenal azotemia** due to dehydration and hypovolemia, but overt acute kidney injury is not the most common immediate primary cause of death.- Renal issues can be exacerbated later by **refeeding syndrome** or chronic diuretic/laxative abuse, but not typically the imminent threat.*Liver dysfunction*- Mild elevation of liver enzymes (**transaminitis**) is sometimes seen due to metabolic stress or fatty infiltration, but acute hepatic failure is uncommon.- This complication is generally less frequent and less immediately lethal than the severe disruption of cardiac function.*Hypothermia*- **Hypothermia** is a common sign of severe starvation resulting from loss of subcutaneous fat and a drastically reduced basal metabolic rate (**BMR**).- While dangerous, it is usually managed by warming measures; the immediate risk of **sudden death** is directly tied to the underlying cardiac instability.

Question 18: A 67-year-old man presents with progressive memory loss and personality changes over 12 months. His wife reports he has become disinhibited and uses inappropriate language. MR shows asymmetric frontotemporal atrophy. What is the most likely diagnosis?

A. Alzheimer's disease
B. Vascular dementia
C. Frontotemporal dementia (Correct Answer)
D. Lewy body dementia
E. Normal pressure hydrocephalus

Explanation: ***Frontotemporal dementia*** - The presentation of progressive **personality changes**, **disinhibition**, **inappropriate language**, and **asymmetric frontotemporal atrophy** on MR is highly characteristic of frontotemporal dementia (FTD). - FTD primarily affects the frontal and temporal lobes, leading to behavioral and language variants, often sparing memory in early stages. *Alzheimer's disease* - While memory loss is prominent, the early and striking **personality changes** and **disinhibition** are less typical for Alzheimer's disease, which usually presents with profound memory deficits first. - MR imaging in Alzheimer's typically shows initial **hippocampal** and **parietal lobe atrophy**, rather than primary frontotemporal involvement. *Vascular dementia* - Vascular dementia usually presents with a **step-wise decline** in cognitive function and may have a history of strokes or transient ischemic attacks, often with focal neurological signs. - Imaging would typically show evidence of **infarcts** or **white matter ischemic changes**, rather than distinct asymmetric frontotemporal atrophy as the primary finding. *Lewy body dementia* - Lewy body dementia is characterized by **fluctuating cognition**, recurrent **visual hallucinations**, and **parkinsonism**, which are not described in this patient. - While some personality changes can occur, the core features and predominant presentation differ significantly from the described symptoms. *Normal pressure hydrocephalus* - Normal pressure hydrocephalus (NPH) presents with a classic triad of **gait disturbance**, **urinary incontinence**, and **dementia** (often executive dysfunction, apathy). - MR imaging would reveal **ventriculomegaly** without significant sulcal atrophy, contrasting with the described frontotemporal atrophy.

Question 19: A 40-year-old woman with bipolar affective disorder has been maintained on lithium carbonate 800mg daily for 6 years. Her recent blood tests show: lithium level 0.75 mmol/L, creatinine 145 μmol/L (baseline 78 μmol/L one year ago), eGFR 42 ml/min/1.73m² (previously 88). Thyroid function and calcium are normal. What is the most appropriate management?

A. Stop lithium and switch to sodium valproate due to chronic kidney disease
B. Continue lithium and monitor renal function more frequently
C. Refer to nephrology and consider switching to alternative mood stabiliser (Correct Answer)
D. Reduce lithium dose to 400mg daily to reduce renal burden
E. Continue lithium with increased monitoring and commence ACE inhibitor for renal protection

Explanation: ***Refer to nephrology and consider switching to alternative mood stabiliser*** - This patient demonstrates significant **lithium-induced nephropathy**, evidenced by a drop in **eGFR** from 88 to 42 ml/min/1.73m² (Stage 3b CKD) and a rising **creatinine**. - Guidelines recommend **specialist nephrology referral** when the eGFR is below 45 ml/min or shows a rapid decline, as professional guidance is needed to weigh the risks of renal failure against the risk of psychiatric relapse. *Stop lithium and switch to sodium valproate due to chronic kidney disease* - Abruptly stopping lithium without a planned transition or specialist input carries a high risk of **rapid relapse** or rebound psychosis. - Decisions on discontinuation in stable patients should ideally involve a **multidisciplinary approach** between psychiatry and nephrology rather than an immediate, unilateral change. *Continue lithium and monitor renal function more frequently* - Simply increasing monitoring is insufficient given the **significant deterioration** (nearly 50% loss of eGFR) and the high risk of **lithium toxicity** as renal clearance reduces. - Lithium is potentially **nephrotoxic**; ignoring the progression from Stage 1/2 to Stage 3b CKD could lead to irreversible end-stage renal disease. *Reduce lithium dose to 400mg daily to reduce renal burden* - While some patients require dose reductions as clearance falls, a simple reduction does not address the underlying **tubulointerstitial damage** caused by chronic use. - Dose reduction alone without **nephrology consultation** fails to provide an adequate management plan for the patient’s long-term renal prognosis. *Continue lithium with increased monitoring and commence ACE inhibitor for renal protection* - **ACE inhibitors** are generally contraindicated with lithium because they decrease renal clearance, potentially leading to **acute lithium toxicity**. - Unlike diabetic nephropathy, lithium-induced damage is typically **interstitial fibrosis**, which is not primarily managed with ACE inhibitors for renal protection.

Question 20: A 34-year-old man with paranoid schizophrenia presents to A&E with his family who report he has become increasingly restless over 24 hours. He is pacing continuously, reports feeling 'unable to sit still', and appears distressed. He started haloperidol 10mg daily 5 days ago. On examination, he has objective restlessness but no rigidity, normal temperature, and normal creatine kinase. What is the most likely diagnosis?

A. Akathisia (Correct Answer)
B. Neuroleptic malignant syndrome
C. Acute dystonia
D. Agitation due to psychosis
E. Tardive dyskinesia

Explanation: ***Akathisia***- Characterized by a subjective sense of **inner restlessness** and an objective inability to sit still, typically appearing within **days to weeks** of starting dopamine-blocking agents like **haloperidol**.- It is distinguished from other movement disorders by the clinical presentation of **pacing** and the patient’s significant distress regarding the physical need to move.*Neuroleptic malignant syndrome*- This is a life-threatening emergency characterized by **lead-pipe rigidity**, **hyperthermia**, and autonomic instability, which are absent in this patient.- Laboratory tests in this condition typically show significantly **elevated creatine kinase (CK)** and leukocytosis, neither of which are seen here.*Acute dystonia*- Presents as sudden, involuntary **sustained muscle contractions**, often resulting in abnormal postures such as **torticollis** or oculogyric crisis.- Typically occurs within the first **24 to 72 hours** of starting a high-potency antipsychotic, whereas this patient presents with pacing rather than muscle spasms.*Agitation due to psychosis*- While psychosis can cause hyperactivity, it lacks the specific **subjective sensation** of the physical inability to sit still described by the patient.- Psychotic agitation is usually driven by **delusions or hallucinations** rather than a primary motor urge localized to the limbs.*Tardive dyskinesia*- A late-onset side effect occurring after **months to years** of antipsychotic exposure, characterized by rhythmic, involuntary movements like **lip-smacking** or tongue protrusion.- Unlike akathisia, tardive dyskinesia is often **not perceived** or distressing to the patient and does not present as generalized pacing.

Question 21: A 47-year-old man with bipolar affective disorder type I has had six mood episodes in the past 14 months, alternating between manic and depressive episodes. He is currently taking lithium carbonate 1200mg daily with therapeutic levels (0.8 mmol/L). What is the most appropriate additional treatment?

A. Add sodium valproate for rapid-cycling bipolar disorder (Correct Answer)
B. Switch lithium to lamotrigine
C. Add quetiapine to the lithium regimen
D. Increase lithium dose to achieve higher therapeutic level
E. Add cognitive behavioural therapy for bipolar disorder

Explanation: ***Add sodium valproate for rapid-cycling bipolar disorder***- The patient's history of **six mood episodes in 14 months** clearly meets the diagnostic criteria for **rapid-cycling bipolar disorder**, defined as four or more mood episodes within a 12-month period.- When **lithium monotherapy** at therapeutic levels (0.8 mmol/L) is insufficient to control rapid cycling, adding **sodium valproate** is an evidence-based and highly effective strategy for stabilization.*Switch lithium to lamotrigine*- **Lamotrigine** is primarily indicated for preventing **depressive episodes** in bipolar disorder and has limited efficacy in preventing or treating **manic episodes**.- Switching away from lithium, which has established anti-manic properties, could potentially worsen the manic component of this patient's **Bipolar Type I** and rapid cycling.*Add quetiapine to the lithium regimen*- While **quetiapine** is an effective mood stabilizer for bipolar disorder, the combination of **lithium and sodium valproate** typically has stronger evidence for managing **rapid-cycling** that is refractory to lithium monotherapy.- Quetiapine might be considered if valproate is contraindicated or ineffective, but it is not the primary add-on recommendation for this specific **refractory rapid-cycling** pattern.*Increase lithium dose to achieve higher therapeutic level*- The patient is already at a **therapeutic lithium level of 0.8 mmol/L**; increasing the dose further would significantly elevate the risk of **lithium toxicity**.- Higher lithium levels (e.g., >1.0 mmol/L) are generally used for acute mania rather than for long-term maintenance in rapid-cycling, and the risk-benefit ratio would be unfavorable here.*Add cognitive behavioural therapy for bipolar disorder*- **Cognitive behavioral therapy (CBT)** is a valuable adjunctive treatment for bipolar disorder, aiding in symptom management and adherence, but it is not a primary intervention for acute or **rapid-cycling stabilization**.- For a patient experiencing **six mood episodes in 14 months** despite therapeutic medication, immediate and effective **pharmacological intervention** is paramount to stabilize the mood before psychological therapies can be fully beneficial.

Question 22: A 26-year-old man with schizophrenia has been taking clozapine 400mg daily for 6 months with good response. He now develops fever (38.5°C), sore throat, and malaise. His blood tests show: white cell count 2.8 × 10⁹/L, neutrophils 0.8 × 10⁹/L. What is the most appropriate immediate action?

A. Continue clozapine and treat symptomatically with paracetamol
B. Stop clozapine immediately, admit to hospital, and start broad-spectrum antibiotics (Correct Answer)
C. Reduce clozapine to 200mg daily and monitor closely
D. Stop clozapine temporarily until infection resolves then rechallenge
E. Continue clozapine and repeat blood tests in 24 hours

Explanation: ***Stop clozapine immediately, admit to hospital, and start broad-spectrum antibiotics*** - The patient's presentation with **fever**, **sore throat**, **malaise**, and a **neutrophil count of 0.8 × 10⁹/L** indicates **clozapine-induced agranulocytosis** (or severe neutropenia) with **neutropenic sepsis**. - This is a medical emergency requiring **immediate cessation of clozapine**, urgent **hospitalization**, and initiation of **broad-spectrum antibiotics** to prevent life-threatening infection. *Continue clozapine and treat symptomatically with paracetamol* - Continuing clozapine in the setting of severe **neutropenia** is extremely dangerous as it perpetuates the bone marrow suppression, leading to worsening agranulocytosis. - Symptomatic treatment with paracetamol alone does not address the underlying **life-threatening condition** caused by drug-induced bone marrow toxicity and increased infection risk. *Reduce clozapine to 200mg daily and monitor closely* - A **neutrophil count below 1.0 × 10⁹/L** (especially 0.8) while on clozapine mandates **immediate and permanent discontinuation**, not a dose reduction. - This reaction is often idiosyncratic and not dose-dependent; reducing the dose still leaves the patient at severe risk of **septic complications**. *Stop clozapine temporarily until infection resolves then rechallenge* - While stopping clozapine is correct, **rechallenge** after documented severe neutropenia or agranulocytosis is **absolutely contraindicated** due to the high risk of a rapid and severe recurrence. - Such a severe reaction necessitates permanent discontinuation of clozapine, and the patient should be registered in a national monitoring system. *Continue clozapine and repeat blood tests in 24 hours* - A **neutrophil count of 0.8 × 10⁹/L** combined with symptoms of infection (fever, sore throat) signifies an acute and severe adverse drug reaction requiring **immediate intervention**, not delayed monitoring. - Waiting 24 hours would dangerously prolong exposure to the drug and allow the **neutropenic sepsis** to progress, potentially leading to septic shock and death.

Question 23: A 33-year-old woman with bipolar affective disorder type I presents for preconception counselling. She has been stable on sodium valproate 1000mg daily for 4 years following multiple failed treatments. She has had no mood episodes in this time but had four manic admissions before starting valproate. What is the most appropriate management approach?

A. Switch to lithium carbonate before conception and optimise dose (Correct Answer)
B. Continue valproate with high-dose folic acid supplementation throughout pregnancy
C. Switch to lamotrigine before conception with gradual titration
D. Stop all mood stabilisers and monitor closely during pregnancy
E. Switch to quetiapine before conception as first-line option

Explanation: ***Switch to lithium carbonate before conception and optimise dose*** - **Sodium valproate** is strictly contraindicated in women of childbearing potential due to high risks of **major congenital malformations** (e.g., neural tube defects) and significant **neurodevelopmental impairment**. - **Lithium** is the preferred alternative here due to its robust efficacy in preventing **manic episodes** and its relatively lower teratogenic risk, offering essential mood stabilization for this patient's severe history of mania.*Continue valproate with high-dose folic acid supplementation throughout pregnancy* - Continuing **valproate** during pregnancy is strongly advised against because **high-dose folic acid** cannot reliably prevent its significant **teratogenic effects** and risks of **neurodevelopmental disorders**. - Current guidelines mandate that valproate should be **discontinued and switched** to a safer alternative before conception whenever possible, making this option inappropriate.*Switch to lamotrigine before conception with gradual titration* - While **lamotrigine** has a favorable safety profile in pregnancy, it is primarily effective in preventing **bipolar depressive episodes**, with less robust evidence for preventing severe mania. - Given the patient's history of **multiple severe manic admissions**, lamotrigine may not provide sufficient protection against manic relapse, which is the greater clinical concern. *Stop all mood stabilisers and monitor closely during pregnancy* - For a patient with a history of **Bipolar Affective Disorder Type I** and multiple severe **manic episodes**, abrupt discontinuation of mood stabilizers carries a very high risk of **relapse**. - Pregnancy and the postpartum period are periods of increased vulnerability to **mood episodes**, making close monitoring alone insufficient without adequate pharmacological stabilization, posing risks to both mother and fetus.*Switch to quetiapine before conception as first-line option* - Although **quetiapine** is an atypical antipsychotic used in bipolar disorder, **lithium** is generally considered the **gold standard** and most effective mood stabilizer for long-term **manic relapse prevention** in high-risk patients. - Given the patient's history of multiple failed treatments before stabilization, transitioning to the most **potent mood stabilizer** (lithium) is more appropriate than an atypical antipsychotic as a first-line switch.

Question 24: A 52-year-old woman with a 25-year history of schizophrenia has been on clozapine 600mg daily for 8 years with good symptom control. Recent investigations show: white cell count 3.2 × 10⁹/L, neutrophils 1.8 × 10⁹/L, platelets 180 × 10⁹/L. She is asymptomatic with no signs of infection. What is the most appropriate management?

A. Continue clozapine and repeat blood tests in one week (Correct Answer)
B. Stop clozapine immediately and switch to olanzapine
C. Reduce clozapine dose to 400mg and repeat bloods in 3 days
D. Stop clozapine immediately and never rechallenge
E. Continue clozapine and repeat blood tests in 3 days

Explanation: ***Continue clozapine and repeat blood tests in one week*** - The patient's **neutrophil count (1.8 × 10⁹/L)** falls into the **'Amber' category** (1.5–2.0 × 10⁹/L), which requires increased monitoring rather than immediate drug cessation. - Guidelines suggest that for patients on stable long-term therapy, if results enter the amber range, treatment should continue with **increased frequency of blood monitoring** (twice weekly) until counts stabilize. *Stop clozapine immediately and switch to olanzapine* - Immediate cessation is only mandatory for **'Red' category** results, defined by an **absolute neutrophil count (ANC) < 1.5 × 10⁹/L** or WBC < 3.0 × 10⁹/L. - Switching to **olanzapine** is premature given that the patient has been stable for 8 years and does not meeting the threshold for **agranulocytosis** risk. *Reduce clozapine dose to 400mg and repeat bloods in 3 days* - **Dose reduction** is not a standard evidence-based response to hematological fluctuations in clozapine monitoring; the risk is the **idiosyncratic reaction**, not dose-dependent toxicity. - Management hinges on **monitoring frequency** rather than adjusting the dosage of the antipsychotic. *Stop clozapine immediately and never rechallenge* - A **'never rechallenge'** rule applies strictly to patients who experience confirmed **clozapine-induced agranulocytosis** (ANC < 0.5 × 10⁹/L). - The patient currently has a **mild neutropenia**, and stopping therapy would unnecessarily risk a relapse of her **schizophrenia** symptoms. *Continue clozapine and repeat blood tests in 3 days* - While continuing treatment is correct, the protocol for an **Amber result** specifically dictates **twice-weekly** testing until results improve. - This option is less precise than the requirement to ensure testing occurs twice every 7 days to closely monitor for a further **downward trend** in neutrophils.

Question 25: A 38-year-old man with schizoaffective disorder has been maintained on depot paliperidone 100mg monthly for 18 months. He now presents with new-onset diabetes mellitus (HbA1c 68 mmol/mol, fasting glucose 8.2 mmol/L). His mental state remains stable with no psychotic symptoms. His BMI is 32 kg/m². What is the most appropriate next step in management?

A. Continue paliperidone, commence metformin, and refer to diabetic services
B. Switch to amisulpride which has lower metabolic risk
C. Switch to lurasidone which has favourable metabolic profile
D. Continue paliperidone and manage diabetes with lifestyle modifications alone
E. Switch to aripiprazole depot which has lower diabetes risk (Correct Answer)

Explanation: ***Switch to aripiprazole depot which has lower diabetes risk*** - When a patient develops **metabolic complications** like new-onset diabetes while on an antipsychotic with known metabolic risk (like paliperidone), switching to a **metabolically safer** alternative is the most appropriate first-line intervention, especially when the mental state is stable. - **Aripiprazole** is an atypical antipsychotic with a **favorable metabolic profile** and is available as a **depot formulation**, which is crucial for maintaining **treatment adherence** and preventing relapse in patients with schizoaffective disorder. *Continue paliperidone, commence metformin, and refer to diabetic services* - While **metformin** and referral to diabetic services are important steps in managing diabetes, continuing the offending antipsychotic (paliperidone, known for moderate-to-high metabolic risk) without attempting a switch is not ideal given the patient's stable mental state and significant hyperglycemia. - The priority should be to minimize the **metabolic burden** by adjusting the psychotropic medication if a safer alternative is available and feasible. *Switch to amisulpride which has lower metabolic risk* - **Amisulpride** does have a better metabolic profile, but it is primarily available in **oral form**. Switching from a stable **depot regimen** to an oral medication significantly increases the risk of **non-adherence** and psychiatric relapse in patients with schizoaffective disorder. - Maintaining a **long-acting injectable** is crucial for this patient population to ensure consistent medication levels. *Switch to lurasidone which has favourable metabolic profile* - **Lurasidone** is known for its excellent **metabolic safety profile**, but like amisulpride, it is currently not available in a **depot (long-acting injectable)** formulation. - Transitioning to an oral-only medication could compromise **treatment adherence** in a patient with a chronic severe mental illness, potentially leading to symptom exacerbation. *Continue paliperidone and manage diabetes with lifestyle modifications alone* - The patient's **HbA1c of 68 mmol/mol** (8.4%) and **fasting glucose of 8.2 mmol/L** indicate established diabetes requiring pharmacological intervention, not just lifestyle modifications. - Relying solely on **lifestyle changes** while continuing a medication that contributes to metabolic dysfunction is insufficient and will likely result in poor glycemic control, increasing the risk of long-term diabetic complications.

Question 26: A 29-year-old woman with a first episode of psychosis has been treated with olanzapine 15mg daily for 4 months with complete resolution of symptoms. She asks about the duration of treatment required. According to current evidence and NICE guidance, what is the minimum recommended duration of antipsychotic treatment following a first episode of psychosis?

A. 6 months after symptom resolution
B. 1 year after symptom resolution
C. 2 years after symptom resolution (Correct Answer)
D. Until the patient feels ready to discontinue
E. Lifelong maintenance therapy

Explanation: ***2 years after symptom resolution*** - According to **NICE guidelines (CG178)**, antipsychotic treatment should be continued for a minimum of **1 to 2 years** following a first episode of psychosis to prevent relapse. - Evidence shows that maintaining medication for **2 years** significantly reduces the **relapse rate** compared to earlier discontinuation. *6 months after symptom resolution* - This duration is often recommended for a **first-episode depressive disorder**, but it is generally too short for preventing relapse in **psychosis**. - Stopping antipsychotic treatment this early carries a high risk of **recurrent psychotic symptoms** and functional deterioration. *1 year after symptom resolution* - While some guidelines historically considered **1 year** a minimum, current evidence and **NICE recommendations** now favor **2 years** for better long-term stability and reduced relapse risk. - One year might be considered for highly stable patients, but **2 years** is the more robust clinical standard for optimal outcomes. *Until the patient feels ready to discontinue* - Discontinuing antipsychotics solely based on **patient preference** without clinical guidance and a recommended duration risks **rebound psychosis** and poor prognosis. - The decision to stop must be a **shared clinical decision**, involving gradual tapering and close monitoring *after* the evidence-based treatment period. *Lifelong maintenance therapy* - **Lifelong antipsychotic treatment** is typically reserved for patients with **multiple relapses**, severe chronic symptoms, or an established diagnosis of a chronic psychotic disorder like **schizophrenia**. - For a **first episode of psychosis** with complete resolution, a supervised withdrawal after the two-year mark is generally attempted, not immediate lifelong therapy.

Question 27: A 35-year-old man with bipolar affective disorder type I has been taking lithium carbonate 800mg daily for 3 years with good stability. He presents to A&E with 3 days of vomiting and diarrhoea due to gastroenteritis. He appears dehydrated and reports tremor and confusion today. His lithium level is 1.8 mmol/L. What is the most appropriate immediate management?

A. Admit for intravenous fluids and withhold lithium until level normalises (Correct Answer)
B. Reduce lithium dose to 400mg daily and arrange review in 24 hours
C. Continue current lithium dose and treat gastroenteritis symptomatically
D. Stop lithium permanently and commence sodium valproate
E. Arrange urgent haemodialysis for lithium toxicity

Explanation: ***Admit for intravenous fluids and withhold lithium until level normalises***- The patient presents with **symptoms of lithium toxicity** (tremor, confusion) and an elevated lithium level (1.8 mmol/L), precipitated by **dehydration** from gastroenteritis, necessitating immediate **intravenous fluid resuscitation** to restore renal function and enhance lithium excretion.- **Withholding lithium** is crucial to prevent further drug accumulation and worsening toxicity, while monitoring clinical status and lithium levels until they return to the **therapeutic range** (typically 0.4-1.0 mmol/L).*Reduce lithium dose to 400mg daily and arrange review in 24 hours*- A symptomatic patient with a toxic lithium level due to **acute dehydration** requires immediate and complete cessation of lithium, not just a dose reduction, to prevent further harm.- Arranging a review in 24 hours is inadequate for the **acute and potentially life-threatening nature** of symptomatic lithium toxicity, which demands urgent inpatient management.*Continue current lithium dose and treat gastroenteritis symptomatically*- Continuing the current lithium dose would lead to further **dangerous accumulation** of the drug, exacerbating **lithium toxicity** and potentially causing severe complications.- Symptomatic treatment of gastroenteritis does not address the underlying issue of **impaired lithium excretion** due to dehydration, which is the direct cause of the toxicity.*Stop lithium permanently and commence sodium valproate*- Permanent cessation of lithium and immediate switching to another agent like **sodium valproate** is a long-term management decision, not the primary concern for acute, reversible lithium toxicity.- Lithium can often be cautiously **reintroduced** once the patient is stable and the precipitating factor (dehydration) has resolved, making permanent cessation premature.*Arrange urgent haemodialysis for lithium toxicity*- **Haemodialysis** is generally reserved for **severe lithium toxicity**, typically defined by levels >2.5 mmol/L or >2.0 mmol/L with severe neurological symptoms or renal failure.- For this patient's lithium level of 1.8 mmol/L, **aggressive intravenous fluid resuscitation** is the initial and most appropriate management, as it often resolves toxicity by enhancing renal clearance.

Question 28: A 44-year-old woman with schizophrenia presents to her GP with a 6-week history of galactorrhoea and amenorrhoea. She has been taking risperidone 6mg daily for 8 months with good control of psychotic symptoms. Pregnancy test is negative. Prolactin level is 3200 mU/L (normal range 102-496). What is the most appropriate next step in management?

A. Reduce risperidone dose to 4mg daily and reassess in 4 weeks
B. Switch to aripiprazole and monitor prolactin levels (Correct Answer)
C. Add cabergoline to reduce prolactin levels while continuing risperidone
D. Arrange urgent MRI pituitary to exclude prolactinoma
E. Switch to clozapine as it has lower risk of hyperprolactinaemia

Explanation: ***Switch to aripiprazole and monitor prolactin levels*** - **Risperidone** is a potent **D2 receptor antagonist** that frequently causes hyperprolactinaemia due to its strong blockade of dopamine receptors in the pituitary. - **Aripiprazole** acts as a **dopamine partial agonist**, which helps normalize prolactin levels while maintaining antipsychotic efficacy, making it a suitable switch. *Add cabergoline to reduce prolactin levels while continuing risperidone* - **Cabergoline** is a dopamine agonist that can potentially **exacerbate or trigger psychotic symptoms** by counteracting the antipsychotic effect of risperidone. - It is generally reserved for prolactinomas and is not the first-line management for **drug-induced hyperprolactinaemia**. *Reduce risperidone dose to 4mg daily and reassess in 4 weeks* - Lowering the dose may not be sufficient to resolve **symptomatic hyperprolactinaemia** like galactorrhoea and amenorrhoea at this significantly elevated level. - Reducing an effective antipsychotic dose risks **psychotic relapse**, which is a greater clinical concern given the patient's stable psychotic symptoms. *Arrange urgent MRI pituitary to exclude prolactinoma* - Drug-induced prolactin elevations (especially with risperidone) commonly range from **2000-4000 mU/L**, and the cause is clearly medication-related in this case. - An **MRI pituitary** is typically indicated for very high prolactin levels (>5000 mU/L) or if symptoms persist despite switching the offending drug. *Switch to clozapine as it has lower risk of hyperprolactinaemia* - **Clozapine** is reserved for **treatment-resistant schizophrenia** due to its significant side effect profile, including the risk of **agranulocytosis**, requiring intensive monitoring. - Since the patient’s psychotic symptoms are well-controlled on risperidone, switching to a high-risk medication like clozapine is not justified.

Question 29: A 27-year-old man presents with a 5-month history of believing that MI5 is monitoring him through his mobile phone. He has become socially withdrawn, stopped attending work, and reports hearing occasional whispers but cannot make out what they say. His affect is blunted. There is no history of substance misuse or mood episodes. What is the most likely diagnosis?

A. Paranoid schizophrenia (Correct Answer)
B. Delusional disorder - persecutory type
C. Schizotypal personality disorder
D. Schizoaffective disorder
E. Brief psychotic disorder

Explanation: ***Paranoid schizophrenia*** - The patient presents with classic features including **persecutory delusions** (MI5 monitoring), **auditory hallucinations** (occasional whispers), and **negative symptoms** (blunted affect, social withdrawal). - The duration of **5 months** and resulting **functional impairment** (stopped work), in the absence of mood episodes or substance misuse, strongly support a diagnosis of schizophrenia. *Delusional disorder - persecutory type* - This disorder is characterized by the presence of one or more delusions for at least one month **without other significant psychotic symptoms** like prominent hallucinations or marked negative symptoms. - The presence of **occasional whispers** (auditory hallucinations) and **blunted affect** in this patient makes a pure delusional disorder less likely than schizophrenia. *Schizotypal personality disorder* - This is a pervasive pattern of social and interpersonal deficits, with **cognitive or perceptual distortions** and eccentricities of behavior, but typically **lacks the intensity and persistence of frank delusions and hallucinations** seen here. - While individuals may have odd beliefs, it is a **personality disorder** and does not typically involve the acute onset and significant functional deterioration due to active psychotic symptoms as described. *Schizoaffective disorder* - This diagnosis requires that a **major mood episode** (depressive or manic) co-occur with symptoms of schizophrenia, and that delusions or hallucinations be present for at least two weeks **without a major mood episode**. - The history explicitly states there is **no history of substance misuse or mood episodes**, thereby ruling out schizoaffective disorder. *Brief psychotic disorder* - By definition, a brief psychotic disorder involves psychotic symptoms lasting **more than one day but less than one month**, followed by a full return to premorbid functioning. - The patient's symptoms have persisted for **five months**, which far exceeds the maximum duration for a brief psychotic disorder.

Question 30: A 31-year-old woman with bipolar affective disorder type I has been stable on quetiapine 400mg daily for 18 months following a manic episode. She now presents requesting to stop medication as she feels well and dislikes the weight gain. She has had two previous manic episodes requiring admission. What is the most appropriate management approach?

A. Support gradual medication reduction with close monitoring and psychoeducation about relapse risk
B. Advise continuation of current medication emphasising high relapse rates with discontinuation (Correct Answer)
C. Switch to lithium carbonate which has better long-term outcomes for relapse prevention
D. Reduce quetiapine to 200mg daily and review in 3 months
E. Stop quetiapine and commence cognitive behavioural therapy for bipolar disorder

Explanation: ***Advise continuation of current medication emphasising high relapse rates with discontinuation***- For a patient with **Bipolar I Disorder** and a history of **multiple severe manic episodes** requiring admission, long-term maintenance treatment is critically indicated to prevent further morbidity.- Discontinuation of mood stabilizers in such high-risk individuals is associated with a **relapse rate of 50-90%** within two years; clinician counseling must focus on these risks and strategies to manage **adverse effects** like weight gain.*Support gradual medication reduction with close monitoring and psychoeducation about relapse risk*- Given the patient's history of **three previous manic episodes** (one recent, two requiring admission), she is considered **high-risk for relapse**, making any medication reduction inappropriate at this stage.- While psychoeducation is essential, supporting medication reduction would significantly increase her risk of a **recurrent manic or depressive episode**, outweighing the benefit of addressing weight gain at this time.*Switch to lithium carbonate which has better long-term outcomes for relapse prevention*- The patient is currently **stable** on quetiapine, indicating its effectiveness for her. Switching stable medication without a compelling clinical reason (e.g., intolerance, ineffectiveness) is generally discouraged.- Switching to lithium would involve a **cross-titration process**, which can destabilize the patient and introduce new **side effects** or compliance challenges, despite lithium's established efficacy.*Reduce quetiapine to 200mg daily and review in 3 months*- Reducing the dose from 400mg daily, especially given her history of severe episodes, could render the medication **sub-therapeutic** for mood stabilization, significantly increasing relapse risk.- The 400mg dose has maintained stability for 18 months; lowering it primarily for weight gain without exploring other management strategies or a more gradual, justified approach is clinically unsound and might trigger a **manic episode**.*Stop quetiapine and commence cognitive behavioural therapy for bipolar disorder*- **Cognitive Behavioral Therapy (CBT)** is a valuable adjunctive treatment for bipolar disorder, but it is **not a substitute for pharmacotherapy**, especially in **Bipolar I Disorder** with a history of severe episodes.- Abruptly stopping quetiapine, a crucial mood stabilizer, would almost certainly precipitate a **manic or depressive episode**, as CBT alone is insufficient for mood stabilization in such cases.

Question 31: A 42-year-old man with a 10-year history of paranoid schizophrenia is being assessed for community treatment order (CTO). He has had five admissions in the past 3 years, each following medication non-adherence. He lives independently and has partial insight. What is the primary legal requirement that must be met before a CTO can be established?

A. The patient must be currently detained under Section 3 of the Mental Health Act (Correct Answer)
B. The patient must have capacity to consent to the community treatment order
C. The patient must have been detained for at least 6 months in the past year
D. The patient must agree to accept depot antipsychotic medication
E. Two independent psychiatrists must assess and agree on the need for CTO

Explanation: ***The patient must be currently detained under Section 3 of the Mental Health Act***- A **Community Treatment Order (CTO)** requires that the patient is currently liable to be detained for treatment under **Section 3** or other applicable sections (e.g., Section 37) of the **Mental Health Act**.- This legal framework allows for a transition from **hospital-based detention** to supervised treatment in the community, retaining the power of **recall** if conditions are not met.*The patient must have capacity to consent to the community treatment order*- **Capacity** is not a legal prerequisite for the implementation of a CTO under the **Mental Health Act**.- A CTO can be applied even if a patient lacks the **mental capacity** to consent, provided it is necessary for their health, safety, or the protection of others.*The patient must have been detained for at least 6 months in the past year*- There is no specific legal requirement regarding the **minimum duration** of prior hospital detention (e.g., 6 months) to qualify for a CTO.- The decision is based on the **history of relapse** and the need for ongoing supervision rather than a fixed number of months spent as an inpatient.*The patient must agree to accept depot antipsychotic medication*- While **medication adherence** is often a condition of a CTO, the patient’s agreement to a specific formulation like **depot medication** is not a primary legal requirement for its establishment.- If a patient refuses treatment under a CTO, they may be **recalled to the hospital**, where they can be treated under the original detention powers.*Two independent psychiatrists must assess and agree on the need for CTO*- The legal requirement for establishing a CTO involves the agreement between the **Responsible Clinician (RC)** and an **Approved Mental Health Professional (AMHP)**.- It does not specifically mandate **two independent psychiatrists** to assess and agree, as the AMHP provides an independent perspective.

Question 32: A 36-year-old woman with bipolar affective disorder type I has had three admissions for mania over the past 5 years despite trials of lithium, sodium valproate, and quetiapine. She is currently taking sodium valproate 1500mg daily with plasma levels in therapeutic range but continues to experience frequent hypomanic episodes every 2-3 months. She has just discovered she is 8 weeks pregnant (unplanned). Ultrasound confirms viable intrauterine pregnancy. What is the most appropriate management of her mood stabilizer?

A. Continue sodium valproate at current dose as risks of relapse outweigh teratogenic risks
B. Stop sodium valproate immediately and do not start alternative medication during pregnancy
C. Continue sodium valproate but add high-dose folic acid supplementation
D. Stop sodium valproate and switch to lithium with close monitoring (Correct Answer)
E. Stop sodium valproate and switch to lamotrigine with rapid titration

Explanation: ***Stop sodium valproate and switch to lithium with close monitoring*** - **Sodium valproate** is highly teratogenic, causing a 10% risk of major malformations and a 30-40% risk of **neurodevelopmental delay**; it must be stopped immediately in pregnancy. - **Lithium** is the preferred choice for severe, treatment-resistant bipolar disorder in pregnancy, as its risk of **Ebstein’s anomaly** (0.1%) is significantly lower than the risks associated with valproate. *Continue sodium valproate at current dose as risks of relapse outweigh teratogenic risks* - Regulatory bodies (like the MHRA/NICE) state that valproate should **not be used** in pregnancy for bipolar disorder due to its extreme risk profile. - The risks of **fetal valproate syndrome** and cognitive impairment far outweigh the potential benefits of continuing the medication in this scenario. *Stop sodium valproate immediately and do not start alternative medication during pregnancy* - This patient has **Bipolar Type I** with a history of three hospitalizations, making the risk of a severe **manic relapse** during pregnancy extremely high if untreated. - Relapse poses significant dangers, including **suicidality**, poor prenatal care, and potential harm to the fetus from maternal behavior. *Continue sodium valproate but add high-dose folic acid supplementation* - While **5mg folic acid** is recommended for women on antiepileptics, it does not mitigate the significant **neurodevelopmental risks** or many physical malformations caused by valproate. - Continuing valproate in a pregnant woman with bipolar disorder is considered **contraindicated** if alternative treatments like lithium are available. *Stop sodium valproate and switch to lamotrigine with rapid titration* - **Lamotrigine** requires a very slow titration over weeks to avoid **Stevens-Johnson Syndrome**, leaving the patient unprotected during a high-risk period. - Although it has a good safety profile, lamotrigine is primarily effective for the **depressive pole** and may not be robust enough to manage her recurring hypomania and severe mania history.

Question 33: A 25-year-old woman presents with a 3-month history of hearing multiple voices discussing her in the third person, believing her thoughts are being stolen, and that external forces control her movements. She has become socially withdrawn and her self-care has deteriorated. She has no past psychiatric history and no substance misuse. Her mother had bipolar affective disorder. Physical examination and basic investigations are normal. She is started on risperidone. According to NICE guidelines, what duration of treatment at therapeutic dose is required before considering treatment resistance if there is inadequate response?

A. 2 weeks of treatment at adequate therapeutic dose
B. 4 weeks of treatment at adequate therapeutic dose
C. 4-6 weeks of treatment at adequate therapeutic dose (Correct Answer)
D. 8 weeks of treatment at adequate therapeutic dose
E. 12 weeks of treatment at adequate therapeutic dose

Explanation: ***4-6 weeks of treatment at adequate therapeutic dose***- According to **NICE guidelines** for schizophrenia, an adequate trial of an antipsychotic medication requires treatment at an optimal dose for a period of **4 to 6 weeks**.- This duration is necessary to assess clinical efficacy; if the response is inadequate after this window, the medication is considered **ineffective** and a switch is indicated.*2 weeks of treatment at adequate therapeutic dose*- This duration is too short for a definitive trial, as many patients show significant **symptom reduction** only after the first 14 days of therapeutic dosing.- Declaring failure at this stage risks premature discontinuation of a medication that may have been **clinically effective** with more time.*4 weeks of treatment at adequate therapeutic dose*- While some guidelines mention 4 weeks, **NICE specifically specifies a range** of 4-6 weeks to allow for individual variation in pharmacodynamics.- Assessment at 4 weeks alone might miss the **delayed therapeutic benefit** often seen in patients with severe psychosis.*8 weeks of treatment at adequate therapeutic dose*- Waiting 8 weeks exceeds the standard recommended timeframe for assessing initial drug response in **first-episode psychosis**.- Prolonged trials of ineffective medication unnecessarily extend the **duration of untreated psychosis**, which is associated with poorer long-term outcomes.*12 weeks of treatment at adequate therapeutic dose*- A 12-week trial is far beyond the **4-6 week benchmark** used to define treatment failure or move toward a diagnosis of **treatment-resistant schizophrenia**.- At this point, the patient should have already been evaluated for **clozapine eligibility** if two previous sequential trials of 4-6 weeks had failed.

Question 34: A 40-year-old man with paranoid schizophrenia attends his depot clinic. He has been on paliperidone palmitate 100mg monthly for 6 months following multiple relapses on oral medication. He complains of restlessness, inability to sit still, and constant need to pace. He describes it as 'torture' and says he would rather stop all treatment. Examination reveals constant leg movements and hand wringing but no tremor or rigidity. What is the most appropriate management?

A. Add procyclidine 5mg three times daily to manage extrapyramidal side effects
B. Reduce paliperidone palmitate dose to 75mg monthly and review in 4 weeks
C. Add propranolol 30mg three times daily to manage akathisia symptoms (Correct Answer)
D. Switch from paliperidone palmitate to clozapine for treatment-resistant schizophrenia
E. Continue current treatment and reassure that symptoms will improve with time

Explanation: ***Add propranolol 30mg three times daily to manage akathisia symptoms*** - The patient's symptoms of subjective **restlessness**, inability to sit still, constant need to pace, and objective **constant leg movements** and hand wringing are classic for **akathisia**, a distressing **extrapyramidal side effect (EPS)** of antipsychotics. - **Propranolol**, a **lipophilic beta-blocker**, is the **first-line pharmacological treatment** for akathisia, offering effective relief by acting on central serotonin receptors. *Add procyclidine 5mg three times daily to manage extrapyramidal side effects* - **Procyclidine** is an **anticholinergic medication** primarily used to treat **parkinsonism** (e.g., tremor, rigidity) or **acute dystonia**, not typically effective for **akathisia**. - Anticholinergics can cause significant side effects like **blurred vision**, dry mouth, constipation, and cognitive impairment, and are generally less effective for akathisia. *Reduce paliperidone palmitate dose to 75mg monthly and review in 4 weeks* - While dose reduction can alleviate EPS, this patient has a history of **multiple relapses** on oral medication, making dose reduction a high risk for **psychotic recurrence** and potential destabilization. - Due to the **long half-life** of paliperidone palmitate depot, a dose reduction would not provide immediate symptomatic relief for his severe distress, which is crucial for adherence. *Switch from paliperidone palmitate to clozapine for treatment-resistant schizophrenia* - **Clozapine** is indicated for **treatment-resistant schizophrenia**, defined as failure of at least two adequate trials of different antipsychotics, which is not clearly established here as the issue is a manageable side effect. - Switching to clozapine involves significant risks, including the need for intensive **hematological monitoring** due to agranulocytosis risk, and would be premature before addressing the akathisia directly. *Continue current treatment and reassure that symptoms will improve with time* - Akathisia is profoundly distressing (described as "torture") and is a major cause of **treatment non-adherence** and can increase the **risk of suicide** or violence. - Reassurance alone is insufficient and inappropriate given the severity of his symptoms and the need for prompt, effective **active management** to alleviate his distress and maintain treatment adherence.

Question 35: A 33-year-old man with bipolar affective disorder type I has been stable on lithium carbonate 1200mg daily for 4 years. He is admitted to the medical ward with suspected acute appendicitis requiring emergency laparoscopic appendicectomy. Preoperative bloods show: lithium level 0.85 mmol/L, creatinine 92 μmol/L, eGFR >90 ml/min. What is the most appropriate perioperative management of his lithium?

A. Continue lithium throughout the perioperative period with daily level monitoring
B. Omit lithium on the day of surgery and restart when oral intake resumes (Correct Answer)
C. Stop lithium 48 hours preoperatively and restart 24 hours postoperatively
D. Stop lithium 24 hours preoperatively and restart when renal function is confirmed stable
E. Continue lithium but reduce dose by 50% on day of surgery

Explanation: ***Omit lithium on the day of surgery and restart when oral intake resumes*** - For emergency or minor surgery, **omitting lithium** on the day of the procedure is sufficient to minimize the risk of **toxicity** caused by fluid shifts and dehydration. - It should be restarted as soon as the patient is **fluid-stable** and oral intake is resumed to prevent the risk of a **bipolar relapse**. *Continue lithium throughout the perioperative period with daily level monitoring* - This approach is dangerous because **general anesthesia** and intraoperative **fluid loss** can cause rapid fluctuations in serum levels, leading to **neurotoxicity**. - Lithium also interacts with **neuromuscular blocking agents**, potentially prolonging their effects during surgery. *Stop lithium 48 hours preoperatively and restart 24 hours postoperatively* - This protocol is typically reserved for **major surgeries** involving significant fluid shifts, such as cardiac or major abdominal surgery, which does not apply to this laparoscopy. - Prolonged cessation of lithium, especially without a gradual taper, is associated with a high rate of **rapid relapse** in bipolar I patients. *Stop lithium 24 hours preoperatively and restart when renal function is confirmed stable* - While cautious regarding **renal clearance**, a 24-hour cessation is often unnecessary for stable patients undergoing procedures where they can quickly resume **oral intake**. - Extended cessation increases the time the patient is without therapeutic coverage, raising the risk of **acute mood episodes**. *Continue lithium but reduce dose by 50% on day of surgery* - **Dose reduction** is not a standard perioperative practice; it makes levels unpredictable and does not protect against the risk of **acute kidney injury** during surgery. - The narrow **therapeutic index** of lithium makes a fixed-percentage reduction unsafe compared to simply omitting a single dose.

Question 36: A 28-year-old woman with schizoaffective disorder has been maintained on amisulpride 400mg daily for 3 years. She presents with new-onset amenorrhoea for 4 months and galactorrhoea. She is sexually active and a pregnancy test is negative. Blood tests show: prolactin 3200 mU/L (normal <500 mU/L), TSH 2.4 mU/L, LH and FSH suppressed. MRI pituitary is normal. What is the most appropriate management?

A. Continue amisulpride and add cabergoline to lower prolactin levels
B. Switch amisulpride to quetiapine which has lower risk of hyperprolactinaemia
C. Reduce amisulpride dose to 200mg daily and monitor prolactin levels
D. Continue amisulpride and reassure that hyperprolactinaemia is benign
E. Switch amisulpride to aripiprazole which may reduce prolactin levels (Correct Answer)

Explanation: ***Switch amisulpride to aripiprazole which may reduce prolactin levels*** - **Amisulpride** is a potent **D2 antagonist** leading to high prolactin, while **aripiprazole** is a **partial dopamine agonist** known to reduce elevated prolactin levels. - Switching to an antipsychotic like **aripiprazole** with a different mechanism is the most appropriate management for drug-induced hyperprolactinaemia. *Continue amisulpride and add cabergoline to lower prolactin levels* - Adding **cabergoline**, a **dopamine agonist**, to an antipsychotic (dopamine antagonist) can counteract its therapeutic effects and **exacerbate psychotic symptoms**. - It is generally not advisable to treat antipsychotic-induced side effects with another drug that may interfere with the primary psychiatric treatment. *Switch amisulpride to quetiapine which has lower risk of hyperprolactinaemia* - While **quetiapine** is **prolactin-sparing**, **aripiprazole** is often preferred because its unique **partial agonism** can actively *reduce* already elevated prolactin levels, rather than just preventing further increases. - Aripiprazole's mechanism offers a more direct and effective approach for resolving existing hyperprolactinaemia symptoms. *Reduce amisulpride dose to 200mg daily and monitor prolactin levels* - Reducing the dose of **amisulpride** may not be sufficient to normalize prolactin levels due to its high affinity for pituitary dopamine receptors. - Dose reduction carries a significant risk of **psychiatric relapse** for a patient previously stable on a higher dose, without guaranteeing resolution of **amenorrhoea** or **galactorrhoea**. *Continue amisulpride and reassure that hyperprolactinaemia is benign* - Long-term **hyperprolactinaemia** is not benign; it can lead to **hypogonadism**, **reduced bone mineral density** (osteoporosis), and sexual dysfunction. - Symptomatic cases with **amenorrhoea** and **galactorrhoea** require intervention to protect the patient's long-term physical health and quality of life.

Question 37: A 31-year-old man with first-episode psychosis was commenced on olanzapine 10mg daily 6 weeks ago with good initial response. He now presents with increasing agitation, refuses to take medication, and believes his food is being poisoned. Mental state examination reveals thought disorder, auditory hallucinations, and persecutory delusions. He lacks capacity to consent to treatment. He lives alone and has limited family support. What is the most appropriate management approach?

A. Arrange urgent assessment for admission under Mental Health Act and commence depot antipsychotic (Correct Answer)
B. Increase oral olanzapine to 20mg daily and arrange daily supervised administration
C. Initiate community treatment order to ensure medication compliance
D. Arrange crisis team intensive home treatment as alternative to admission
E. Administer intramuscular olanzapine and observe response before deciding on admission

Explanation: ***Arrange urgent assessment for admission under Mental Health Act and commence depot antipsychotic*** - The patient is experiencing an **acute psychotic relapse** with severe symptoms, **lacks capacity** to make treatment decisions, and **refuses oral medication** due to paranoia, necessitating **involuntary admission** under the **Mental Health Act** to ensure safety and initiate treatment. - Given the clear history of **medication non-adherence** leading to relapse (believing food/meds are poisoned), initiating a **long-acting injectable (depot) antipsychotic** is the most appropriate strategy to improve adherence and prevent future relapses once stabilized. *Increase oral olanzapine to 20mg daily and arrange daily supervised administration* - This approach is unsuitable because the patient is **actively refusing** oral medication, believing it is **poisoned**, making daily supervised administration impractical and likely ineffective. - Increasing the dose of a medication the patient won't take does not address the core issue of **non-adherence** and his current **lack of capacity** to engage with treatment. *Initiate community treatment order to ensure medication compliance* - A **Community Treatment Order (CTO)** is typically implemented for patients who have been **detained** under the Mental Health Act and are being discharged from hospital, to ensure compliance in the community. It is not for *initiating* treatment in an acutely unwell patient who requires admission. - The patient's current severe symptoms, **lack of capacity**, and **refusal of treatment** in the community make him unsuitable for a CTO at this stage; he first requires inpatient stabilization. *Arrange crisis team intensive home treatment as alternative to admission* - **Intensive home treatment** requires a degree of **patient cooperation** and engagement, which is absent here due to his severe **psychotic symptoms**, **agitation**, and **refusal of care**. - Furthermore, the patient **lives alone** and has **limited family support**, making home treatment challenging and potentially unsafe given the severity of his **persecutory delusions** and risk of harm to self or others. *Administer intramuscular olanzapine and observe response before deciding on admission* - While **intramuscular olanzapine** can be used for **acute agitation** and symptom control, it is a **short-term measure** and does not address the need for a comprehensive, ongoing treatment plan for a patient with **acute relapse** and **lack of capacity**. - Given the severity of his symptoms, **lack of capacity**, and **poor support**, admission is strongly indicated for **safety**, thorough assessment, and initiation of effective long-term treatment, regardless of the immediate response to a single IM dose.

Question 38: A 45-year-old woman with a 20-year history of bipolar affective disorder type I presents for review. She has had 8 hospital admissions for mania and 3 for severe depression. She has tried lithium, sodium valproate, and quetiapine with poor response. She experiences mood episodes every 3-4 months. Recent thyroid function and renal function are normal. What is the most appropriate long-term pharmacological management strategy?

A. High-dose quetiapine monotherapy up to 800mg daily
B. Lithium and sodium valproate combination therapy (Correct Answer)
C. Lamotrigine monotherapy with gradual titration to therapeutic dose
D. Depot antipsychotic with mood stabilizer augmentation
E. Carbamazepine monotherapy as alternative mood stabilizer

Explanation: ***Lithium and sodium valproate combination therapy*** - This patient exhibits **treatment-resistant rapid-cycling bipolar disorder** (defined as ≥4 episodes per year), having failed trials of lithium, valproate, and quetiapine monotherapy. - **NICE guidelines** recommend combination therapy with two mood stabilizers, like **lithium and sodium valproate**, specifically for patients who do not respond to monotherapy and have a high frequency of relapse. *High-dose quetiapine monotherapy up to 800mg daily* - While **quetiapine** is effective in both mania and depression, this patient has already failed quetiapine trials, making further monotherapy unlikely to succeed. - Higher doses increase the risk of **metabolic side effects** and sedation without guaranteeing better mood stabilization in **rapid-cycling** cases. *Lamotrigine monotherapy with gradual titration to therapeutic dose* - **Lamotrigine** is primarily effective for preventing **bipolar depression** but has significantly less efficacy in preventing or treating **manic episodes**. - Given the patient's history of 8 manic admissions, lamotrigine monotherapy would not provide sufficient protection against further **mania**. *Depot antipsychotic with mood stabilizer augmentation* - **Depot antipsychotics** are generally reserved for patients with poor **medication adherence**, which is not the primary issue identified here. - While augmentation is useful, the combination of two gold-standard **mood stabilizers** is preferred over depot therapy for complex maintenance in **treatment-resistant** patients. *Carbamazepine monotherapy as alternative mood stabilizer* - **Carbamazepine** is generally considered a second-line mood stabilizer due to its **enzyme-induction** properties and multiple drug-drug interactions. - It has a weaker evidence base compared to lithium and valproate for long-term **prophylaxis** in severe, refractory bipolar type I.

Question 39: According to the ICD-10 diagnostic criteria, which of the following is classified as a first-rank symptom of schizophrenia?

A. Persistent delusions that are culturally inappropriate and completely impossible
B. Thought echo, thought insertion, thought withdrawal, or thought broadcasting (Correct Answer)
C. Persistent hallucinations in any modality occurring daily for at least one month
D. Breaks or interpolations in the train of thought resulting in incoherence
E. Marked apathy, paucity of speech, and blunting of emotional responses

Explanation: ***Thought echo, thought insertion, thought withdrawal, or thought broadcasting*** - These are classic **Schneiderian first-rank symptoms**, representing a disturbance in the **boundary of the self** or **thought possession**, crucial for schizophrenia diagnosis in ICD-10. - **ICD-10** specifies that the presence of at least one of these clear-cut symptoms of **thought alienation** for a period of one month or more is sufficient for diagnosis. *Persistent delusions that are culturally inappropriate and completely impossible* - While these are descriptive of **bizarre delusions**, a significant feature of schizophrenia, they are considered a broader category of delusion rather than a specific **first-rank symptom** itself. - **Schneider's first-rank symptoms** focus on very specific types of delusions, such as **delusional perception**, rather than general bizarre content. *Persistent hallucinations in any modality occurring daily for at least one month* - For hallucinations to be classified as first-rank, they must be highly specific, such as **auditory hallucinations** in the form of voices giving a **running commentary** or **discussing the patient** in the third person, or **thought echo**. - General persistent hallucinations in *any modality* (e.g., visual, tactile) are characteristic of schizophrenia but do not meet the strict criteria for **first-rank symptoms**. *Breaks or interpolations in the train of thought resulting in incoherence* - This describes **formal thought disorder** or **loosening of associations**, which is a core feature of the **disorganization syndrome** in schizophrenia. - Although a major diagnostic criterion for schizophrenia in ICD-10, formal thought disorder is not categorized as one of the specific **Schneiderian first-rank symptoms**. *Marked apathy, paucity of speech, and blunting of emotional responses* - These are quintessential **negative symptoms** of schizophrenia, reflecting a reduction or absence of normal mental functions and behaviors. - While critical for diagnosis and indicating significant impairment, **negative symptoms** are distinct from the specific **first-rank symptoms** defined by Schneider and utilized in ICD-10.

Question 40: A 37-year-old woman with bipolar affective disorder type I has been maintained on lithium carbonate 1000mg daily for 5 years with excellent mood stability. Recent routine blood tests show: lithium level 0.9 mmol/L, creatinine 145 μmol/L (baseline 85 μmol/L 6 months ago), eGFR 48 ml/min/1.73m², TSH 5.8 mU/L (normal range 0.5-4.5), free T4 12 pmol/L (normal range 9-25). She is asymptomatic. What is the most appropriate next step in management?

A. Stop lithium immediately and switch to sodium valproate due to renal impairment
B. Continue lithium but reduce dose and increase monitoring frequency of renal function (Correct Answer)
C. Continue lithium at current dose as levels are therapeutic and side effects are acceptable
D. Stop lithium and switch to lamotrigine as first-line alternative for mood stabilization
E. Add amiloride to lithium therapy to reduce polyuria and protect renal function

Explanation: ***Continue lithium but reduce dose and increase monitoring frequency of renal function*** - The patient exhibits **declining renal function** (eGFR 48 ml/min, CKD stage 3a) and **subclinical hypothyroidism** (TSH 5.8 mU/L), which are common long-term side effects of lithium that require dose adjustment and closer surveillance. - Given the **excellent mood stability**, the preferred approach is to reduce the lithium dose to target a lower therapeutic level (0.6–0.8 mmol/L) and increase monitoring of renal function, typically every 3 months, before considering discontinuation. *Stop lithium immediately and switch to sodium valproate due to renal impairment* - **Abrupt discontinuation** of lithium is associated with a very high risk of relapse (up to 50% within a year) in stable bipolar I patients. - Lithium is not strictly contraindicated until **eGFR falls below 30 ml/min**, so an immediate switch is not yet mandatory at CKD stage 3a. *Continue lithium at current dose as levels are therapeutic and side effects are acceptable* - A **rising creatinine** (from 85 to 145 μmol/L) and an eGFR below 60 ml/min indicate significant **nephrotoxicity** that cannot be ignored. - Maintaining the same dose increases the risk of **lithium toxicity**, as lithium is primarily excreted by the kidneys and its clearance decreases with renal impairment. *Stop lithium and switch to lamotrigine as first-line alternative for mood stabilization* - While **lamotrigine** is effective for bipolar depression, it is generally less effective than lithium or valproate for preventing **manic relapses** in bipolar type I disorder. - Switching is a complex process and should only be initiated if dose reduction fails to stabilize the **eGFR decline** or if the patient becomes symptomatic. *Add amiloride to lithium therapy to reduce polyuria and protect renal function* - **Amiloride** is specifically used to treat **nephrogenic diabetes insipidus** by blocking lithium entry into the epithelial sodium channels of the collecting duct, but the patient is asymptomatic for polyuria. - It does not directly improve the **glomerular filtration rate (eGFR)** or treat the interstitial fibrosis associated with long-term lithium use.

Question 41: A 34-year-old man with paranoid schizophrenia presents with a 4-week history of decreased motivation, social withdrawal, and neglect of self-care. He describes feeling empty and lacking energy. He denies low mood, anhedonia, or suicidal ideation. He has been stable on risperidone 4mg daily for 2 years with good control of positive symptoms. Mental state examination reveals blunted affect and poverty of speech but no hallucinations or delusions. What is the most likely explanation for his current presentation?

A. Comorbid depressive episode requiring antidepressant augmentation
B. Relapse of schizophrenia with re-emergence of positive symptoms
C. Extrapyramidal side effects from risperidone requiring anticholinergic medication
D. Negative symptoms of schizophrenia requiring treatment modification (Correct Answer)
E. Post-psychotic depression requiring psychological intervention

Explanation: ***Negative symptoms of schizophrenia requiring treatment modification*** - The patient exhibits core **negative symptoms** including **avolition** (decreased motivation), **asociality** (withdrawal), **blunted affect**, and **poverty of speech** (alogia). - These symptoms occur despite effective control of **positive symptoms** (hallucinations/delusions) by risperidone, requiring potential shifts to medications like **cariprazine** or **amisulpride** that target negative domains. *Comorbid depressive episode requiring antidepressant augmentation* - This patient specifically **denies low mood**, anhedonia, or **suicidal ideation**, which are essential criteria for a major depressive episode. - Clinical focus is on a lack of energy and motivation (**avolition**) rather than the cognitive symptoms of depression like **guilt** or **hopelessness**. *Relapse of schizophrenia with re-emergence of positive symptoms* - Mental state examination confirms that **hallucinations** and **delusions** are absent, and his positive symptoms have remained stable for two years. - A relapse of positive symptoms would typically involve **disorganized speech** or perceptual disturbances rather than just social withdrawal. *Extrapyramidal side effects from risperidone requiring anticholinergic medication* - While **akinesia** or **bradykinesia** can occasionally mimic negative symptoms, there is no mention of **cogwheel rigidity**, tremors, or other motor signs of **parkinsonism**. - Anticholinergics treat motor stiffness but would not address the core deficits in **motivation** and **social engagement** described here. *Post-psychotic depression requiring psychological intervention* - **Post-psychotic depression** typically presents with prominent depressive cognitions occurring after the acute psychotic phase has resolved. - This patient’s presentation is dominated by **deficit syndrome** (primary negative symptoms) rather than the **affective distress** and sadness typical of post-psychotic depression.

Question 42: A 26-year-old woman with bipolar affective disorder type I presents to the emergency department with a 2-day history of productive cough, fever, and general malaise. She has been stable on lithium carbonate 800mg daily for 3 years. Examination reveals temperature 38.5°C, respiratory rate 24/min, and coarse crepitations in the right lung base. Chest X-ray confirms right lower lobe pneumonia. What is the most appropriate management of her lithium therapy?

A. Continue lithium at current dose and monitor levels in 1 week
B. Temporarily stop lithium until the infection resolves then restart
C. Continue lithium but check level immediately and monitor closely (Correct Answer)
D. Reduce lithium dose by half until clinical improvement occurs
E. Switch from lithium to sodium valproate during the acute illness

Explanation: ***Continue lithium but check level immediately and monitor closely*** - In the setting of an acute infection with fever, there is a significant risk of **lithium toxicity** due to potential **dehydration** and reduced renal clearance. - Immediate levels and **close monitoring** allow for early detection of rising levels while maintaining psychiatric stability in a patient who has been stable for 3 years. *Continue lithium at current dose and monitor levels in 1 week* - Waiting one week to monitor levels is dangerous because **acute physiological stress** and fever can rapidly alter renal function and lithium excretion. - A **delayed assessment** increases the risk of the patient developing severe neurological or cardiac signs of **lithium toxicity**. *Temporarily stop lithium until the infection resolves then restart* - Abruptly stopping lithium in a patient with **Bipolar I disorder** carries a high risk of **rapid relapse**, particularly into an acute manic episode. - Complete cessation should be reserved for those showing actual symptoms of toxicity or profound **renal impairment**, which is not yet confirmed here. *Reduce lithium dose by half until clinical improvement occurs* - Reducing the dose by half without checking the baseline level is **arbitrary** and may lead to **sub-therapeutic levels**, risking a mood breakthrough. - Clinical management should be guided by **serum lithium levels** and hydration status rather than preemptive blind dose reductions. *Switch from lithium to sodium valproate during the acute illness* - Switching agents during an acute physical illness adds unnecessary complexity and the risk of **drug-to-drug interactions** with new medications. - **Sodium valproate** requires dose titration and its own monitoring, making it an inappropriate choice for immediate management of an acute infection.

Question 43: A 42-year-old man with a 15-year history of schizophrenia is reviewed in the outpatient clinic. He has tried multiple antipsychotics with poor response and was commenced on clozapine 6 months ago. His current dose is 400mg daily. Recent bloods show: neutrophils 1.2 × 10⁹/L, WCC 3.5 × 10⁹/L, platelets 180 × 10⁹/L. He is asymptomatic with no signs of infection. What is the most appropriate management?

A. Stop clozapine immediately and never rechallenge
B. Continue clozapine but increase monitoring to twice weekly (Correct Answer)
C. Reduce clozapine dose to 200mg daily and recheck bloods in one week
D. Stop clozapine temporarily until neutrophils normalize then rechallenge
E. Continue clozapine at current dose with weekly monitoring

Explanation: ***Continue clozapine but increase monitoring to twice weekly*** - The patient's neutrophil count of **1.2 × 10⁹/L** falls into the **amber zone** (neutrophils between 1.0–1.5 × 10⁹/L) of the clozapine monitoring guidelines. - Management of an amber result requires **continuing clozapine** while increasing blood count frequency to **twice weekly** until the count stabilizes or improves. *Stop clozapine immediately and never rechallenge* - Immediate cessation and a permanent ban are only indicated for **red zone** results, specifically when neutrophils fall below **0.5 × 10⁹/L** (**agranulocytosis**). - Termination at this stage would prematurely stop a vital treatment for a **treatment-resistant** patient without clinical necessity. *Reduce clozapine dose to 200mg daily and recheck bloods in one week* - **Dose reduction** is not an appropriate response to hematological toxicity; the reaction is **idiosyncratic** rather than dose-dependent. - Monitoring once a week is insufficient for an **amber zone** reading, which requires more frequent surveillance to catch further drops early. *Stop clozapine temporarily until neutrophils normalize then rechallenge* - Temporary cessation is usually reserved for **red zone** results (neutrophils <1.0 × 10⁹/L) where the risk of infection outweighs the benefit of the drug. - In the **amber range**, the drug can be safely continued with **vigilant monitoring** unless the patient becomes symptomatic. *Continue clozapine at current dose with weekly monitoring* - **Weekly monitoring** is the standard protocol for patients during months 6–12 of therapy, but it must be intensified when results transition to the **amber range**. - Maintaining the status quo monitoring frequency fails to mitigate the risk of progressing to **severe neutropenia**.

Question 44: A 30-year-old woman with paranoid schizophrenia has been stable on aripiprazole 15mg daily for 18 months. She attends her community mental health team review reporting she wishes to start a family. She asks about the safety of continuing her current medication during pregnancy. What is the most appropriate advice regarding aripiprazole use in pregnancy?

A. Aripiprazole should be continued at the current dose as the benefits outweigh any potential risks (Correct Answer)
B. Aripiprazole is absolutely contraindicated and must be stopped before conception
C. Aripiprazole should be switched to haloperidol which has more safety data in pregnancy
D. Aripiprazole can be continued but the dose should be reduced by half during pregnancy
E. Aripiprazole should be stopped and she should remain medication-free throughout pregnancy

Explanation: ***Aripiprazole should be continued at the current dose as the benefits outweigh any potential risks*** - Maintaining **maternal mental health stability** is the priority, as **psychotic relapse** carries significant risks such as self-neglect, poor prenatal care, and potential harm to both mother and fetus. - Current clinical guidelines recommend that if a patient is stable on an **antipsychotic**, it should be continued during pregnancy because there is no evidence of aripiprazole being a major **teratogen**. *Aripiprazole is absolutely contraindicated and must be stopped before conception* - **Aripiprazole** is not categorized as absolutely contraindicated; medications are only stopped if the risk of **teratogenicity** specifically outweighs the severity of the mental illness. - Stopping treatment in a patient with **schizophrenia** carries a very high risk of relapse, which is often more dangerous than the medication itself. *Aripiprazole should be switched to haloperidol which has more safety data in pregnancy* - While **haloperidol** has been used longer, switching a patient who is currently **stable** on an effective medication increases the risk of breakthrough symptoms. - Guidelines generally advise against switching stable patients unless the current medication has a known high risk of **major malformations**, such as valproate. *Aripiprazole can be continued but the dose should be reduced by half during pregnancy* - Reducing the dose by half significantly increases the risk of **sub-therapeutic levels** and subsequent relapse of **paranoid schizophrenia**. - In fact, physiological changes in late pregnancy, such as increased **metabolism** and blood volume, may actually require a dose increase rather than a reduction. *Aripiprazole should be stopped and she should remain medication-free throughout pregnancy* - Remaining medication-free is rarely recommended for **severe mental illness** like schizophrenia due to the profound risk of acute relapse and psychiatric emergencies. - **Schizophrenia** is a chronic condition, and the postpartum period is a particularly **high-risk window** for severe psychotic episodes if medication is absent.

Question 45: A 39-year-old woman with bipolar affective disorder type I is admitted to hospital with severe mania. She is hostile, aggressive, refusing all oral medications, and poses significant risk to herself and others. She requires urgent treatment. She has no known drug allergies and normal renal function. Under the Mental Health Act, what is the most appropriate initial pharmacological management?

A. Intramuscular lorazepam 2mg as monotherapy
B. Intramuscular haloperidol 5mg combined with promethazine 50mg (Correct Answer)
C. Oral olanzapine orodispersible 10mg
D. Commence lithium carbonate via nasogastric tube
E. Intramuscular aripiprazole 9.75mg as monotherapy

Explanation: ***Intramuscular haloperidol 5mg combined with promethazine 50mg***- For an aggressive patient refusing oral medications, **rapid tranquillisation** with IM **haloperidol** combined with **promethazine** is the gold standard for immediate risk management.- **Promethazine** is crucial here as it provides additional sedation and reduces the risk of **extrapyramidal side effects** (EPS) associated with haloperidol.*Intramuscular lorazepam 2mg as monotherapy*- While **lorazepam** is effective for calming, it serves as a sedative and lacks the **antimanic efficacy** required to treat the underlying bipolar episode.- It is often used as a second-line or adjunct, but in severe mania with high risk, the **antipsychotic combination** (haloperidol/promethazine) is more potent for rapid behavioural control.*Oral olanzapine orodispersible 10mg*- **Orodispersible tablets** require a level of cooperation that a **hostile and aggressive** patient refusing all oral medications is unlikely to provide.- There is a high risk that the patient will **spit out** or hide the medication, making it inappropriate for an **urgent, high-risk** scenario where reliable administration is paramount.*Commence lithium carbonate via nasogastric tube*- **Lithium** has a slow onset of action (taking several days to weeks) and is entirely unsuitable for the **acute management** of severe behavioral disturbance requiring immediate control.- Attempting to pass a **nasogastric tube** in an aggressive, non-consenting patient is highly distressing, impractical, and medically **unjustified** for this indication in an acute emergency.*Intramuscular aripiprazole 9.75mg as monotherapy*- Although **aripiprazole** has an IM formulation, it is generally considered less effective than haloperidol for **rapid tranquillisation** in cases of extreme aggression and acute mania.- NICE guidelines (and clinical practice) favor the combination of an **antipsychotic with promethazine** over monotherapy to ensure both rapid behavioral control and minimize adverse effects.

Question 46: A 35-year-old man with schizophrenia treated with risperidone 6mg daily attends his GP reporting reduced libido and erectile dysfunction for 3 months. He denies low mood or other depressive symptoms. Physical examination is unremarkable. Blood tests show: prolactin 2850 mIU/L (normal 86-324), testosterone 8.5 nmol/L (normal 10-30), TSH 2.4 mU/L, glucose 5.2 mmol/L. His psychotic symptoms are well controlled. What is the most appropriate management?

A. Add cabergoline to reduce prolactin levels
B. Switch to aripiprazole (Correct Answer)
C. Add testosterone replacement therapy
D. Reassure and continue current medication
E. Reduce risperidone dose to 4mg daily

Explanation: ***Switch to aripiprazole*** - **Aripiprazole** is a **partial dopamine agonist**, meaning it can act as a functional antagonist in dopamine-rich areas but a functional agonist in dopamine-deficient areas, effectively lowering or normalizing **prolactin levels** by activating D2 receptors in the **tuberoinfundibular pathway**. - For psychiatrically stable patients with **symptomatic hyperprolactinaemia** (e.g., sexual dysfunction, low testosterone) due to antipsychotics, switching to a **prolactin-sparing antipsychotic** like aripiprazole is the recommended first-line management. *Add cabergoline to reduce prolactin levels* - **Cabergoline** is a potent **dopamine agonist** that can effectively reduce prolactin, but its use in schizophrenia is generally avoided due to the significant risk of **exacerbating psychotic symptoms** by increasing dopamine activity in the mesolimbic pathway. - Dopamine agonists like cabergoline are typically reserved for prolactinomas or specific cases where antipsychotic adjustments are not feasible, and only with careful specialist oversight. *Add testosterone replacement therapy* - While the patient has low testosterone, adding **testosterone replacement therapy** only addresses a symptom (**hypogonadism**) without treating the underlying cause, which is **hyperprolactinaemia** induced by risperidone. - Unaddressed hyperprolactinaemia can lead to other long-term complications beyond sexual dysfunction, such as decreased **bone mineral density** and galactorrhoea. *Reassure and continue current medication* - This approach is inappropriate given the patient's significantly elevated **prolactin (2850 mIU/L)** and symptomatic **hypogonadism** (reduced libido, erectile dysfunction). - Long-standing hyperprolactinaemia can result in adverse health consequences, including **osteoporosis**, cardiovascular risks, and persistent sexual dysfunction, necessitating active management. *Reduce risperidone dose to 4mg daily* - **Risperidone** is known for causing significant dose-dependent **hyperprolactinaemia** due to its potent dopamine D2 receptor blockade, even at lower doses. - Reducing the dose carries a considerable risk of **psychotic relapse** in a patient whose symptoms are currently well controlled, and a small dose reduction may not sufficiently resolve the hyperprolactinaemia or its symptoms.

Question 47: A 42-year-old woman with rapid cycling bipolar affective disorder has had 5 mood episodes in the past 12 months despite treatment with lithium carbonate 1200mg daily (lithium level 0.9 mmol/L). She has no other medical conditions. What is the most appropriate next step in pharmacological management according to current evidence?

A. Add lamotrigine to lithium
B. Switch from lithium to sodium valproate
C. Add quetiapine to lithium (Correct Answer)
D. Increase lithium dose to achieve level of 1.0-1.2 mmol/L
E. Switch from lithium to carbamazepine

Explanation: ***Add quetiapine to lithium*** - For **rapid cycling bipolar disorder** (≥4 episodes/year), combination therapy is often required when optimized monotherapy fails; lithium combined with **quetiapine** has strong evidence for efficacy. - Quetiapine provides a broad spectrum of stability by targeting both **manic and depressive poles**, making it a preferred adjunct in treatment-resistant rapid cycling cases. *Add lamotrigine to lithium* - While **lamotrigine** is effective for preventing **bipolar depression**, it lacks significant efficacy in treating or preventing **mania**, which is necessary for managing rapid cycling. - It requires a **slow titration** period to avoid Stevens-Johnson syndrome, which may not be ideal during active rapid cycling phases. *Switch from lithium to sodium valproate* - Switching to **valproate monotherapy** is unlikely to be more effective than optimized lithium (0.9 mmol/L) for a patient already experiencing frequent breakthroughs. - Current guidelines recommend **combination therapy** (adding an agent) rather than switching when a primary stabilizer is at a therapeutic level but insufficient. *Increase lithium dose to achieve level of 1.0-1.2 mmol/L* - This patient's level is already at **0.9 mmol/L**, which is within the therapeutic range (0.6–1.0 mmol/L) for maintenance; further increases significantly raise the risk of **toxicity**. - Increasing the dose is unlikely to control **rapid cycling** if the patient is already failing to respond at a high-normal therapeutic concentration. *Switch from lithium to carbamazepine* - **Carbamazepine** is generally considered a **third-line** option due to its complex drug-drug interactions via **CYP450 induction** and overall tolerability issues. - Evidence for its use as a solitary switch in rapid cycling is less robust compared to adding an **atypical antipsychotic** to an existing stabilizer.

Question 48: A 25-year-old man presents to the early intervention in psychosis service with a first episode of psychosis. He has responded well to aripiprazole 15mg daily over 8 weeks, with resolution of positive symptoms. He asks about the duration of treatment. According to evidence-based guidelines, what is the recommended minimum duration of antipsychotic treatment following a first episode of psychosis with good response?

A. 6 months after symptom resolution
B. 12 months after symptom resolution
C. 24 months after symptom resolution (Correct Answer)
D. 36 months after symptom resolution
E. Continue indefinitely

Explanation: ***24 months after symptom resolution***- Evidence-based guidelines (including **NICE**) recommend that antipsychotic treatment for a **first episode of psychosis** should continue for **1 to 2 years** (24 months) to minimize the high risk of relapse.- Maintaining treatment for **2 years** allows for brain recovery, consolidation of psychosocial interventions, and stable reintegration into the community.*6 months after symptom resolution*- Treatment for only 6 months is insufficient and is associated with exceptionally high **relapse rates** (up to 80%) following a first episode.- This duration is more commonly associated with the acute treatment phase rather than the **maintenance phase** required for long-term stability.*12 months after symptom resolution*- While 12 months is considered the absolute minimum by some, it carries a higher risk of **recurrent symptoms** compared to the standard 24-month recommendation.- Guidelines have shifted toward the **2-year mark** to ensure a more robust protection against the neurobiological and social consequences of a second episode.*36 months after symptom resolution*- While some patients with high-risk factors may benefit from 3 years of therapy, it is not the **standard minimum duration** for a first episode with a good response.- Extending treatment to 36 months is typically a clinical decision based on **residual symptoms** or frequent precursors to relapse rather than a universal guideline.*Continue indefinitely*- Indefinite treatment is generally reserved for patients with **multiple relapses**, a diagnosis of **chronic schizophrenia**, or significant risk of harm to self or others.- For a **first episode** patient who has responded well, the goal is often to eventually trial a slow, monitored **titration/discontinuation** after the maintenance period.

Question 49: A 48-year-old woman with a 20-year history of bipolar affective disorder type I has been maintained on lithium carbonate 1000mg daily. She has been stable for 18 months. Routine blood tests show: lithium level 0.8 mmol/L, creatinine 156 μmol/L (baseline 85 μmol/L), eGFR 35 mL/min (previously >60), urea 9.2 mmol/L. Urinalysis shows no proteinuria or haematuria. What is the most appropriate next step in management?

A. Continue lithium at current dose and recheck renal function in 3 months
B. Reduce lithium dose to 600mg daily and monitor levels
C. Stop lithium and switch to lamotrigine (Correct Answer)
D. Refer to nephrology and continue lithium pending review
E. Stop lithium immediately and switch to sodium valproate

Explanation: ***Stop lithium and switch to lamotrigine***- Lithium is **renally excreted**, and a significant decline in **eGFR below 45 mL/min** (CKD Stage 3b) necessitates discontinuation to prevent further **nephrotoxicity** and toxicity risk.- **Lamotrigine** is an appropriate alternative for bipolar prophylaxis, especially for preventing depressive episodes, and lacks the renal toxicity profile of lithium.*Continue lithium at current dose and recheck renal function in 3 months*- Continuing the current dose despite a significant rise in **creatinine** and drop in **eGFR** (35 mL/min) poses a high risk of **lithium toxicity** and further renal damage.- Guidelines mandate active intervention when renal function shows such a marked decline from **baseline (85 μmol/L to 156 μmol/L)**, not just continued monitoring.*Reduce lithium dose to 600mg daily and monitor levels*- While reducing the dose might lower serum levels, it does not address the underlying **chronic kidney disease** progression caused by long-term lithium use.- In patients with a rapid and significant decline in **estimated glomerular filtration rate (eGFR)**, stopping the offending agent is prioritized over dose adjustment.*Refer to nephrology and continue lithium pending review*- While a **nephrology referral** is indicated for investigating renal impairment, continuing the lithium in the interim is unsafe given the severe decline to an **eGFR of 35 mL/min**.- Delaying the cessation of lithium increases the risk of irreversible **interstitial fibrosis** and permanent renal damage, and lithium should be stopped immediately.*Stop lithium immediately and switch to sodium valproate*- **Sodium valproate** is an alternative, but it carries significant risks regarding **teratogenicity** and metabolic side effects compared to lamotrigine.- Although stopping lithium is correct, **lamotrigine** is often preferred for long-term maintenance in bipolar I, especially if the patient is stable and of childbearing age.

Question 50: A 33-year-old man with paranoid schizophrenia has been taking clozapine 450mg daily for 8 months. He presents to the emergency department with sudden onset of severe central chest pain and dyspnoea. ECG shows widespread ST elevation. Troponin T is significantly elevated at 2500 ng/L (normal <14). Echocardiography reveals global hypokinesia with reduced ejection fraction of 35%. Coronary angiography shows no significant coronary artery disease. What is the most likely diagnosis?

A. Pulmonary embolism
B. Clozapine-induced myocarditis (Correct Answer)
C. Acute myocardial infarction
D. Pericarditis
E. Anxiety-related chest pain

Explanation: ***Clozapine-induced myocarditis*** - The patient's presentation with sudden severe chest pain, dyspnoea, widespread ST elevation, significantly **elevated troponin T**, **global hypokinesia**, and reduced **ejection fraction (35%)** despite **normal coronary arteries** is highly characteristic of clozapine-induced myocarditis, a serious adverse effect. - This rare but life-threatening complication, though more common in the first few months of treatment, can occur later and necessitates immediate **cessation of clozapine**. *Pulmonary embolism* - While causing chest pain and dyspnoea, pulmonary embolism typically presents with **pleuritic chest pain** and characteristic ECG changes like **S1Q3T3** or right heart strain, not widespread ST elevation and global hypokinesia. - A massive pulmonary embolism can impact cardiac function, but it wouldn't directly cause such significant global myocardial injury and massive troponin elevation without obstructive coronary disease. *Acute myocardial infarction* - Although presenting with chest pain, ST elevation, and elevated troponin, the **normal coronary angiography** conclusively rules out **obstructive coronary artery disease** as the cause of an acute myocardial infarction. - The **global hypokinesia** is more indicative of diffuse myocardial inflammation (myocarditis) than the regional wall motion abnormalities expected with an infarction. *Pericarditis* - Pericarditis can cause widespread ST elevation and chest pain, but it rarely leads to such a dramatic **reduction in ejection fraction** or massive **troponin elevation** unless there is significant myocardial involvement (myopericarditis). - The combination of **severe myocardial dysfunction** and troponin elevation in a patient on clozapine points more specifically to drug-induced myocarditis. *Anxiety-related chest pain* - This diagnosis is inconsistent with the objective findings of widespread **ST elevation**, critically **elevated troponin T** levels, and severe **global hypokinesia** with a reduced ejection fraction. - Anxiety does not cause these significant structural and biochemical abnormalities of the heart.

Question 51: According to current NICE guidelines, what is the recommended first-line pharmacological treatment for acute mania in bipolar affective disorder in a patient not currently taking prophylactic medication?

A. Lithium carbonate monotherapy
B. Sodium valproate monotherapy
C. Haloperidol, olanzapine, quetiapine, or risperidone (Correct Answer)
D. Lamotrigine monotherapy
E. Carbamazepine monotherapy

Explanation: ***Haloperidol, olanzapine, quetiapine, or risperidone*** - According to **NICE guidelines (CG185)**, these **antipsychotics** are the first-line pharmacological treatment for **acute mania** due to their **rapid onset of action** in controlling severe symptoms. - The choice of agent depends on the patient's **previous response**, side effect profile, and clinical preference. *Lithium carbonate monotherapy* - While highly effective for **long-term prophylaxis**, lithium has a **slower onset of action** compared to antipsychotics for acute stabilization. - It is usually considered if the patient is already taking it or after first-line antipsychotics have proven ineffective. *Sodium valproate monotherapy* - NICE recommends this as a **second-line** option rather than first-line for acute mania episodes. - It must be avoided in **women of childbearing potential** due to significant risks of **teratogenicity** and developmental disorders. *Lamotrigine monotherapy* - This medication is **not effective** for the treatment of **acute mania** episodes. - Its primary role is in the prevention of **bipolar depression** and long-term maintenance therapy. *Carbamazepine monotherapy* - This is generally considered a **third-line** option for acute mania when other mood stabilizers or antipsychotics have failed. - Its use is complicated by significant **drug-drug interactions** and the induction of cytochrome P450 enzymes.

Question 52: A 27-year-old woman with bipolar affective disorder type I has been stable on lithium carbonate 800mg daily for 2 years. She attends for routine monitoring. Blood tests show: lithium level 0.7 mmol/L, TSH 8.5 mU/L (normal 0.5-5.0), free T4 11 pmol/L (normal 10-20), creatinine 95 μmol/L, eGFR >90 mL/min. She reports feeling more tired than usual but denies other symptoms. What is the most appropriate management?

A. Stop lithium and switch to sodium valproate
B. Continue lithium and start levothyroxine replacement (Correct Answer)
C. Reduce lithium dose to 600mg daily
D. Continue lithium and monitor thyroid function in 3 months
E. Continue lithium and refer to endocrinology

Explanation: ***Continue lithium and start levothyroxine replacement*** - The patient has **subclinical hypothyroidism** (elevated **TSH**, normal **fT4**) with symptoms of fatigue, which is a common side effect of **lithium therapy**. - Since the patient is psychiatrically stable on **lithium**, the appropriate management is to continue the mood stabilizer and treat the thyroid dysfunction with **levothyroxine replacement** to alleviate symptoms and prevent progression. *Stop lithium and switch to sodium valproate* - Abruptly stopping **lithium** in a stable patient with bipolar disorder carries a high risk of **psychiatric relapse**, including manic or depressive episodes. - **Sodium valproate** has significant **teratogenic risks** and is generally avoided in women of **childbearing potential** unless absolutely necessary and with strict precautions. *Reduce lithium dose to 600mg daily* - Reducing the **lithium dose** may drop the serum concentration below the **therapeutic range** (0.6–1.0 mmol/L), risking a loss of mood control and psychiatric instability. - Dose reduction is typically not an effective strategy to reverse **lithium-induced hypothyroidism** once established, and it doesn't address the underlying thyroid deficiency. *Continue lithium and monitor thyroid function in 3 months* - The patient is **symptomatic** (fatigue) and has clear biochemical evidence of **subclinical hypothyroidism**; thus, active treatment is warranted rather than just monitoring. - **Lithium-induced thyroid dysfunction** is unlikely to resolve spontaneously while the patient remains on the medication and often requires replacement therapy. *Continue lithium and refer to endocrinology* - **Lithium-induced hypothyroidism** is a common and well-understood side effect that can typically be managed by the treating psychiatrist or general practitioner. - Referral to **endocrinology** is usually reserved for more complex cases, unclear diagnoses, or thyroid dysfunction refractory to standard **levothyroxine replacement**.

Question 53: A 38-year-old man with paranoid schizophrenia has been taking olanzapine 20mg daily for 5 years. He develops increasing social withdrawal, reduced self-care, and loss of motivation over 8 months. Mental state examination reveals flat affect, poverty of speech, and lack of volition. There are no positive psychotic symptoms. What is the most appropriate medication adjustment?

A. Increase olanzapine to 30mg daily
B. Add an SSRI antidepressant to current regimen
C. Switch to amisulpride monotherapy
D. Add aripiprazole to current olanzapine (Correct Answer)
E. Switch to clozapine monotherapy

Explanation: ***Add aripiprazole to current olanzapine***- The patient exhibits core **negative symptoms** (avolition, flat affect, poverty of speech) which are effectively targeted by the **partial dopamine agonism** of aripiprazole.- Adding aripiprazole as an **augmentation strategy** can improve negative symptom scores and social functioning without losing control of positive symptoms.*Increase olanzapine to 30mg daily*- Increasing the dose of a **second-generation antipsychotic** typically addresses **positive symptoms** rather than the deficit syndrome observed here.- Higher doses may worsen **secondary negative symptoms** due to increased **sedation** and potentially greater dopamine receptor blockade.*Add an SSRI antidepressant to current regimen*- While useful for co-morbid **depression**, SSRIs are not considered first-line treatments for the **primary negative symptoms** of schizophrenia.- The clinical picture describes typical **schizophrenia-specific deficits** (poverty of speech, lack of volition) rather than a clear depressive episode.*Switch to amisulpride monotherapy*- Although **low-dose amisulpride** has evidence for treating negative symptoms, a complete switch risks the recurrence of **positive psychotic symptoms**.- Managing chronic stable patients usually involves **augmentation** before a complete switch if a specific symptom cluster emerges late in the course.*Switch to clozapine monotherapy*- Clozapine is reserved for **treatment-resistant schizophrenia**, defined as failure of two different antipsychotics at adequate doses.- While it can help negative symptoms, its side effect profile (e.g., **agranulocytosis**, **seizures**) makes it inappropriate as a first step for managing emerging social withdrawal.

Question 54: A 41-year-old woman with schizoaffective disorder has been maintained on depot paliperidone palmitate 150mg monthly for 3 years with good symptom control. She now presents requesting to try for pregnancy. Her mental state remains stable with no active psychotic symptoms. She has previously relapsed rapidly when antipsychotic medication was discontinued. What is the most appropriate advice regarding her medication management?

A. Continue paliperidone depot throughout pregnancy as benefits outweigh risks
B. Stop paliperidone immediately and remain unmedicated during pregnancy
C. Switch to haloperidol oral medication before conception
D. Switch to quetiapine oral medication before conception (Correct Answer)
E. Continue paliperidone until pregnancy confirmed, then stop immediately

Explanation: ***Switch to quetiapine oral medication before conception*** - **Quetiapine** is generally considered a safer option for use during pregnancy among antipsychotics, with more established **safety data** and a relatively lower risk of **hyperprolactinemia** compared to paliperidone. - Switching to an **oral medication** allows for greater flexibility in dose adjustment and the ability to discontinue the medication promptly if adverse effects or complications arise during pregnancy, which is not feasible with a **long-acting injectable** (depot). *Continue paliperidone depot throughout pregnancy as benefits outweigh risks* - **Paliperidone depot** has limited human pregnancy data, and its **long-acting nature** means that exposure to the fetus would continue for an extended period, even if complications arose and discontinuation was desired. - The **irreversibility** and prolonged systemic presence of a depot injection make it less ideal for managing the dynamic physiological changes and potential adverse events during pregnancy where immediate therapeutic adjustments might be necessary. *Stop paliperidone immediately and remain unmedicated during pregnancy* - The patient has a clear history of **rapid relapse** upon discontinuation of antipsychotic medication, indicating a high risk of symptom exacerbation if unmedicated. - A psychiatric relapse during pregnancy poses significant risks to both maternal and fetal health, including poor **antenatal care**, self-harm, inadequate nutrition, and potential need for urgent hospitalization, outweighing the risks of medication. *Switch to haloperidol oral medication before conception* - While **haloperidol** has been used in pregnancy for many years, it is a **first-generation antipsychotic** associated with a higher risk of **extrapyramidal side effects** in the mother and potential **neonatal withdrawal symptoms** or neuromuscular disturbances. - **Second-generation antipsychotics** like quetiapine are often preferred due to a generally better **tolerability profile** and lower rates of motor side effects, making them a more suitable choice for long-term management, especially during pregnancy. *Continue paliperidone until pregnancy confirmed, then stop immediately* - Discontinuing an antipsychotic abruptly, especially one like paliperidone with a history of **rapid relapse** upon cessation, significantly increases the risk of a **psychotic episode** during early pregnancy. - Given that paliperidone is a **depot injection**, stopping further injections upon confirmed pregnancy would still result in prolonged drug exposure due to its long half-life, negating the intention of immediate cessation.

Question 55: A 29-year-old man with bipolar affective disorder type I presents to the emergency department with a 2-day history of increasing confusion, fever (39.2°C), muscle rigidity, and profuse sweating. He was started on haloperidol 10mg twice daily 5 days ago for an acute manic episode. Observations show: BP 165/95 mmHg, HR 115 bpm, RR 22/min. Blood tests reveal: CK 8500 U/L, WCC 15.2 × 10⁹/L, creatinine 145 μmol/L. What is the most likely diagnosis?

A. Serotonin syndrome
B. Malignant hyperthermia
C. Neuroleptic malignant syndrome (Correct Answer)
D. Acute dystonic reaction
E. Sepsis secondary to pneumonia

Explanation: ***Neuroleptic malignant syndrome***- Characterized by the tetrad of **fever**, **lead-pipe muscle rigidity**, **autonomic instability** (tachycardia, hypertension, sweating), and **altered mental status** following the start of high-potency antipsychotics like **haloperidol**.- Laboratory findings typically show significantly **elevated Creatine Kinase (CK)**, **leukocytosis**, and potential **acute kidney injury** due to rhabdomyolysis.*Serotonin syndrome*- This condition is usually triggered by **selective serotonin reuptake inhibitors (SSRIs)** and is characterized by **hyperreflexia** and **myoclonus**, rather than the rigidity seen in this case.- While it shares some autonomic features, the presentation lacks the extreme elevation of **CK levels** and the specific association with **dopamine antagonists**.*Malignant hyperthermia*- This is a rare, life-threatening reaction that occurs specifically in response to **volatile anesthetic gases** (e.g., halothane) or **succinylcholine**.- The clinical timeline does not fit this patient, as it typically presents in the **operating room** or immediate post-operative period.*Acute dystonic reaction*- Usually presents with sudden, involuntary muscle contractions such as **torticollis** or **oculogyric crisis** shortly after starting an antipsychotic.- It lacks systemic symptoms like **high grade fever**, **sweating**, and severe **lab abnormalities** seen in this presentation.*Sepsis secondary to pneumonia*- While sepsis causes **fever**, **tachycardia**, and **confusion**, it does not explain the profound **generalized muscle rigidity** or the massive **CK elevation**.- The recent initiation of **haloperidol** acts as a specific red flag for a drug-induced emergency rather than a primary infectious process.

Question 56: A 32-year-old woman with treatment-resistant paranoid schizophrenia has been taking clozapine 500mg daily for 14 months with excellent symptom control. She attends for routine monitoring. Her full blood count shows: Hb 132 g/L, WCC 3.2 × 10⁹/L, neutrophils 1.8 × 10⁹/L, platelets 245 × 10⁹/L. She is asymptomatic with no signs of infection. What is the most appropriate management?

A. Stop clozapine immediately and arrange urgent haematology review
B. Continue clozapine and repeat FBC in 1 week
C. Reduce clozapine dose to 300mg daily and check FBC in 3 days
D. Continue clozapine at current dose and repeat FBC in 3 days (Correct Answer)
E. Stop clozapine permanently and switch to olanzapine

Explanation: ***Continue clozapine at current dose and repeat FBC in 3 days***- This patient's **absolute neutrophil count (ANC)** is 1.8 × 10⁹/L, which falls into the **Amber light code** range (1.5–2.0 × 10⁹/L) under standard clozapine monitoring guidelines.- Management of an Amber result involves continuing the medication at the same dose while increasing monitoring frequency to **twice-weekly** (every 3 days) until the count stabilizes or improves.*Stop clozapine immediately and arrange urgent haematology review*- Immediate cessation and hematology review are mandatory for a **Red light code**, defined as an ANC <1.5 × 10⁹/L.- Stopping the drug prematurely risks relapse of **treatment-resistant schizophrenia** when the patient is not yet in the critical danger zone.*Continue clozapine and repeat FBC in 1 week*- A 1-week interval is appropriate for standard "Green" zone monitoring after the first year, but it is insufficient for an **Amber result**.- More frequent assessment is required to detect early progression to **agranulocytosis**, which can be life-threatening.*Reduce clozapine dose to 300mg daily and check FBC in 3 days*- Clozapine-induced blood dyscrasias are generally **idiosyncratic** rather than dose-dependent, so dose reduction does not mitigate the hematological risk.- Reducing the dose unnecessarily may lead to **loss of symptom control** and clinical destabilization for the patient.*Stop clozapine permanently and switch to olanzapine*- Permanent discontinuation is reserved for cases of severe **neutropenia or agranulocytosis** (ANC <1.5 × 10⁹/L or WCC <3.0 × 10⁹/L).- Since the patient is currently **asymptomatic** and in the Amber zone, the clinical priority is to preserve the use of this high-efficacy antipsychotic through strictly increased monitoring.

Question 57: A 36-year-old man with a 10-year history of bipolar affective disorder type I presents to his psychiatrist. He has had three previous manic episodes requiring hospitalisation. For the past 8 months, he has been stable on lithium carbonate 1200mg daily. His most recent lithium level was 0.9 mmol/L (therapeutic range 0.6-1.0). He now presents with a 4-day history of persistent vomiting and diarrhoea due to gastroenteritis. What is the most appropriate immediate management?

A. Continue lithium at current dose and check levels in one week
B. Reduce lithium dose by 50% until gastroenteritis resolves
C. Temporarily stop lithium and check urgent lithium level (Correct Answer)
D. Switch to sodium valproate immediately
E. Continue lithium and prescribe oral rehydration solution

Explanation: ***Temporarily stop lithium and check urgent lithium level*** - Dehydration from **persistent vomiting and diarrhoea** increases the risk of **lithium toxicity** as the kidneys prioritize sodium reabsorption, leading to decreased renal clearance of lithium. - **Lithium** has a **narrow therapeutic index**, and since the patient's level is already at the high end (0.9 mmol/L), the drug should be withheld until the acute illness resolves and levels are reassessed. *Continue lithium at current dose and check levels in one week* - This approach is dangerous because continued dosing during dehydration can lead to **acute-on-chronic lithium toxicity**, which is life-threatening. - Waiting one week for levels is inappropriate as **renal function** and lithium concentration can change drastically within hours in the setting of gastroenteritis. *Reduce lithium dose by 50% until gastroenteritis resolves* - Even a reduced dose can lead to accumulation and toxicity when the patient is in a **hypovolemic state** with impaired excretion. - Clinical guidelines recommend **temporary cessation** during such metabolic disturbances rather than dose adjustment. *Switch to sodium valproate immediately* - This is not the immediate priority; the primary concern is managing the potential for **lithium toxicity** and stabilizing the patient's hydration. - Starting a new **mood stabilizer** while the patient is acutely unwell with gastroenteritis could confound the clinical picture and introduce new side effects. *Continue lithium and prescribe oral rehydration solution* - While rehydration is important, simply adding fluids is insufficient because the patient's **gastrointestinal losses** might still exceed intake, maintaining a toxic state. - **Lithium** must be stopped to eliminate the source of toxicity while the underlying cause of **dehydration** is being treated.

Question 58: A 45-year-old woman with schizophrenia presents to the community mental health team. She has been taking quetiapine 750mg daily for 18 months with good symptom control. Blood tests reveal: HbA1c 58 mmol/mol, fasting glucose 7.8 mmol/L, total cholesterol 6.2 mmol/L, triglycerides 3.4 mmol/L. Her BMI has increased from 24 to 31 kg/m² since starting quetiapine. She has no cardiovascular symptoms. What is the most appropriate next step in management?

A. Continue quetiapine and refer to dietitian for lifestyle modification
B. Switch to aripiprazole and refer for metabolic monitoring (Correct Answer)
C. Add metformin to current regimen and continue quetiapine
D. Reduce quetiapine dose to 400mg daily
E. Stop quetiapine immediately and start haloperidol

Explanation: ***Switch to aripiprazole and refer for metabolic monitoring***- The patient presents with established **metabolic syndrome**, including elevated **HbA1c (58 mmol/mol)**, **dyslipidemia**, and significant **weight gain (BMI 24 to 31 kg/m²)**, all attributable to long-term quetiapine use, a **second-generation antipsychotic (SGA)** known for its high metabolic risk. - Switching to an SGA with a **lower metabolic risk profile**, such as **aripiprazole**, which is considered **metabolically neutral**, is the most appropriate intervention to mitigate further metabolic complications while maintaining psychiatric stability. *Continue quetiapine and refer to dietitian for lifestyle modification*- Relying solely on **lifestyle modification** is insufficient given the severity of the established **metabolic abnormalities** (diabetes/pre-diabetes, obesity) while continuing the primary causative agent, **quetiapine**.- This approach does not address the underlying pharmacological cause and risks further progression of **diabetes** and **cardiovascular disease** despite potential lifestyle changes. *Add metformin to current regimen and continue quetiapine*- While **metformin** can aid in managing antipsychotic-induced weight gain and hyperglycemia, it represents an additional **pill burden** and does not remove the primary offending agent, quetiapine.- A **medication switch** to a metabolically safer antipsychotic is generally preferred over adding more drugs when psychiatric symptoms are stable, addressing the root cause more effectively. *Reduce quetiapine dose to 400mg daily*- Reducing the quetiapine dose carries a significant risk of **psychotic relapse** as the patient is currently stable at 750mg daily, and the lower dose may be sub-therapeutic.- Dose reduction is unlikely to reverse the already established and severe **metabolic syndrome** and significant weight gain, which typically requires a change in medication. *Stop quetiapine immediately and start haloperidol*- **Abrupt cessation** of quetiapine can precipitate severe **withdrawal symptoms** and a high risk of **psychotic relapse**, necessitating a gradual **cross-taper** when switching antipsychotics.- **Haloperidol**, a first-generation antipsychotic, has a high propensity for **extrapyramidal symptoms (EPS)** and **tardive dyskinesia**, making it a less favorable choice compared to newer, metabolically neutral SGAs like aripiprazole.

Question 59: A 33-year-old woman with schizophrenia treated with risperidone 6mg daily for 2 years presents to her GP. She has gained 18kg in weight (BMI now 34 kg/m²) and her most recent blood tests show: fasting glucose 6.9 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L. She is psychiatrically stable with good symptom control. What is the most appropriate management of her metabolic complications?

A. Switch from risperidone to aripiprazole to reduce metabolic effects while maintaining symptom control (Correct Answer)
B. Continue risperidone and start metformin 500mg twice daily for prediabetes
C. Continue risperidone and start atorvastatin 20mg daily for dyslipidaemia
D. Switch from risperidone to ziprasidone which has lower metabolic risk
E. Reduce risperidone dose to 4mg daily to minimize metabolic side effects

Explanation: ***Switch from risperidone to aripiprazole to reduce metabolic effects while maintaining symptom control*** - **Risperidone** is associated with significant **metabolic side effects** like weight gain, dyslipidaemia, and impaired glucose tolerance, all present in this patient. - **Aripiprazole** has a significantly more favorable **metabolic profile** and is a suitable alternative for a psychiatrically stable patient, addressing the root cause of her metabolic syndrome. *Continue risperidone and start metformin 500mg twice daily for prediabetes* - While **metformin** can aid in glucose control and weight management, it treats the symptoms rather than the underlying **antipsychotic-induced** metabolic burden. - The preferred approach is to change the causative agent, if possible, before adding additional medications for side effect management. *Continue risperidone and start atorvastatin 20mg daily for dyslipidaemia* - **Atorvastatin** will address the dyslipidaemia, but it will not resolve the **weight gain** or **prediabetes** caused by risperidone. - This option increases **polypharmacy** without tackling the primary driver of her overall metabolic complications and cardiovascular risk. *Switch from risperidone to ziprasidone which has lower metabolic risk* - While **ziprasidone** has a low metabolic risk, it often requires **ECG monitoring** for **QTc prolongation**, which can limit its practical use. - **Aripiprazole** is generally considered a first-line option among agents with low metabolic risk due to its broader safety profile and good tolerability. *Reduce risperidone dose to 4mg daily to minimize metabolic side effects* - **Dose reduction** may not be sufficient to reverse or adequately manage established **metabolic syndrome** and carries a risk of **psychiatric relapse**. - The metabolic effects of second-generation antipsychotics are often not solely dose-dependent, making a change to a different antipsychotic a more effective strategy.

Question 60: A 48-year-old man with bipolar affective disorder type I is admitted with acute mania. He is verbally aggressive and physically threatening. He has not slept for 4 days and refuses all oral medication. Observations show: HR 110 bpm, BP 165/95 mmHg, temperature 37.4°C. He has no significant physical health problems. What is the most appropriate pharmacological management for rapid tranquilization?

A. Intramuscular haloperidol 5mg plus promethazine 50mg (Correct Answer)
B. Intramuscular lorazepam 2mg alone
C. Intravenous diazepam 10mg
D. Intramuscular olanzapine 10mg plus lorazepam 2mg
E. Intramuscular zuclopenthixol acetate 100mg

Explanation: ***Intramuscular haloperidol 5mg plus promethazine 50mg***- This combination is a recommended first-line option for **rapid tranquilization** in acute agitation, especially when oral medication is refused, due to its effectiveness in controlling aggression and agitation in **acute mania**.- **Promethazine** provides additional sedation and helps to mitigate the **extrapyramidal side effects** (EPS) associated with **haloperidol**, offering a safer profile compared to combining antipsychotics with benzodiazepines.*Intramuscular lorazepam 2mg alone*- While **lorazepam** can provide sedation, it may not be sufficiently effective as **monotherapy** for the profound aggression and agitation seen in severe **acute mania**.- Benzodiazepines alone carry a higher risk of **respiratory depression** when used in high-arousal states compared to an antipsychotic-antihistamine combination.*Intravenous diazepam 10mg*- **Intravenous administration** for rapid tranquilization is generally avoided due to the increased risk of sudden **cardiorespiratory arrest** and the practical difficulties of safe delivery in a physically aggressive patient.- **Diazepam** has a longer half-life and active metabolites, making it less ideal for immediate, controlled behavioral management in a psychiatric emergency compared to shorter-acting agents.*Intramuscular olanzapine 10mg plus lorazepam 2mg*- Combining **intramuscular olanzapine** with **parenteral benzodiazepines** is strictly contraindicated due to a significantly increased risk of severe **cardiorespiratory depression** and profound sedation.- If both are considered necessary, they must be administered with a minimum of **one hour** interval between doses to minimize severe adverse effects.*Intramuscular zuclopenthixol acetate 100mg*- **Zuclopenthixol acetate** (Acuphase) has a **delayed onset of action** (full effect within 2-3 hours) and a prolonged duration (2-3 days), making it unsuitable for **rapid tranquilization** where immediate control is needed.- It is generally reserved for patients with a **known positive response** to the drug and should not be used in **antipsychotic-naïve** individuals or when rapid reversibility is a concern.

Question 61: A 36-year-old man with schizophrenia has been taking clozapine 450mg daily for 9 months with good symptom control. He now presents with constipation for 10 days, abdominal distension, vomiting, and absent bowel sounds. Abdominal X-ray shows dilated loops of bowel. What is the most likely underlying mechanism of his presentation?

A. Mechanical obstruction from adhesions secondary to clozapine-induced inflammation
B. Anticholinergic effects causing reduced bowel motility and paralytic ileus (Correct Answer)
C. Direct toxic effect of clozapine on enteric smooth muscle cells
D. Clozapine-induced mesenteric ischaemia causing bowel infarction
E. Bacterial overgrowth syndrome from clozapine-altered gut flora

Explanation: ***Anticholinergic effects causing reduced bowel motility and paralytic ileus*** - **Clozapine** possesses potent **antimuscarinic (anticholinergic)** properties that significantly inhibit the enteric nervous system, leading to reduced peristalsis and gastrointestinal hypomotility. - The clinical triad of **absent bowel sounds**, abdominal distension, and **dilated bowel loops** on imaging characterizes **paralytic ileus**, a potentially life-threatening complication of clozapine therapy. *Mechanical obstruction from adhesions secondary to clozapine-induced inflammation* - This mechanism involves physical barriers like scar tissue; however, clozapine causes a **functional obstruction** (ileus) rather than a mechanical one. - Adhesions typically follow **abdominal surgery** or chronic inflammatory conditions, which are not described in this medication-induced scenario. *Direct toxic effect of clozapine on enteric smooth muscle cells* - While clozapine affects the gut, it does so primarily by blocking **muscarinic receptors** rather than via direct **cytotoxic damage** to smooth muscle histology. - The dysfunction is **pharmacological blockade** of neurotransmission, not a drug-induced myopathy or cellular necrosis. *Clozapine-induced mesenteric ischaemia causing bowel infarction* - Although severe untreated ileus can eventually lead to **intestinal ischemia** due to high intraluminal pressure, it is a secondary consequence rather than the primary mechanism. - **Mesenteric ischemia** usually presents with pain out of proportion to exam findings and risk factors like **atrial fibrillation**, rather than chronic drug-induced constipation. *Bacterial overgrowth syndrome from clozapine-altered gut flora* - While stasis can lead to **Small Intestinal Bacterial Overgrowth (SIBO)**, it does not explain the acute clinical presentation of **bowel obstruction** and absent sounds. - The primary driver of the physical findings is the **neurogenic failure** of the bowel to move contents, not a primary change in the **microbiome profile**.

Question 62: A 43-year-old woman with rapid-cycling bipolar affective disorder has had 6 mood episodes in the past 12 months despite lithium monotherapy at therapeutic levels. She has a history of polycystic ovary syndrome. Which medication would be most appropriate to add or switch to for optimizing her mood stabilization?

A. Lamotrigine as add-on therapy to lithium (Correct Answer)
B. Sodium valproate as replacement for lithium
C. Carbamazepine as add-on therapy to lithium
D. Olanzapine as add-on therapy to lithium
E. High-dose lithium aiming for levels of 1.2 mmol/L

Explanation: ***Lamotrigine as add-on therapy to lithium*** - **Lamotrigine** is highly effective for the prevention of **depressive episodes** in **rapid-cycling bipolar disorder** and is a suitable add-on when lithium monotherapy fails. - It has a **favorable metabolic profile** and does not exacerbate **polycystic ovary syndrome (PCOS)** symptoms, unlike other mood stabilizers. *Sodium valproate as replacement for lithium* - **Sodium valproate** carries a significant **teratogenic risk** and is contraindicated or strongly avoided in women of childbearing potential, necessitating a Pregnancy Prevention Programme. - It can cause **weight gain** and worsen metabolic and endocrine disturbances associated with **PCOS**, such as insulin resistance. *Carbamazepine as add-on therapy to lithium* - **Carbamazepine** is a potent **enzyme inducer**, leading to numerous **drug-drug interactions** and requiring careful monitoring of drug levels, complicating long-term management. - While effective, it is generally considered a second-line agent for **rapid cycling** due to its side effect profile and interaction potential compared to lamotrigine. *Olanzapine as add-on therapy to lithium* - **Olanzapine** is associated with significant **metabolic side effects**, including substantial **weight gain** and impaired glucose tolerance, which would negatively impact the patient's existing **PCOS**. - While effective for acute mania, its long-term use for maintenance, especially in patients with metabolic concerns, is often limited by these adverse effects. *High-dose lithium aiming for levels of 1.2 mmol/L* - Aiming for a **lithium level of 1.2 mmol/L** significantly increases the risk of **lithium toxicity**, including renal impairment, tremors, and gastrointestinal distress, without necessarily increasing efficacy for rapid cycling. - When a patient with **rapid cycling** fails therapeutic lithium monotherapy, adding a second mood stabilizer is generally more effective and safer than escalating lithium to potentially toxic levels.

Question 63: A 27-year-old man with schizophrenia has persistent auditory hallucinations despite trials of risperidone, olanzapine, and quetiapine at therapeutic doses for adequate durations. He has poor insight and refuses depot medication. His family reports good compliance with witnessed medication taking. Before starting clozapine, which investigation result would be an absolute contraindication?

A. Prolonged QTc interval of 485 milliseconds on ECG
B. Neutrophil count of 1.8 × 10⁹/L on baseline blood test (Correct Answer)
C. History of epileptic seizure 5 years ago, now seizure-free without medication
D. Mild left ventricular systolic dysfunction with ejection fraction of 48%
E. BMI of 32 kg/m² with impaired fasting glucose of 6.5 mmol/L

Explanation: ***Neutrophil count of 1.8 × 10⁹/L on baseline blood test*** - A baseline **Absolute Neutrophil Count (ANC)** below 2.0 × 10⁹/L (or 1.5 × 10⁹/L depending on specific local guidelines like the FDA) is an **absolute contraindication** to starting clozapine. - This restriction is vital to mitigate the risk of **life-threatening agranulocytosis**, which occurs in approximately 1-2% of patients treated with clozapine. *Prolonged QTc interval of 485 milliseconds on ECG* - While clozapine can cause **QT prolongation**, a value of 485 ms is considered a **relative contraindication** rather than an absolute one. - Initiation would require specialist **cardiac consultation** and frequent ECG monitoring rather than an immediate disqualification. *History of epileptic seizure 5 years ago, now seizure-free without medication* - Clozapine is known to **lower the seizure threshold** in a dose-dependent manner, but a remote history of seizures is not an absolute barrier. - Treatment can often proceed with **prophylactic anticonvulsants** or cautious dose titration and monitoring. *Mild left ventricular systolic dysfunction with ejection fraction of 48%* - This represents **relative caution**; although clozapine is associated with **myocarditis** and **cardiomyopathy**, mild dysfunction does not strictly prohibit use if the clinical need is high. - Absolute contraindications are reserved for **severe cardiac disease** or clinically unstable heart failure. *BMI of 32 kg/m² with impaired fasting glucose of 6.5 mmol/L* - These are markers of **metabolic syndrome**, a common side effect of second-generation antipsychotics, requiring strictly managed **metabolic monitoring**. - While they increase the risk of **type 2 diabetes**, they do not prevent clozapine use for treatment-resistant schizophrenia.

Question 64: A 31-year-old woman with paranoid schizophrenia presents with sudden onset of fever (39.2°C), muscle rigidity, and reduced consciousness. She was started on haloperidol 10mg twice daily 5 days ago. Examination shows lead-pipe rigidity and profuse sweating. Blood tests show: WBC 16.2 × 10⁹/L, CK 8500 U/L, creatinine 165 μmol/L. Which pathophysiological mechanism best explains this clinical syndrome?

A. Excessive dopaminergic stimulation in the nigrostriatal pathway
B. Severe dopamine receptor blockade in the hypothalamus and striatum (Correct Answer)
C. Serotonin syndrome from excessive serotonergic activity
D. Cholinergic excess from acetylcholine accumulation
E. GABA receptor antagonism in the central nervous system

Explanation: ***Severe dopamine receptor blockade in the hypothalamus and striatum***- This patient presents with **Neuroleptic Malignant Syndrome (NMS)**, which is driven by massive **D2 receptor antagonism** following high-potency antipsychotic use (e.g., haloperidol).- Blockade in the **hypothalamus** disrupts thermoregulation leading to high fever, while blockade in the **striatum** causes the characteristic **lead-pipe rigidity** and massive **CK elevation**.*Excessive dopaminergic stimulation in the nigrostriatal pathway*- This mechanism is characteristic of **levodopa** therapy or stimulant use and would typically present with **dyskinesias** or psychosis rather than rigidity.- NMS is specifically caused by a **deficiency or blockade** of dopamine, not an excess of it.*Serotonin syndrome from excessive serotonergic activity*- While it also features fever and altered mental status, it is distinguished by **hyperreflexia** and **clonus** rather than lead-pipe rigidity.- It is associated with **SSRI** or **MAOI** use rather than dopamine-blocking anti-psychotics like haloperidol.*Cholinergic excess from acetylcholine accumulation*- This typically results from **organophosphate poisoning** and presents with symptoms like **bradycardia**, miosis, and diarrhea (DUMBELS).- It does not cause the severe muscular rigidity or the specific pattern of **hyperthermia** seen in NMS.*GABA receptor antagonism in the central nervous system*- GABA antagonism primarily results in **seizures** and CNS excitability due to a lack of inhibitory signaling.- It is not the physiological basis for the autonomic instability and **muscle breakdown** observed in this patient.

Question 65: A 52-year-old man with bipolar affective disorder has been taking lithium carbonate for 12 years with good effect. Recent annual monitoring shows: eGFR 52 ml/min/1.73m² (previously 78 ml/min/1.73m² two years ago), lithium level 0.7 mmol/L, TSH 6.2 mU/L. He has had no mood episodes for 5 years. What is the most appropriate next step in management?

A. Continue lithium as current level is therapeutic and benefits outweigh risks
B. Stop lithium immediately and switch to sodium valproate
C. Reduce lithium dose and recheck levels and renal function in 3 months
D. Refer to nephrology and consider switching to alternative mood stabilizer (Correct Answer)
E. Add levothyroxine for hypothyroidism and continue lithium unchanged

Explanation: ***Refer to nephrology and consider switching to alternative mood stabilizer*** - The patient exhibits a **significant decline in eGFR** (from 78 to 52 ml/min/1.73m²), indicating **Chronic Kidney Disease (CKD) stage 3a** likely due to long-term lithium use. - According to **NICE guidelines**, a rapid decline in renal function or an eGFR <60 ml/min requires **specialist nephrology referral** and a multidisciplinary review to transition to alternative mood stabilizers like **valproate or quetiapine**. *Continue lithium as current level is therapeutic and benefits outweigh risks* - Ignoring a decline of **26 ml/min in eGFR** over just two years risks permanent **end-stage renal disease** and lithium toxicity. - While the lithium level is **0.7 mmol/L (therapeutic range)**, the progressive renal impairment suggests the patient is no longer tolerating the drug's systemic effects. *Stop lithium immediately and switch to sodium valproate* - **Abrupt discontinuation** of lithium after 12 years of stability carries a very high risk of **relapse** into mania or depression. - The transition should be gradual and supervised by a psychiatrist, as immediate withdrawal can trigger a **rebound effect**. *Reduce lithium dose and recheck levels and renal function in 3 months* - Dose reduction may lower the serum level, but it does not address the **progressive nature** of lithium-induced **nephropathy**. - Delaying a specialist referral for three months is inappropriate given the **rate of renal decline** already observed. *Add levothyroxine for hypothyroidism and continue lithium unchanged* - While the **TSH of 6.2 mU/L** indicates **subclinical hypothyroidism** (common with lithium), it is a secondary concern compared to the renal failure. - Treating the thyroid alone does not mitigate the **interstitial fibrosis** and tubular damage occurring in the kidneys due to chronic lithium exposure.

Question 66: A 35-year-old woman with schizoaffective disorder has been stable on amisulpride 800mg daily for 3 years. She presents with amenorrhoea for 6 months and galactorrhoea. Blood tests show: prolactin 4500 mU/L (normal <500 mU/L), TSH 2.1 mU/L, negative pregnancy test. MRI pituitary is normal. She refuses to switch antipsychotic. What is the most appropriate management strategy?

A. Add cabergoline to reduce prolactin levels while continuing amisulpride (Correct Answer)
B. Add bromocriptine as it does not interact with antipsychotics
C. Switch to aripiprazole despite patient refusal as hyperprolactinaemia is dangerous
D. Reduce amisulpride dose to 400mg daily and monitor symptoms
E. Continue current treatment and provide reassurance as hyperprolactinaemia is benign

Explanation: ***Add cabergoline to reduce prolactin levels while continuing amisulpride***- **Amisulpride** is a potent **D2 antagonist** known for causing significant **hyperprolactinaemia**, and adding a dopamine agonist like **cabergoline** is an effective strategy when a patient refuses to switch antipsychotics.- Research suggests that **cabergoline** can normalize prolactin levels and resolve symptoms like **galactorrhoea** and **amenorrhoea** without necessarily exacerbating psychotic symptoms.*Add bromocriptine as it does not interact with antipsychotics*- While **bromocriptine** is a dopamine agonist, it is generally **less well-tolerated** than cabergoline and has a higher risk of worsening **psychotic symptoms**.- It does interact functionally with antipsychotics by acting on the same **D2 receptors**, potentially neutralizing the antipsychotic effect.*Switch to aripiprazole despite patient refusal as hyperprolactinaemia is dangerous*- Forcing a medication switch against a stable patient's wishes violates **autonomy** and significantly increases the risk of **treatment disengagement** and **relapse**.- Although **aripiprazole** (a partial agonist) effectively lowers prolactin, clinical management must balance physiological risks with the patient's **mental stability**.*Reduce amisulpride dose to 400mg daily and monitor symptoms*- Reducing the dose by half in a patient stable for 3 years carries a high risk of **psychotic relapse** or clinical instability.- Even at lower doses, **amisulpride** frequently maintains prolactin levels above the normal range due to its high affinity for **tuberoinfundibular** D2 receptors.*Continue current treatment and provide reassurance as hyperprolactinaemia is benign*- Chronic **hyperprolactinaemia** is not benign; it leads to **hypogonadism**, which increases the long-term risk of **osteoporosis** and cardiovascular disease.- Symptomatic presentation with **galactorrhoea** and **amenorrhoea** requires active management to prevent physical health complications and patient distress.

Question 67: A 29-year-old man presents with a 2-month history of believing he is Jesus Christ and that he must save humanity. He has grandiose delusions, pressured speech, reduced sleep (3 hours nightly), and has spent his entire savings. He has no past psychiatric history or substance use. Which additional feature would most strongly suggest a diagnosis of bipolar affective disorder type I rather than schizophrenia?

A. Presence of grandiose delusions with religious content
B. Clear episodic pattern with complete return to baseline functioning between episodes (Correct Answer)
C. Reduced need for sleep without fatigue
D. Family history of psychotic illness
E. Absence of auditory hallucinations

Explanation: ***Clear episodic pattern with complete return to baseline functioning between episodes*** - **Bipolar Affective Disorder Type I** is fundamentally defined by its **episodic nature**, where patients typically achieve a **full recovery** and return to their prior level of social and occupational functioning between episodes. - In contrast, **Schizophrenia** often follows a **chronic, deteriorating course** with persistent negative symptoms or functional decline, even when active psychosis is absent. *Presence of grandiose delusions with religious content* - While common in **Mania**, religious and **grandiose delusions** are non-specific and are frequently observed in **Schizophrenia** during acute exacerbations. - The content of the delusion itself does not provide a definitive diagnostic distinction between these two **psychotic disorders**. *Reduced need for sleep without fatigue* - A **decreased need for sleep** is a hallmark symptom of a **manic episode**; however, disorganized behavior and agitation in **Schizophrenia** can also lead to significant sleep disruption. - While this feature highly supports a manic state, it does not confirm the **long-term prognosis** or episodic pattern required to differentiate it from other psychotic illnesses. *Family history of psychotic illness* - A positive **family history** for psychosis is a shared risk factor for both **Schizophrenia** and **Bipolar Disorder**, as they share significant **genetic overlap**. - This finding lacks the specificity needed to distinguish between the two diagnoses in a clinical setting. *Absence of auditory hallucinations* - The presence or absence of **hallucinations** does not differentiate the two; **Bipolar I** often presents with **psychotic features** (both hallucinations and delusions) during severe mania. - Schizophrenia can also present with delusions only (without active hallucinations) during certain phases of the illness.

Question 68: A 44-year-old woman with chronic paranoid schizophrenia on clozapine 600mg daily attends for routine blood monitoring. She is clinically well with no new symptoms. Her blood results show: WBC 2.8 × 10⁹/L, neutrophils 1.2 × 10⁹/L, platelets 245 × 10⁹/L, haemoglobin 128 g/L. What is the most appropriate immediate action?

A. Continue clozapine and repeat blood test in 1 week as per normal monitoring
B. Stop clozapine immediately, admit urgently, and refer to haematology (Correct Answer)
C. Reduce clozapine dose to 400mg daily and repeat bloods in 3 days
D. Continue clozapine but increase monitoring to twice weekly
E. Stop clozapine immediately and start olanzapine 20mg daily

Explanation: ***Stop clozapine immediately, admit urgently, and refer to haematology*** - This patient's blood results show **neutropenia** (neutrophils 1.2 × 10⁹/L) and **leukopenia** (WBC 2.8 × 10⁹/L), both falling below the critical thresholds (neutrophils <1.5 × 10⁹/L or WBC <3.0 × 10⁹/L) that mandate immediate action in clozapine monitoring protocols. - **Immediate cessation** of clozapine is crucial to prevent progression to **agranulocytosis**, a life-threatening condition, and urgent hospital admission with hematology referral is necessary for specialized management and protective isolation. *Continue clozapine and repeat blood test in 1 week as per normal monitoring* - Continuing clozapine is **contraindicated** given the significant drop in neutrophil and white blood cell counts, which places the patient at a high risk of severe infection. - Normal weekly monitoring is only appropriate when blood counts remain within the **'Green' safety range**, which is not the case here. *Reduce clozapine dose to 400mg daily and repeat bloods in 3 days* - Dose reduction is an **insufficient intervention** for these critical blood results; clozapine must be stopped entirely to prevent further bone marrow suppression. - Delaying complete cessation and merely repeating bloods in 3 days significantly increases the risk of the patient developing **severe agranulocytosis**. *Continue clozapine but increase monitoring to twice weekly* - Increased monitoring, such as twice weekly, is typically reserved for less severe deviations (e.g., **'Amber' results** where neutrophils are 1.5-2.0 × 10⁹/L), not for the **'Red' category** values seen here. - Once blood counts fall into the 'Red' range, the drug must be **stopped immediately**, not merely monitored more frequently. *Stop clozapine immediately and start olanzapine 20mg daily* - While stopping clozapine is the correct immediate action, the priority after cessation is **medical stabilization** and assessment by hematology, not the immediate initiation of another antipsychotic. - Switching to olanzapine, even at a high dose, before the patient's hematological status is stable and evaluated could delay crucial medical care and management of potential complications.

Question 69: A 38-year-old man with bipolar affective disorder type I has been stable on lithium for 6 years. He presents to A&E with a 48-hour history of vomiting and diarrhoea following gastroenteritis. He appears clinically dehydrated. His lithium level taken 6 hours ago is 1.3 mmol/L. What is the most appropriate immediate management?

A. Continue lithium at current dose and start oral rehydration therapy
B. Temporarily stop lithium, admit for IV fluids and monitor lithium levels (Correct Answer)
C. Reduce lithium dose by 50% and encourage oral fluids
D. Continue lithium and start haemodialysis immediately
E. Switch from lithium to sodium valproate and discharge home

Explanation: ***Temporarily stop lithium, admit for IV fluids and monitor lithium levels***- The patient exhibits features of **lithium toxicity** (1.3 mmol/L, which is above the therapeutic range of 0.4-1.0 mmol/L) exacerbated by **dehydration** from gastroenteritis, which reduces renal clearance and increases lithium retention.- Immediate **admission for IV fluid resuscitation** is crucial to restore renal function, promote **lithium excretion**, and prevent further neurotoxicity.*Continue lithium at current dose and start oral rehydration therapy*- Continuing the dose in a patient with a toxic level and active vomiting/diarrhoea will rapidly lead to **severe neurotoxicity** or renal failure.- **Oral rehydration** is often insufficient for rapid correction of electrolyte imbalances and volume depletion in the presence of ongoing gastrointestinal losses.*Reduce lithium dose by 50% and encourage oral fluids*- A simple dose reduction does not address the current **hyperlithemia** and the underlying physiological cause (dehydration).- Management requires a complete pause until levels return to the **therapeutic range** (typically 0.4–1.0 mmol/L) and renal function is stabilized.*Continue lithium and start haemodialysis immediately*- **Haemodialysis** is usually reserved for severe toxicity (levels >2.0 mmol/L with symptoms or >3.5 mmol/L if asymptomatic) or **renal failure**.- Continuing lithium while performing dialysis is counterproductive and clinically inappropriate.*Switch from lithium to sodium valproate and discharge home*- Switching medications during an acute **medical emergency** (lithium toxicity/dehydration) is unsafe and does not address the immediate risk of lithium-induced injury.- Discharging the patient is contraindicated as they require **inpatient monitoring** for hemodynamic stability and serial lithium level checks.

Question 70: A 26-year-old woman with a first episode of psychosis has been treated with aripiprazole 15mg daily for 8 weeks. Her positive symptoms have completely resolved. She asks about duration of treatment. According to current NICE guidelines, what is the minimum recommended duration of antipsychotic treatment following complete remission of a first episode of psychosis?

A. 6 months
B. 1 year
C. 2 years (Correct Answer)
D. 5 years
E. Lifelong treatment

Explanation: ***2 years*** - According to **NICE guidelines (CG178)**, individuals who achieve complete remission after a **first episode of psychosis** should continue antipsychotic medication for at least **1 to 2 years**. - This duration is recommended to significantly reduce the high risk of **relapse** observed in the early years following the initial episode. *6 months* - This duration is insufficient for a first episode of psychosis; it is more typically associated with the minimum treatment duration for a **single episode of depression** after remission. - Discontinuing antipsychotics at 6 months carries a significantly higher risk of **early clinical relapse**. *1 year* - While some guidelines suggest a minimum of one year, **NICE clinical standards** generally favor a **1–2 year** period to ensure stability before considering tapering. - Choosing only 1 year without acknowledging the 2-year standard may lead to **premature discontinuation** in high-risk patients. *5 years* - A 5-year treatment plan is generally reserved for patients who have experienced **multiple relapses** or have a history of **serious harm** during episodes. - For a first episode with complete remission, this duration would cause unnecessary exposure to **long-term side effects** such as metabolic syndrome. *Lifelong treatment* - **Lifelong maintenance** therapy is typically only considered for patients with chronic **Schizophrenia** involving frequent, severe relapses or treatment-resistant symptoms. - For a first episode, the goal is eventually to attempt a **gradual dose reduction** and discontinuation after the stable 2-year period has passed.

Question 71: A 41-year-old man with a 15-year history of bipolar affective disorder presents with tremor, confusion, and ataxia. He takes lithium carbonate 800mg twice daily. Blood tests show: sodium 138 mmol/L, potassium 4.2 mmol/L, urea 9.8 mmol/L, creatinine 145 μmol/L, lithium level 2.1 mmol/L. Which medication started in the past week is most likely responsible?

A. Paracetamol for headache
B. Ramipril for hypertension (Correct Answer)
C. Ranitidine for dyspepsia
D. Salbutamol inhaler for asthma
E. Loratadine for hay fever

Explanation: ***Ramipril for hypertension***- **ACE inhibitors** like **ramipril** can significantly increase serum **lithium levels** by reducing its renal clearance.- This interaction often leads to **lithium toxicity**, consistent with the patient's symptoms of **tremor, confusion, ataxia**, and a high **lithium level of 2.1 mmol/L**. *Paracetamol for headache*- **Paracetamol** (acetaminophen) is generally considered safe with lithium and does not have a significant interaction that would cause a rise in **lithium levels**.- It does not affect **renal lithium excretion** pathways. *Ranitidine for dyspepsia*- **Ranitidine**, an H2-receptor antagonist, does not have a known significant drug interaction with lithium.- It does not impair **lithium metabolism** or **excretion**, and thus would not cause toxicity. *Salbutamol inhaler for asthma*- **Salbutamol**, a beta-2 adrenergic agonist, does not significantly interact with lithium.- There is no established mechanism by which salbutamol would increase **lithium concentrations** to toxic levels. *Loratadine for hay fever*- **Loratadine**, a non-sedating antihistamine, does not have any significant drug interactions with lithium.- It does not alter **lithium pharmacokinetics** or its elimination, making it an unlikely cause of toxicity.

Question 72: A 32-year-old woman with schizophrenia has been stable on paliperidone palmitate depot injection (150mg monthly) for 18 months. She now wishes to conceive. Her last depot injection was 2 weeks ago. What is the most appropriate management plan?

A. Continue paliperidone depot throughout pregnancy as it is safe in all trimesters
B. Switch immediately to oral risperidone and monitor closely during pregnancy (Correct Answer)
C. Stop all antipsychotic medication immediately and monitor for relapse
D. Wait 6 months after last depot injection before attempting conception
E. Switch to clozapine as it has the best safety profile in pregnancy

Explanation: ***Switch immediately to oral risperidone and monitor closely during pregnancy*** - Switching from a **long-acting injectable (LAI)** to an **oral antipsychotic** is preferred during pregnancy planning to allow for rapid dose adjustments if side effects or complications arise. - **Risperidone** is the active metabolite (parent compound) of paliperidone, making it a logical and safer oral alternative with more documented data in pregnancy. *Continue paliperidone depot throughout pregnancy as it is safe in all trimesters* - **Depot injections** lack flexibility; if a fetus develops a complication or the mother experiences toxicity, the medication cannot be quickly washed out of the system. - While not strictly contraindicated, the **prolonged half-life** of paliperidone palmitate makes it less ideal than oral formulations for managing pregnancy transitions. *Stop all antipsychotic medication immediately and monitor for relapse* - Discontinuing treatment in a patient stable for 18 months with **schizophrenia** carries a high risk of **psychotic relapse**, which can be dangerous for both the mother and the fetus. - Expert consensus recommends maintaining stability with the **lowest effective dose** of an oral antipsychotic rather than complete cessation. *Wait 6 months after last depot injection before attempting conception* - While the depot does remain in the system for several months, delaying conception for **6 months** is often clinically unnecessary and can be distressing for the patient. - Management focuses on transitioning to **oral therapy** immediately to establish a stable dose before the patient successfully conceives. *Switch to clozapine as it has the best safety profile in pregnancy* - **Clozapine** is not first-line due to risks of **agranulocytosis**, metabolic disturbances, and the requirement for frequent **blood monitoring**, which complicates pregnancy. - It is generally reserved for **treatment-resistant schizophrenia**, and switching a stable patient to it solely for pregnancy is not recommended.

Question 73: A 27-year-old woman with bipolar affective disorder type I has had three manic episodes requiring admission in the past 4 years. She is currently stable on lithium carbonate 800mg daily (level 0.75 mmol/L). She presents to the preconception clinic requesting advice as she and her partner are planning pregnancy. She has no other medical conditions and takes only folic acid 5mg. What represents the most evidence-based approach to minimising fetal risk while preventing maternal relapse?

A. Continue lithium throughout pregnancy with increased monitoring and dose adjustment (Correct Answer)
B. Stop lithium and switch to sodium valproate before conception
C. Stop lithium at conception and remain medication-free during first trimester
D. Switch to lamotrigine before conception and continue throughout pregnancy
E. Continue lithium but discontinue during first trimester only, then restart

Explanation: ***Continue lithium throughout pregnancy with increased monitoring and dose adjustment*** - For patients with **severe bipolar disorder** (multiple admissions for mania), the risk of maternal **relapse** upon discontinuation is extremely high and carries significant fetal risks from untreated illness. - While **lithium** is associated with **Ebstein's anomaly**, the absolute risk is low (0.05-0.1%), and it is managed with increased **serum monitoring** and **fetal echocardiography** to detect and manage potential issues. *Stop lithium and switch to sodium valproate before conception* - **Sodium valproate** is strictly **contraindicated** in women of childbearing potential due to high rates of **major congenital malformations** (e.g., neural tube defects) and **neurodevelopmental delay**. - It is considered the most teratogenic mood stabilizer and would significantly increase fetal risk compared to lithium, making this an inappropriate switch. *Stop lithium at conception and remain medication-free during first trimester* - Abruptly stopping lithium, especially in a patient with a history of severe illness, leads to a very high risk of **rebound mania**, which can be life-threatening and require more harmful medications. - The **postpartum period** is a time of exceptionally high risk for relapse into **puerperal psychosis**, which is more likely if the patient is unstable during pregnancy. *Switch to lamotrigine before conception and continue throughout pregnancy* - **Lamotrigine** is primarily effective for preventing **bipolar depression** but has weak evidence for preventing **manic episodes**, making it unsuitable for this patient's history of recurrent mania. - Switching a stable patient with a history of severe mania to a less effective agent risks **destabilization** during a critical period, increasing maternal and fetal risks. *Continue lithium but discontinue during first trimester only, then restart* - Discontinuing in the first trimester does not eliminate the risk of **Ebstein's anomaly** as cardiac development occurs very early in gestation, often before pregnancy is confirmed. - This approach is associated with high **relapse rates** mid-pregnancy, often necessitating emergency interventions that carry higher fetal and maternal risks than continuous maintenance therapy.

Question 74: A 39-year-old man with schizoaffective disorder has been maintained on risperidone long-acting injection 50mg fortnightly for 3 years. He attends his GP with concerns about sexual dysfunction including erectile dysfunction and loss of libido for 8 months. Blood tests show: prolactin 3200 mIU/L, testosterone 8.5 nmol/L (normal 10-30), thyroid function normal, glucose 5.4 mmol/L. He is otherwise stable mentally. Which management strategy addresses both his psychiatric stability and endocrine complications?

A. Switch to paliperidone depot and add testosterone replacement
B. Continue risperidone depot and add cabergoline 0.5mg weekly
C. Switch to aripiprazole long-acting injection and monitor (Correct Answer)
D. Reduce risperidone depot to 37.5mg and add sildenafil
E. Switch to quetiapine immediate release and monitor prolactin

Explanation: ***Switch to aripiprazole long-acting injection and monitor***- **Aripiprazole** is a **partial dopamine D2 agonist**, which typically normalizes or significantly reduces **prolactin** levels while maintaining antipsychotic efficacy.- Moving to a **long-acting injection** (LAI) ensures continued **psychiatric stability** and adherence in a patient who has been stable on a depot for three years.*Switch to paliperidone depot and add testosterone replacement*- **Paliperidone** is the active metabolite of **risperidone** and is highly likely to continue causing significant **hyperprolactinaemia**.- Adding **testosterone** treats the symptom rather than the underlying cause and carries potential **cardiovascular risks** without resolving the high prolactin.*Continue risperidone depot and add cabergoline 0.5mg weekly*- **Cabergoline**, a dopamine agonist used to lower prolactin, carries a significant risk of **exacerbating psychosis** in patients with schizoaffective disorder.- It is generally preferred to switch the offending antipsychotic rather than adding a second medication to manage **iatrogenic side effects**.*Reduce risperidone depot to 37.5mg and add sildenafil*- A minor **dose reduction** is often insufficient to normalize such severely elevated **prolactin levels** (3200 mIU/L).- **Sildenafil** may help with erectile dysfunction but fails to address the underlying **hypogonadism** (low testosterone) and loss of libido caused by the medication.*Switch to quetiapine immediate release and monitor prolactin*- Switching from a long-acting injection to an **immediate-release oral medication** significantly increases the risk of **non-adherence** and relapse.- While **quetiapine** is prolactin-sparing, the loss of the **depot formulation** compromises the patient's long-term psychiatric stability.

Question 75: A 28-year-old woman with paranoid schizophrenia attends the community mental health team clinic. She has been on clozapine 350mg daily for 9 months with good symptom control. She reports a 6-week history of new-onset constipation with bowel movements every 4-5 days. Today she has abdominal pain and distension. Examination reveals absent bowel sounds and generalised abdominal tenderness. Temperature 37.8°C, pulse 110 bpm. What is the most appropriate immediate management?

A. Prescribe high-dose laxatives and review in 48 hours
B. Arrange urgent abdominal X-ray and surgical review (Correct Answer)
C. Reduce clozapine dose and commence regular laxatives
D. Continue clozapine and refer to gastroenterology outpatients
E. Stop clozapine immediately and observe for 24 hours

Explanation: ***Arrange urgent abdominal X-ray and surgical review*** - The patient's presentation with **abdominal pain**, **distension**, **absent bowel sounds**, **generalised abdominal tenderness**, **fever (37.8°C)**, and **tachycardia (110 bpm)** indicates a severe, acute abdomen, highly suggestive of **clozapine-induced paralytic ileus** or **bowel obstruction** which can progress to **toxic megacolon** or **perforation**. - Urgent **abdominal imaging** (e.g., X-ray) and immediate **surgical consultation** are crucial to diagnose the extent of the pathology and intervene, as mortality from severe clozapine-induced gastrointestinal complications is high without prompt management. *Prescribe high-dose laxatives and review in 48 hours* - Administering **high-dose laxatives** is contraindicated in suspected **bowel obstruction** or **ileus** because it can exacerbate distension, potentially leading to **bowel perforation** or worsening the clinical picture. - A review in 48 hours is dangerously delayed for a patient presenting with an **acute abdomen** and systemic signs of inflammation, which necessitates immediate assessment and intervention. *Reduce clozapine dose and commence regular laxatives* - While clozapine is the underlying cause, reducing the dose and commencing regular laxatives are appropriate for **mild to moderate constipation** but are wholly inadequate for an acute, life-threatening presentation like this. - This approach fails to address the immediate surgical emergency suggested by the clinical signs and symptoms, potentially leading to severe adverse outcomes. *Continue clozapine and refer to gastroenterology outpatients* - Continuing **clozapine** would be extremely dangerous as its potent **anticholinergic effects** would further worsen the already compromised gastrointestinal motility, increasing the risk of **bowel perforation** and **sepsis**. - Referral to **gastroenterology outpatients** is inappropriate for an acute abdomen with signs of systemic distress, which requires immediate emergency department evaluation and inpatient management. *Stop clozapine immediately and observe for 24 hours* - Although **stopping clozapine** is a necessary immediate step to prevent further gastrointestinal harm, simple observation for 24 hours is insufficient and highly risky given the severe clinical signs like **absent bowel sounds**, **fever**, and **tachycardia**. - This approach delays critical **diagnostic imaging** and **surgical evaluation**, which are essential to manage conditions like **bowel obstruction** or **toxic megacolon** and prevent mortality.

Question 76: A 35-year-old man with bipolar affective disorder type I is admitted with his fourth manic episode in 2 years despite apparent adherence to oral sodium valproate 1500mg daily. His valproate level is therapeutic at 85 mg/L. Previous episodes occurred on lithium (stopped due to tremor) and quetiapine (ineffective). He has no medical comorbidities. What is the most appropriate next step in long-term mood stabilisation?

A. Add lithium to sodium valproate as combination therapy (Correct Answer)
B. Switch to depot antipsychotic monotherapy
C. Add lamotrigine to current sodium valproate
D. Increase sodium valproate dose to 2000mg daily
E. Add aripiprazole to current sodium valproate

Explanation: ***Add lithium to sodium valproate as combination therapy*** - Combining **lithium** with an **anticonvulsant** (like valproate) is a gold-standard step for patients who experience breakthrough episodes on monotherapy, especially in **rapid cycling** scenarios. - While the patient previously had a **tremor**, this side effect is often **dose-dependent** and can be managed while providing the superior prophylactic benefits that dual-agent mood stabilization offers. *Switch to depot antipsychotic monotherapy* - **Depot antipsychotics** are primarily used to address **medication non-adherence**, which is not the primary issue here given the patient's **therapeutic valproate level**. - Monotherapy is generally insufficient for a patient failing established treatments; **combination therapy** is preferred by guidelines like **NICE** for treatment-resistant bipolar disorder. *Add lamotrigine to current sodium valproate* - **Lamotrigine** is highly effective for preventing **bipolar depression**, but it has limited efficacy in preventing or treating **acute manic episodes**. - There is an increased risk of **Stevens-Johnson Syndrome** when combining these drugs as valproate inhibits the metabolism of lamotrigine, doubling its plasma concentration. *Increase sodium valproate dose to 2000mg daily* - The patient's valproate level is already **85 mg/L**, which is within the established **therapeutic range** (50-100 mg/L or 125 mg/L depending on lab standards). - Increasing the dose further is unlikely to provide significant additional control for breakthrough mania and significantly increases the risk of **hepatotoxicity** and **thrombocytopenia**. *Add aripiprazole to current sodium valproate* - While adding an **atypical antipsychotic** is an option, adding **lithium** is generally prioritized for long-term stabilization in patients failing monotherapy due to its unique **anti-suicidal properties**. - The patient previously failed **quetiapine** (another atypical antipsychotic), making the addition of another agent from the same class a less robust strategic move than adding a second **mood stabilizer**.

Question 77: A 46-year-old man with bipolar affective disorder type I has been maintained on lithium carbonate 1000mg daily for 8 years. He presents with a 3-month history of polyuria, polydipsia (drinking 6-7 litres daily), and nocturia 5 times per night. Blood tests show: sodium 148 mmol/L, lithium 0.85 mmol/L, glucose 5.2 mmol/L, calcium 2.4 mmol/L, serum osmolality 298 mOsm/kg. Urine osmolality is 180 mOsm/kg. What is the most likely diagnosis?

A. Diabetes insipidus secondary to lithium (Correct Answer)
B. Diabetes mellitus type 2
C. Primary polydipsia
D. Hypercalcaemia causing polyuria
E. Syndrome of inappropriate ADH secretion

Explanation: ***Diabetes insipidus secondary to lithium***- Long-term **lithium therapy** is a common cause of **nephrogenic diabetes insipidus**, as it interferes with the action of **ADH** on the collecting ducts of the kidney.- The diagnostic profile includes **high serum osmolality** (298 mOsm/kg) and **hypernatremia** (148 mmol/L) with inappropriately **low urine osmolality** (180 mOsm/kg), matching this patient's presentation.*Diabetes mellitus type 2*- This is excluded by a **normal glucose level** of 5.2 mmol/L; hyperglycemia would be the hallmark for polyuria/polydipsia in diabetes mellitus.- While it causes similar symptoms, the underlying mechanism involves osmotic diuresis due to glucose, which is not supported by lab tests here.*Primary polydipsia*- In **primary polydipsia**, excessive water intake would lead to **low serum osmolality** and **hyponatremia**, which contradicts the patient's hypernatremia and elevated serum osmolality.- This condition involves a psychological drive for water intake, not a defect in renal concentrating ability.*Hypercalcaemia causing polyuria*- While **hypercalcaemia** can induce nephrogenic diabetes insipidus-like symptoms by impairing renal ADH response, the patient's **calcium level** of 2.4 mmol/L is within the normal range.- Therefore, hypercalcaemia is not the cause of the polyuria in this specific case.*Syndrome of inappropriate ADH secretion*- **SIADH** presents with the opposite biochemical profile: **hyponatraemia** (low serum sodium) and inappropriately **high urine osmolality** (concentrated urine).- The patient exhibits hypernatremia and dilute urine, which rules out SIADH.

Question 78: According to NICE guidelines for schizophrenia management, what is the recommended duration of antipsychotic continuation after a single episode of psychosis with full remission?

A. 6-12 months after symptom remission
B. 1-2 years after symptom remission (Correct Answer)
C. 3-5 years after symptom remission
D. Lifelong treatment is recommended
E. Antipsychotics can be discontinued immediately after remission

Explanation: ***1-2 years after symptom remission***- According to **NICE guidelines**, patients who experience a first episode of psychosis and achieve full remission should continue **antipsychotic medication** for at least 1-2 years.- This duration is specified to significantly reduce the high **risk of relapse** seen when treatment is discontinued prematurely while balancing potential **side-effect burdens**.*6-12 months after symptom remission*- While some general medical conditions require 6 months of treatment, this is considered **insufficient duration** for schizophrenia spectrum disorders.- Discontinuing treatment before the **1-year mark** is clinically associated with a much higher rate of **acute psychotic relapse**.*3-5 years after symptom remission*- This duration is typically reserved for patients who have suffered **multiple relapses** or have a history of **severe risk** to themselves or others.- For a **single episode** with full remission, extending the primary maintenance phase to 5 years is not the standard **initial guideline** recommendation.*Lifelong treatment is recommended*- Lifelong medication is primarily indicated for patients with **recurrent episodes** or chronic, treatment-resistant symptoms.- It is not routinely mandated for a **first episode** of psychosis if the patient remains stable and symptom-free during the **maintenance phase**.*Antipsychotics can be discontinued immediately after remission*- Immediate discontinuation leads to a nearly universal and **rapid relapse** of psychotic symptoms due to the underlying pathophysiology.- NICE guidelines emphasize a **gradual dose reduction** and close monitoring rather than abrupt cessation, even after the maintenance period is over.

Question 79: A 40-year-old man with a 15-year history of paranoid schizophrenia presents to A&E with sudden onset severe headache, fever of 39.1°C, and confusion. He was started on depot flupentixol 3 weeks ago after non-adherence to oral medication. On examination, he is sweating profusely, has generalised rigidity, and blood pressure of 165/95 mmHg. Blood tests show: CK 8500 U/L, WBC 15.2 × 10⁹/L, creatinine 165 μmol/L. What is the most likely diagnosis?

A. Neuroleptic malignant syndrome (Correct Answer)
B. Serotonin syndrome
C. Acute bacterial meningitis
D. Malignant catatonia
E. Encephalitis

Explanation: ***Neuroleptic malignant syndrome*** - This diagnosis is strongly supported by the classic tetrad of **fever**, **rigidity**, **altered mental status (confusion)**, and **autonomic dysfunction (sweating, hypertension)**, all present in a patient recently started on a **depot antipsychotic (flupentixol)**. - The elevated **creatine kinase (CK)** indicates **rhabdomyolysis**, and the elevated **creatinine** suggests **acute kidney injury**, both common and severe complications of NMS. *Serotonin syndrome* - Typically results from **excess serotonergic activity**, often due to interactions between antidepressant medications or illicit drugs, which is not the context with flupentixol. - Key features often include **hyperreflexia**, **myoclonus**, **tremor**, and gastrointestinal symptoms like diarrhea, which are not predominant here. *Acute bacterial meningitis* - While presenting with **fever**, **headache**, and **confusion**, it would typically show **nuchal rigidity** and possibly focal neurological signs. - It does not explain the profound **generalised muscular rigidity** or the significantly elevated **CK levels** seen in this patient. *Malignant catatonia* - Can present with **fever**, **rigidity**, and autonomic instability, mimicking NMS, but typically arises in the context of severe psychiatric illness or withdrawal states, rather than directly post-initiation of an antipsychotic. - While it shares features, the explicit link to recent **antipsychotic initiation** and the severe rhabdomyolysis with very high CK are more characteristic of NMS. *Encephalitis* - Presents with **fever**, **headache**, **confusion**, and can cause seizures or focal neurological deficits. - It does not typically cause the severe, generalized **muscular rigidity** or the dramatic elevation in **CK** indicative of muscle breakdown seen in this case.

Question 80: A 34-year-old woman with bipolar affective disorder type II presents to her psychiatrist requesting advice about pregnancy planning. She has been stable on lamotrigine 200mg daily for 3 years with no mood episodes. She previously failed trials of lithium and sodium valproate. She takes no other medications and has no medical comorbidities. What is the most appropriate advice regarding her medication during pregnancy?

A. Continue lamotrigine at current dose throughout pregnancy
B. Switch to lithium in first trimester then continue throughout pregnancy
C. Discontinue lamotrigine and remain medication-free during pregnancy
D. Continue lamotrigine with dose adjustment based on therapeutic monitoring (Correct Answer)
E. Switch to olanzapine before conception and continue throughout pregnancy

Explanation: ***Continue lamotrigine with dose adjustment based on therapeutic monitoring*** - **Lamotrigine clearance** increases significantly (up to 50-65%) during pregnancy due to the induction of **glucuronidation** by estrogen, leading to subtherapeutic levels and high risk of relapse. - Monitoring **serum levels** and adjusting the dose proportionately is necessary to maintain clinical stability while minimizing **teratogenic risk**, which is relatively low for lamotrigine. *Continue lamotrigine at current dose throughout pregnancy* - Maintaining a static dose is likely to result in **subtherapeutic plasma concentrations** as the pregnancy progresses, increasing the risk of a **bipolar mood episode**. - Dose adjustments are standard clinical practice for **antiepileptic drugs** used in pregnancy to compensate for altered **pharmacokinetics**. *Switch to lithium in first trimester then continue throughout pregnancy* - **Lithium** is associated with a specific risk of **Ebstein’s anomaly** (a cardiac defect) if used during the first trimester, making it a second-line choice compared to stable lamotrigine therapy. - This patient has already **failed a trial of lithium**, so switching back to it would be clinically inappropriate and risk destabilizing her condition. *Discontinue lamotrigine and remain medication-free during pregnancy* - **Bipolar affective disorder** carries a very high risk of **postpartum psychosis** and relapse during pregnancy; medication-free periods are generally discouraged for patients with severe mental illness. - Abruptly stopping medication after being stable for three years poses a significant threat to both **maternal well-being** and the safety of the pregnancy. *Switch to olanzapine before conception and continue throughout pregnancy* - While **olanzapine** is an option in bipolar disorder, switching a patient who is already stable on an effective, relatively safe medication increases the risk of **relapse**. - Antipsychotics like olanzapine are associated with **metabolic side effects** such as weight gain and **gestational diabetes**, which require additional monitoring.

Question 81: A 29-year-old man with a 5-year history of paranoid schizophrenia has been on clozapine 400mg daily for 14 months with good symptom control. He attends for routine monitoring. His full blood count shows: WBC 3.2 × 10⁹/L, neutrophils 1.8 × 10⁹/L, haemoglobin 14.2 g/dL, platelets 256 × 10⁹/L. He is clinically well with no signs of infection. His previous neutrophil count 1 week ago was 2.1 × 10⁹/L. What is the most appropriate management according to current guidelines?

A. Continue clozapine and repeat FBC in 1 week
B. Stop clozapine immediately and repeat FBC daily
C. Reduce clozapine dose to 200mg and monitor weekly
D. Continue clozapine and repeat FBC in 3 days (Correct Answer)
E. Stop clozapine permanently and commence olanzapine

Explanation: ***Continue clozapine and repeat FBC in 3 days*** - A neutrophil count between **1.5 and 2.0 × 10⁹/L** falls into the **Amber** category of clozapine monitoring guidelines (yellow/amber zone). - For an Amber result, the drug is continued, but the frequency of **Full Blood Count (FBC)** monitoring must increase to **twice weekly** (every 3 days) until the count stabilizes or improves. *Continue clozapine and repeat FBC in 1 week* - **Weekly monitoring** is the routine schedule for patients who have been on clozapine for over a year (Green zone), but it is insufficient for an **Amber result**. - Since the neutrophil count has dropped below 2.0 × 10⁹/L, more frequent surveillance is mandatory to detect early signs of **agranulocytosis**. *Stop clozapine immediately and repeat FBC daily* - Immediate cessation is only required for **Red results**, which occur when the neutrophil count drops below **1.5 × 10⁹/L**. - As this patient is clinically well and remains in the Amber range, stopping the medication would unnecessarily risk **psychotic relapse**. *Reduce clozapine dose to 200mg and monitor weekly* - **Dose reduction** is not a standard response to hematological abnormalities; the issue is an idiosyncratic reaction rather than dose-dependent toxicity. - Monitoring only once a week for a declining neutrophil count below **2.0 × 10⁹/L** violates the patient safety protocol for clozapine management. *Stop clozapine permanently and commence olanzapine* - **Permanent discontinuation** is reserved for severe neutropenia or agranulocytosis (Red results) and requires specialist hematological consultation. - This patient’s count of **1.8 × 10⁹/L** does not warrant changing medication, as the treatment remains effective and the risk is currently manageable via **increased monitoring**.

Question 82: A 37-year-old woman with bipolar affective disorder type I is admitted to the psychiatric unit with severe mania. She is aggressive, sexually disinhibited, and refusing all oral medication. She has a history of neuroleptic malignant syndrome following haloperidol use 3 years ago. Her family reports she stopped taking lithium 6 weeks ago. Physical examination reveals BP 145/90 mmHg, pulse 105 bpm, temperature 37.2°C. What is the most appropriate initial pharmacological management?

A. Intramuscular aripiprazole and oral lorazepam
B. Intramuscular olanzapine and restart lithium (Correct Answer)
C. Oral sodium valproate and intramuscular lorazepam
D. Intramuscular haloperidol and oral promethazine
E. Electroconvulsive therapy as first-line treatment

Explanation: ***Intramuscular olanzapine and restart lithium*** - **Intramuscular (IM) olanzapine** is effective for rapid control of **acute agitation** and aggression in severe mania, especially when the patient is refusing oral medication. - **Restarting lithium** is crucial because the patient had a documented response to it previously, and its abrupt discontinuation is a common cause of **manic relapse**. *Intramuscular aripiprazole and oral lorazepam* - While **IM aripiprazole** can be used for acute agitation, **olanzapine** often has a faster onset and more robust evidence for severe manic agitation. - **Oral lorazepam** is unsuitable as the patient is actively **refusing all oral medications**, necessitating a parenteral approach for all initial treatments. *Oral sodium valproate and intramuscular lorazepam* - **Oral sodium valproate** cannot be administered given the patient's refusal of all oral medications, making it an inappropriate initial choice for rapid stabilization. - Although **IM lorazepam** helps with sedation and anxiety, it does not directly address the underlying **psychotic features** and severe mania as effectively as an antipsychotic. *Intramuscular haloperidol and oral promethazine* - **Intramuscular haloperidol** is absolutely contraindicated due to the patient's history of **Neuroleptic Malignant Syndrome (NMS)** following its use. - Administering a **first-generation antipsychotic** like haloperidol in this scenario carries a significant and life-threatening risk of **NMS recurrence**. *Electroconvulsive therapy as first-line treatment* - **Electroconvulsive therapy (ECT)** is highly effective for severe mania but is typically reserved for **treatment-resistant cases**, catatonia, or when rapid response is critical due to severe medical compromise. - It is not considered the **first-line pharmacological management** for initial stabilization before attempting rapid tranquilization with antipsychotics.

Question 83: A 25-year-old man presents to the early intervention service with his first episode of psychosis. He describes a 6-month history of believing his neighbours can read his mind through the walls. He hears voices discussing his actions in the third person. His speech shows knight's move thinking. There is no substance misuse. Which symptom cluster represents first-rank symptoms of schizophrenia according to Schneider's criteria?

A. Knight's move thinking, third-person auditory hallucinations, and paranoid delusions
B. Thought broadcasting, third-person auditory hallucinations, and passivity phenomena (Correct Answer)
C. Social withdrawal, affective flattening, and thought disorder
D. Grandiose delusions, pressure of speech, and decreased need for sleep
E. Paranoid delusions, formal thought disorder, and negative symptoms

Explanation: ***Thought broadcasting, third-person auditory hallucinations, and passivity phenomena***- These are classic **Schneider's first-rank symptoms**, which include thought interference (insertion, withdrawal, broadcasting), specific auditory hallucinations, and **passivity phenomena** (of affect, impulse, or volition).- The patient's belief that his neighbors can read his mind is a form of **thought broadcasting**, and hearing voices discussing his actions in the third person is a definitive **third-person auditory hallucination**.*Knight's move thinking, third-person auditory hallucinations, and paranoid delusions*- **Knight's move thinking** (derailment) is a formal thought disorder but is not considered a Schneiderian first-rank symptom.- **Paranoid delusions** are common in schizophrenia but are only first-rank if they specifically involve **delusional perception** or other specific experiences of influence.*Social withdrawal, affective flattening, and thought disorder*- These are categorized as **negative symptoms** of schizophrenia and general formal thought disorder, rather than first-rank symptoms.- Schneider's criteria focus primarily on specific **positive symptoms** and experiences of alien control or thought interference.*Grandiose delusions, pressure of speech, and decreased need for sleep*- This cluster is characteristic of a **manic episode** in bipolar disorder, not the core diagnostic criteria for schizophrenia.- **Pressure of speech** and **decreased need for sleep** are objective signs of increased psychomotor activity, whereas first-rank symptoms focus on the subjective experience of disturbed thought and perception.*Paranoid delusions, formal thought disorder, and negative symptoms*- While these are frequently present in a schizophrenia diagnosis, they do not belong to the specific list of **Schneider's first-rank symptoms**.- **First-rank symptoms** are prioritized due to their high specificity for schizophrenia in the absence of organic brain disease, rather than general symptoms.

Question 84: A 43-year-old woman with a 12-year history of bipolar affective disorder type I attends her GP. She has had four previous manic episodes requiring admission. She has been stable on lithium carbonate 800mg daily for 6 years. Recent blood tests show: lithium 0.9 mmol/L, sodium 141 mmol/L, potassium 4.2 mmol/L, creatinine 145 μmol/L (baseline 95 μmol/L), eGFR 38 ml/min (baseline 72 ml/min). Thyroid function is normal. What is the most appropriate management?

A. Continue lithium and repeat renal function in 3 months
B. Reduce lithium dose and recheck levels in 1 week
C. Switch to sodium valproate and monitor renal function (Correct Answer)
D. Stop lithium immediately and commence olanzapine
E. Refer to nephrology and maintain lithium pending review

Explanation: ***Switch to sodium valproate and monitor renal function*** - The patient exhibits **chronic kidney disease (CKD)** progression with an **eGFR falling below 45 ml/min** and a creatinine increase of >50 μmol/L, which necessitates discontinuing lithium according to **NICE guidelines**. - **Sodium valproate** is a recommended alternative for **bipolar disorder prophylaxis** that does not carry the same risk of nephrotoxicity as lithium. *Continue lithium and repeat renal function in 3 months* - Continuing lithium despite a significant decline in **eGFR** and rising **creatinine** risks irreversible **nephrogenic diabetes insipidus** or end-stage renal failure. - Standard monitoring intervals are inappropriate when current results show **stage 3B CKD**, requiring immediate clinical intervention. *Reduce lithium dose and recheck levels in 1 week* - While lower doses of lithium reduce the risk of acute toxicity, they do not halt the **chronic interstitial nephritis** associated with long-term use. - Because lithium is **renally excreted**, any reduction in kidney function leads to higher serum levels, making dose adjustment insufficient for long-term safety in this patient. *Stop lithium immediately and commence olanzapine* - Immediate cessation of lithium without a gradual taper or transition to another mood stabilizer is associated with a high risk of **rapid relapse** into mania. - While **olanzapine** is effective for acute episodes, **sodium valproate** or **quetiapine** are preferred transitions for long-term prophylaxis in this clinical scenario. *Refer to nephrology and maintain lithium pending review* - While a **nephrology referral** is indicated for declining renal function, the GP must act promptly to remove the offending **nephrotoxic agent**. - Maintaining lithium while waiting for a specialist review allows for further **renal deterioration** and potential lithium toxicity.

Question 85: A 31-year-old man with schizophrenia has been stable on risperidone 4mg daily for 18 months. He attends routine follow-up with his care coordinator. Physical examination reveals bilateral breast enlargement with milky discharge from both nipples. His prolactin level is 2800 mIU/L (normal range 86-324). He is otherwise well and his mental state remains stable. What is the most appropriate next step in management?

A. Continue current medication and monitor prolactin levels 3-monthly
B. Add cabergoline to current antipsychotic regimen
C. Switch to aripiprazole and monitor mental state closely (Correct Answer)
D. Reduce risperidone dose to 2mg daily
E. Switch to quetiapine and monitor mental state closely

Explanation: ***Switch to aripiprazole and monitor mental state closely*** - **Aripiprazole** is a **partial dopamine agonist** which effectively reduces prolactin levels by providing enough dopamine activity to inhibit the pituitary gland without blocking dopamine receptors extensively in the mesolimbic pathway. - It is the treatment of choice for **antipsychotic-induced hyperprolactinaemia** when switching is feasible, as it balances efficacy in managing psychosis with a low risk of hormonal side effects. *Continue current medication and monitor prolactin levels 3-monthly* - Symptomatic **hyperprolactinaemia**, evidenced by galactorrhoea and gynaecomastia, requires intervention to prevent long-term complications such as **osteoporosis**, sexual dysfunction, and infertility. - Simply monitoring is inappropriate when the patient is already experiencing **distressing physical symptoms** and significantly elevated prolactin levels. *Add cabergoline to current antipsychotic regimen* - **Dopamine agonists** like cabergoline can potentially **exacerbate or precipitate psychosis** by stimulating dopamine receptors in the mesolimbic pathway, which is counterproductive in schizophrenia. - They are generally reserved as a last resort for hyperprolactinaemia when antipsychotic switching or dose reduction has failed or is clinically impossible due to high relapse risk. *Reduce risperidone dose to 2mg daily* - While a dose reduction may lower prolactin, it is often insufficient to resolve **symptomatic galactorrhoea** and significantly increases the **risk of relapse** in a patient with stable schizophrenia. - This patient is on a therapeutic dose of 4mg; reducing to 2mg may fall below the **therapeutic threshold** required for maintaining mental state stability. *Switch to quetiapine and monitor mental state closely* - **Quetiapine** is prolactin-sparing, but switching from a potent D2 antagonist like risperidone to quetiapine may carry a **higher risk of relapse** or require careful titration to maintain mental state stability. - **Aripiprazole** is generally preferred in clinical guidelines for this specific scenario due to its unique **partial agonist mechanism** at the D2 receptor, offering a more balanced approach to managing both psychosis and hyperprolactinaemia.

Question 86: A 37-year-old man with bipolar affective disorder type I presents for preconception counselling with his partner. He has been stable on lithium carbonate 1200mg daily for 3 years with no relapses. He is concerned about the risks to the baby. His partner is not yet pregnant. What is the most appropriate advice regarding his lithium treatment in the context of preconception planning?

A. Continue lithium as paternal use has no effect on fetal development (Correct Answer)
B. Switch to sodium valproate before conception
C. Stop all mood stabilisers 3 months before conception attempt
D. Switch to lamotrigine before conception
E. Reduce lithium dose by half before conception attempt

Explanation: ***Continue lithium as paternal use has no effect on fetal development*** - Teratogenic risks associated with **lithium**, such as **Ebstein's anomaly**, are strictly related to **maternal exposure** during pregnancy and do not occur via paternal medication use. - Since the patient has been **stable for 3 years**, maintaining the current regimen is crucial to prevent a **relapse of bipolar disorder** during the stressful transition to parenthood. *Switch to sodium valproate before conception* - **Sodium valproate** is highly teratogenic when used by the mother, and there is no clinical indication to switch a stable patient from lithium to valproate for **preconception planning**. - While some recent data suggests potential risks with paternal valproate, it offers no benefit over lithium in this scenario and risks **destabilizing** the patient's mental state. *Stop all mood stabilisers 3 months before conception attempt* - Discontinuing a mood stabilizer in a patient with **Bipolar I Disorder** who has been stable for years carries a very high risk of **manic or depressive relapse**. - Since **paternal lithium use** does not harm the fetus, there is no medical justification to stop treatment for the sake of the pregnancy. *Switch to lamotrigine before conception* - **Lamotrigine** might be a preferred option for **maternal preconception planning** to manage depressive episodes, but it is unnecessary for male patients. - Switching from an effective treatment like lithium to lamotrigine can lead to **loss of mood control**, as lamotrigine is less effective at preventing **mania**. *Reduce lithium dose by half before conception attempt* - Reducing the dose of lithium below the **therapeutic window** (usually 0.6–1.0 mmol/L) significantly increases the risk of **clinical relapse**. - **Dose-dependent toxicity** to the fetus is only a concern in maternal use; there is no evidence that a lower paternal dose reduces any nonexistent risk to the baby.

Question 87: A 28-year-old woman presents with a 3-month history of believing that her thoughts are being broadcast on television and that the government is controlling her actions through radio waves. She hears multiple voices commenting on her actions. She has become increasingly socially withdrawn. She has no previous psychiatric history, no substance misuse, and no medical comorbidities. What is the most appropriate first-line pharmacological treatment?

A. Haloperidol
B. Clozapine
C. Olanzapine (Correct Answer)
D. Chlorpromazine
E. Amisulpride and an anticholinergic

Explanation: ***Olanzapine*** - This patient presents with **first-episode schizophrenia**, characterized by positive symptoms like **thought broadcasting**, **delusions of control**, and **third-person auditory hallucinations**. - **Second-generation (atypical) antipsychotics** like Olanzapine are the preferred first-line treatment due to a lower risk of **extrapyramidal side effects (EPSEs)** compared to older agents. *Haloperidol* - This is a high-potency **first-generation (typical) antipsychotic** which is effective but associated with a high incidence of **dystonia** and **parkinsonism**. - It is generally not used as a routine first-line agent in modern practice unless specific rapid tranquilization or patient factors dictate its use. *Clozapine* - This drug is specifically reserved for **treatment-resistant schizophrenia**, defined as failure to respond to adequate trials of at least **two different antipsychotics**. - It requires intensive monitoring due to the risk of life-threatening **agranulocytosis** and is never the first-line choice for a new diagnosis. *Chlorpromazine* - A low-potency **typical antipsychotic** that is rarely used as a first-line agent due to its significant side-effect profile, including **sedation** and **anticholinergic effects**. - While effective for positive symptoms, it offers no clinical advantage over better-tolerated **atypical antipsychotics** in first-episode psychosis. *Amisulpride and an anticholinergic* - While **Amisulpride** is an effective atypical antipsychotic, the routine **prophylactic use of anticholinergics** is not recommended by clinical guidelines. - Anticholinergics should only be added if **extrapyramidal symptoms** emerge, as they carry their own risks such as **cognitive impairment** and blurred vision.

Question 88: A 52-year-old woman with a 20-year history of bipolar affective disorder has been stable on lithium carbonate 1000mg daily for 15 years. She develops hypertension and her GP starts her on ramipril 2.5mg daily. Three weeks later, she presents feeling generally unwell. Examination shows mild tremor. Blood tests show: lithium 1.7 mmol/L (previous levels 0.7-0.9 mmol/L), creatinine 95 μmol/L (baseline 88), sodium 138 mmol/L. What is the mechanism for the change in lithium level?

A. ACE inhibitors increase lithium reabsorption in the proximal tubule
B. ACE inhibitors reduce renal blood flow causing lithium retention
C. Ramipril displaces lithium from protein binding sites
D. ACE inhibitors increase lithium reabsorption in the distal tubule due to sodium depletion (Correct Answer)
E. Ramipril inhibits hepatic metabolism of lithium

Explanation: ***ACE inhibitors increase lithium reabsorption in the distal tubule due to sodium depletion*** - **ACE inhibitors** like ramipril block the formation of **angiotensin II**, leading to decreased **aldosterone** secretion and increased **sodium excretion**. - In response to this **sodium depletion**, the renal tubules (especially the distal nephron) enhance **sodium reabsorption**. As **lithium** is handled similarly to sodium by the kidneys, its reabsorption also increases, leading to elevated serum lithium levels and toxicity. *ACE inhibitors increase lithium reabsorption in the proximal tubule* - While approximately 80% of **lithium** is reabsorbed in the **proximal tubule**, the primary mechanism by which ACE inhibitors cause lithium toxicity is through changes in **sodium balance** affecting more distal parts of the nephron. - The direct effect of **ACE inhibitors** on proximal tubule lithium reabsorption is less significant than the compensatory reabsorption driven by overall **sodium depletion** caused by the drug. *ACE inhibitors reduce renal blood flow causing lithium retention* - **ACE inhibitors** can cause a modest reduction in **glomerular filtration rate (GFR)** by dilating the **efferent arteriole**, which could theoretically contribute to some drug retention. - However, the more pronounced and direct mechanism for **lithium toxicity** with ACE inhibitors is the alteration in **tubular reabsorption** due to induced **sodium depletion**, rather than a significant drop in overall renal blood flow. *Ramipril displaces lithium from protein binding sites* - **Lithium** is a small, inorganic ion that circulates freely in the plasma and does **not bind to plasma proteins**. - Therefore, drug interactions involving **protein displacement**, where one drug displaces another from its binding sites, cannot occur with lithium. *Ramipril inhibits hepatic metabolism of lithium* - **Lithium** is unique in that it is not metabolized by the **liver** or any other organ in the body. - It is excreted 100% unchanged by the **kidneys**; thus, any drug interaction affecting lithium levels must primarily involve changes in **renal clearance** or excretion.

Question 89: A 44-year-old man with chronic schizophrenia on clozapine 550mg daily presents to A&E with 12-hour history of fever (39.2°C), muscle rigidity, and confusion. His heart rate is 125 bpm, BP 160/95 mmHg. He is sweating profusely. Blood tests show: WCC 16 × 10⁹/L (neutrophils 14), CK 8500 U/L, creatinine 145 μmol/L (baseline 80). He last took clozapine 18 hours ago. What is the most likely diagnosis?

A. Clozapine-induced agranulocytosis with sepsis
B. Neuroleptic malignant syndrome (Correct Answer)
C. Serotonin syndrome
D. Clozapine-induced myocarditis
E. Bacterial meningitis

Explanation: ***Neuroleptic malignant syndrome***- This patient presents with the classic tetrad of **Neuroleptic Malignant Syndrome (NMS)**: hyperpyrexia (39.2°C), severe **muscle rigidity**, altered mental status (confusion), and **autonomic instability** (tachycardia, hypertension, diaphoresis).- Laboratory findings of significantly elevated **Creatine Kinase (CK) (8500 U/L)** and **leukocytosis (WCC 16 × 10⁹/L)** are characteristic markers of NMS, reflecting severe muscle damage and systemic stress induced by antipsychotic therapy.*Clozapine-induced agranulocytosis with sepsis*- **Agranulocytosis** is defined by a severe lack of white blood cells (specifically **neutrophils < 0.5 x 10⁹/L**), whereas this patient has an **elevated white cell count (16 x 10⁹/L)** with high neutrophils.- While sepsis causes fever and tachycardia, it does not typically cause the profound **muscle rigidity** or the massive **CK elevation** seen in this clinical picture.*Serotonin syndrome*- While it shares features of autonomic instability and altered mental status, it is often distinguished by **hyperreflexia**, **clonus**, and **myoclonus**, rather than the severe 'lead-pipe' rigidity seen in NMS.- It is usually precipitated by **serotonergic agents** and less commonly presents with such extreme CK levels reflecting severe rhabdomyolysis.*Clozapine-induced myocarditis*- This typically presents with **chest pain**, dyspnea, and signs of heart failure, usually within the **first 4-8 weeks** of starting clozapine.- While it can cause tachycardia and fever, it would not explain the **generalized muscle rigidity** or the specific laboratory finding of **rhabdomyolysis** (elevated CK).*Bacterial meningitis*- Diagnosis usually involves **neck stiffness**, headache, photophobia, and altered mental status, which are not fully aligning with the primary presentation here.- Meningitis would not account for the **marked elevation in CK** or the severe **generalized muscle rigidity** characteristic of dopamine-antagonist toxicity.

Question 90: A 30-year-old woman with bipolar affective disorder type II has had six depressive episodes in the past 2 years despite treatment with lithium carbonate 1200mg daily (therapeutic levels). She has had only two brief hypomanic episodes. She finds the depressive episodes debilitating. What is the most appropriate medication adjustment to reduce the frequency of depressive episodes?

A. Add quetiapine
B. Add lamotrigine (Correct Answer)
C. Switch lithium to sodium valproate
D. Add fluoxetine
E. Increase lithium dose

Explanation: ***Add lamotrigine*** - **Lamotrigine** is specifically indicated and highly effective for preventing the recurrence of **depressive episodes** in patients with bipolar disorder, particularly **Bipolar II**, where depressive symptoms predominate. - It is the treatment of choice for depression prophylaxis when depressive relapses occur despite therapeutic **lithium** levels, offering superior evidence for this specific indication over most other mood stabilizers. *Add quetiapine* - While **quetiapine** is effective for acute bipolar depression and maintenance, it is generally considered a second-line option compared to **lamotrigine** for preventing depressive relapses due to its metabolic side-effect profile. - It is often reserved for those who do not respond to or cannot tolerate lamotrigine or lithium combination therapy. *Switch lithium to sodium valproate* - **Sodium valproate** is more effective for preventing **manic episodes** and mixed states than depressive ones, making it less suitable for this patient's predominant depressive presentation. - Switching away from **lithium**, which provides foundational mood stability and some depressive prophylaxis, may destabilize the patient's overall mood management. *Add fluoxetine* - Adding an **antidepressant** like fluoxetine carries a significant risk of inducing **hypomania** or **rapid cycling** in patients with bipolar disorder, even when combined with a mood stabilizer. - Current clinical guidelines recommend optimizing **mood stabilizers** for bipolar depression before considering antidepressants, which have limited long-term prophylactic evidence and higher risks in this population. *Increase lithium dose* - Since the patient already has **therapeutic lithium levels** at 1200mg daily, increasing the dose further is unlikely to provide additional prophylactic benefit specifically for depressive episodes. - Further titration significantly increases the risk of **lithium toxicity**, which can manifest as tremors, renal impairment, and thyroid dysfunction.

Question 91: A 35-year-old man with schizophrenia stabilised on risperidone 6mg daily for 2 years presents with reduced libido and erectile dysfunction. Examination reveals bilateral gynaecomastia. Blood tests show: prolactin 1850 mU/L (normal <400), testosterone 8.2 nmol/L (normal 10-30), TSH 2.1 mU/L, free T4 14 pmol/L. Pituitary MRI shows no structural abnormality. He is distressed and considering stopping medication. What is the most appropriate management?

A. Add cabergoline 0.5mg twice weekly
B. Switch to aripiprazole (Correct Answer)
C. Reduce risperidone to 4mg daily
D. Add testosterone replacement therapy
E. Continue risperidone and provide reassurance

Explanation: ***Switch to aripiprazole*** - **Aripiprazole** acts as a **partial D2 agonist**, which helps lower or normalize prolactin levels while maintaining antipsychotic efficacy. - It is the most appropriate management for **antipsychotic-induced hyperprolactinaemia** when symptoms like **gynaecomastia** and **sexual dysfunction** are present. *Add cabergoline 0.5mg twice weekly* - **Dopamine agonists** like cabergoline are generally avoided in schizophrenia because they can potentially **exacerbate psychotic symptoms**. - They are also associated with **cardiac valvular disease** and are for prolactinomas rather than drug-induced cases. *Reduce risperidone to 4mg daily* - Small dose reductions often fail to significantly reverse **hyperprolactinaemia** and increase the risk of **psychotic relapse**. - **Risperidone** has a high affinity for D2 receptors in the **tuberoinfundibular pathway**, making prolactin elevation likely even at moderate doses. *Add testosterone replacement therapy* - **Testosterone therapy** does not address the primary cause (prolactin-induced suppression of the **HPA axis**) and may be ineffective while prolactin is high. - Correcting the **hyperprolactinaemia** itself is the priority to restore endogenous hormone balance. *Continue risperidone and provide reassurance* - Reassurance is insufficient because the patient is **distressed** and at high risk of **treatment non-adherence**, which could lead to relapse. - Long-term hyperprolactinaemia can lead to systemic complications such as **osteoporosis**, necessitating active clinical management.

Question 92: A 26-year-old woman with bipolar affective disorder type I presents to the emergency department with a 2-day history of confusion, tremor, and vomiting. She has been taking lithium carbonate 800mg daily. On examination, she is drowsy with a GCS of 13, temperature 37.8°C, pulse 110 bpm regular, BP 105/70 mmHg. She has coarse tremor and hyperreflexia. Blood tests show: lithium 2.8 mmol/L, sodium 148 mmol/L, potassium 4.2 mmol/L, creatinine 185 μmol/L (baseline 70), eGFR 28 ml/min/1.73m². What is the most appropriate immediate management?

A. Stop lithium and commence IV 0.9% sodium chloride rehydration
B. Stop lithium and arrange urgent haemodialysis (Correct Answer)
C. Give activated charcoal and IV fluids
D. Stop lithium, give IV fluids, and commence sodium bicarbonate
E. Reduce lithium dose to 400mg daily and recheck level in 12 hours

Explanation: ***Stop lithium and arrange urgent haemodialysis*** - **Haemodialysis** is the definitive treatment for severe lithium toxicity, indicated when serum lithium levels exceed **2.5 mmol/L** (or 4.0 mmol/L in chronic toxicity) in the presence of severe neurological symptoms like **confusion**, **altered GCS**, **coarse tremor**, and **hyperreflexia**. - The patient also has significant **acute kidney injury** (creatinine 185 μmol/L, eGFR 28 ml/min/1.73m²), which severely impairs renal lithium clearance, making aggressive removal via haemodialysis essential to prevent permanent neurological damage. *Stop lithium and commence IV 0.9% sodium chloride rehydration* - While **intravenous fluids** (0.9% sodium chloride) are crucial for volume repletion and enhancing renal lithium excretion, they are insufficient as the sole treatment for severe lithium toxicity with profound **neurological compromise** and **acute kidney injury**. - This approach is typically appropriate for milder cases of lithium toxicity or as an adjunct therapy while preparing for more definitive interventions in severe cases. *Give activated charcoal and IV fluids* - **Activated charcoal** is ineffective in binding lithium due to lithium's small size and ionic nature, making it unsuitable for gastrointestinal decontamination in lithium overdose. - Management of recent ingestions typically focuses on **whole bowel irrigation** if within 1-2 hours of ingestion, or gastric lavage, not activated charcoal. *Stop lithium, give IV fluids, and commence sodium bicarbonate* - **Sodium bicarbonate** is used to alkalinize urine and serum in specific toxicities, such as salicylate overdose, to enhance drug excretion, but it has no established role in increasing **lithium elimination**. - The primary fluid for rehydration in lithium toxicity is **0.9% sodium chloride** to restore euvolemia and promote renal clearance, not bicarbonate. *Reduce lithium dose to 400mg daily and recheck level in 12 hours* - With a critically high lithium level of **2.8 mmol/L** and severe neurological symptoms and **acute kidney injury**, continuing or merely reducing the lithium dose is **medically contraindicated** and extremely dangerous. - Immediate and complete **discontinuation of lithium** is mandatory in any suspected or confirmed case of toxicity, followed by aggressive measures to eliminate the drug.

Question 93: A 41-year-old man with a 12-year history of paranoid schizophrenia has persistent auditory hallucinations despite trials of risperidone, olanzapine, and amisulpride at therapeutic doses for adequate durations. He is commenced on clozapine. After titration, he has been on clozapine 400mg daily for 8 weeks. His clozapine level is 380 ng/mL (therapeutic range 350-600 ng/mL) and norclozapine level is 190 ng/mL. He reports minimal improvement in hallucinations. What is the most appropriate next management step?

A. Increase clozapine to 500mg daily and recheck levels in 2 weeks (Correct Answer)
B. Add aripiprazole as augmentation
C. Switch to depot antipsychotic
D. Continue current dose for another 4 weeks before considering changes
E. Add amisulpride as augmentation

Explanation: ***Increase clozapine to 500mg daily and recheck levels in 2 weeks***- In **treatment-resistant schizophrenia**, clozapine monotherapy should be optimized to the maximum tolerated dose and **therapeutic levels** (ideally >420 ng/mL) before considering augmentation.- While the patient's level is technically within range (380 ng/mL), the **Maudsley Guidelines** recommend titration toward higher levels (up to 600 ng/mL) if clinical response remains inadequate after 8 weeks.*Add aripiprazole as augmentation*- Augmentation with **aripiprazole** is typically reserved for patients who have failed an optimized trial of clozapine monotherapy at higher serum levels.- It is often used to manage **clozapine-induced weight gain** or hyperprolactinemia rather than being the first step for therapeutic non-response.*Switch to depot antipsychotic*- **Clozapine** is the gold-standard treatment for **refractory schizophrenia**, and switching back to a depot form of a drug he has likely already failed (like risperidone) would be clinically inappropriate.- Depot medications address **non-adherence**, but the patient's current serum levels demonstrate he is already taking the oral medication reliably.*Continue current dose for another 4 weeks before considering changes*- While a full clozapine trial can take 3–6 months, continuing a **suboptimal dose** when the serum level is at the lower end of the range unnecessarily delays recovery.- Clinical guidelines advise proactive **dose adjustment** if a patient shows minimal improvement after the initial 8-week stabilization period.*Add amisulpride as augmentation*- **Amisulpride augmentation** is a recognized strategy for clozapine-resistant symptoms, but only after **clozapine monotherapy** has been fully optimized.- This patient's **clozapine/norclozapine ratio** and serum levels suggest there is still room to increase the primary medication before adding a second agent.

Question 94: A 38-year-old woman with bipolar affective disorder type I is admitted to the psychiatric ward with acute mania. She is agitated, hyperactive, and has had no sleep for 4 days. She is already taking sodium valproate 1500mg daily. Her valproate level is therapeutic at 85 mg/L. She has no known allergies. Physical examination is unremarkable except for agitation. What is the most appropriate additional pharmacological treatment?

A. Add haloperidol
B. Switch to lithium
C. Add lamotrigine
D. Increase sodium valproate to 2000mg daily
E. Add olanzapine (Correct Answer)

Explanation: ***Add olanzapine*** - In cases of **acute mania** where symptoms are not controlled by a mood stabilizer despite a **therapeutic serum level** (85 mg/L), NICE guidelines recommend adding an **antipsychotic** such as olanzapine. - **Atypical antipsychotics** like olanzapine are preferred due to their rapid onset of action and lower risk of **extrapyramidal symptoms** compared to typical agents. *Add haloperidol* - While effective for mania, **haloperidol** is a first-generation antipsychotic associated with a higher incidence of **extrapyramidal side effects** and tardive dyskinesia. - Current clinical preference favors **atypical antipsychotics** such as olanzapine, quetiapine, or risperidone as first-line add-on therapy. *Switch to lithium* - **Lithium** is a gold-standard mood stabilizer but has a **slow onset of action**, making it unsuitable as the sole change during a severe acute manic crisis. - Switching drugs during an acute episode creates a dangerous **treatment gap** that could worsen the patient's agitation and insomnia. *Add lamotrigine* - **Lamotrigine** is primarily indicated for the prevention of **bipolar depression** and maintenance therapy; it is not effective for treating **acute mania**. - Using this medication would fail to address the patient's immediate need for **sedation** and rapid mood stabilization. *Increase sodium valproate to 2000mg daily* - The patient's current **valproate level** is already within the therapeutic range (50-125 mg/L), so further dose escalation may increase **toxicity** without significantly improving the mania. - Adding a drug from a different class (antipsychotic) provides a more robust and **synergistic clinical response** than pushing a single mood stabilizer beyond therapeutic levels.

Question 95: A 29-year-old man with paranoid schizophrenia has been taking olanzapine 20mg daily for 18 months with good symptom control. He attends for routine monitoring. His weight has increased from 78kg to 96kg (BMI from 24 to 29.5 kg/m²). Fasting blood tests show: glucose 6.8 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L. He is concerned about the weight gain. What is the most appropriate management?

A. Continue olanzapine and refer to dietitian for lifestyle modification
B. Switch to aripiprazole (Correct Answer)
C. Add metformin 500mg twice daily
D. Switch to amisulpride
E. Reduce olanzapine to 15mg daily

Explanation: ***Switch to aripiprazole*** - **Olanzapine** is well-known for its high risk of inducing **metabolic syndrome**, including significant **weight gain**, dyslipidemia, and impaired glucose tolerance. - **Aripiprazole** has a significantly more favorable metabolic profile, being considered **metabolically neutral** or causing less weight gain, making it a suitable switch to mitigate the patient's established metabolic risks. *Continue olanzapine and refer to dietitian for lifestyle modification* - While lifestyle modifications are crucial, they are often insufficient to counteract the severe **metabolic side effects** caused by olanzapine, especially given the degree of **weight gain** and dyslipidemia. - The patient already exhibits pre-diabetes and significant metabolic derangement, requiring a more proactive intervention than just lifestyle advice to prevent progression to **Type 2 Diabetes** and cardiovascular disease. *Add metformin 500mg twice daily* - **Metformin** is an appropriate adjunctive treatment for antipsychotic-induced metabolic issues, but the primary management when a high-risk antipsychotic like olanzapine is the cause is to consider switching to a lower-risk agent. - Adding another medication increases **pill burden** and potential side effects, and doesn't address the underlying cause, which is the high metabolic risk of olanzapine. *Switch to amisulpride* - **Amisulpride** carries an intermediate risk of weight gain and metabolic side effects, and is also strongly associated with **hyperprolactinemia**, making it less ideal than aripiprazole when metabolic concerns are paramount. - While better than olanzapine, it does not offer the same **metabolic advantage** as aripiprazole, which is preferred when significant metabolic disturbance is the reason for switching. *Reduce olanzapine to 15mg daily* - A small dose reduction is unlikely to significantly reverse the established **metabolic dysfunction** and severe weight gain the patient has already experienced with olanzapine. - Reducing the dose also carries the risk of **relapse** of **paranoid schizophrenia**, as the patient's symptoms are currently well-controlled on the 20mg dose.

Question 96: A 34-year-old woman with bipolar affective disorder type I has been stable on lithium carbonate 1000mg daily for 4 years. She develops recurrent urinary tract infections and her GP requests blood tests. Results show: lithium level 0.8 mmol/L, creatinine 145 μmol/L (baseline 85 μmol/L), eGFR 42 ml/min/1.73m² (baseline 88). She is otherwise well with no oedema. What is the most appropriate next step in managing her bipolar disorder?

A. Continue lithium and monitor renal function closely
B. Reduce lithium dose and recheck levels
C. Stop lithium and switch to sodium valproate (Correct Answer)
D. Stop lithium and switch to lamotrigine
E. Add amiloride to protect renal function

Explanation: ***Stop lithium and switch to sodium valproate*** - The patient has developed significant **chronic kidney disease (CKD)** with eGFR falling from 88 to **42 ml/min/1.73m²**; guidelines recommend stopping lithium when eGFR is consistently below **45 ml/min/1.73m²**. - **Sodium valproate** is a first-line alternative for maintenance therapy in **Bipolar I disorder** to prevent mania and is not cleared renally, making it safer in this context. *Continue lithium and monitor renal function closely* - Continuing lithium despite a significant and sustained drop in **eGFR** risks progression to end-stage renal failure and increases the risk of **lithium toxicity** due to reduced clearance. - Monitoring alone is insufficient when the eGFR has already halved and is below the recommended threshold for **discontinuation**. *Reduce lithium dose and recheck levels* - While dose reduction lowers current serum levels, it does not stop the underlying **lithium-induced interstitial nephritis** which is likely driving the renal decline. - Guidelines emphasize that persistent renal impairment at this level requires an **alternative mood stabilizer** rather than just dosage adjustment. *Stop lithium and switch to lamotrigine* - **Lamotrigine** is primarily effective for preventing **bipolar depression** and is generally not the first choice for preventing mania in **Bipolar I disorder**. - Although it is safer for the kidneys, **sodium valproate** or an antipsychotic is usually preferred for stabilizing patients with a history of significant manic episodes. *Add amiloride to protect renal function* - **Amiloride** is specifically used to treat **lithium-induced nephrogenic diabetes insipidus** (polyuria) by blocking epithelial sodium channels in the collecting duct. - It does not reverse or prevent the decline in **glomerular filtration rate (GFR)** associated with chronic lithium-induced kidney disease.

Question 97: What is the minimum duration of symptoms required to diagnose schizophrenia according to ICD-11 criteria?

A. 2 weeks
B. 1 month (Correct Answer)
C. 3 months
D. 6 months
E. 1 year

Explanation: ***1 month*** - This is the minimum duration of **core clinical features** required for a diagnosis of schizophrenia according to **ICD-11 criteria**. - These features include **delusions, hallucinations, disorganized thinking, or negative symptoms** that cause significant impairment, present for most of the time during this period. *2 weeks* - A duration of **2 weeks** is typically too short for a diagnosis of schizophrenia and is more consistent with an **Acute and Transient Psychotic Disorder**. - Schizophrenia requires a more sustained pattern of symptoms to differentiate it from brief, self-limiting psychotic episodes. *3 months* - While schizophrenic symptoms often persist for this duration, **3 months** is not the specific minimum diagnostic criterion used by ICD-11. - This period may represent an **active phase** of the illness but is not the established cutoff for initial diagnosis. *6 months* - This duration, including prodromal, active, and residual symptoms, is the diagnostic requirement for **schizophrenia according to DSM-5 criteria**. - **ICD-11** employs a shorter **1-month** criterion to facilitate earlier diagnosis and clinical intervention. *1 year* - A duration of **one year** is significantly longer than the minimum required for an initial diagnosis of schizophrenia by either ICD-11 or DSM-5. - This timeframe is typically used to describe the **chronicity** or long-term course of the illness rather than its initial diagnostic threshold.

Question 98: A 32-year-old man with a 2-year history of schizophrenia presents with increasingly disorganised behaviour and poor self-care. He has been non-adherent with oral risperidone. His care coordinator reports he forgets to take medication and lacks insight into his illness. He has had three hospital admissions in the past year. He agrees he needs treatment but finds it difficult to remember tablets. What is the most appropriate pharmacological intervention?

A. Commence clozapine
B. Switch to paliperidone palmitate depot injection (Correct Answer)
C. Increase frequency of care coordinator visits to supervise oral medication
D. Commence community treatment order for enforced oral medication
E. Switch to quetiapine as it can be given once daily

Explanation: ***Switch to paliperidone palmitate depot injection*** - A **long-acting injectable (LAI)** antipsychotic is the first-line choice for patients with **non-adherence** to oral medication to prevent relapse and hospital readmission. - Since the patient has previously tolerated risperidone, **paliperidone palmitate** (the active metabolite of risperidone) is an appropriate choice that ensures consistent therapeutic levels without daily dosing. *Commence clozapine* - **Clozapine** is indicated for **treatment-resistant schizophrenia**, defined as failure of at least two different antipsychotics (one being an atypical) at an adequate dose for 6-8 weeks. - This patient's relapse is clearly linked to **non-adherence** rather than a failure of the medication's therapeutic efficacy itself. *Increase frequency of care coordinator visits to supervise oral medication* - While increasing supervision may help temporarily, it is **resource-intensive** and less reliable than the biochemical certainty of a depot injection. - It does not address the patient's specific struggle with **forgetfulness** as effectively as a long-acting formulation does. *Commence community treatment order for enforced oral medication* - A **Community Treatment Order (CTO)** is a legal framework that should only be used if less restrictive options, such as switching to a **depot injection**, have been considered or tried. - Since the patient **agrees he needs treatment**, a clinical solution to medication delivery is preferred over a legal enforcement of oral tablets. *Switch to quetiapine as it can be given once daily* - Switching to another oral medication like **quetiapine** does not solve the underlying issue of **non-adherence** due to forgetfulness. - Even **once-daily dosing** still requires the patient to remember a specific task every day, whereas a depot injection requires action only once every few weeks or months.

Question 99: A 45-year-old woman with schizophrenia presents to the community mental health team. She has been stable on aripiprazole for 2 years but reports distressing akathisia affecting her quality of life. Physical examination reveals restlessness and pacing. Vital signs are normal. Blood tests including prolactin are within normal limits. What is the most appropriate next management step?

A. Reduce aripiprazole dose
B. Add propranolol (Correct Answer)
C. Switch to quetiapine
D. Add procyclidine
E. Switch to paliperidone

Explanation: ***Add propranolol*** - **Propranolol**, a lipophilic **beta-blocker**, is the first-line pharmacological treatment for antipsychotic-induced **akathisia** due to its superior efficacy in reducing subjective distress and objective restlessness. - It is effective at low doses (e.g., 30–90 mg/day) and is preferred when the patient's primary psychiatric condition is otherwise stable on their current medication, avoiding medication changes that could risk relapse. *Switch to quetiapine* - While **quetiapine** has a lower risk of **extrapyramidal side effects (EPSEs)**, switching antipsychotics in a patient stable for 2 years carries a significant risk of **psychotic relapse**. - This strategy is usually reserved for cases where primary treatments for akathisia have failed or the current antipsychotic is not otherwise tolerated. *Add procyclidine* - **Procyclidine** is an anticholinergic medication primarily used for **parkinsonism** and **acute dystonia**, but it is generally ineffective for treating **akathisia**. - Using anticholinergics unnecessarily can lead to side effects like **cognitive impairment**, dry mouth, and blurred vision without resolving the restlessness. *Reduce aripiprazole dose* - Dose reduction can alleviate **akathisia**, but in a patient who has been stable for 2 years, lowering the dose may drop the serum level below the **therapeutic threshold**. - This intervention risks the return of **positive symptoms** of schizophrenia, making it a less desirable first step than adding a targeted treatment. *Switch to paliperidone* - **Paliperidone** is a potent **D2 receptor antagonist** and is frequently associated with a significant risk of **akathisia** and other EPSEs, similar to or even higher than aripiprazole in some cases. - Switching to another high-affinity antipsychotic would likely maintain or worsen the patient's restlessness rather than provide relief, and also carries the risk of destabilizing their schizophrenia.

Question 100: A 50-year-old man with a 22-year history of paranoid schizophrenia has been on clozapine 550mg daily for 8 years. He attends A&E with a 4-day history of increasing confusion, fever, and reduced mobility. Examination shows temperature 38.9°C, pulse 115 bpm, blood pressure 170/105 mmHg, marked muscle rigidity, profuse sweating, and fluctuating consciousness (GCS 13/15). Blood tests show: WBC 15.2 × 10⁹/L, neutrophils 12.1 × 10⁹/L, CK 8500 U/L, creatinine 156 µmol/L. What is the most likely diagnosis and immediate management priority?

A. Clozapine-induced agranulocytosis; stop clozapine and start antibiotics
B. Neuroleptic malignant syndrome; stop clozapine and provide supportive care in HDU/ICU (Correct Answer)
C. Serotonin syndrome; stop clozapine and give cyproheptadine
D. Bacterial meningitis; continue clozapine and start ceftriaxone
E. Acute catatonia; continue clozapine and give lorazepam

Explanation: ***Neuroleptic malignant syndrome; stop clozapine and provide supportive care in HDU/ICU***- The patient presents with the classic tetrad of **Neuroleptic Malignant Syndrome (NMS)**: **hyperthermia** (fever 38.9°C), **autonomic instability** (tachycardia, hypertension, profuse sweating), **marked muscle rigidity**, and **altered mental status** (confusion, fluctuating consciousness).- Lab findings of significantly elevated **Creatine Kinase (CK)** (8500 U/L) and **leukocytosis** further confirm NMS, necessitating the immediate withdrawal of the antipsychotic and intensive supportive care in a high-dependency unit or ICU.*Clozapine-induced agranulocytosis; stop clozapine and start antibiotics*- **Agranulocytosis** is characterized by a dangerously low **neutrophil count** (<0.5 x 10⁹/L), but this patient exhibits **neutrophilia** (12.1 × 10⁹/L), making this diagnosis incorrect.- While fever and confusion can occur in agranulocytosis-induced sepsis, they would not be accompanied by profound **lead-pipe muscle rigidity** and massive CK elevation.*Serotonin syndrome; stop clozapine and give cyproheptadine*- **Serotonin syndrome** is typically characterized by **hyperreflexia**, **clonus**, and myoclonus, in contrast to the **"lead-pipe" muscle rigidity** seen in NMS.- It usually results from excessive serotonergic activity, often due to drug interactions involving SSRIs or MAOIs, not primarily from dopamine-blocking agents like clozapine.*Bacterial meningitis; continue clozapine and start ceftriaxone*- While fever and confusion are present, the absence of classic signs like **neck stiffness**, **photophobia**, or a characteristic rash makes meningitis a less likely primary diagnosis.- Meningitis does not explain the **markedly elevated CK** level or the severe autonomic instability and pronounced muscle rigidity observed.*Acute catatonia; continue clozapine and give lorazepam*- **Catatonia** involves motor signs such as stupor, mutism, or waxy flexibility, but it typically lacks the extreme **hyperthermia** and significant **autonomic instability** (e.g., severe sweating, labile blood pressure) seen here.- Continuing clozapine in a patient with suspected NMS is highly dangerous and could lead to worsening of the condition and potential fatal outcomes, whereas NMS necessitates immediate withdrawal of the antipsychotic.

Question 101: A 27-year-old man diagnosed with paranoid schizophrenia 14 months ago has been treated with olanzapine 20mg daily with good control of positive symptoms. He now presents with concerns about weight gain (BMI increased from 24 to 31 kg/m²), excessive daytime sleepiness, and loss of libido. Fasting blood tests show: glucose 6.8 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L, prolactin 420 mU/L (normal). He is worried about these side effects but anxious about changing medication. What is the most appropriate management?

A. Continue olanzapine and add metformin 500mg twice daily
B. Switch to aripiprazole with gradual cross-titration (Correct Answer)
C. Reduce olanzapine to 15mg daily and monitor weight
D. Continue olanzapine and refer to dietician and lifestyle programme
E. Switch to amisulpride 400mg twice daily

Explanation: ***Switch to aripiprazole with gradual cross-titration*** - **Aripiprazole** is a **partial dopamine agonist** known for its favorable **metabolic profile**, making it a good choice for patients experiencing significant weight gain, dyslipidemia, and glucose dysregulation with other antipsychotics. - A **gradual cross-titration** allows for a smooth transition, minimizing the risk of **withdrawal symptoms** from olanzapine and reducing the chance of **psychotic relapse** as aripiprazole is introduced, while addressing metabolic concerns. *Continue olanzapine and add metformin 500mg twice daily* - While **metformin** can help mitigate **weight gain** and improve **insulin sensitivity**, it does not fully address other olanzapine-related side effects such as **excessive daytime sleepiness** or **loss of libido**. - Continuing the causative agent (olanzapine) fails to resolve the holistic burden of side effects as effectively as a medication switch that targets the root cause. *Reduce olanzapine to 15mg daily and monitor weight* - A minor dose reduction from 20mg to 15mg is unlikely to significantly reverse established **metabolic side effects** and **weight gain** (BMI from 24 to 31 kg/m²). - This approach risks **psychotic relapse** if the lower dose is insufficient, and it does not adequately address the patient's concerns regarding **libido loss** and **sedation**. *Continue olanzapine and refer to dietician and lifestyle programme* - While **lifestyle interventions** are recommended, they are often insufficient to counteract the potent **orexigenic effects** and metabolic shifts caused by high-dose olanzapine, especially with established impaired fasting glucose and hypertriglyceridemia. - This option does not address the **excessive daytime sleepiness** or **loss of libido**, and provides insufficient intervention for significant **cardiovascular risk** factors. *Switch to amisulpride 400mg twice daily* - **Amisulpride** is associated with a relatively high risk of **hyperprolactinemia**, which could worsen the patient's existing concern about **loss of libido** and potentially lead to other prolactin-related side effects. - Although it has a lower metabolic risk than olanzapine, it is not as **metabolically neutral** as aripiprazole, and its **prolactin-elevating potential** makes it less suitable given the patient's current symptoms.

Question 102: A 39-year-old woman with bipolar affective disorder has been taking sodium valproate 1500mg daily for 6 years with excellent mood stability and no episodes. She now wishes to conceive. She has tried lamotrigine previously but experienced rash requiring discontinuation. She has had three severe manic episodes in the past requiring hospital admission. What is the most appropriate management approach?

A. Continue valproate with pregnancy prevention programme and high-dose folic acid
B. Switch to lithium carbonate 800mg daily before conception (Correct Answer)
C. Stop valproate and trial quetiapine 300mg twice daily
D. Continue valproate during conception but stop immediately when pregnancy confirmed
E. Stop valproate and remain on no medication with close monitoring

Explanation: ***Switch to lithium carbonate 800mg daily before conception*** - **Sodium valproate** is strictly contraindicated for women planning pregnancy due to high risks of **teratogenicity** (e.g., neural tube defects) and **neurodevelopmental delay**. - **Lithium** is the preferred alternative for prophylaxis of severe **manic episodes** in those planning pregnancy, as it has a lower teratogenic risk than valproate and robust evidence for long-term mood stability. *Continue valproate with pregnancy prevention programme and high-dose folic acid* - The **Pregnancy Prevention Programme (PPP)** aims to *prevent* pregnancy while on valproate, not to enable conception due to its significant risks. - Even with high-dose **folic acid**, the risk of **major congenital malformations** and cognitive impairment from valproate exposure remains unacceptably high. *Stop valproate and trial quetiapine 300mg twice daily* - While **quetiapine** can be used in pregnancy, it generally has less robust evidence for the prevention of **severe mania** compared to lithium, especially in a patient with a history of frequent hospitalizations. - Given the patient's history of **three severe manic episodes**, lithium is clinically prioritized as the most effective mood stabilizer to prevent recurrence. *Continue valproate during conception but stop immediately when pregnancy confirmed* - The most critical period for **neural tube development** occurs in the first few weeks of gestation, often before pregnancy is confirmed. - Continuing valproate during the conception phase exposes the fetus during this **high-risk window**, potentially causing irreversible structural defects before discontinuation. *Stop valproate and remain on no medication with close monitoring* - The risk of **relapse** into severe mania in the perinatal period is extremely high (up to 50-70%) for women with a history of serious bipolar disorder. - Abruptly stopping medication without a cross-taper to a new **mood stabilizer** is unsafe given her history of severe illness requiring **hospital admission**.

Question 103: A 46-year-old man with bipolar affective disorder type I is admitted with acute mania (YMRS score 38). He is aggressive, refusing oral medication, and requires restraint. He has no known allergies. Physical examination shows pulse 118 bpm, blood pressure 165/95 mmHg, temperature 37.4°C. He has no cardiovascular history and ECG shows sinus tachycardia only. What is the most appropriate initial pharmacological intervention?

A. Intramuscular haloperidol 5mg plus promethazine 50mg (Correct Answer)
B. Intramuscular olanzapine 10mg
C. Intramuscular lorazepam 4mg
D. Oral risperidone 3mg dissolved in water
E. Intramuscular aripiprazole 9.75mg

Explanation: ***Intramuscular haloperidol 5mg plus promethazine 50mg*** - This combination is a first-line recommendation for **rapid tranquilisation** in patients with severe **acute mania** and aggression who refuse oral medication. - The addition of **promethazine** provides essential sedation and reduces the risk of **extrapyramidal side effects**, particularly acute dystonia, caused by high-potency antipsychotics. *Intramuscular olanzapine 10mg* - While effective, **IM olanzapine** carries a significant risk of fatal **cardiorespiratory depression** if administered within an hour of benzodiazepines. - It is generally avoided in rapid tranquilisation protocols where multiple agents or rescue benzodiazepines might be needed shortly after. *Intramuscular lorazepam 4mg* - **Lorazepam** is an alternative for rapid tranquilisation but acts primarily as a sedative without specific **antimanic efficacy**. - A dose of **4mg IM** exceeds the standard initial recommended dose (usually 1-2mg) for most rapid tranquilisation protocols. *Oral risperidone 3mg dissolved in water* - **Oral medication** is inappropriate in this scenario as the patient is actively **aggressive and refusing** oral intake, requiring restraint. - Rapid tranquilisation protocols must bypass the oral route when a patient presents a high risk of **violence and aggression** and refuses cooperation. *Intramuscular aripiprazole 9.75mg* - **IM aripiprazole** has limited evidence and is less commonly used than the haloperidol/promethazine combination for **acute behavioral disturbance** in mania. - It is generally less effective for achieving the rapid, profound **sedation** required for a patient with a very high YMRS score and physical aggression.

Question 104: A 33-year-old woman with paranoid schizophrenia has been taking amisulpride 800mg daily for 18 months with partial improvement in positive symptoms but persistent negative symptoms including social withdrawal, lack of motivation, and blunted affect. She reports feeling 'emotionally flat' and unable to experience pleasure. Physical examination and blood tests including prolactin are normal. She is concerned about her quality of life. What is the most appropriate management to address her negative symptoms?

A. Increase amisulpride to 1200mg daily
B. Add cognitive behavioural therapy for psychosis (Correct Answer)
C. Switch to aripiprazole monotherapy
D. Add an SSRI antidepressant
E. Add lamotrigine 200mg daily

Explanation: ***Add cognitive behavioural therapy for psychosis*** - **NICE guidelines** recommend offering **CBTp** (Cognitive Behavioural Therapy for psychosis) to all patients with schizophrenia to address both positive and negative symptoms. - Evidence suggests that psychological interventions are more effective than pharmacological adjustments for improving **negative symptoms** and overall **quality of life** in stable patients. *Increase amisulpride to 1200mg daily* - Higher doses of antipsychotics primarily target **D2 receptors** to control positive symptoms and are generally ineffective for **negative symptoms**. - Exceeding the standard dose (800mg) increases the risk of **extrapyramidal side effects** and secondary negative symptoms due to excessive dopamine blockade. *Switch to aripiprazole monotherapy* - While **aripiprazole** has partial agonist properties that might theoretically aid negative symptoms, switching risks **relapse** of the partially controlled positive symptoms. - The patient's **prolactin** is already normal, so the specific benefit of switching to a 'prolactin-sparing' drug to alleviate emotional flattening is less justified here. *Add an SSRI antidepressant* - **SSRIs** are indicated if the patient has a comorbid **depressive episode**, but they are not the primary treatment for core **negative symptoms** of schizophrenia. - The patient's symptoms (blunted affect, amotivation) are consistent with **primary negative symptoms** rather than secondary depressive features. *Add lamotrigine 200mg daily* - **Lamotrigine** is primarily used as a mood stabilizer in **bipolar disorder** or for specific types of epilepsy and is not routinely indicated for schizophrenia. - There is no strong clinical evidence to support adding lamotrigine to improve **negative symptoms** such as social withdrawal or anhedonia.

Question 105: What is the recommended frequency of lithium level monitoring in a patient who has been stable on lithium therapy for more than 2 years with consistent results?

A. Every 3 months (Correct Answer)
B. Every 6 months
C. Every 12 months
D. Every month
E. Every 2 months

Explanation: ***Every 3 months*** - For patients stable on **lithium therapy** for more than 2 years with consistent levels, the standard monitoring interval is **every 3 months**. - This frequency is necessary due to lithium's **narrow therapeutic index** and the risk of toxicity from dehydration or drug interactions. *Every 6 months* - This interval is typically reserved for monitoring **thyroid function (TSH)** and **renal function (U&Es)** in stable patients. - Monitoring lithium levels only twice a year is insufficient to ensure safety and detect fluctuations in **serum concentration**. *Every 12 months* - Annual monitoring is inappropriate for lithium because it does not allow for timely detection of **nephrotoxicity** or toxic lithium levels. - Such a long interval significantly increases the risk of unrecognized **lithium toxicity** and long-term side effects. *Every month* - Monthly monitoring is primarily indicated during the **titration phase** or when dose adjustments are being made to reach a **steady state**. - While safe, it is unnecessary and not cost-effective for a patient who has remained **clinically stable** for over two years. *Every 2 months* - This frequency is generally used for patients transitioning from titration to stability or those with **borderline renal function**. - It is more frequent than required by guidelines for patients with a proven history of **consistent therapeutic levels**.

Question 106: A 55-year-old man with chronic paranoid schizophrenia has been on clozapine 600mg daily for 5 years with good symptom control. He presents to A&E with a 2-day history of severe constipation, abdominal distension, and vomiting. Examination shows temperature 37.8°C, pulse 105 bpm, blood pressure 110/70 mmHg, abdomen markedly distended with absent bowel sounds. Abdominal X-ray shows dilated bowel loops with maximum caecal diameter of 11cm. Blood tests show WBC 11.2 × 10⁹/L, neutrophils 8.5 × 10⁹/L, CRP 45 mg/L. What is the most important immediate management step?

A. Stop clozapine and start lactulose
B. Urgent surgical review for possible bowel obstruction (Correct Answer)
C. Continue clozapine and start metoclopramide
D. Stop clozapine and check clozapine level
E. Start broad-spectrum antibiotics and IV fluids

Explanation: ***Urgent surgical review for possible bowel obstruction*** - The patient presents with classic signs of **clozapine-induced gastrointestinal hypomotility (CIGH)**, which has progressed to a severe state of suspected **bowel obstruction** or pseudo-obstruction.- A **caecal diameter of 11cm** (critical threshold >9cm), absent bowel sounds, and systemic signs of inflammation (tachycardia, fever, elevated WBC/CRP) strongly indicate a **surgical emergency** requiring immediate assessment and intervention to prevent **perforation** or **toxic megacolon**.*Stop clozapine and start lactulose* - While stopping clozapine is critical, **lactulose** is an osmotic laxative that can produce gas and worsen **abdominal distension** and pressure in a patient with a potentially complete bowel obstruction.- In acute, severe bowel obstruction, laxatives are contraindicated as they can exacerbate the condition and increase the risk of **perforation**.*Continue clozapine and start metoclopramide* - Continuing clozapine is contraindicated as its potent **anticholinergic effects** are the direct cause of the severe gastrointestinal hypomotility.- **Metoclopramide** (a prokinetic agent) should be avoided in suspected mechanical bowel obstruction as it can increase pressure against the obstruction, potentially leading to **bowel ischemia** or **perforation**.*Stop clozapine and check clozapine level* - While stopping clozapine is appropriate, checking **clozapine levels** is not the most immediate or critical management step in this acute, life-threatening presentation.- The patient's clinical picture is a **surgical emergency** that requires urgent physical assessment and intervention, not a delay for routine lab results.*Start broad-spectrum antibiotics and IV fluids* - **IV fluids** are crucial for supportive care in a distressed patient, but they do not address the primary issue of **bowel obstruction**.- **Broad-spectrum antibiotics** may be indicated later if perforation or sepsis is confirmed, but the immediate priority is identifying and managing the underlying **mechanical/functional obstruction** through surgical assessment.

Question 107: A 42-year-old woman with bipolar affective disorder type II has experienced eight depressive episodes in the past 2 years despite treatment with lithium carbonate 800mg daily (level 0.7 mmol/L). She has had only two brief hypomanic episodes in the same period. She reports the depressive episodes are severely impacting her ability to work and maintain relationships. Physical examination and routine blood tests are normal. What is the most appropriate medication adjustment?

A. Add lamotrigine 25mg daily and titrate to 200mg daily (Correct Answer)
B. Switch lithium to sodium valproate 1000mg daily
C. Add quetiapine 300mg at night
D. Increase lithium to achieve level of 0.9-1.0 mmol/L
E. Add olanzapine 10mg daily

Explanation: ***Add lamotrigine 25mg daily and titrate to 200mg daily*** - **Lamotrigine** is highly effective specifically for preventing **depressive episodes** in patients with **bipolar II disorder**, making it the first-line augmentation choice for this patient's clinical profile. - A slow titration starting at **25mg daily** is mandatory to minimize the risk of serious dermatological adverse effects, such as **Stevens-Johnson syndrome**. *Switch lithium to sodium valproate 1000mg daily* - **Sodium valproate** is generally more effective at preventing **manic** rather than depressive episodes and is less suitable for a patient with frequent depression. - It is generally contraindicated in **women of childbearing potential** due to significant **teratogenic risks**, unless no other options are available. *Add quetiapine 300mg at night* - While **quetiapine** is effective for treating **acute bipolar depression**, it is often less preferred than lamotrigine for long-term **maintenance/prevention** of frequent depressive relapses specifically in bipolar II. - Use is frequently limited by metabolic side effects such as **sedation**, **weight gain**, and glucose dysregulation compared to lamotrigine. *Increase lithium to achieve level of 0.9-1.0 mmol/L* - The patient's lithium level is already within the **therapeutic range (0.6–0.8 mmol/L)** for maintenance, and the clinical issue is a lack of efficacy for prophylaxis, not sub-therapeutic levels. - Increasing to a higher range significantly increases the risk of **lithium toxicity** and chronic renal impairment without guaranteeing better control of depressive symptoms. *Add olanzapine 10mg daily* - **Olanzapine** is primarily utilized for the management of **mania** and preventing manic relapses rather than treating or preventing bipolar depression. - It is associated with significant **metabolic syndrome** risks, including substantial weight gain and lipid abnormalities, which make it less ideal for long-term maintenance.

Question 108: A 28-year-old man with a 4-year history of paranoid schizophrenia presents to the community mental health team. Despite trials of risperidone, olanzapine, and quetiapine at adequate doses for sufficient duration, he continues to experience persistent auditory hallucinations and delusions significantly impairing his functioning. He has been concordant with all treatments. Physical examination and baseline blood tests including FBC, U&Es, LFTs, lipids, HbA1c, and ECG are normal. What is the most appropriate next step in management?

A. Start clozapine 12.5mg daily and titrate according to protocol (Correct Answer)
B. Add aripiprazole to current antipsychotic
C. Trial of amisulpride 400mg twice daily
D. Start depot paliperidone 150mg monthly
E. Refer for cognitive behavioural therapy for psychosis

Explanation: ***Start clozapine 12.5mg daily and titrate according to protocol***- The patient meets the criteria for **treatment-resistant schizophrenia**, defined as a lack of response to at least two different antipsychotics (one being a second-generation) at adequate doses and duration.- **Clozapine** is the gold-standard treatment for resistance and must be started at a low dose with strict **Full Blood Count (FBC)** monitoring due to the risk of **agranulocytosis**.*Add aripiprazole to current antipsychotic*- Antipsychotic **polypharmacy** is generally not recommended until clozapine has been trialed alone and found to be insufficient.- Prioritizing **clozapine monotherapy** is the evidence-based next step over adding a second-generation partial agonist like aripiprazole.*Trial of amisulpride 400mg twice daily*- After failing three different antipsychotics (risperidone, olanzapine, and quetiapine), trying a fourth non-clozapine agent like **amisulpride** is unlikely to achieve clinical remission.- Guidelines emphasize that delaying clozapine in favor of multiple standard antipsychotic trials leads to poorer long-term **functional outcomes**.*Start depot paliperidone 150mg monthly*- **Long-acting injectables (LAIs)** or depots are primarily used to address issues with **treatment concordance** (adherence).- Since this patient has been **concordant** with his oral medications, the failure is pharmacological rather than behavioral, making a depot formulation inappropriate.*Refer for cognitive behavioural therapy for psychosis*- **CBTp** is a valuable adjunctive treatment but should not delay the pharmacological management of treatment-resistant symptoms with **clozapine**.- While recommended for all patients with schizophrenia, it is secondary to resolving **persistent hallucinations and delusions** that have failed multiple biological interventions.

Question 109: A 31-year-old woman with bipolar affective disorder type I has been stable on lithium carbonate 1000mg daily for 4 years. She attends preconception counselling as she is planning pregnancy with her partner. Her current lithium level is 0.75 mmol/L and she has had no mood episodes for 3 years. She is very concerned about risks to the baby and asks about the safest option. What is the most appropriate advice regarding lithium management?

A. Continue lithium throughout pregnancy as risk of relapse outweighs teratogenic risk (Correct Answer)
B. Stop lithium immediately and remain on no medication during pregnancy
C. Switch to lamotrigine before conception and maintain throughout pregnancy
D. Stop lithium immediately and start quetiapine before conception
E. Gradually withdraw lithium after conception is confirmed

Explanation: ***Continue lithium throughout pregnancy as risk of relapse outweighs teratogenic risk***- For patients stable on **lithium** with severe **Bipolar I Disorder**, the risk of a high-severity **relapse** during pregnancy (often exceeding 50-70%) typically outweighs the low absolute risk of **Ebstein’s anomaly**.- Modern evidence suggests the risk of **Ebstein’s anomaly** is approximately 1 in 1000–2000, which is lower than historical estimates, and can be monitored via **fetal echocardiography**.*Stop lithium immediately and remain on no medication during pregnancy*- Stopping medication abruptly in **Bipolar I** carries an extremely high risk of **postpartum psychosis** and relapse, which can be life-threatening for both mother and baby.- Relapse during pregnancy is associated with poor maternal self-care, **obstetric complications**, and increased risk of hospitalization.*Switch to lamotrigine before conception and maintain throughout pregnancy*- While **lamotrigine** is safer regarding teratogenicity, it is primarily effective for preventing **bipolar depression** but is not effective in preventing **mania** in Bipolar I.- Switching a patient who has been stable for 4 years on a specific regimen introduces significant **clinical instability** during a vulnerable period.*Stop lithium immediately and start quetiapine before conception*- Although **quetiapine** has a lower teratogenic profile, switching medications when a patient is currently stable on a known effective dose of **lithium** risks **breakthrough mood episodes**.- NICE guidelines recommend against switching if the patient has a history of **severe relapses** that were only controlled by their current medication.*Gradually withdraw lithium after conception is confirmed*- Initial **organogenesis** occurs very early in the first trimester; withdrawing lithium after conception is confirmed may not completely eliminate the risk of **congenital malformations**.- Relapse risk is highest during the first few months after discontinuation, creating a high-stress environment for the developing **fetus**.

Question 110: A 36-year-old man with paranoid schizophrenia has been on clozapine 400mg daily for 18 months with good symptom control. He attends for routine blood monitoring. His results show: WBC 3.2 × 10⁹/L, neutrophils 1.4 × 10⁹/L, haemoglobin 138 g/L, platelets 245 × 10⁹/L. He is asymptomatic with no signs of infection. His previous WBC 3 weeks ago was 4.1 × 10⁹/L with neutrophils 2.1 × 10⁹/L. What is the most appropriate immediate action?

A. Continue clozapine and repeat blood tests in 1 week
B. Stop clozapine immediately and arrange urgent haematology review
C. Continue clozapine and repeat blood tests in 3 days (Correct Answer)
D. Reduce clozapine dose to 300mg daily and repeat bloods in 1 week
E. Stop clozapine immediately and start olanzapine 20mg daily

Explanation: ***Continue clozapine and repeat blood tests in 3 days*** - The patient's **neutrophil count of 1.4 × 10⁹/L** falls into the **Amber light** monitoring category, which, in some protocols, is defined for an ANC between 1.0 and 1.5 × 10⁹/L. - In this **Amber light** situation, clozapine treatment is continued, but monitoring frequency must be increased to at least **twice weekly** (every 3-4 days) until counts stabilize or improve. *Continue clozapine and repeat blood tests in 1 week* - **Weekly monitoring** is the routine frequency for stable patients in the Green light category, not for those with an Amber light result indicating a potential risk. - Waiting a full week before rechecking bloods for an **Amber light** result could delay critical intervention if the neutrophil count continues to decline rapidly. *Stop clozapine immediately and arrange urgent haematology review* - **Immediate cessation** of clozapine is indicated for **Red light** results, typically when the neutrophil count drops below 1.0 × 10⁹/L or the WBC is <3.0 × 10⁹/L. - The patient's current results do not meet these **Red light** criteria, and premature discontinuation risks a severe **psychotic relapse** in treatment-resistant schizophrenia. *Reduce clozapine dose to 300mg daily and repeat bloods in 1 week* - **Dose reduction** is not a recommended or evidence-based strategy for managing clozapine-induced **neutropenia**; the focus is on monitoring and cessation if thresholds are met. - Repeating blood tests in **1 week** is insufficient for an Amber light scenario, which requires more frequent monitoring to detect any further deterioration promptly. *Stop clozapine immediately and start olanzapine 20mg daily* - This action is premature, as the patient's hematological parameters have not yet reached the **Red light** threshold that necessitates immediate clozapine discontinuation. - Replacing clozapine with **olanzapine** may not be effective for a patient whose condition has been controlled by clozapine, a drug reserved for **treatment-resistant schizophrenia**.

Question 111: A 24-year-old woman is brought to A&E by her family. Over the past 5 days, she has become increasingly agitated, claiming she is a prophet chosen by God to save humanity. She has not slept for 72 hours, has spent £8000 on credit cards buying gifts for strangers, and attempted to break into a church to preach. She has no previous psychiatric history. Physical examination shows pulse 110 bpm, blood pressure 145/90 mmHg, temperature 37.2°C, and pupils equal and reactive. Urine drug screen is negative. What is the most appropriate initial pharmacological management?

A. Oral olanzapine 15mg daily (Correct Answer)
B. Oral haloperidol 5mg three times daily
C. Oral lithium carbonate 400mg twice daily
D. Intramuscular lorazepam 2mg stat
E. Oral sodium valproate 500mg twice daily

Explanation: ***Oral olanzapine 15mg daily*** - The patient presents with **acute mania with psychotic features** (grandiose delusions, reduced sleep, impulsivity); **NICE guidelines** recommend an **antipsychotic** (quetiapine, risperidone, or **olanzapine**) as first-line monotherapy. - **Atypical antipsychotics** are preferred due to their rapid onset of action and lower risk of **extrapyramidal side effects** compared to first-generation options. *Oral haloperidol 5mg three times daily* - While effective for acute mania, **haloperidol** carries a significantly higher risk of **acute dystonia** and other **extrapyramidal symptoms**. - Modern clinical practice prefers **atypical antipsychotics** over typical ones for the initial management of a first episode unless specifically contraindicated. *Oral lithium carbonate 400mg twice daily* - **Lithium** is highly effective for long-term maintenance but has a **slow onset of action**, typically taking 5 to 7 days to reach therapeutic effects. - For an acute psychiatric emergency with severe symptoms, it is not used as first-line monotherapy but can be **added later** if antipsychotics are insufficient. *Intramuscular lorazepam 2mg stat* - **Benzodiazepines** like **lorazepam** are useful as adjunctive therapy for immediate **sedation** and behavioral control but do not treat the underlying **manic process** or psychosis. - **Intramuscular** administration is reserved for patients refusing oral medication or requiring **rapid tranquilization** for safety; this patient is currently accepting oral options. *Oral sodium valproate 500mg twice daily* - **Sodium valproate** is a mood stabilizer that generally takes longer to work than antipsychotics in the **acute phase** of mania. - It is strictly **contraindicated** in women of **childbearing potential** (unless a pregnancy prevention program is in place) due to its high **teratogenic risk**, making it an inappropriate initial choice for this 24-year-old woman.

Question 112: A 53-year-old man with bipolar affective disorder type I has been maintained on lithium carbonate 800mg daily for 8 years with excellent mood stability. Recent routine blood tests show: serum creatinine 145 µmol/L (baseline 85 µmol/L), eGFR 48 ml/min/1.73m² (previously 78 ml/min/1.73m²), lithium level 0.85 mmol/L (therapeutic range 0.6-1.0), TSH 5.2 mU/L. Urine dipstick shows no proteinuria. He has no other medical conditions and takes no other regular medications. What is the most appropriate next step in management?

A. Continue lithium and repeat renal function in 3 months
B. Reduce lithium dose to 600mg daily
C. Switch to sodium valproate 1000mg daily
D. Refer to nephrology and continue lithium pending review (Correct Answer)
E. Stop lithium immediately and switch to lamotrigine

Explanation: ***Refer to nephrology and continue lithium pending review***- NICE guidelines recommend a **nephrology referral** if the eGFR falls below **60 ml/min/1.73m²** or if there is a significant decline in renal function while on lithium.- Given the patient's **mood stability** for 8 years, lithium should not be stopped abruptly without specialist consultation to weigh the risks of **lithium nephrotoxicity** against the risk of **bipolar relapse**.*Continue lithium and repeat renal function in 3 months*- This approach is inappropriate because the **eGFR decline** (from 78 to 48) is substantial and places the patient in **Stage 3B Chronic Kidney Disease**.- Waiting three months ignores the need for a specialist evaluation to determine the cause of the **rising serum creatinine** and potential long-term damage.*Reduce lithium dose to 600mg daily*- While reducing the dose may lower serum levels, it does not address the underlying **renal impairment** that requires specialist diagnostic workup.- Adjusting the dose without expert advice may also drop levels below the **therapeutic range**, risking a **manic or depressive relapse**.*Switch to sodium valproate 1000mg daily*- Changing maintenance therapy in a stable patient is a high-risk decision that should be guided by a multidisciplinary approach involving a **nephrologist** and psychiatrist.- **Sodium valproate** is an alternative, but the immediate priority is investigating the **acute-on-chronic decline** in renal function rather than switching medication.*Stop lithium immediately and switch to lamotrigine*- Abrupt discontinuation of lithium carries a high risk of **rebound mania** and should be avoided in patients with long-term stability.- **Lamotrigine** is primarily used for **bipolar depression prophylaxis** and is not the first-choice replacement for preventing mania in Type I bipolar disorder.

Question 113: A 47-year-old woman with a 15-year history of paranoid schizophrenia presents to the community mental health team. She has been stable on risperidone long-acting injection 50mg fortnightly for the past 3 years. She reports new onset amenorrhoea for 6 months and occasional milky discharge from her nipples. Blood tests show prolactin level of 2800 mU/L (normal range 102-496 mU/L). She is otherwise well and wishes to continue her current treatment as she feels it controls her symptoms effectively. What is the most appropriate management?

A. Switch to aripiprazole long-acting injection (Correct Answer)
B. Add cabergoline to current regimen
C. Reduce risperidone dose to 37.5mg fortnightly
D. Switch to olanzapine oral therapy
E. Continue current treatment and monitor prolactin levels

Explanation: ***Switch to aripiprazole long-acting injection***- **Aripiprazole** is a **dopamine partial agonist** that effectively reduces **prolactin** levels while maintaining adequate therapeutic efficacy for schizophrenia.- Switching to the **long-acting injection** (LAI) formulation ensures continued **adherence** and stability in her psychiatric treatment, while resolving the symptomatic **hyperprolactinaemia** (amenorrhoea and galactorrhoea).*Add cabergoline to current regimen*- **Cabergoline** is a potent **dopamine agonist** that would counteract the antipsychotic effect of risperidone, significantly risking **psychotic relapse**.- Adding another medication increases **polypharmacy**, the risk of drug-drug interactions, and potential for adverse effects, which should be avoided if a monotherapy alternative exists.*Reduce risperidone dose to 37.5mg fortnightly*- While **risperidone-induced hyperprolactinaemia** is dose-dependent, a small reduction may not sufficiently lower the severely elevated prolactin level (2800 mU/L) to resolve symptoms.- Lowering the dose of an effective, stable maintenance treatment carries a high risk of **psychotic relapse** in a patient who has been well-controlled for three years.*Switch to olanzapine oral therapy*- Moving from a long-acting injection to **oral therapy** in a patient with chronic paranoid schizophrenia significantly increases the risk of **non-adherence**, which is a primary reason for relapse.- Although **olanzapine** has a lower propensity for hyperprolactinaemia compared to risperidone, it is not as effective at reducing existing elevated prolactin as aripiprazole, and the adherence risk is paramount.*Continue current treatment and monitor prolactin levels*- Simply monitoring is an inappropriate management strategy given the patient is **symptomatic** (amenorrhoea and galactorrhoea), indicating a significant clinical problem.- Long-term untreated hyperprolactinaemia leads to **hypoestrogenism**, increasing the risk of serious complications like **osteoporosis**, bone fractures, and potential cardiovascular issues, necessitating intervention.

Question 114: A 52-year-old woman with a 25-year history of bipolar affective disorder has been stable on lithium carbonate 1000mg daily for 15 years. She presents for routine monitoring. Blood tests show: lithium level 0.75 mmol/L, sodium 138 mmol/L, potassium 4.0 mmol/L, urea 8.2 mmol/L, creatinine 125 μmol/L, eGFR 52 ml/min/1.73m², calcium 2.65 mmol/L (normal 2.20-2.60), PTH 8.5 pmol/L (normal 1.6-6.9), TSH 2.8 mU/L, free T4 14 pmol/L. She is clinically euthymic with no symptoms. Previous eGFR 1 year ago was 68 ml/min/1.73m². What is the most appropriate next step in management?

A. Continue lithium and refer for parathyroid imaging
B. Stop lithium immediately due to declining renal function
C. Switch lithium to sodium valproate due to hypercalcaemia
D. Reduce lithium dose to 800mg daily and recheck renal function in 1 month
E. Continue lithium, monitor renal function monthly, and refer to endocrinology for hyperparathyroidism (Correct Answer)

Explanation: ***Continue lithium, monitor renal function monthly, and refer to endocrinology for hyperparathyroidism*** - The elevated **calcium (2.65 mmol/L)** and inappropriately high **PTH (8.5 pmol/L)** are characteristic of **lithium-induced primary hyperparathyroidism**, necessitating an endocrinology referral. - Despite the decline in **eGFR (52 ml/min/1.73m²)**, abrupt cessation of lithium in a stable patient risks relapse; therefore, continuation with **monthly renal function monitoring** is the most appropriate balance. *Continue lithium and refer for parathyroid imaging* - While parathyroid involvement is central, referral to **endocrinology** for a comprehensive assessment is the initial step before determining the need for and type of parathyroid imaging. - This option overlooks the critical need for increased **renal function monitoring** given the documented decline in eGFR. *Stop lithium immediately due to declining renal function* - **Immediate discontinuation** of lithium after 15 years of stability carries a very high risk of **bipolar relapse**, which could be clinically devastating for the patient. - The current **eGFR (52 ml/min/1.73m²)**, though reduced, is not typically an absolute indication for immediate cessation, but rather for closer monitoring and specialist review. *Switch lithium to sodium valproate due to hypercalcaemia* - **Hypercalcaemia** is a manifestation of the underlying hyperparathyroidism, which requires direct management by an **endocrinologist**, not an immediate switch to a different mood stabilizer. - Switching from a long-established and effective treatment like lithium risks **destabilizing the patient's mood** and does not directly treat the hyperparathyroidism. *Reduce lithium dose to 800mg daily and recheck renal function in 1 month* - The patient's **lithium level (0.75 mmol/L)** is currently within the therapeutic range, and dose reduction could lead to a loss of **mood stability**. - A simple dose reduction does not address the underlying **hyperparathyroidism** or provide a comprehensive plan for managing the progressive renal decline.

Question 115: A 26-year-old woman presents with her first episode of psychosis. She describes a 2-month history of hearing her thoughts spoken aloud, believing that her colleagues can hear her thoughts, and experiencing her actions being controlled by an external force. She has social withdrawal and neglect of self-care. Mental state examination confirms thought echo, thought broadcasting, and passivity phenomena. There is no substance use, and medical investigations are normal. Considering the prognostic factors in first-episode psychosis, which feature in her presentation is associated with the poorest long-term outcome?

A. Young age of onset at 26 years
B. Presence of Schneiderian first-rank symptoms
C. Insidious onset over 2 months (Correct Answer)
D. Female gender
E. Absence of prominent affective symptoms

Explanation: ***Insidious onset over 2 months***- An **insidious onset** (gradual development) of psychotic symptoms is a well-established predictor of a **poorer long-term prognosis** and higher risk of chronic disability compared to an acute onset.- This pattern often reflects a more severe underlying neurobiological process and is linked to **greater functional decline** and a lower likelihood of returning to baseline functioning.*Presence of Schneiderian first-rank symptoms*- While **thought echo**, **broadcasting**, and **passivity phenomena** are classically used to diagnose schizophrenia, they do not correlate with the severity of the long-term **prognostic outcome**.- Studies show that these specific positive symptoms respond similarly to antipsychotics and do not necessarily predict future **relapse rates** or social functioning.*Female gender*- **Female gender** is actually considered a **good prognostic factor** in psychotic disorders.- Women typically have a **later age of onset**, better premorbid adjustment, and a more favorable response to treatment compared to men.*Young age of onset at 26 years*- While a very young onset (e.g., childhood or early adolescence) is a poor prognostic sign, an onset at **26 years** is relatively standard for females and is not as significant a negative predictor as an **insidious onset**.- Generally, the **older the age of onset**, the better the prognosis, as the individual has had more time for social and occupational development.*Absence of prominent affective symptoms*- The lack of mood symptoms (like depression or mania) makes a diagnosis of **schizoaffective disorder** less likely and shifts the profile toward schizophrenia, which generally has a worse prognosis than mood-related psychosis.- However, on its own, it is considered less of a negative prognostic indicator than the **gradual, insidious development** of the primary psychotic symptoms.

Question 116: A 35-year-old man with a 10-year history of bipolar affective disorder type I is reviewed in clinic. He has had five manic episodes and three depressive episodes. He has tried lithium (stopped due to tremor), sodium valproate (stopped due to weight gain), and quetiapine (stopped due to sedation). He is currently on lamotrigine 200mg daily but has had two depressive episodes in the past year requiring admission. His current mood is stable. He consents to trying a new medication. What is the mechanism of action of lamotrigine that makes it particularly effective for bipolar depression?

A. Inhibition of voltage-gated sodium channels reducing glutamate release (Correct Answer)
B. Enhancement of GABA-mediated inhibitory neurotransmission
C. Blockade of dopamine D2 receptors in the mesolimbic pathway
D. Inhibition of serotonin reuptake at the synaptic cleft
E. Antagonism of NMDA glutamate receptors

Explanation: ***Inhibition of voltage-gated sodium channels reducing glutamate release*** - Lamotrigine's clinical efficacy in **bipolar depression** is driven by its ability to stabilize neuronal membranes and prevent the presynaptic release of **excitatory glutamate**. - This modulation of the **glutamatergic system** is a unique property among mood stabilizers, which typically target mania more effectively than depression. *Enhancement of GABA-mediated inhibitory neurotransmission* - This is the primary mechanism for medications like **benzodiazepines** and certain other anticonvulsants such as **valproate**. - While lamotrigine is an anticonvulsant, it does not significantly increase **GABA levels** or activity. *Blockade of dopamine D2 receptors in the mesolimbic pathway* - This mechanism describes the action of **antipsychotic medications** like quetiapine, which the patient previously stopped due to sedation. - **D2 receptor antagonism** is useful for treating acute mania and psychosis but is not how lamotrigine exerts its antidepressant effects. *Inhibition of serotonin reuptake at the synaptic cleft* - This is the mechanism of action for **SSRIs**, which carry a risk of inducing **manic switches** if used as monotherapy in bipolar I disorder. - Lamotrigine does not have clinically significant effects on the **serotonin transporter (SERT)**. *Antagonism of NMDA glutamate receptors* - This mechanism is associated with drugs like **ketamine** or **memantine**, which act post-synaptically on glutamate receptors. - Lamotrigine acts **pre-synaptically** to reduce glutamate release rather than blocking the **NMDA receptor** itself.

Question 117: A 49-year-old man with treatment-resistant paranoid schizophrenia has been on clozapine 700mg daily for 4 years. He presents with a 2-week history of worsening auditory hallucinations and persecutory delusions despite good previous response. He has been compliant with medication. He is a heavy smoker (30 cigarettes/day) but stopped smoking 3 weeks ago using nicotine patches after developing pneumonia. Clozapine level taken yesterday is 620 ng/mL (therapeutic range 350-600 ng/mL). Which pharmacokinetic interaction best explains his elevated clozapine level?

A. Nicotine patches inhibit cytochrome P450 1A2 enzyme activity
B. Smoking cessation reduces cytochrome P450 1A2 enzyme induction (Correct Answer)
C. Pneumonia causes reduced hepatic metabolism of clozapine
D. Nicotine replacement therapy increases clozapine absorption
E. Inflammation from pneumonia inhibits cytochrome P450 enzymes

Explanation: ***Smoking cessation reduces cytochrome P450 1A2 enzyme induction***- Polycyclic aromatic hydrocarbons in **tobacco smoke** are potent inducers of the **CYP1A2** enzyme, which significantly increases the metabolism and clearance of clozapine.- When a heavy smoker stops smoking, this **enzymatic induction** is lost, leading to decreased clozapine metabolism and a subsequent **increase in plasma levels** (as observed at 620 ng/mL). *Nicotine patches inhibit cytochrome P450 1A2 enzyme activity*- The **nicotine** itself does not significantly induce or inhibit the **CYP1A2** enzyme; the induction effects are primarily caused by other compounds like **polycyclic aromatic hydrocarbons** in tobacco smoke.- **Nicotine patches** deliver nicotine without these enzyme-inducing chemicals, thus they do not inhibit CYP1A2 activity. *Pneumonia causes reduced hepatic metabolism of clozapine*- While severe acute illness can sometimes impact drug metabolism, **pneumonia** is not a direct or common mechanism for causing a sustained reduction in hepatic metabolism sufficient to explain this clozapine elevation.- The **cessation of smoking** is a far more potent and well-established factor in altering **CYP1A2** activity and clozapine levels, making it the most likely explanation. *Nicotine replacement therapy increases clozapine absorption*- **Nicotine replacement therapy (NRT)**, including patches, is used to manage withdrawal symptoms and does not significantly alter the **gastrointestinal absorption** or bioavailability of clozapine.- The interaction between smoking and clozapine is predominantly a **metabolic (pharmacokinetic)** one involving enzyme induction, not altered absorption. *Inflammation from pneumonia inhibits cytochrome P450 enzymes*- High levels of **inflammatory cytokines** can indeed inhibit some CYP enzymes, but this effect is generally less potent and more transient compared to the well-documented impact of **smoking cessation** on **CYP1A2 induction**.- Given the 3-week timeline coinciding with **smoking cessation** and the known interaction with clozapine, the loss of enzyme induction is a more direct and clinically relevant explanation for the elevated levels than a non-specific inflammatory effect.

Question 118: A 27-year-old woman with a 4-year history of bipolar affective disorder type I presents to the emergency department with confusion, coarse tremor, vomiting, and diarrhoea for 2 days. She has been taking lithium carbonate 1200mg daily. One week ago, her GP prescribed ibuprofen 400mg three times daily for ankle pain following a sports injury. Observations: temperature 37.8°C, pulse 95/min, BP 110/70 mmHg. Blood tests show: sodium 144 mmol/L, potassium 4.8 mmol/L, urea 12.5 mmol/L, creatinine 145 μmol/L, lithium level 1.9 mmol/L. What is the underlying mechanism causing her presentation?

A. NSAIDs enhance lithium transport across the blood-brain barrier
B. NSAIDs reduce renal lithium clearance by inhibiting prostaglandin synthesis (Correct Answer)
C. NSAIDs cause gastric irritation leading to reduced lithium absorption
D. NSAIDs increase lithium absorption in the gastrointestinal tract
E. NSAIDs cause volume depletion through gastrointestinal side effects

Explanation: ***NSAIDs reduce renal lithium clearance by inhibiting prostaglandin synthesis***- **NSAIDs** like ibuprofen inhibit **prostaglandin synthesis** in the kidneys, which normally maintain renal blood flow and function.- This inhibition leads to decreased **Glomerular Filtration Rate (GFR)** and increased **proximal tubule reabsorption** of sodium and lithium, causing the observed toxic lithium level (1.9 mmol/L) and renal impairment (elevated urea and creatinine).*NSAIDs enhance lithium transport across the blood-brain barrier*- While lithium toxicity causes neurological symptoms like **confusion** and **coarse tremor**, this is a result of high systemic lithium levels, not enhanced transport across the **blood-brain barrier** by NSAIDs.- The primary drug interaction mechanism between **ibuprofen** and **lithium** involves renal excretion, not direct central nervous system transport.*NSAIDs cause gastric irritation leading to reduced lithium absorption*- **Gastric irritation** by NSAIDs would typically lead to **reduced drug absorption** and lower therapeutic levels, which is contrary to the presentation of **lithium toxicity**.- The gastrointestinal symptoms (vomiting and diarrhoea) in this patient are manifestations of **lithium toxicity** itself, rather than a cause of altered absorption.*NSAIDs increase lithium absorption in the gastrointestinal tract*- There is no established pharmacological mechanism by which **NSAIDs** increase the rate or extent of **lithium absorption** from the gastrointestinal tract.- **Lithium** is already almost completely absorbed orally; the problem in toxicity is usually related to its **elimination**.*NSAIDs cause volume depletion through gastrointestinal side effects*- While **volume depletion** (which can be exacerbated by gastrointestinal symptoms) can worsen lithium toxicity by increasing reabsorption, the **primary and direct mechanism** of NSAID-induced toxicity is their effect on **renal prostaglandin synthesis**.- The patient's elevated **urea** and **creatinine** directly indicate impaired renal function, which is a consequence of the NSAID's direct effect on kidney physiology, leading to reduced **lithium clearance**.

Question 119: A 31-year-old man diagnosed with schizophrenia 18 months ago has been treated with risperidone 4mg daily with good response. Over the past 3 months, he has developed progressive breast enlargement and tenderness, reduced libido, and erectile dysfunction. He is distressed by these symptoms and considering stopping medication. Physical examination confirms bilateral gynaecomastia. Blood tests show: prolactin 3200 mU/L (normal <450). His psychotic symptoms remain well controlled. Which antipsychotic would be the most appropriate alternative?

A. Amisulpride 400mg daily
B. Haloperidol 5mg daily
C. Aripiprazole 15mg daily (Correct Answer)
D. Paliperidone 6mg daily
E. Olanzapine 15mg daily

Explanation: ***Aripiprazole 15mg daily*** - **Aripiprazole** is a **partial dopamine agonist** at D2 receptors, which means it provides enough dopaminergic activity to prevent the excessive rise of prolactin. - It is the most appropriate alternative because it is considered **prolactin-sparing** and can even lower prolactin levels when added to other antipsychotics. *Amisulpride 400mg daily* - This medication is notorious for causing **hyperprolactinaemia** because it does not cross the **blood-brain barrier** well, leading to high D2 occupancy in the pituitary gland. - Switching to this would likely worsen or maintain the patient's **gynaecomastia** and sexual dysfunction. *Haloperidol 5mg daily* - As a high-potency **first-generation antipsychotic**, haloperidol has a strong propensity to increase prolactin through **tuberoinfundibular pathway** blockade. - It would not address the patient's current side effects and would increase the risk of **extrapyramidal symptoms**. *Paliperidone 6mg daily* - **Paliperidone** is the active metabolite of risperidone and shares a very similar pharmacological profile regarding **D2 receptor antagonism**. - It is highly associated with **elevated prolactin levels** and would be unlikely to resolve the patient’s clinical symptoms. *Olanzapine 15mg daily* - While olanzapine causes less prolactin elevation than risperidone, its effect is not neutral, and it may not fully resolve severe **hyperprolactinaemia**. - Additionally, it carries a high risk of **metabolic side effects**, such as weight gain and dyslipidaemia, which may not be the optimal trade-off for this patient.

Question 120: A 33-year-old woman with bipolar affective disorder type I has been stable on sodium valproate 1000mg daily for 3 years. She attends for pre-conception counselling as she wishes to become pregnant. She has had two previous manic episodes requiring admission, both when not on medication. She tried lamotrigine previously but discontinued due to rash. She is currently euthymic. What is the most appropriate management of her mood stabiliser for pregnancy planning?

A. Continue sodium valproate and start high-dose folic acid 5mg daily
B. Switch to lithium carbonate with careful monitoring (Correct Answer)
C. Discontinue all mood stabilisers as she is currently stable
D. Switch to quetiapine monotherapy
E. Continue sodium valproate at reduced dose of 500mg daily

Explanation: ***Switch to lithium carbonate with careful monitoring*** - **Sodium valproate** is highly **teratogenic**, posing significant risks of **neurodevelopmental disorders** and neural tube defects, and is contraindicated in pregnancy for women of childbearing potential. - **Lithium** is the preferred mood stabilizer for bipolar I disorder during pregnancy, as its risk of malformation (primarily **Ebstein's anomaly**) is lower than valproate and manageable with careful monitoring, including **fetal echocardiography**. *Continue sodium valproate and start high-dose folic acid 5mg daily* - High-dose **folic acid** can reduce the risk of neural tube defects but does not mitigate the substantial risk of **neurodevelopmental delay** and other malformations associated with valproate exposure. - Current guidelines strictly prohibit valproate use in women of childbearing age unless part of a **Pregnancy Prevention Programme** and no suitable alternatives exist. *Discontinue all mood stabilisers as she is currently stable* - Discontinuing all mood stabilizers for a patient with a history of two **manic episodes requiring admission** carries a very high risk of **relapse**, especially during the **peripartum and postpartum periods**. - Maintaining mood stability is critical for both maternal health and the safety of the pregnancy, making discontinuation an unsafe option. *Switch to quetiapine monotherapy* - While **quetiapine** is an antipsychotic used in bipolar disorder, its efficacy as monotherapy for preventing severe **manic episodes** is not as robust as lithium, particularly in a patient with a history of severe illness. - Given her previous failure with **lamotrigine**, a more established and effective mood stabilizer like lithium is generally preferred for severe bipolar I disorder. *Continue sodium valproate at reduced dose of 500mg daily* - Reducing the dose of **sodium valproate** does not eliminate its **teratogenic risks**; even lower doses are associated with unacceptable risks of fetal harm, including neurodevelopmental issues. - The management strategy must involve switching to a safer medication altogether, rather than attempting to find a 'safe' dose of a highly teratogenic drug during pregnancy.

Question 121: A 45-year-old man with chronic paranoid schizophrenia has been stable on clozapine 450mg daily for 18 months. He presents to his GP with a 6-week history of progressive heartburn, regurgitation of food, and difficulty swallowing solids. He has gained 8kg since starting clozapine. Examination reveals a BMI of 31 kg/m². There are no signs of infection. Recent clozapine level was therapeutic. ECG shows: HR 105/min, normal sinus rhythm, QTc 425ms. What is the most likely cause of his symptoms?

A. Clozapine-induced gastro-oesophageal reflux disease
B. Clozapine-induced oesophageal hypomotility (Correct Answer)
C. Clozapine-induced constipation with overflow
D. Oesophageal candidiasis secondary to immunosuppression
E. Oesophageal stricture from chronic acid reflux

Explanation: ***Clozapine-induced oesophageal hypomotility*** - Clozapine has potent **antimuscarinic (anticholinergic)** effects that reduce peristalsis throughout the gastrointestinal tract, leading to **delayed oesophageal transit** and dysphagia. - The clinical presentation of **dysphagia to solids** and food regurgitation is a classic indicator of a motility disorder rather than simple acid reflux. *Clozapine-induced gastro-oesophageal reflux disease* - While Clozapine can cause reflux by relaxing the **lower oesophageal sphincter**, it does not typically cause progressive **difficulty swallowing solids**. - Reflux symptoms are common in patients on Clozapine, but the addition of **dysphagia** points toward a more severe underlying motility issue. *Clozapine-induced constipation with overflow* - This condition, known as **Clozapine-induced gastrointestinal hypomotility (CIGH)**, usually affects the lower bowel and presents with abdominal pain or distension. - It would not explain upper gastrointestinal symptoms like **heartburn and dysphagia** unless it reached the stage of a complete bowel obstruction. *Oesophageal candidiasis secondary to immunosuppression* - While Clozapine can cause **agranulocytosis**, there are no signs of active infection, and the patient's neutropenic status is not confirmed here. - Candidiasis typically presents with **odynophagia (painful swallowing)** and visible oral thrush, which are not described in this case. *Oesophageal stricture from chronic acid reflux* - Strictures are a complication of **long-term gastro-oesophageal reflux disease (GORD)** and usually take many years of untreated inflammation to develop. - It is unlikely for a stricture to cause this level of symptomatology within only **18 months** of starting the causative medication.

Question 122: A 28-year-old woman presents to the crisis team with a 3-day history of elevated mood, grandiose beliefs that she is a famous singer, pressured speech, and significantly decreased need for sleep. She has spent £15,000 on credit cards buying recording equipment. This is her first psychiatric presentation. She has no medical history and takes no medications. Her mother mentions the patient seemed 'low in mood' for several weeks about 4 months ago but didn't seek help. Urine drug screen is negative. Physical examination and routine blood tests are normal. What is the most appropriate diagnosis?

A. Bipolar affective disorder type I
B. Bipolar affective disorder type II
C. Cyclothymia
D. Schizoaffective disorder, manic type
E. Manic episode, single episode (Correct Answer)

Explanation: ***Manic episode, single episode***- This patient is experiencing her **first presentation** of severe mood elevation, grandiosity, and **functional impairment** (spending £15,000), which meets the criteria for a **manic episode**.- Per **ICD-10** criteria, if it is the first such psychiatric event and previous "low mood" was never clinically diagnosed as a depressive episode, it is classified as a **single manic episode**.*Bipolar affective disorder type I*- A diagnosis of **Bipolar I** typically requires at least **two separate mood episodes**, at least one of which must be mania or mixed.- Although the mother reported a period of low mood, this was **not formally diagnosed** or treated, precluding an immediate diagnosis of Bipolar I at the first presentation.*Bipolar affective disorder type II*- This requires at least one **major depressive episode** and at least one **hypomanic episode**.- The patient's symptoms (grandiosity and severe financial recklessness) classify as **full mania**, not hypomania, which excludes Bipolar II.*Cyclothymia*- **Cyclothymia** involves a chronic period of at least **two years** of mood instability with fluctuations between mild depression and hypomania.- The severity and **acute onset** of the patient's manic symptoms (grandiose beliefs) are inconsistent with the low-grade nature of cyclothymic shifts.*Schizoaffective disorder, manic type*- This diagnosis requires **psychotic symptoms** (like hallucinations or delusions) to occur for at least two weeks in the **absence** of prominent mood symptoms.- In this case, the **grandiose beliefs** are occurring concurrently with elevated mood and pressures of speech, suggesting they are mood-congruent features of mania rather than an independent psychotic disorder.

Question 123: A 39-year-old man with a 12-year history of paranoid schizophrenia has been treated with clozapine 600mg daily for the past 3 years with good symptom control. He attends routine blood monitoring. Results show: WBC 3.2 × 10⁹/L, neutrophils 1.4 × 10⁹/L, haemoglobin 142 g/L, platelets 245 × 10⁹/L. He is clinically well with no signs of infection. His previous blood test 1 week ago showed: WBC 4.5 × 10⁹/L, neutrophils 2.5 × 10⁹/L. What is the most appropriate immediate action?

A. Stop clozapine immediately, admit to hospital, and start broad-spectrum antibiotics
B. Stop clozapine immediately and repeat blood test within 24 hours (Correct Answer)
C. Continue clozapine and repeat blood test in 1 week
D. Reduce clozapine dose to 400mg daily and repeat blood test in 3 days
E. Continue clozapine and repeat blood test in 3 days with increased monitoring frequency

Explanation: ***Stop clozapine immediately and repeat blood test within 24 hours*** - This patient's **neutrophil count of 1.4 × 10⁹/L**, following a significant drop from 2.5 × 10⁹/L, meets the criteria for a **Red Signal** or critical neutropenia, mandating immediate cessation of clozapine. - Repeating the blood test within **24 hours** is crucial for urgent re-evaluation, to confirm the declining trend, and to monitor for any further, potentially rapid, fall in neutrophil count. *Stop clozapine immediately, admit to hospital, and start broad-spectrum antibiotics* - While stopping clozapine is correct, **urgent admission to hospital** and initiation of **broad-spectrum antibiotics** are only indicated if the patient shows signs of **infection** or is **clinically unwell**. - The patient is described as **clinically well** with no signs of infection, so these aggressive measures are premature at this stage. *Continue clozapine and repeat blood test in 1 week* - **Continuing clozapine** with a critically low and declining neutrophil count carries a high risk of developing **life-threatening agranulocytosis**. - Waiting for **1 week** for a repeat blood test is dangerously long, as clozapine-induced neutropenia can progress very rapidly over a few days. *Reduce clozapine dose to 400mg daily and repeat blood test in 3 days* - **Clozapine-induced neutropenia** is an **idiosyncratic reaction**, not typically dose-dependent; therefore, **reducing the dose** will not mitigate the risk of severe hematological toxicity. - The established protocol for significant neutropenia with clozapine is **complete cessation** of the drug, not dose reduction, and repeating the test in **3 days** is too long for this critical situation. *Continue clozapine and repeat blood test in 3 days with increased monitoring frequency* - **Continuing clozapine** is unsafe given the significant drop in neutrophil count, which requires immediate cessation as per

Question 124: A 36-year-old woman with bipolar affective disorder type I is admitted to the psychiatric ward with severe mania. She is extremely agitated, verbally aggressive, and has not slept for 4 days. She is physically threatening staff and refuses all oral medication. Her past history includes three previous manic episodes, all requiring admission. Physical examination shows: pulse 110/min, BP 145/92 mmHg, temperature 37.2°C. ECG shows sinus tachycardia. What is the most appropriate immediate pharmacological management?

A. Intramuscular haloperidol 5mg
B. Intramuscular lorazepam 2mg and intramuscular haloperidol 5mg (Correct Answer)
C. Oral lithium carbonate 400mg
D. Intramuscular olanzapine 10mg
E. Intravenous diazepam 10mg

Explanation: ***Intramuscular lorazepam 2mg and intramuscular haloperidol 5mg*** - For **rapid tranquillisation** in severe mania with **agitation, aggression**, and refusal of oral medication, the combination of an **antipsychotic** (haloperidol) and a **benzodiazepine** (lorazepam) is most effective. - This combination provides immediate **sedation** and helps manage psychotic symptoms synergistically, with the benzodiazepine also helping to mitigate **extrapyramidal side effects** of haloperidol. *Intramuscular haloperidol 5mg* - While **haloperidol** is an effective antipsychotic for mania, monotherapy is generally less effective for immediate **behavioral control** in severely agitated patients compared to the combination regimen. - Using an antipsychotic alone without a benzodiazepine can increase the risk of developing **acute dystonia** and other **extrapyramidal side effects**. *Oral lithium carbonate 400mg* - **Lithium** has a **slow onset of action**, typically requiring several days to reach therapeutic levels, making it unsuitable for immediate management of acute agitation and aggression. - The patient's explicit **refusal of oral medication** makes this option impractical and ineffective in an emergency situation. *Intramuscular olanzapine 10mg* - **Intramuscular olanzapine** is an effective agent for acute agitation, but it has a significant contraindication: it should **not be administered concurrently with parenteral benzodiazepines** due to the risk of severe **respiratory depression** and hypotension. - While an alternative, the haloperidol/lorazepam combination is often preferred as a first-line option for high-risk aggression due to its established safety profile for **rapid tranquillisation**. *Intravenous diazepam 10mg* - **Intravenous administration** of benzodiazepines like diazepam for rapid tranquillisation is generally avoided in psychiatric emergencies due to a significantly higher risk of **respiratory arrest** and the need for intensive monitoring, often in an ICU setting. - The **intramuscular route** is preferred for rapid, safer absorption in these scenarios, providing effective sedation while reducing the risks associated with IV administration.

Question 125: A 22-year-old man is assessed in the early intervention service. He presents with a 10-week history of social withdrawal, reduced self-care, bizarre beliefs that he can control the weather, and hearing two voices discussing him in the third person. His mother reports personality change over the past year with declining university performance. There is no substance use. He has no past psychiatric history. What is the minimum duration of symptoms required to diagnose schizophrenia according to ICD-10 criteria?

A. 2 weeks
B. 4 weeks
C. 1 month (Correct Answer)
D. 6 weeks
E. 3 months

Explanation: ***1 month*** - According to **ICD-10 criteria**, the characteristic symptoms of schizophrenia must be present for the majority of the time during a period of at least **one month**. - This duration criterion helps distinguish schizophrenia from **acute and transient psychotic disorders**, which have a shorter duration. *2 weeks* - A two-week duration is insufficient for a diagnosis of schizophrenia under both **ICD-10** and **DSM-5** frameworks. - This timeframe is more commonly associated with the minimum duration required to diagnose a **depressive episode**. *4 weeks* - While four weeks is approximately one month, the **ICD-10** specifically defines the requirement as **one month**. - Using "weeks" as a metric is statistically less precise than the defined **monthly clinical requirement** for formal diagnosis. *6 weeks* - A six-week duration exceeds the minimum **ICD-10** requirement of one month, meaning the patient already met the criteria two weeks prior. - It does not represent the **earliest threshold** required for a clinician to confirm the diagnosis of schizophrenia. *3 months* - A three-month timeframe is not a standard diagnostic threshold for the primary diagnosis of **schizophrenia** in major classification systems. - This duration is more relevant to certain **delusional disorders** or chronic monitoring rather than the minimum diagnostic criteria.

Question 126: A 41-year-old man with bipolar affective disorder type I is reviewed in the outpatient clinic. He has had multiple manic episodes over the past 8 years requiring hospitalisation. He has been on lithium carbonate 800mg daily for 5 years with good effect. Recent blood tests show: lithium level 0.58 mmol/L (therapeutic range 0.6-1.0), sodium 139 mmol/L, potassium 4.2 mmol/L, urea 6.5 mmol/L, creatinine 95 μmol/L, eGFR 72 ml/min, TSH 5.8 mU/L (normal 0.5-5.0), free T4 11 pmol/L (normal 10-22). He reports feeling well with no mood symptoms. What is the most appropriate management?

A. Increase lithium dose to achieve therapeutic level
B. Continue current lithium dose and monitor lithium level in 3 months
C. Start levothyroxine and continue current lithium dose (Correct Answer)
D. Switch from lithium to sodium valproate
E. Add lamotrigine to current lithium treatment

Explanation: ***Start levothyroxine and continue current lithium dose*** - The patient has **elevated TSH** (5.8 mU/L) with **normal free T4**, indicative of **subclinical hypothyroidism**, a common side effect of **lithium**. Starting **levothyroxine** is appropriate to prevent symptomatic progression. - Despite a lithium level of 0.58 mmol/L, the patient has been **clinically stable** for 5 years with no mood symptoms, indicating the current dose is effective for prophylaxis. *Increase lithium dose to achieve therapeutic level* - The patient is **euthymic** and stable, so increasing the lithium dose is unnecessary and could risk **lithium toxicity**, especially given his mildly reduced **eGFR** (72 ml/min). - A higher lithium dose could also worsen the existing **thyroid dysfunction**, as lithium is known to cause hypothyroidism. *Continue current lithium dose and monitor lithium level in 3 months* - This approach neglects the **elevated TSH**, which signifies established **subclinical hypothyroidism** that requires intervention rather than just observation. - Active management with **levothyroxine** is needed to address the **endocrine abnormality** induced by lithium. *Switch from lithium to sodium valproate* - Switching is not indicated as the patient has demonstrated a **good and stable response** to lithium for 5 years, and the **hypothyroidism** is a treatable side effect. - Lithium is a highly effective mood stabilizer for **bipolar disorder**, and an unnecessary switch risks precipitating a **relapse of manic episodes**. *Add lamotrigine to current lithium treatment* - Lamotrigine is primarily used for **bipolar depression prophylaxis** and is not indicated here as the patient is currently **euthymic** and not experiencing depressive symptoms. - Adding an additional medication does not address the **lithium-induced hypothyroidism** and introduces unnecessary polypharmacy.

Question 127: A 34-year-old woman with a 7-year history of schizophrenia is brought to A&E by her family. She has been non-compliant with oral risperidone for 6 months. She presents with bizarre behaviour, belief that her neighbours are poisoning her water supply, and auditory hallucinations. She lacks insight into her illness and refuses voluntary treatment. Her family reports this is her fourth relapse due to medication non-adherence. Physical examination is unremarkable. Which long-acting injectable antipsychotic would be the most appropriate first-line depot treatment?

A. Paliperidone palmitate monthly
B. Aripiprazole monthly
C. Flupentixol decanoate fortnightly
D. Risperidone long-acting injection fortnightly (Correct Answer)
E. Olanzapine pamoate monthly

Explanation: ***Risperidone long-acting injection fortnightly*** - Since the patient was previously treated with **oral risperidone**, moving to the long-acting injectable (LAI) form is the most appropriate step to ensure **continuity of care** and predictability of response. - **Risperidone LAI** is highly effective for managing relapses associated with **medication non-adherence**, though it requires oral supplementation during the initial three weeks. *Paliperidone palmitate monthly* - While this is the active metabolite of risperidone and offers a convenient monthly dosing schedule, it is generally considered if the direct **depot equivalent** of her previous medication is not chosen first. - In clinical practice, if a patient has already shown **tolerability** to oral risperidone, the risperidone-specific LAI is the logical first-line transition. *Aripiprazole monthly* - This requires establishing **oral tolerability** and a specific lead-in period which may not be as straightforward as continuing the drug class she was previously prescribed. - Switching to a different class of antipsychotic (Partial Agonist) during an acute **psychotic relapse** is less ideal than optimizing the current regimen. *Flupentixol decanoate fortnightly* - This is a **first-generation antipsychotic (FGA)** depot which carries a significantly higher risk of **extrapyramidal side effects (EPSEs)** compared to second-generation options. - It is not preferred as a first-line depot choice when the patient has been managed on a **second-generation antipsychotic (SGA)** like risperidone. *Olanzapine pamoate monthly* - Use of this injectable is often restricted due to the risk of **post-injection delirium sedation syndrome (PDSS)**, requiring strict monitoring for 3 hours post-dose. - Due to the administrative burden and **metabolic side effects**, it is rarely selected as the first-line depot option for a patient previously on risperidone.

Question 128: A 47-year-old man with treatment-resistant paranoid schizophrenia has been taking clozapine 600mg daily for 5 years with partial response. He continues to experience persistent auditory hallucinations and paranoid delusions affecting his quality of life despite optimal clozapine dosing and confirmed therapeutic plasma levels. He has tried clozapine augmentation with amisulpride without benefit. Which intervention has the strongest evidence base for management of his persistent symptoms?

A. Add lamotrigine 200mg daily to augment clozapine
B. Refer for cognitive behavioural therapy for psychosis (Correct Answer)
C. Switch from clozapine to long-acting injectable paliperidone
D. Add sodium valproate for mood stabilization
E. Increase clozapine to 900mg daily

Explanation: ***Refer for cognitive behavioural therapy for psychosis*** - **Cognitive Behavioural Therapy for psychosis (CBTp)** is a recommended intervention for patients with **persistent positive symptoms** (e.g., hallucinations, delusions) despite optimal clozapine treatment, according to major clinical guidelines. - **CBTp** helps patients develop **coping strategies** and alter their interpretations of psychotic experiences, leading to reduced distress and improved quality of life. *Add lamotrigine 200mg daily to augment clozapine* - While **lamotrigine** has some evidence as a clozapine augmentation strategy, particularly for negative or mood symptoms, its efficacy for persistent positive symptoms is not as strongly established as **CBTp**. - It is typically considered a secondary pharmacological option if psychological interventions and other augmentations have not been effective. *Switch from clozapine to long-acting injectable paliperidone* - **Clozapine** is the most effective antipsychotic for **treatment-resistant schizophrenia**, and switching from it is rarely recommended unless there are severe adverse effects or non-compliance. - The patient has been on clozapine for 5 years with partial response, indicating some benefit, and paliperidone is not superior to clozapine for treatment resistance. *Add sodium valproate for mood stabilization* - **Sodium valproate** is primarily an **anticonvulsant** and **mood stabilizer** and is typically used for comorbid mood symptoms, aggression, or catatonia in schizophrenia, not as a direct augmentation for persistent positive symptoms. - The patient's primary symptoms are auditory hallucinations and paranoid delusions, not mood instability, making this a less targeted intervention. *Increase clozapine to 900mg daily* - The patient is already on **clozapine 600mg daily** with **confirmed therapeutic plasma levels**; increasing the dose further is unlikely to provide additional benefit for symptoms. - Doses above 600mg increase the risk of **adverse effects** (e.g., seizures, agranulocytosis, myocarditis) without a proportional increase in efficacy when therapeutic levels are already achieved.

Question 129: A 32-year-old woman with bipolar affective disorder type I presents to the emergency department 3 weeks postpartum. Her partner reports that over the past 5 days she has become increasingly agitated, sleeping only 2 hours per night, talking rapidly about having special powers, and expressing beliefs that the baby is in danger from demons. She has attempted to perform an exorcism. She is hostile and uncooperative with assessment. She stopped taking quetiapine during pregnancy. On examination she is agitated, with pressured speech and grandiose and persecutory delusions. What is the most appropriate immediate management setting?

A. Admission to general psychiatric ward and restart quetiapine
B. Admission to mother and baby unit with mental health act assessment (Correct Answer)
C. Home treatment team with daily visits
D. Voluntary admission to mother and baby unit
E. Outpatient crisis team with partner supervision

Explanation: ***Admission to mother and baby unit with mental health act assessment*** - This patient presents with **Postpartum Psychosis**, a psychiatric emergency with high risks of **infanticide** and maternal suicide, requiring the specialized care of a **Mother and Baby Unit (MBU)** to preserve the bond while ensuring safety. - An assessment under the **Mental Health Act** is necessary because she is hostile, uncooperative, and lacks **insight**, making voluntary admission unsafe or impossible. *Admission to general psychiatric ward and restart quetiapine* - While inpatient care is needed, a **general psychiatric ward** often separates the mother from the infant, which can disrupt **bonding** and negatively affect recovery. - This option is generally reserved for when an **MBU bed** is unavailable and the risk is too high for the community. *Home treatment team with daily visits* - The presence of **delusions concerning the baby** (demons/exorcism) indicates a high and immediate **risk of harm** to the infant that cannot be safely managed in the community. - **Postpartum psychosis** is characterized by rapid clinical fluctuations, making the monitoring provided by daily visits insufficient for safety. *Voluntary admission to mother and baby unit* - Although admission to an MBU is correct, the patient is currently **hostile and uncooperative**, suggesting she does not recognize her illness or need for care. - A **voluntary admission** is unlikely to be successful or sustainable given her **delusional state** and agitation. *Outpatient crisis team with partner supervision* - This management plan is inadequate for **manic psychosis**, which requires intensive clinical monitoring and stabilization that a partner cannot provide at home. - The **safeguarding concerns** for the baby and the severity of **pressured speech** and agitation necessitate a more restrictive environment.

Question 130: A 40-year-old woman with schizoaffective disorder has been maintained on depot risperidone 37.5mg every 2 weeks for 3 years. She presents to her psychiatrist with new-onset involuntary movements. Examination reveals repetitive lip-smacking, tongue protrusion, and choreiform finger movements. These movements persist during distraction and partially suppress with voluntary effort. She is not distressed by them and has not noticed them herself. Her psychotic symptoms are well controlled. What is the most appropriate management?

A. Stop depot risperidone immediately and switch to oral quetiapine
B. Add tetrabenazine to treat the movement disorder
C. Continue depot risperidone as she is psychiatrically stable
D. Switch to clozapine as it has the lowest risk of tardive dyskinesia (Correct Answer)
E. Reduce depot risperidone to 25mg and review in 3 months

Explanation: ***Switch to clozapine as it has the lowest risk of tardive dyskinesia*** - The patient's symptoms, including **repetitive lip-smacking**, **tongue protrusion**, and **choreiform finger movements** after long-term risperidone, are characteristic of **tardive dyskinesia (TD)**. - **Clozapine** is the antipsychotic of choice for TD due to its unique pharmacology, including a very low affinity for **dopamine D2 receptors**, which minimizes EPS risk and can often improve existing TD while maintaining psychiatric stability. *Stop depot risperidone immediately and switch to oral quetiapine* - **Abrupt cessation** of depot risperidone can lead to severe **withdrawal dyskinesia** and significantly increase the risk of an acute **psychotic relapse** in a patient with a chronic condition like schizoaffective disorder. - While **quetiapine** has a lower EPS risk than risperidone, it is not as effective as **clozapine** for the management of established **tardive dyskinesia**. *Add tetrabenazine to treat the movement disorder* - **Tetrabenazine** (a VMAT2 inhibitor) can help reduce the symptoms of TD but does not address the underlying **dopamine receptor hypersensitivity** caused by the offending antipsychotic. - Adding symptomatic treatment without addressing the cause increases **polypharmacy** and potential side effects, which is less ideal than switching to a safer antipsychotic. *Continue depot risperidone as she is psychiatrically stable* - Continuing the causative agent would allow the **tardive dyskinesia** to potentially worsen and become **irreversible**, significantly impacting the patient's quality of life. - Psychiatric stability does not justify ignoring a progressive and potentially **disabling movement disorder** when safer and effective alternatives exist. *Reduce depot risperidone to 25mg and review in 3 months* - A minor **dose reduction** is often insufficient to halt or reverse established **tardive dyskinesia**, especially with long-acting injectable formulations. - Waiting **3 months** for a review is an unacceptable delay for a condition that can become permanent, indicating a need for more urgent and definitive management.

Question 131: A 24-year-old man is assessed by the early intervention in psychosis team. He has experienced a first episode of psychosis 6 months ago and has been treated with risperidone 4mg daily with good response. He now has minimal residual symptoms. According to NICE guidance on the management of first-episode psychosis, what is the recommended duration of antipsychotic treatment after remission of first episode, assuming he remains well?

A. 6 months
B. At least 1 year
C. At least 2 years (Correct Answer)
D. 5 years
E. Lifelong treatment

Explanation: ***At least 2 years*** - According to **NICE guidance** on first-episode psychosis, antipsychotic treatment should be continued for **at least 1 to 2 years** after remission to significantly reduce the risk of **relapse**. - This duration is supported by evidence showing that approximately **80% of patients** relapse if medication is discontinued prematurely after a single episode. *6 months* - This duration is generally considered **insufficient** for a first episode of psychosis and significantly increases the **risk of recurrence**. - 6 months is more commonly associated with the duration of treatment for a first episode of **unipolar depression** after achieving remission, not psychosis. *At least 1 year* - While some guidelines mention 1 year as a minimum, **NICE guidance** specifically recommends the **1 to 2-year range**, with **2 years** being the more robust clinical standard for first-episode management. - A 1-year cutoff may be considered in very specific circumstances, but it is not the preferred **standard of care** in primary guidelines for maintaining stability. *5 years* - A 5-year treatment duration is typically reserved for patients who have experienced **multiple relapses** or have a history of **significant risk** to themselves or others. - For a first episode with **good response** and minimal residual symptoms, 5 years is an unnecessarily long initial recommendation. *Lifelong treatment* - **Lifelong treatment** is generally only considered for patients with a diagnosis of **treatment-resistant schizophrenia** or those with a history of **frequent relapses** upon medication withdrawal. - Most clinicians aim for a supervised **trial of dose reduction** after the initial 2-year stability period rather than indefinite therapy.

Question 132: A 51-year-old man with bipolar affective disorder has been taking lithium carbonate 900mg daily for 8 years. He presents to his GP feeling generally unwell. Blood tests show: serum lithium 1.6 mmol/L (therapeutic range 0.6-1.0 mmol/L), urea 12.4 mmol/L, creatinine 156 µmol/L (baseline 95 µmol/L), eGFR 42 ml/min/1.73m². He was recently started on ramipril 5mg daily by the cardiology team for hypertension. He reports no symptoms of toxicity, tremor, or confusion. What is the most appropriate immediate management?

A. Stop lithium immediately and arrange urgent psychiatric review
B. Continue lithium but reduce dose to 600mg daily
C. Stop ramipril and recheck lithium level in 5-7 days (Correct Answer)
D. Admit for intravenous fluids and haemodialysis
E. Continue both medications but increase monitoring frequency

Explanation: ***Stop ramipril and recheck lithium level in 5-7 days***- The patient presents with **mild lithium toxicity** (1.6 mmol/L) and an **acute kidney injury** (AKI), primarily due to the recent initiation of an **ACE inhibitor (Ramipril)**. Ramipril reduces lithium clearance, leading to elevated levels.- Since the patient is currently **asymptomatic** from lithium toxicity, the most appropriate immediate management is to discontinue the precipitating medication (ramipril) and closely monitor lithium levels and renal function. It is important to recheck lithium levels as the half-life is long.*Stop lithium immediately and arrange urgent psychiatric review*- Abruptly stopping lithium, even with elevated levels, carries a significant risk of **bipolar relapse**, especially when the toxicity is mild and primarily due to a drug interaction.- The immediate priority is to address the **pharmacokinetic interaction** causing the elevated lithium and AKI, rather than discontinuing the essential mood stabilizer directly.*Continue lithium but reduce dose to 600mg daily*- Reducing the lithium dose without addressing the **ACE inhibitor interaction** would not fully resolve the issue, as ramipril continues to impair lithium excretion.- It is unsafe to maintain a patient on a medication known to cause an **AKI** (in this case, by precipitating lithium toxicity) without removing the offending agent.*Admit for intravenous fluids and haemodialysis*- **Haemodialysis** is reserved for severe lithium toxicity (e.g., levels >2.0 mmol/L with significant symptoms, or >3.5 mmol/L regardless of symptoms) or in patients with severe renal impairment where lithium cannot be excreted.- This patient is **asymptomatic**, and his lithium level, while elevated, does not meet the criteria for urgent haemodialysis or aggressive intravenous fluid resuscitation beyond general supportive care if needed.*Continue both medications but increase monitoring frequency*- Continuing both ramipril and lithium would perpetuate the **drug interaction**, leading to further worsening of lithium levels and potentially irreversible kidney damage.- **ACE inhibitors**, along with NSAIDs and thiazide diuretics, are well-known to increase lithium levels by reducing its renal clearance.

Question 133: A 29-year-old woman with schizophrenia is reviewed in the community mental health team. She has been stable on paliperidone 6mg daily for 18 months. She and her partner are planning to start a family. She asks about the safety of continuing her medication during pregnancy. What is the most appropriate advice?

A. Paliperidone should be stopped immediately before attempting conception
B. The risks and benefits should be discussed; if medication is continued, use the lowest effective dose and monitor for complications (Correct Answer)
C. Switch to clozapine as it is safer in pregnancy
D. Switch to a typical antipsychotic as these have better safety data
E. Paliperidone is completely safe in pregnancy with no additional monitoring required

Explanation: ***The risks and benefits should be discussed; if medication is continued, use the lowest effective dose and monitor for complications***- Management requires a **risk-benefit analysis** comparing the risks of untreated maternal illness (relapse, poor prenatal care) against potential fetal risks from **antipsychotic exposure**.- If continued, the **lowest effective dose** should be used, with monitoring for **neonatal withdrawal symptoms** or **extrapyramidal symptoms** following delivery.*Paliperidone should be stopped immediately before attempting conception*- Abruptly stopping medication in a stable patient with **schizophrenia** carries a high risk of **relapse**, which can be dangerous for both mother and fetus.- Discontinuation should only be considered after a thorough consultation and usually involves a gradual **tapering** rather than immediate cessation.*Switch to clozapine as it is safer in pregnancy*- **Clozapine** is generally not recommended for switching during pregnancy due to risks of **maternal agranulocytosis** and potential fetal **seizures**.- It is usually reserved for **treatment-resistant schizophrenia** and requires intensive blood monitoring that complicates pregnancy management.*Switch to a typical antipsychotic as these have better safety data*- While **typical antipsychotics** like haloperidol have longer safety records, they carry a higher risk of **extrapyramidal side effects** for the mother and neonate.- Switching a stable patient from an effective **atypical antipsychotic** to a typical one can lead to **destabilization** and breakthrough symptoms.*Paliperidone is completely safe in pregnancy with no additional monitoring required*- No antipsychotic is considered **completely safe**; they are classified as **Category C** or similar, meaning potential risks cannot be ruled out.- Additional monitoring is mandatory, specifically for **gestational diabetes** due to metabolic side effects and **neonatal distress** post-delivery.

Question 134: A 44-year-old man with paranoid schizophrenia has been on clozapine 550mg daily for 3 years with good symptom control. He presents to his GP with a 3-week history of constipation, only opening his bowels once in the past 10 days with great difficulty. He reports some abdominal discomfort and bloating. He has not taken any laxatives. Examination reveals a distended, tympanic abdomen with reduced bowel sounds. There is mild generalized tenderness but no guarding or rebound. Temperature is 37.2°C, heart rate 78 bpm, blood pressure 128/82 mmHg. What is the most appropriate immediate management?

A. Prescribe lactulose and review in 1 week
B. Arrange urgent surgical review
C. Prescribe senna and increase dietary fiber
D. Arrange same-day abdominal X-ray and surgical assessment (Correct Answer)
E. Stop clozapine immediately and admit to psychiatry ward

Explanation: ***Arrange same-day abdominal X-ray and surgical assessment*** - This patient shows signs of **clozapine-induced gastrointestinal hypomotility (CIGH)**, a potentially fatal complication presenting with severe constipation and a **distended, tympanic abdomen**. - Same-day assessment and imaging are critical to rule out **paralytic ileus**, bowel obstruction, or **ischaemic colitis**, which have a higher mortality rate than agranulocytosis. *Prescribe lactulose and review in 1 week* - **Lactulose** is an osmotic laxative that may worsen **abdominal bloating** and gas in the presence of an underlying obstruction. - Relies on a delayed review period which is unsafe given the **reduced bowel sounds** and severe frequency of bowel movements (once in 10 days). *Arrange urgent surgical review* - While a surgical review is necessary, it is usually coordinated alongside **imaging (X-ray)** to provide a definitive diagnosis of fecal loading or bowel dilation. - This option is partially correct but less comprehensive as the **abdominal X-ray** is the standard immediate investigation to quantify the severity of hypomotility. *Prescribe senna and increase dietary fiber* - Increasing **dietary fiber** can be detrimental in cases of severe hypomotility or fecal impaction as it increases stool bulk against a non-moving colon. - While **senna** (a stimulant laxative) is part of standard prevention, the current clinical presentation suggests a **surgical emergency** rather than simple constipation. *Stop clozapine immediately and admit to psychiatry ward* - Sudden cessation of **clozapine** can lead to **rebound psychosis** or cholinergic rebound; management of bowel complications should take priority in a medical/surgical setting. - A **psychiatric ward** is not equipped to manage potential **bowel perforation** or obstruction indicated by the physical findings.

Question 135: A 37-year-old woman with a 12-year history of bipolar affective disorder attends the psychiatry clinic. She describes episodes where her mood becomes persistently low for several weeks, with reduced energy, hypersomnia (sleeping 12-14 hours per day), increased appetite with carbohydrate craving, and feeling extremely sensitive to interpersonal rejection. Between episodes, she functions well. She has never had a manic episode requiring hospitalization but has had brief periods of elevated mood lasting 3-4 days with increased energy and reduced sleep. What is the most appropriate diagnosis?

A. Bipolar affective disorder type I
B. Bipolar affective disorder type II (Correct Answer)
C. Recurrent depressive disorder with atypical features
D. Cyclothymia
E. Schizoaffective disorder

Explanation: ***Bipolar affective disorder type II*** - This diagnosis is characterized by at least one **hypomanic episode** (lasting at least 4 consecutive days) and at least one **major depressive episode**, perfectly matching the patient's brief elevated mood and persistent low mood periods. - The depressive episodes exhibit **atypical features** like **hypersomnia**, **increased appetite with carbohydrate craving**, and **rejection sensitivity**, which are commonly associated with bipolar II depression. *Bipolar affective disorder type I* - Requires a history of at least one full **manic episode**, defined by a distinct period of abnormally and persistently elevated, expansive, or irritable mood, and abnormally and persistently increased goal-directed activity or energy, lasting at least 1 week (or any duration if hospitalization is required). - The patient explicitly states she has **never had a manic episode requiring hospitalization** and her elevated moods were brief (3-4 days), indicating hypomania, not mania. *Recurrent depressive disorder with atypical features* - This diagnosis is ruled out by the patient's history of distinct periods of **elevated mood**, **increased energy**, and **reduced sleep** (hypomanic episodes). - Recurrent depressive disorder is a unipolar mood disorder, meaning it involves only depressive episodes without any history of manic or hypomanic symptoms. *Cyclothymia* - Involves numerous periods of **hypomanic symptoms** and **depressive symptoms** (that do not meet full criteria for hypomanic or major depressive episodes) for at least two years. - The patient's depressive episodes are described as "persistently low for several weeks" with significant features, suggesting full **major depressive episodes** rather than the milder, more fluctuating symptoms of cyclothymia. *Schizoaffective disorder* - This diagnosis requires the presence of **psychotic symptoms** (e.g., delusions, hallucinations) occurring for at least two weeks in the absence of a major mood episode. - The patient's presentation does not include any mention of **psychosis** or other symptoms characteristic of schizophrenia, only mood disturbances.

Question 136: A 33-year-old man with schizophrenia has been taking clozapine 400mg daily for 18 months with excellent control of psychotic symptoms. He attends his routine blood monitoring appointment. His absolute neutrophil count is 1.8 × 10⁹/L (previous result 4 weeks ago was 3.2 × 10⁹/L). He feels well and has no symptoms of infection. His temperature is 36.7°C. What is the most appropriate management according to clozapine monitoring guidelines?

A. Continue clozapine and repeat blood test in 1 week
B. Stop clozapine immediately and refer to haematology urgently
C. Reduce clozapine dose to 300mg daily and repeat bloods in 48 hours
D. Continue clozapine and repeat blood test in 48-72 hours (Correct Answer)
E. Stop clozapine permanently and start an alternative antipsychotic

Explanation: ***Continue clozapine and repeat blood test in 48-72 hours***- An **absolute neutrophil count (ANC)** between 1.5 and 2.0 × 10⁹/L is classified as an **amber result** according to clozapine monitoring guidelines, requiring more frequent monitoring but allowing continuation of the drug.- Since the patient is **clinically stable** and lacks signs of infection, the protocol mandates repeating blood tests twice weekly (e.g., in 48-72 hours) until the count stabilizes or returns to the **green zone** (>2.0 × 10⁹/L).*Continue clozapine and repeat blood test in 1 week*- This approach is incorrect because an **amber alert** (ANC 1.5-2.0 × 10⁹/L) requires more rapid follow-up than the standard weekly monitoring.- A **7-day wait** is too long given the significant drop from the previous result of 3.2 × 10⁹/L, potentially missing a rapid progression to **agranulocytosis**.*Stop clozapine immediately and refer to haematology urgently*- Immediate cessation and urgent referral are only required for a **red alert**, which occurs when the **ANC falls below 1.5 × 10⁹/L** (or below 1.0 × 10⁹/L for benign ethnic neutropenia) or for a severe drop from baseline.- Interrupting treatment prematurely can lead to **psychotic relapse** in patients with treatment-resistant schizophrenia and complicates the monitoring status.*Reduce clozapine dose to 300mg daily and repeat bloods in 48 hours*- **Dose reduction** is not a standard or recommended management strategy for neutropenia in clozapine guidelines; the risk of neutropenia is generally considered **idiosyncratic** rather than dose-dependent.- Managing hematological side effects focuses on the decision to **continue, temporarily interrupt, or permanently discontinue** the medication based on specific ANC thresholds.*Stop clozapine permanently and start an alternative antipsychotic*- **Permanent discontinuation** is strictly reserved for cases where the ANC falls below **0.5 × 10⁹/L** (severe agranulocytosis) or after multiple 'red' alerts that prevent safe re-challenge.- Discarding clozapine at this stage is inappropriate as it is the **gold standard** for treatment-resistant schizophrenia and the patient is achieving excellent symptom control.

Question 137: A 26-year-old woman with bipolar affective disorder type I has had three admissions in the past 2 years for manic episodes. She has tried lithium, sodium valproate, and quetiapine as mood stabilizers but discontinued each due to side effects or poor efficacy. She is currently stable on olanzapine 20mg daily but has gained 18kg over 18 months. Her fasting glucose is 6.4 mmol/L, HbA1c is 43 mmol/mol, and lipid profile shows total cholesterol 6.2 mmol/L. She is very distressed about the weight gain. Which medication would be the most appropriate alternative mood stabilizer to consider?

A. Lamotrigine
B. Aripiprazole (Correct Answer)
C. Carbamazepine
D. Risperidone long-acting injection
E. Increase olanzapine to 30mg

Explanation: ***Aripiprazole*** - **Aripiprazole** is an **atypical antipsychotic** with a significantly more **favorable metabolic profile** compared to olanzapine, making it a suitable choice for patients experiencing **weight gain** and **metabolic syndrome** features. - It is an effective mood stabilizer for **preventing manic episodes**, addressing the patient's history of recurrent mania while mitigating the severe metabolic side effects of olanzapine. *Lamotrigine* - **Lamotrigine** is primarily indicated for the prevention of **bipolar depressive episodes** and has limited efficacy in preventing or treating **acute manic episodes**. - Given this patient's history of three admissions for **manic episodes**, lamotrigine would not provide adequate anti-manic protection. *Carbamazepine* - While effective for bipolar disorder, **carbamazepine** is a potent **enzyme inducer**, leading to significant drug-drug interactions and requiring intensive **therapeutic drug monitoring**. - Its side effect profile includes risks of **hyponatremia**, **blood dyscrasias**, and **sedation**, which may not be more tolerable than the current issues. *Risperidone long-acting injection* - **Risperidone** is associated with a moderate to high risk of **weight gain** and **metabolic side effects**, similar to olanzapine, and would likely exacerbate the patient's current metabolic concerns. - A long-acting injection primarily addresses **treatment adherence** issues, which is not the main problem; the patient is distressed by specific side effects. *Increase olanzapine to 30mg* - Increasing the dose of **olanzapine** would almost certainly worsen the patient's already significant **weight gain**, **dyslipidemia**, and **impaired fasting glucose**. - The current goal is to mitigate the metabolic risks, not escalate them, as the patient is already experiencing severe distress and clinical complications at 20mg.

Question 138: A 30-year-old man presents to the emergency department brought by police under Section 136 of the Mental Health Act. He was found shouting in the street that he is Jesus Christ and can perform miracles. He is extremely agitated, has pressured speech, and demonstrates flight of ideas. His girlfriend reports he has had no sleep for 5 days, has spent £15,000 on a new car, and has been increasingly sexually disinhibited. He has no past psychiatric history. Physical examination reveals temperature 37.8°C, heart rate 110 bpm, blood pressure 145/92 mmHg, and pupils that are 4mm and reactive. What investigation is most important to perform immediately?

A. Thyroid function tests
B. CT head scan
C. Urine drug screen (Correct Answer)
D. Serum calcium
E. HIV test

Explanation: ***Urine drug screen***- A **urine drug screen** is the most critical immediate step to exclude substance-induced psychosis or mania, especially in a first-time presentation with **sympathomimetic signs** like tachycardia and hypertension.- Stimulants such as **cocaine** or **amphetamines** can closely mimic acute mania with grandiose delusions and pressured speech, requiring different emergency management.*Thyroid function tests*- While **hyperthyroidism** can cause agitation, anxiety, and tachycardia, it rarely presents with such severe **grandiose delusions** and sudden flight of ideas.- These tests are part of the standard baseline workup for psychiatric admissions but are less urgent than screening for acute **intoxication**.*CT head scan*- A **CT head** is indicated if there are focal neurological deficits, a history of trauma, or atypical features like a sudden onset **first-episode psychosis** in an older patient.- In this young patient with classic manic symptoms and autonomic arousal, organic brain lesions are a less likely primary cause than **drug misuse**.*Serum calcium*- **Hypercalcaemia** can lead to psychiatric symptoms, though it more commonly presents as "moans" (depression or confusion) rather than acute **manic psychosis**.- It should be checked during the routine metabolic screen, but it does not take priority over the immediate clinical suspicion of **stimulant-induced mania**.*HIV test*- **Neuropsychiatric HIV** can manifest as mania or psychosis, but these are typically later-stage complications rather than an acute primary presentation in a healthy 30-year-old.- While HIV testing is recommended in a comprehensive workup for **first-episode psychosis**, it is not the most important immediate investigation in the emergency department.

Question 139: A 42-year-old woman with bipolar affective disorder type I has been taking sodium valproate 1200mg daily for 5 years with excellent mood stability. She attends her GP to discuss contraception as she is in a new relationship. She is currently not using any contraception. Her body mass index is 32 kg/m². She has no other medical conditions and does not smoke. What is the most appropriate advice regarding contraception?

A. The combined oral contraceptive pill would be suitable
B. Sodium valproate reduces the efficacy of hormonal contraception
C. She should use barrier methods only due to valproate teratogenicity
D. A copper intrauterine device would be most appropriate (Correct Answer)
E. She should switch to lithium before starting hormonal contraception

Explanation: ***A copper intrauterine device would be most appropriate***- Women of childbearing potential on **sodium valproate** must adhere to a **Pregnancy Prevention Programme**, which mandates the use of **highly effective contraception**.- The **copper intrauterine device (IUD)** is an ideal choice as it is a **long-acting reversible contraceptive (LARC)** that is >99% effective and has no metabolic interactions with valproate.*The combined oral contraceptive pill would be suitable*- The **combined oral contraceptive pill (COCP)** carries a higher risk of failure compared to LARCs and may be contraindicated as her **BMI of 32 kg/m²** approaches threshold limits for cardiovascular risk.- Guidelines prioritize LARCs over oral pills for women on valproate to minimize any possibility of **teratogenic exposure** due to user error.*Sodium valproate reduces the efficacy of hormonal contraception*- Unlike enzyme-inducing antiepileptics (e.g., carbamazepine), **sodium valproate** does not induce hepatic enzymes and therefore **does not reduce the efficacy** of hormonal contraceptives.- However, the high **teratogenic risk** of valproate necessitates the most reliable methods regardless of metabolic interactions.*She should use barrier methods only due to valproate teratogenicity*- **Barrier methods** (condoms) have a high typical-use failure rate and are not considered **highly effective contraception** under the valproate safety guidelines.- While they protect against STIs, they must be used in conjunction with a more reliable method like a **LARC** or an injectable.*She should switch to lithium before starting hormonal contraception*- While valproate use in childbearing age requires annual review, switching a patient with **excellent mood stability** to **lithium** is a complex clinical decision and not a prerequisite for starting contraception.- The immediate priority is establishing **highly effective contraception** while she remains on her current stable regimen.

Question 140: A 35-year-old man with a 10-year history of paranoid schizophrenia presents to his psychiatrist. He has been adherent to depot flupentixol decanoate 40mg every 2 weeks for the past 4 years with good symptom control. Over the past 6 months, his family has noticed he has become increasingly withdrawn, speaks very little, and shows minimal emotional expression. He spends most of his day in bed and has lost interest in his previous hobbies. There are no positive psychotic symptoms. Cognitive examination reveals no significant deficits. What is the most likely explanation for his current presentation?

A. Relapse of positive symptoms of schizophrenia
B. Predominant negative symptoms of schizophrenia
C. Depot-induced parkinsonism (Correct Answer)
D. Comorbid depressive episode
E. Development of dementia

Explanation: ***Depot-induced parkinsonism***- The patient is on a **first-generation antipsychotic** (flupentixol decanoate) known to cause **extrapyramidal symptoms (EPS)**, including **drug-induced parkinsonism**.- Symptoms like **withdrawal**, **alogia** (speaking very little), **apathy** (lost interest, spends day in bed), and **blunted affect** (minimal emotional expression) are consistent with **bradykinesia** and **hypokinesia** seen in parkinsonism, often referred to as **pseudonegative symptoms**.*Relapse of positive symptoms of schizophrenia*- The patient explicitly **lacks positive psychotic symptoms** such as **hallucinations** or **delusions**, which are hallmarks of a positive symptom relapse.- He has been **adherent to medication** with good symptom control for years, making a sudden relapse without typical positive symptoms less likely than a medication side effect.*Predominant negative symptoms of schizophrenia*- While the described symptoms (withdrawal, alogia, anhedonia, avolition) are **negative symptoms**, it is crucial to differentiate between primary negative symptoms and **secondary negative symptoms** caused by medication.- Given the long-term use of a **typical antipsychotic**, drug-induced parkinsonism mimicking negative symptoms (pseudonegative symptoms) is a more plausible explanation, especially with the onset after years of stability.*Comorbid depressive episode*- Although symptoms like **anhedonia** (loss of interest) and withdrawal can occur in depression, the overall clinical picture, particularly the **blunted affect** and **motor slowing** (implied by withdrawal and spending time in bed) on a **first-generation antipsychotic**, strongly points towards **drug-induced parkinsonism**.- There's no mention of core depressive symptoms like **depressed mood**, **guilt**, or **suicidal ideation**, which are typically present in a major depressive episode.*Development of dementia*- The patient's **cognitive examination** revealed **no significant deficits**, directly ruling out dementia as the cause of his current presentation.- At 35 years old, the development of dementia with these specific symptoms and without cognitive decline is highly improbable, making **antipsychotic side effects** a far more likely explanation.

Question 141: A 28-year-old woman with schizophrenia attends the community mental health team for review. She has been stable on risperidone 4mg daily for 2 years. She reports no active psychotic symptoms but mentions she has been feeling increasingly restless and has difficulty sitting still during the appointment. She paces around the room and frequently shifts her weight from one foot to the other. Her cognitive function is intact and she denies mood symptoms. Examination reveals no parkinsonian features or dystonia. What is the most appropriate immediate management?

A. Add propranolol (Correct Answer)
B. Reduce the dose of risperidone
C. Add procyclidine
D. Switch to a depot antipsychotic
E. Add diazepam

Explanation: ***Add propranolol*** - This patient's symptoms of subjective restlessness, difficulty sitting still, pacing, and shifting weight are classic presentations of **akathisia**, a common extrapyramidal side effect of **risperidone**. - **Propranolol**, a lipophilic **beta-blocker**, is considered the **first-line pharmacological treatment** for akathisia due to its effectiveness in reducing both the subjective and objective motor restlessness. *Reduce the dose of risperidone* - The patient has been **stable on risperidone for 2 years**, indicating the current dose is effective for her schizophrenia. **Reducing the dose** carries a significant risk of **psychotic relapse**. - While dose adjustment can be considered for side effects, in a clinically stable patient, managing the side effect with an additional agent is often preferred before risking efficacy. *Add procyclidine* - **Procyclidine** is an **anticholinergic medication** primarily used to treat other extrapyramidal symptoms such as **Parkinsonism** (e.g., tremor, rigidity) and **acute dystonia**. - Anticholinergics are generally **ineffective for akathisia** and may even worsen the restlessness or cause other anticholinergic side effects. *Switch to a depot antipsychotic* - Switching to a **long-acting injectable (depot)** antipsychotic is typically indicated for issues with **medication adherence** or patient preference, neither of which is suggested in this case. - A depot formulation would not inherently resolve the akathisia; the underlying propensity for the side effect with the medication would likely persist or recur. *Add diazepam* - **Benzodiazepines** like diazepam can be used as a **second-line option** to alleviate the distress and restlessness associated with akathisia, but they are not the first choice. - They carry risks of **sedation, tolerance, and dependence**, making them less favorable for long-term or first-line management compared to propranolol.

Question 142: A 32-year-old woman with bipolar affective disorder type II experiences predominantly depressive episodes with occasional hypomanic episodes lasting 4-5 days. She has had three major depressive episodes in the past 2 years requiring time off work. She has tried lithium (caused tremor and polyuria) and quetiapine (excessive sedation). She is currently depressed with moderate severity. Which medication would be most appropriate as monotherapy for long-term management?

A. Lamotrigine (Correct Answer)
B. Sodium valproate
C. Carbamazepine
D. Olanzapine
E. Fluoxetine

Explanation: ***Lamotrigine***- **Lamotrigine** is highly effective for the **prevention of depressive episodes** in Bipolar II disorder, especially when depression is the predominant polarity.- It is generally **well-tolerated** with no weight gain, making it a suitable alternative for patients who cannot tolerate side effects of **Lithium** or **Quetiapine**.*Sodium valproate*- While used as a mood stabilizer, it is more effective at **preventing mania** than depression and is not first-line for bipolar depression monotherapy.- It is strictly **contraindicated** in women of childbearing potential due to high **teratogenic risk** (valproate pregnancy prevention program).*Carbamazepine*- Primarily used for **acute mania** or prophylaxis when other agents fail; it has very limited evidence for treating or preventing **bipolar depression**.- It is a potent **enzyme inducer**, leading to numerous drug interactions and a higher side-effect profile compared to lamotrigine.*Olanzapine*- Highly effective for **acute mania** and relapse prevention, but monotherapy is less effective for the depressive pole compared to combination therapy.- Associated with significant **metabolic side effects**, including substantial **weight gain** and increased risk of diabetes.*Fluoxetine*- **Antidepressant monotherapy** is generally avoided in bipolar disorder because it carries a risk of inducing **treatment-emergent mania** or rapid cycling.- If used for bipolar depression, it should typically be co-administered with a **mood stabilizer** or an antipsychotic to ensure mood stability.

Question 143: A 45-year-old woman with chronic paranoid schizophrenia has been on clozapine 600mg daily for 5 years with good symptom control. She presents to A&E with acute onset chest pain and shortness of breath. ECG shows: sinus tachycardia 115 bpm, PR interval 220 ms, QRS duration 95 ms, QTc 485 ms. Troponin is mildly elevated. Echocardiogram reveals left ventricular ejection fraction of 35% with global hypokinesia. She has no cardiac risk factors. What is the most likely diagnosis?

A. Acute coronary syndrome
B. Clozapine-induced cardiomyopathy (Correct Answer)
C. Pulmonary embolism
D. Acute pericarditis
E. QT prolongation with arrhythmia

Explanation: ***Clozapine-induced cardiomyopathy*** - **Clozapine** is known to cause **cardiomyopathy** and **myocarditis**, often presenting with **reduced ejection fraction** and **global hypokinesia**, along with symptoms like chest pain and shortness of breath. - The patient's long-term **clozapine** use, lack of other **cardiac risk factors**, presence of **sinus tachycardia**, elevated **troponin**, and **severely reduced LVEF (35%)** strongly indicate this diagnosis. *Acute coronary syndrome* - While **mildly elevated troponin** and chest pain are present, the absence of typical **cardiac risk factors** and the finding of **global hypokinesia** rather than regional wall motion abnormalities make this less likely. - The **ECG** lacks specific **ischemic changes** (e.g., ST-segment elevation or depression, T-wave inversions) that define acute coronary syndrome. *Pulmonary embolism* - **Pulmonary embolism** typically causes **right ventricular strain** or dysfunction on echocardiogram, not primary **left ventricular global hypokinesia** and severely reduced ejection fraction. - Although tachycardia and shortness of breath are common, the elevated **troponin** and **echo findings** point more towards intrinsic myocardial damage. *Acute pericarditis* - **Acute pericarditis** usually presents with characteristic **widespread ST-segment elevation** and **PR-segment depression** on ECG, which were not observed here. - Significant **left ventricular dysfunction** (LVEF 35%) and **global hypokinesia** are not typical features of isolated pericarditis. *QT prolongation with arrhythmia* - A **QTc of 485 ms** is prolonged and a known adverse effect of **clozapine**, increasing the risk of **Torsades de Pointes**. - However, the primary clinical picture is dominated by structural **left ventricular dysfunction** (global hypokinesia, reduced LVEF), which is not directly explained by QT prolongation itself but rather by a broader cardiac insult like cardiomyopathy.

Question 144: A 38-year-old man with bipolar affective disorder type I has had three manic episodes over 7 years, each requiring hospitalization. He has been stable on lithium 1000mg daily for 18 months with therapeutic levels (0.8 mmol/L). He now presents with low mood, anhedonia, poor sleep, and suicidal ideation for 3 weeks. There are no psychotic features or mixed features. His lithium level remains therapeutic. What is the most appropriate pharmacological management?

A. Increase lithium dose to achieve level of 1.0-1.2 mmol/L
B. Add quetiapine to lithium (Correct Answer)
C. Switch lithium to lamotrigine
D. Add fluoxetine to lithium
E. Add sodium valproate to lithium

Explanation: ***Add quetiapine to lithium*** - This patient presents with a **severe depressive episode** with **suicidal ideation** despite therapeutic lithium levels for prophylaxis. **Quetiapine** is a first-line treatment for **bipolar depression**, especially when added to a mood stabilizer like lithium, and is **licensed** for this indication. - It provides relatively **rapid symptom relief**, which is critical given the urgency of suicidal ideation, and helps stabilize mood without the risk of inducing mania often associated with antidepressants alone. *Increase lithium dose to achieve level of 1.0-1.2 mmol/L* - The patient's current lithium level (0.8 mmol/L) is already within the **therapeutic range** for maintenance. Higher levels (1.0-1.2 mmol/L) are typically targeted for **acute mania**, not for breakthrough depressive episodes. - There is limited evidence that increasing lithium beyond the standard maintenance range effectively treats a **breakthrough depressive episode**, and it increases the risk of **adverse effects**. *Switch lithium to lamotrigine* - **Switching off lithium** in a patient with a history of recurrent severe manic episodes carries a significant risk of **manic relapse**, as lithium is highly effective in preventing mania. - **Lamotrigine** is effective for preventing bipolar depression but requires a **slow upward titration** over several weeks to avoid **Stevens-Johnson syndrome**, making it unsuitable for acute management of severe depression with suicidal ideation. *Add fluoxetine to lithium* - While SSRIs can be used in bipolar depression, adding an antidepressant like **fluoxetine** to lithium carries a substantial risk of **inducing mania**, hypomania, or **rapid cycling** in a patient with a history of multiple manic episodes. - Guidelines generally prefer atypical antipsychotics like **quetiapine** or **lurasidone** over antidepressants for the acute phase of bipolar depression due to a lower risk of mood destabilization. *Add sodium valproate to lithium* - **Sodium valproate** is primarily effective for managing and preventing **manic episodes** and can be used as an alternative or adjunct to lithium for manic prophylaxis. - It has significantly **less evidence** for efficacy in treating the **acute depressive phase** of bipolar disorder compared to quetiapine, making it less appropriate for the patient's current presentation of depression with suicidal ideation.

Question 145: A 25-year-old man presents with his first episode of psychosis characterized by 8 weeks of auditory hallucinations, persecutory delusions, and social withdrawal. Drug screen is negative. Brain MRI is normal. He is commenced on risperidone with good initial response. According to current evidence and guidelines, what is the recommended minimum duration of antipsychotic treatment following complete remission of his first psychotic episode?

A. 6 months
B. 1 year
C. 2 years (Correct Answer)
D. 5 years
E. Lifelong treatment

Explanation: ***2 years*** - Major international guidelines, including **NICE** and **RANZCP**, recommend continuing antipsychotic treatment for **1 to 2 years** post-remission of a first psychotic episode to reduce the high risk of **relapse**. - Maintaining treatment during this period reduces the **relapse rate** from approximately 80% (without medication) to 20%, ensuring long-term **functional recovery** and brain health. *6 months* - A 6-month period is considered insufficient for a **first-episode psychosis** because the risk of immediate **rebound psychosis** and symptom recurrence remains extremely high. - This timeframe is typically reserved for brief psychotic disorders lasting less than a month, which is not the case for this patient's **8-week** presentation. *1 year* - While some older guidelines mentioned 1 year, the clinical consensus has shifted toward a minimum of **2 years** to better safeguard against **early relapse**. - For a patient who has established symptoms for 8 weeks (meeting criteria for **schizophreniform disorder** or early schizophrenia), a 1-year duration is often deemed a minimum rather than the standard recommendation. *5 years* - **5 years** of maintenance therapy is generally indicated only after a **second episode** or a significant relapse following the first episode. - Implementing a 5-year requirement for a first episode may lead to unnecessary **side effects** (like metabolic syndrome or tardive dyskinesia) and decreased **patient adherence**. *Lifelong treatment* - **Lifelong treatment** is usually reserved for patients with **multiple relapses**, chronic schizophrenia, or those who pose a significant **risk of harm** to themselves or others if untreated. - For a **first-episode patient** who shows a good initial response, the goal is to assess for the lowest effective dose and eventual trial of discontinuation after a stable interval.

Question 146: A 34-year-old woman with paranoid schizophrenia has been stable on olanzapine 20mg daily for 4 years. She attends for routine monitoring. Her BMI has increased from 24 to 32 kg/m² over this period. Fasting blood tests show: glucose 6.8 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, LDL 4.1 mmol/L, triglycerides 2.8 mmol/L, HDL 0.9 mmol/L. She is reluctant to change antipsychotic due to previous relapses. What is the most appropriate management?

A. Switch to aripiprazole to improve metabolic profile
B. Add metformin and refer to dietitian (Correct Answer)
C. Start atorvastatin and lifestyle advice
D. Add orlistat for weight reduction
E. Reduce olanzapine to 10mg daily

Explanation: ***Add metformin and refer to dietitian*** - **Metformin** is evidence-based for managing **antipsychotic-induced weight gain** and preventing progression to type 2 diabetes in patients with **impaired fasting glucose** (6.1-6.9 mmol/L). - Since the patient is reluctant to switch medication due to a high **risk of relapse**, pharmacological intervention for metabolic syndrome while maintaining psychiatric stability is the priority. *Switch to aripiprazole to improve metabolic profile* - While **aripiprazole** has a significantly lower risk of metabolic side effects, the patient's history of **previous relapses** makes switching risky. - A switch might destabilize her **paranoid schizophrenia**, which has been stable on olanzapine for four years. *Start atorvastatin and lifestyle advice* - This addresses the **dyslipidemia** (low HDL, high LDL) but does not adequately manage the patient's **pre-diabetes** or significant weight gain. - While statins are important for cardiovascular risk, they do not provide the weight reduction or glucose-sensitizing benefits found with **metformin**. *Add orlistat for weight reduction* - **Orlistat** has limited evidence and efficacy in patients with severe **antipsychotic-induced metabolic syndrome** compared to metformin. - It only addresses fat absorption and does not target the **insulin resistance** or glucose abnormalities seen in this patient. *Reduce olanzapine to 10mg daily* - Reducing the dose is likely to trigger a **psychotic relapse** in a patient who has required 20mg daily for long-term stability. - Even at a lower dose of 10mg, **olanzapine** continues to exert significant weight-gain and metabolic side effects through H1 and 5HT2C blockades.

Question 147: A 50-year-old man with bipolar affective disorder has been taking lithium carbonate 800mg daily for 6 years. He is admitted to hospital with pneumonia and treated with IV fluids and antibiotics. On day 3 of admission, he becomes confused, ataxic, and develops coarse tremor. Blood tests show: sodium 138 mmol/L, potassium 4.2 mmol/L, urea 8.5 mmol/L, creatinine 145 μmol/L (baseline 85), lithium level 1.8 mmol/L. What is the most appropriate immediate management?

A. Omit next dose and recheck lithium level in 12 hours
B. Stop lithium and give IV normal saline (Correct Answer)
C. Stop lithium and arrange hemodialysis
D. Reduce lithium dose to 400mg daily
E. Give activated charcoal

Explanation: ***Stop lithium and give IV normal saline*** - The patient presents with **lithium toxicity** (level 1.8 mmol/L) and acute kidney injury, necessitating immediate cessation of the drug and **aggressive hydration**. - **IV normal saline** (0.9% NaCl) is the treatment of choice to increase sodium levels in the kidney, which promotes the **renal excretion** of lithium. *Omit next dose and recheck lithium level in 12 hours* - Simply omitting a single dose is insufficient for a patient showing significant **neurotoxicity** (confusion, ataxia) and a level above 1.5 mmol/L. - Delaying intervention by 12 hours risks further clinical deterioration and permanent **neurological damage** in the setting of rising creatinine. *Stop lithium and arrange hemodialysis* - **Hemodialysis** is generally reserved for severe toxicity where levels exceed **2.0 mmol/L** with symptoms or **>3.5 mmol/L** regardless of symptoms. - While the patient is symptomatic, hydration is the initial step for a level of 1.8 mmol/L unless there is a failure to respond or **refractory renal failure**. *Reduce lithium dose to 400mg daily* - Continuing lithium at any dose during an **acute toxic episode** is contraindicated and will worsen the patient's condition. - Management requires complete **discontinuation** until levels return to the therapeutic range and renal function stabilizes. *Give activated charcoal* - **Activated charcoal** is ineffective because lithium is a small, monovalent cation that does not bind to charcoal. - Gastric lavage or **whole bowel irrigation** might be considered in massive acute ingestions, but not for chronic toxicity associated with illness and dehydration.

Question 148: A 41-year-old woman with treatment-resistant schizophrenia has been on clozapine 400mg daily for 6 months with partial response. Her psychiatrist is considering increasing the dose. Clozapine level is checked at 12 hours post-dose and returns at 280 ng/mL. She smokes 20 cigarettes daily and takes no other medications. Her FBC, U&Es, LFTs, and ECG are normal. What is the most appropriate next step?

A. Increase clozapine to 500mg daily (Correct Answer)
B. Continue current dose as level is therapeutic
C. Check clozapine level again in 2 weeks
D. Add amisulpride to augment clozapine
E. Request smoking cessation and recheck level

Explanation: ***Increase clozapine to 500mg daily*** - The patient's clozapine level of **280 ng/mL** is below the generally accepted **therapeutic range** of 350-600 ng/mL, suggesting an opportunity to improve partial response by increasing the dose. - Daily **smoking induces CYP1A2**, which significantly increases clozapine metabolism, requiring higher doses to achieve target plasma concentrations in smokers compared to non-smokers. *Continue current dose as level is therapeutic* - A clozapine level of **280 ng/mL** is considered **subtherapeutic**; the established therapeutic range for optimal response in treatment-resistant schizophrenia is typically 350-600 ng/mL. - Given the patient's **partial response**, continuing the current dose would miss the chance to achieve better symptom control through dose optimization. *Check clozapine level again in 2 weeks* - The patient has been on clozapine for **6 months**, indicating that **steady-state** levels have already been reached, so rechecking the level without a dose change would not alter management. - With a demonstrable **subtherapeutic level** and partial response, a dose adjustment is the appropriate next step rather than simply re-monitoring. *Add amisulpride to augment clozapine* - **Augmentation strategies** are generally reserved for patients who have failed an adequate trial of clozapine, which includes reaching **therapeutic serum levels** (350-600 ng/mL). - Before resorting to **polypharmacy** with its increased risk of side effects, it is prudent to first optimize the clozapine dose to its full potential. *Request smoking cessation and recheck level* - While smoking cessation would increase clozapine levels, it is a significant lifestyle change that is often difficult to achieve and can lead to a dangerous **sudden increase in clozapine levels** if not carefully managed. - Adjusting the **clozapine dose** to account for the patient's current smoking status is a more practical and safer immediate step than relying on an uncertain behavioral change.

Question 149: A 29-year-old man with bipolar affective disorder type I presents to A&E with a 4-day history of elevated mood, grandiose beliefs about being a prophet, pressured speech, and decreased need for sleep. He stopped taking his medication 2 weeks ago. He is agitated, intrusive with staff, and attempting to leave. Physical examination reveals: HR 110 bpm, BP 145/90 mmHg, temperature 37.2°C. He has no medical comorbidities. What is the most appropriate initial pharmacological management?

A. Oral lithium 400mg twice daily
B. Intramuscular haloperidol 5mg and lorazepam 2mg (Correct Answer)
C. Oral sodium valproate 500mg twice daily
D. Oral olanzapine 15mg stat
E. Oral lamotrigine 25mg daily

Explanation: ***Intramuscular haloperidol 5mg and lorazepam 2mg***- The patient presents with **acute mania**, **agitation**, and **intrusiveness**; intramuscular (IM) medication is indicated for **rapid tranquilization** when oral adherence is unlikely or risk is high.- Combining a **first-generation antipsychotic** (haloperidol) with a **benzodiazepine** (lorazepam) provides superior sedation and reduces the risk of **extrapyramidal side effects** compared to using an antipsychotic alone.*Oral lithium 400mg twice daily*- **Lithium** has a slow onset of action (requiring 5 to 7 days for therapeutic effect) and is therefore inappropriate for managing **acute behavioral agitation**.- It requires careful **serum level monitoring** and is typically used for long-term **maintenance therapy** rather than immediate crisis stabilization.*Oral sodium valproate 500mg twice daily*- While **sodium valproate** is an effective mood stabilizer, the **oral route** is not suitable for a patient who is currently agitated and attempting to leave the hospital, as adherence is unlikely.- Like lithium, it does not provide the **rapid sedation** necessary to manage the immediate safety risks posed by this patient's manic symptoms.*Oral olanzapine 15mg stat*- **Oral olanzapine** can be used as a first-line treatment for acute mania in patients who are **cooperative** with oral administration.- This patient's **agitation** and attempts to leave A&E suggest that **intramuscular therapy** is a safer and more reliable choice to ensure immediate clinical stability.*Oral lamotrigine 25mg daily*- **Lamotrigine** is primarily used for **bipolar depression prophylaxis** and has no role in the management of an **acute manic episode**.- Using this medication in an acute setting would be ineffective and fails to address the patient's **psychosis** and high-risk behaviors.

Question 150: A 36-year-old woman with schizoaffective disorder has been maintained on risperidone long-acting injection 37.5mg fortnightly for 3 years. She now presents with amenorrhea for 8 months and galactorrhea. Blood tests show: prolactin 3200 mIU/L (normal <500), TSH 2.1 mU/L, free T4 14 pmol/L. MRI pituitary is normal. She wishes to continue her current antipsychotic as her mental state has been stable. What is the most appropriate management strategy?

A. Add cabergoline to reduce prolactin levels
B. Switch to quetiapine
C. Reduce risperidone depot dose by 50%
D. Switch to paliperidone long-acting injection
E. Add aripiprazole to current depot (Correct Answer)

Explanation: ***Add aripiprazole to current depot***- **Aripiprazole** is a **partial dopamine agonist** that has a higher affinity for D2 receptors than risperidone, effectively lowering **prolactin** levels by providing some dopaminergic activity in the tuberoinfundibular pathway.- This strategy is ideal when a patient is clinically stable on their current regimen, as it avoids the **risk of relapse** associated with switching or reducing the primary antipsychotic.*Add cabergoline to reduce prolactin levels*- **Cabergoline** is a potent dopamine agonist typically used for prolactinomas but is generally avoided in patients with **schizoaffective disorder** or schizophrenia due to the risk of **exacerbating psychosis**.- While it lowers prolactin effectively, the potential for **psychiatric destabilization** makes it a second-line option compared to aripiprazole augmentation.*Switch to quetiapine*- **Quetiapine** is a "prolactin-sparing" antipsychotic, but switching carries a high **risk of relapse** for a patient who has been stable for three years on a specific regimen.- Transitioning from a **long-acting injection (LAI)** to an oral medication like quetiapine also increases the risk of **treatment non-adherence**.*Reduce risperidone depot dose by 50%*- Reducing the dose may lower prolactin levels, but it significantly increases the **vulnerability to relapse** of psychotic or mood symptoms.- There is no guarantee that a lower dose will resolve the **galactorrhea and amenorrhea**, especially given the patient's significantly elevated prolactin level.*Switch to paliperidone long-acting injection*- **Paliperidone** is the active metabolite of risperidone and shares the same high risk for **hyperprolactinemia** due to its potent D2 antagonism.- This switch would likely be ineffective in resolving the patient's symptoms as both medications have the same **pharmacodynamic profile** regarding prolactin elevation.

Question 151: A 54-year-old man with bipolar affective disorder has been stable on lithium carbonate for 8 years. He presents to his GP with a 3-month history of increased urinary frequency and thirst, passing up to 6 liters of dilute urine daily. Blood tests show: sodium 148 mmol/L, potassium 4.1 mmol/L, urea 7.2 mmol/L, creatinine 98 μmol/L, lithium level 0.7 mmol/L. Urine osmolality is 150 mOsm/kg. What is the most likely diagnosis?

A. Diabetes mellitus
B. Chronic kidney disease
C. Lithium toxicity
D. Nephrogenic diabetes insipidus (Correct Answer)
E. Primary polydipsia

Explanation: ***Nephrogenic diabetes insipidus***- Long-term **lithium therapy** is a classic cause of **nephrogenic diabetes insipidus** because lithium inhibits the action of **antidiuretic hormone (ADH)** on the collecting ducts, preventing water reabsorption.- The patient's **polyuria** (6 liters), **thirst**, **hypernatremia** (148 mmol/L), and **low urine osmolality** (150 mOsm/kg) demonstrate an inability to concentrate urine despite high serum concentration.*Diabetes mellitus*- While diabetes mellitus presents with **polyuria and polydipsia**, it is characterized by **osmotic diuresis** due to high glucose levels.- This patient's presentation lacks mention of **hyperglycemia or glycosuria**, and the urine is explicitly **dilute** rather than concentrated with glucose.*Chronic kidney disease*- Lithium can cause **chronic interstitial nephritis**, but this typically presents with a significant rise in **creatinine** and loss of GFR.- This patient's **creatinine (98 μmol/L)** is within the normal range, making advanced **chronic kidney disease** less likely than a specific tubular defect.*Lithium toxicity*- This patient’s **lithium level is 0.7 mmol/L**, which is within the standard **therapeutic range** (0.4–1.0 mmol/L).- **Acute toxicity** usually presents with neurological symptoms like **ataxia, coarse tremor, and confusion**, rather than isolated chronic polyuria.*Primary polydipsia*- In **primary polydipsia**, the excessive water intake leads to **hyponatremia** or low-normal sodium as the body tries to excrete the excess fluid.- This patient has **hypernatremia** (sodium 148 mmol/L), which indicates a primary **water loss** problem rather than excessive water intake.

Question 152: A 26-year-old man diagnosed with schizophrenia 8 months ago has been treated with olanzapine 15mg daily. He attends for review reporting that although his hallucinations have resolved, he feels emotionally flat, has no motivation, and spends most days in bed. His family confirm he rarely engages in conversation and shows little interest in activities. Mental state examination reveals blunted affect, poverty of speech, and lack of goal-directed behavior. What is the most appropriate next step in management?

A. Increase olanzapine to 20mg daily
B. Add an SSRI for comorbid depression
C. Switch to amisulpride
D. Add cognitive behavioral therapy for psychosis
E. Switch to aripiprazole (Correct Answer)

Explanation: ***Switch to aripiprazole***- This patient is presenting with prominent **negative symptoms** (avolition, blunted affect, poverty of speech) which may be primary or secondary to the sedating effects of **Olanzapine**.- **Aripiprazole** is a **partial dopamine agonist** that has shown benefit in improving negative symptoms and lacks the heavy sedative profile of olanzapine.*Increase olanzapine to 20mg daily*- Increasing the dose of a **second-generation antipsychotic** is unlikely to help negative symptoms and may actually worsen **secondary negative symptoms** by increasing sedation.- Since the patient’s **hallucinations** (positive symptoms) have already resolved, dose escalation is not clinically indicated.*Add an SSRI for comorbid depression*- While the symptoms overlap with depression, the clinical picture of **blunted affect** and **poverty of speech** specifically points toward the **negative symptom cluster** of schizophrenia.- **SSRIs** are generally not the first-line intervention for primary negative symptoms unless a clear **comorbid major depressive disorder** is diagnosed.*Switch to amisulpride*- While **low-dose Amisulpride** is sometimes used for negative symptoms, **Aripiprazole** is often preferred in clinical guidelines when transitioning from a more sedating agent.- Amisulpride can also lead to **hyperprolactinemia**, which is less likely to occur with a partial agonist like aripiprazole.*Add cognitive behavioral therapy for psychosis*- **CBTp** is an important adjunct for managing **residual positive symptoms** and improving social functioning, but it is not the primary immediate step for medication-induced or primary negative symptoms.- **Pharmacological optimization** should be prioritized to reduce the side-effect burden (like sedation) before assessing the full impact of psychotherapeutic interventions.

Question 153: A 31-year-old woman with bipolar affective disorder type I is planning pregnancy and attends for preconception counseling. She has had three previous manic episodes requiring hospitalization, the last being 18 months ago. She is currently stable on lithium 900mg daily with therapeutic levels. She has tried valproate and carbamazepine previously, both ineffective. What is the most appropriate management recommendation?

A. Continue lithium throughout pregnancy with close monitoring (Correct Answer)
B. Stop lithium immediately and remain medication-free
C. Switch to lamotrigine before attempting conception
D. Switch to olanzapine before attempting conception
E. Continue lithium but stop in first trimester only

Explanation: ***Continue lithium throughout pregnancy with close monitoring***- In patients with **severe bipolar I disorder** and a history of multiple hospitalizations, the high risk of **relapse** (up to 70%) often outweighs the small absolute risk of **Ebstein’s anomaly** (0.05-0.1%).- Close monitoring is essential, including **fetal echocardiography** at 18-20 weeks and frequent **serum level checks** due to changes in glomerular filtration rate during pregnancy and delivery.*Stop lithium immediately and remain medication-free*- Abruptly stopping medication in a patient with a history of manic episodes carries a massive risk of **relapse**, which can lead to severe maternal and fetal complications.- NICE guidelines advise against being medication-free in cases where the **severity of the illness** poses a significant threat to the mother's safety.*Switch to lamotrigine before attempting conception*- **Lamotrigine** is primarily effective for preventing **bipolar depression** rather than prophylaxis against the manic episodes this patient frequently experiences.- There is no evidence it would be effective for this specific patient, especially given her history of failing multiple other **mood stabilizers**.*Switch to olanzapine before attempting conception*- While **atypical antipsychotics** are an alternative, this patient is currently stable on **lithium** after failing other first-line treatments like valproate and carbamazepine.- Switching a stable patient with high-risk disease to a new agent during the preconception period risks destabilization before the pregnancy even begins.*Continue lithium but stop in first trimester only*- Stopping lithium during the **first trimester** significantly increases the risk of a relapse during and immediately after the pregnancy.- Recent evidence suggests the risk of **teratogenicity** is lower than previously feared, making continuous treatment safer than a high-risk mid-pregnancy relapse.

Question 154: A 23-year-old man is assessed in the early intervention in psychosis service following his first psychotic episode 4 months ago. He was started on risperidone 4mg daily with good response. His family ask about his prognosis. Which factor in his presentation is associated with the most favorable long-term outcome in schizophrenia?

A. Gradual onset of symptoms over 18 months
B. Prominent negative symptoms at presentation
C. Acute onset with clear precipitating stressor (Correct Answer)
D. Family history of schizophrenia in father
E. Poor premorbid social functioning

Explanation: ***Acute onset with clear precipitating stressor*** - An **acute onset** of psychosis (typically within a month) suggests a more **reactive process** to a stressor rather than a more severe underlying neurodevelopmental deficit. - This is often associated with better **antipsychotic treatment response** and a higher likelihood of achieving full remission and better long-term functional recovery. *Gradual onset of symptoms over 18 months* - A **gradual or insidious onset** is consistently linked with a **poorer prognosis** in schizophrenia, as it often reflects a more progressive neurodevelopmental course. - It typically leads to a longer duration of **untreated psychosis** before intervention, which is itself a factor associated with worse outcomes. *Prominent negative symptoms at presentation* - **Prominent negative symptoms** (e.g., alogia, anhedonia, avolition, flattened affect) are generally considered **poor prognostic indicators** because they are often more resistant to pharmacotherapy. - They contribute significantly to **functional impairment** and can persist even when positive symptoms are controlled, leading to poorer long-term quality of life and social integration. *Family history of schizophrenia in father* - A **positive family history** of schizophrenia, especially in a first-degree relative, indicates a **stronger genetic predisposition** to the illness. - This genetic burden is generally associated with a **less favorable prognosis**, potentially indicating a more severe or chronic disease course. *Poor premorbid social functioning* - **Poor premorbid social functioning** (e.g., social isolation, academic difficulties) before the onset of psychosis is a significant predictor of **poorer long-term outcomes**. - It suggests a lack of robust social and coping skills, making it harder for individuals to recover and reintegrate into society after the psychotic episode.

Question 155: A 48-year-old woman with a 20-year history of schizophrenia presents to the community mental health team with involuntary movements of her mouth and tongue. She has been maintained on fluphenazine decanoate depot injection for 15 years with good symptom control. On examination, she has repetitive chewing movements and occasional tongue protrusion. These movements persist during distraction and worsen with stress. She is otherwise well with stable mental state. What is the most appropriate initial management?

A. Switch to clozapine immediately
B. Add tetrabenazine to current antipsychotic
C. Stop fluphenazine and observe
D. Switch to aripiprazole and monitor closely (Correct Answer)
E. Continue fluphenazine and reassure patient

Explanation: ***Switch to aripiprazole and monitor closely*** - This patient presents with **tardive dyskinesia** (TD) due to long-term use of a first-generation depot antipsychotic; switching to a second-generation antipsychotic like **aripiprazole** is a recommended initial step. - Aripiprazole's **partial dopamine agonism** may help reduce the severity of involuntary movements while maintaining psychiatric stability. *Switch to clozapine immediately* - While **clozapine** has the lowest risk of worsening TD and can be therapeutic for it, it is usually reserved for **treatment-resistant schizophrenia** or severe TD cases after other trials. - It is not the "immediate" first step due to the requirement for intensive **hematological monitoring** and a risk profile (e.g., agranulocytosis) that requires titration. *Add tetrabenazine to current antipsychotic* - **Tetrabenazine** is a VMAT2 inhibitor used for severe or disabling TD, but it is typically introduced after attempting to **lower the dose** or switch the primary antipsychotic. - Adding it while keeping the patient on **fluphenazine** does not address the underlying cause of dopamine receptor hypersensitivity. *Stop fluphenazine and observe* - Abrupt cessation of an antipsychotic in a patient with a 20-year history of schizophrenia carries a high risk of **psychotic relapse**. - Furthermore, stopping the drug can cause **withdrawal dyskinesia**, where the involuntary movements temporarily worsen due to the sudden loss of dopamine blockade. *Continue fluphenazine and reassure patient* - Continuing a first-generation antipsychotic when TD symptoms appear is inappropriate as it can lead to the movements becoming **permanent and irreversible**. - Reassurance alone is insufficient because TD is a **progressive neurological side effect** that requires active clinical management to prevent further deterioration.

Question 156: A 33-year-old man with schizophrenia presents to his GP with a 4-month history of amenorrhea and galactorrhea. He takes risperidone 6mg daily prescribed by the mental health team. His psychotic symptoms are well controlled. Examination confirms bilateral galactorrhea and gynaecomastia. He is distressed by these symptoms and considering stopping his medication. Blood tests show prolactin 4200 mU/L. MRI pituitary is normal. The mental health team states he has previously relapsed on quetiapine and olanzapine. What underlying mechanism best explains his symptoms?

A. Dopamine D2 receptor blockade in the tuberoinfundibular pathway (Correct Answer)
B. Serotonin 5-HT2A receptor antagonism
C. Histamine H1 receptor blockade
D. Alpha-1 adrenergic receptor blockade
E. Muscarinic M1 receptor antagonism

Explanation: ***Dopamine D2 receptor blockade in the tuberoinfundibular pathway*** - **Dopamine** normally acts as a **prolactin-inhibiting factor** via D2 receptors; blocking this pathway in the **anterior pituitary** leads to disinhibition and **hyperprolactinaemia**. - Antipsychotics like **Risperidone** are potent D2 antagonists that commonly cause symptoms such as **galactorrhea**, **gynaecomastia**, and **amenorrhea**. *Serotonin 5-HT2A receptor antagonism* - This mechanism is a hallmark of **atypical antipsychotics** and helps reduce **extrapyramidal side effects** by increasing dopamine in the striatum. - It does not directly cause prolactin elevation and is actually intended to counteract some of the negative effects of pure **D2 blockade**. *Histamine H1 receptor blockade* - Antagonism at this receptor is primarily associated with side effects such as **sedation** and significant **weight gain**. - It has no functional role in the regulation of prolactin secretion or the development of **galactorrhea**. *Alpha-1 adrenergic receptor blockade* - Blockade of these receptors typically results in **orthostatic hypotension**, dizziness, and reflex tachycardia. - It is not involved in the **endocrine pathways** that lead to breast tissue changes or milk production. *Muscarinic M1 receptor antagonism* - This leads to **anticholinergic side effects**, including dry mouth, **blurred vision**, constipation, and urinary retention. - These effects are distinct from the hormonal disturbances seen in **tuberoinfundibular** dopamine disruption.

Question 157: A 43-year-old woman with a 15-year history of schizophrenia has been on clozapine 600mg daily for 5 years with excellent symptom control. She smokes 20 cigarettes daily. She is admitted to a general medical ward for elective cholecystectomy. Post-operatively, she is not permitted to smoke due to oxygen therapy. On day 2 post-operation, she becomes increasingly drowsy and confused. Observations: BP 100/65 mmHg, HR 118 bpm, temperature 37.8°C. What is the most likely explanation for her deterioration?

A. Post-operative sepsis
B. Clozapine toxicity due to smoking cessation (Correct Answer)
C. Neuroleptic malignant syndrome
D. Post-operative delirium
E. Pulmonary embolism

Explanation: ***Clozapine toxicity due to smoking cessation*** - Polycyclic aromatic hydrocarbons in cigarette smoke induce the **CYP1A2** enzyme; sudden cessation leads to a rapid **decrease in enzyme activity**, causing serum clozapine levels to skyrocket. - Presentation of toxicity includes **drowsiness**, **confusion**, **tachycardia**, and hypotension, typically manifesting within **48–72 hours** of stopping smoking. *Post-operative sepsis* - While it can cause tachycardia and confusion, day 2 post-cholecystectomy is relatively early for a full septic picture without a localized source or **significant fever**. - Sepsis would typically present with **hypotension** and elevated inflammatory markers, whereas this patient's symptoms align more specifically with drug-induced toxicity. *Neuroleptic malignant syndrome* - NMS is characterized by **lead-pipe rigidity**, extremely high fevers, and marked **creatine kinase (CK)** elevation, which are not described here. - Although tachycardia is present, the clear history of **smoking cessation** and lack of severe hyperthermia (>38.5°C) makes clozapine toxicity more plausible. *Post-operative delirium* - Delirium is common in older patients, but a 43-year-old with a stable long-term medication regimen is more likely to have a **pharmacological trigger**. - Simple delirium does not usually explain the **autonomic features** like tachycardia and hypotension as clearly as clozapine toxicity does. *Pulmonary embolism* - A PE would typically present with **pleuritic chest pain**, **shortness of breath**, and acute hypoxia rather than primary drowsiness and confusion. - While tachycardia is a common sign of PE, it would not be the best explanation for the **neurological deterioration** seen in the context of enforced smoking cessation.

Question 158: A 39-year-old man with bipolar affective disorder is admitted with acute mania. He is extremely agitated, physically aggressive to staff, has not slept for 3 days, and is refusing all oral medication. He has grandiose delusions about being a prophet. Physical examination shows no signs of head injury. Vital signs: BP 145/92 mmHg, HR 110 bpm, temperature 37.2°C. He requires immediate pharmacological intervention for rapid tranquillisation. What is the most appropriate first-line medication combination?

A. Intramuscular olanzapine alone
B. Intramuscular haloperidol alone
C. Intramuscular lorazepam alone
D. Intramuscular haloperidol and intramuscular promethazine (Correct Answer)
E. Intravenous diazepam alone

Explanation: ***Intramuscular haloperidol and intramuscular promethazine*** - Per **NICE guidelines**, the combination of **IM haloperidol** (5mg) and **IM promethazine** (50mg) is a primary first-line option for **rapid tranquillisation** when oral medication is refused. - **Promethazine** is added to provide synergistic sedation and, crucially, to reduce the risk of **extrapyramidal side effects** such as acute dystonia associated with haloperidol. *Intramuscular olanzapine alone* - While effective, **IM olanzapine** is not typically the very first choice in many clinical settings due to specific restrictions and monitoring requirements. - It carries a significant risk of **hypotension** and **respiratory depression** if the patient later requires or has recently received parenteral benzodiazepines. *Intramuscular haloperidol alone* - Administering **haloperidol** as a monotherapy carries a significantly higher risk of inducing painful **acute dystonic reactions**. - It often provides inadequate **sedation** for a patient in a severe state of physical aggression and sleep deprivation compared to the combination therapy. *Intramuscular lorazepam alone* - **IM lorazepam** is a valid first-line option but may be less effective than the haloperidol combination for a patient requiring both sedation and **antipsychotic** management of mania. - Benchmarked against the combination, it carries a higher risk of **respiratory depression** and may lead to paradoxical disinhibition in some patients. *Intravenous diazepam alone* - **Intravenous (IV)** administration is generally avoided in aggressive, non-compliant patients due to the difficulty of maintaining safe access and the high risk of **respiratory arrest**. - **Diazepam** has an unpredictable absorption profile and prolonged half-life, making it less suitable for rapid control of acute psychosis compared to intramuscular options.

Question 159: A 27-year-old man with paranoid schizophrenia diagnosed 3 years ago presents with worsening symptoms despite medication. Review of his medication history shows: risperidone 6mg daily for 8 weeks (discontinued due to hyperprolactinaemia), then olanzapine 20mg daily for 10 weeks (discontinued due to 12kg weight gain), then aripiprazole 30mg daily for 6 weeks (ongoing). His care coordinator reports good adherence confirmed by witnessed medication. He continues to experience persecutory delusions and auditory hallucinations affecting his functioning. What is the most appropriate next step?

A. Add cognitive behavioural therapy for psychosis
B. Initiate clozapine treatment (Correct Answer)
C. Increase aripiprazole to 40mg daily
D. Switch to paliperidone long-acting injection
E. Add amisulpride to aripiprazole

Explanation: ***Initiate clozapine treatment***- This patient meets the criteria for **treatment-resistant schizophrenia**, having failed adequate trials of at least **two different antipsychotics** (risperidone and olanzapine) at optimal doses and durations.- **Clozapine** is the gold-standard treatment and the only antipsychotic with proven superior efficacy for **treatment-resistant schizophrenia** as per major clinical guidelines.*Add cognitive behavioural therapy for psychosis*- While **CBTp** is a valuable adjunctive treatment for schizophrenia, it is not the primary intervention for **pharmacologically treatment-resistant psychosis**.- Psychological interventions are most effective when some degree of **symptomatic stability** has been achieved through optimal pharmacological management.*Increase aripiprazole to 40mg daily*- The maximum recommended therapeutic dose for **aripiprazole** is typically 30mg daily; increasing to 40mg is off-label and unlikely to provide additional benefit given previous failures.- The patient's history of non-response to multiple agents suggests a need for an agent with a distinct mechanism of action, specifically for **treatment resistance**, rather than simply escalating the current dose.*Switch to paliperidone long-acting injection*- **Long-acting injectable antipsychotics** are primarily indicated for improving **medication adherence**, which is not an issue here as good adherence is confirmed.- Switching to another second-generation antipsychotic without proven efficacy for treatment resistance is unlikely to be more effective and would delay appropriate treatment with clozapine.*Add amisulpride to aripiprazole*- **Antipsychotic polypharmacy** (combining two antipsychotics) is generally discouraged as a first-line strategy for treatment resistance before a trial of **clozapine monotherapy**.- This approach increases the risk of **side effects** and drug interactions without clear evidence of superior efficacy compared to clozapine for treatment-resistant cases.

Question 160: A 35-year-old woman with bipolar affective disorder type II has experienced four depressive episodes in the past 12 months despite treatment with lithium and quetiapine. Each depressive episode lasts 6-8 weeks. She has had two hypomanic episodes in her lifetime, both lasting less than a week. Her current medications are lithium 800mg daily (level 0.8 mmol/L) and quetiapine 300mg at night. She is currently in a depressive episode. What term best describes her current course of illness?

A. Refractory bipolar disorder
B. Rapid cycling bipolar disorder (Correct Answer)
C. Mixed affective state
D. Ultra-rapid cycling bipolar disorder
E. Chronic bipolar depression

Explanation: ***Rapid cycling bipolar disorder*** - **Rapid cycling** is defined by the occurrence of **four or more mood episodes** (depressive, manic, or hypomanic) within a **12-month period**. - This patient meets the criteria with **four distinct depressive episodes** in the past year, a pattern frequently seen in **women** and individuals with **Bipolar II**. *Refractory bipolar disorder* - This term describes **treatment resistance** and is not a specific diagnostic pattern for the frequency of mood episodes. - Although the patient is not responding optimally to treatment, it does not define the *course* of her illness as described by the frequency of episodes. *Mixed affective state* - A **mixed affective state** involves the co-occurrence of symptoms of **mania/hypomania** and **depression** simultaneously or in very rapid succession within a single episode. - The patient's episodes are discrete, lasting **6-8 weeks** each, indicating distinct depressive phases rather than a mixed presentation. *Ultra-rapid cycling bipolar disorder* - This subtype refers to very frequent mood switches, occurring over **days or weeks**. - The patient's depressive episodes lasting **6-8 weeks** are consistent with standard **rapid cycling** rather than the much shorter cycles of ultra-rapid cycling. *Chronic bipolar depression* - This diagnosis would imply a **persistent, non-remitting depressive state**, often lasting two years or more. - The patient experiences distinct, episodic depressive periods, which resolves before another episode begins, characteristic of a **cycling course** rather than chronicity.

Question 161: A 46-year-old woman with treatment-resistant schizophrenia has been on clozapine 400mg daily for 6 months with good symptom control. She attends for routine monitoring. Her white cell count is 3.2 × 10⁹/L (4.0-11.0), neutrophil count 1.8 × 10⁹/L (2.0-7.5), haemoglobin 128 g/L, platelets 245 × 10⁹/L. She is clinically well with no symptoms of infection. Her previous white cell count 4 weeks ago was 4.5 × 10⁹/L with neutrophils 2.8 × 10⁹/L. What is the most appropriate immediate management according to clozapine monitoring guidelines?

A. Continue clozapine and repeat bloods in 1 week
B. Reduce clozapine dose to 300mg daily
C. Stop clozapine immediately and admit for assessment
D. Continue clozapine and repeat bloods in 3 days (Correct Answer)
E. Stop clozapine and switch to olanzapine

Explanation: ***Continue clozapine and repeat bloods in 3 days*** - The patient's **neutrophil count** of 1.8 × 10⁹/L, coupled with a **WCC** of 3.2 × 10⁹/L, places her in the **'Amber'** category according to clozapine monitoring guidelines (neutrophils 1.5-2.0 × 10⁹/L or WCC 3.0-3.5 × 10⁹/L). - For an 'Amber' result, the protocol requires continuing clozapine while increasing the frequency of **blood monitoring** to **twice weekly** (e.g., every 3 days) until counts return to the 'Green' range. *Continue clozapine and repeat bloods in 1 week* - Repeating blood counts only after **one week** is insufficient for an **'Amber' result**, as it does not meet the required **twice-weekly monitoring** frequency. - This delay could lead to a missed opportunity to detect a rapid progression to **severe neutropenia** or **agranulocytosis**. *Reduce clozapine dose to 300mg daily* - **Dose reduction** is not the standard management for **hematological changes** in clozapine monitoring; the risk of **agranulocytosis** is largely idiosyncratic and not strictly dose-dependent. - Decreasing the dose of clozapine in a patient with **treatment-resistant schizophrenia** risks **relapse of psychotic symptoms**, potentially undermining effective symptom control. *Stop clozapine immediately and admit for assessment* - Immediate cessation of clozapine is reserved for **'Red' results**, defined as a **neutrophil count <1.5 × 10⁹/L** or a **WCC <3.0 × 10⁹/L**. - The patient's current counts (neutrophils 1.8, WCC 3.2) do not meet these criteria, and she is **clinically well**, so immediate stopping and admission are not indicated. *Stop clozapine and switch to olanzapine* - Switching to an alternative antipsychotic like **olanzapine** is premature when the patient has **treatment-resistant schizophrenia** and is stable on clozapine, which is the gold standard for this condition. - Permanent discontinuation of clozapine is only considered for severe adverse events, typically **'Red' zone hematological results**, which are not present here.

Question 162: A 32-year-old man with a first episode of psychosis was started on olanzapine 15mg daily 6 weeks ago. His positive symptoms have largely resolved. However, he now complains of excessive thirst, polyuria, and fatigue. Blood tests show: fasting glucose 14.2 mmol/L, HbA1c 58 mmol/mol (7.5%), total cholesterol 6.8 mmol/L, triglycerides 4.2 mmol/L. His BMI has increased from 24 to 28 kg/m². What is the most appropriate management of his antipsychotic medication?

A. Continue olanzapine and add metformin
B. Switch to aripiprazole (Correct Answer)
C. Reduce olanzapine dose to 10mg daily
D. Switch to amisulpride
E. Continue olanzapine and add atorvastatin

Explanation: ***Switch to aripiprazole***- **Olanzapine** carries a very high risk of **metabolic side effects**, including significant **weight gain**, **hyperglycemia**, and **dyslipidemia**, which this patient has developed, indicating new-onset **diabetes mellitus**.- **Aripiprazole** is a **partial dopamine agonist** known for its low **metabolic side-effect profile**, making it a highly suitable choice to switch to while maintaining antipsychotic efficacy and addressing the severe metabolic complications. *Continue olanzapine and add metformin*- Continuing **olanzapine** means perpetuating the primary cause of the severe **metabolic syndrome** and **diabetes**, which is unlikely to be fully controlled by metformin alone.- While **metformin** would help with **glycemic control**, it does not reverse the weight gain or dyslipidemia and fails to address the iatrogenic origin of these problems. *Reduce olanzapine dose to 10mg daily*- Reducing the dose is unlikely to reverse established **diabetes mellitus**, significant **weight gain** (BMI from 24 to 28), or severe **dyslipidemia** once they have developed.- Lowering the dose could also risk a **relapse of psychotic symptoms** if 15mg was the optimal therapeutic dose for his resolved positive symptoms. *Switch to amisulpride*- While **amisulpride** has a better metabolic profile than olanzapine, it is not as metabolically benign as **aripiprazole** and still carries an intermediate risk for **weight gain**.- **Amisulpride** is also frequently associated with significant **prolactin elevation**, which can lead to other endocrine side effects such as sexual dysfunction and galactorrhea. *Continue olanzapine and add atorvastatin*- Adding **atorvastatin** would only address the **dyslipidemia** and would not manage the patient's new-onset **diabetes mellitus**, significant **weight gain**, or the ongoing metabolic insult from olanzapine.- Continuing the offending agent (olanzapine) maintains the primary risk factor for further metabolic deterioration and increased **cardiovascular morbidity** despite symptomatic treatment of one component.

Question 163: A 29-year-old woman with bipolar affective disorder type I presents to the community mental health team reporting a 3-week history of low mood, anhedonia, increased sleep (12 hours daily), increased appetite with 5kg weight gain, and heavy feelings in her limbs. She describes feeling 'slowed down like moving through treacle.' She takes lithium 400mg twice daily with a recent level of 0.7 mmol/L. She has had three previous manic episodes but no previous depressive episodes. What is the most appropriate additional treatment?

A. Increase lithium dose
B. Add fluoxetine
C. Add quetiapine (Correct Answer)
D. Add venlafaxine
E. Add lamotrigine

Explanation: ***Add quetiapine*** - **Quetiapine** is a first-line recommendation for **acute bipolar depression** due to its robust efficacy and its ability to provide relief without significant risk of **mood switching** to mania. - It addresses **atypical features** like hypersomnia and leaden paralysis faster than medications requiring long titration periods. *Increase lithium dose* - The patient's **lithium level is 0.7 mmol/L**, which is within the therapeutic range (0.6–0.8 mmol/L) for maintenance, so increasing it is unlikely to resolve acute depression. - Toxicity risk increases significantly at higher doses without guaranteed improvement in **depressive symptoms**. *Add fluoxetine* - Adding an **SSRI** like fluoxetine in bipolar I disorder carries a risk of inducing **mania/hypomania**, even when used alongside a mood stabilizer. - Current guidelines generally prioritize **second-generation antipsychotics** (like quetiapine) or lamotrigine over antidepressants for acute bipolar depression. *Add venlafaxine* - **SNRIs** like venlafaxine have a higher risk of triggering **mood switching** to mania compared to SSRIs in bipolar patients. - It should be avoided, especially in patients with a history of **multiple manic episodes**, as seen in this clinical presentation. *Add lamotrigine* - While effective for **bipolar depression prophylaxis**, lamotrigine requires a **slow titration** over 6–8 weeks to avoid severe rashes like Stevens-Johnson syndrome. - Its slow onset of action makes it less suitable than quetiapine for the **acute management** of current distressing symptoms.

Question 164: A 44-year-old man with schizoaffective disorder has been treated with amisulpride 800mg daily for 18 months with good symptom control. He now presents with involuntary chewing movements, lip smacking, and darting tongue movements that persist throughout the consultation. He is unaware of these movements. His mental state examination is otherwise unremarkable. Physical examination shows no other abnormalities. What is the most likely diagnosis?

A. Acute dystonic reaction
B. Akathisia
C. Tardive dyskinesia (Correct Answer)
D. Parkinsonism
E. Neuroleptic malignant syndrome

Explanation: ***Tardive dyskinesia*** - This condition is a **late-onset extrapyramidal side effect** occurring after prolonged use of antipsychotics (e.g., 18 months), characterized by involuntary, repetitive movements such as **lip smacking**, **chewing movements**, and **darting tongue** movements. - Patients are frequently **unaware** of these movements, and the symptoms can become **permanent** even if the offending medication is discontinued. *Acute dystonic reaction* - These reactions typically occur within **hours to days** of starting a dopamine antagonist or increasing the dose, rather than after long-term treatment. - Characterized by **sustained muscle contractions** causing abnormal postures like **torticollis** or **oculogyric crisis**, which are not present here. *Akathisia* - Presents as a subjective feeling of **inner restlessness** and a physical inability to sit still, often manifesting as constant pacing or leg swinging. - It does not involve the specific **oro-buccal-lingual dyskinesias** (lip smacking and tongue movements) described in this case. *Parkinsonism* - Drug-induced parkinsonism features a triad of **bradykinesia**, **rigidity**, and a **resting tremor** (pill-rolling). - The movements in parkinsonism are not typically the darting or smacking dyskinetic movements seen in this patient. *Neuroleptic malignant syndrome* - A life-threatening emergency characterized by **autonomic instability**, **lead-pipe rigidity**, and **hyperpyrexia** (high fever). - It is associated with **altered mental status** and high serum **creatine kinase**, which do not match this patient's unremarkable mental state and physical exam.

Question 165: A 37-year-old woman with bipolar affective disorder has been stable on lithium carbonate 800mg twice daily for 4 years. She attends her routine monitoring appointment. Blood tests show: lithium level 0.9 mmol/L (therapeutic range 0.6-1.0), sodium 138 mmol/L, potassium 4.2 mmol/L, urea 8.2 mmol/L, creatinine 145 µmol/L (baseline 95 µmol/L 6 months ago), eGFR 38 ml/min/1.73m² (was 68 ml/min/1.73m² previously), TSH 5.8 mU/L. What is the most appropriate next step in management?

A. Continue lithium and repeat bloods in 3 months
B. Reduce lithium dose to 600mg twice daily
C. Stop lithium and switch to sodium valproate
D. Refer to nephrology and consider switching to alternative mood stabiliser (Correct Answer)
E. Add levothyroxine and continue lithium

Explanation: ***Refer to nephrology and consider switching to alternative mood stabiliser***- The patient shows a significant **decline in eGFR** (from 68 to 38 ml/min) and a rising **creatinine**, indicating **Stage 3b Chronic Kidney Disease**, which requires specialist referral.- NICE guidelines suggest that if **eGFR** falls below 45 ml/min or shows a rapid decline, lithium should be reconsidered and potentially replaced with alternatives like **valproate** or **quetiapine** to prevent further nephrotoxicity.*Continue lithium and repeat bloods in 3 months*- Routine monitoring is inappropriate when there is evidence of **progressive renal impairment**, as waiting 3 months could lead to irreversible damage.- Lithium levels are currently within the therapeutic range, but the toxicity is **structural/interstitial**, meaning a "normal" level does not rule out ongoing renal damage.*Reduce lithium dose to 600mg twice daily*- While dose reduction may lower serum levels, it does not stop the progression of **lithium-induced interstitial nephritis** once significant impairment has occurred.- The drop in **eGFR** to below 40 ml/min is a critical threshold that mandates specialist expert review rather than simple titration.*Stop lithium and switch to sodium valproate*- Abruptly stopping lithium without **specialist psychiatric guidance** and **nephrology consultation** can cause a rebound relapse of bipolar symptoms.- While a switch is likely necessary, the management should be coordinated to balance **renal protection** with the risk of **mood destabilization**.*Add levothyroxine and continue lithium*- The mildly elevated **TSH (5.8 mU/L)** suggests **subclinical hypothyroidism**, which is a common side effect of lithium but not as urgent as the renal decline.- Starting levothyroxine addresses the endocrine issue but completely ignores the life-altering **progressive renal failure** demonstrated by the drop in eGFR.

Question 166: A 25-year-old woman presents to the emergency department with a 6-week history of bizarre behaviour. Her family reports she believes her thoughts are being broadcast on television and that she can control the weather. She has stopped washing and eating properly. She has no previous psychiatric history. On examination, she appears dishevelled with poor eye contact and exhibits thought blocking during the interview. What diagnostic category does the phenomenon of 'thought broadcasting' represent?

A. Delusion of reference
B. Passivity phenomenon (Correct Answer)
C. Thought disorder
D. Overvalued idea
E. Grandiose delusion

Explanation: ***Passivity phenomenon*** - **Thought broadcasting** is a Schneiderian **first-rank symptom** of schizophrenia, where a person believes their thoughts are being divulged to others. - It falls under **passivity phenomena** (or disorders of thought possession), which signify a disturbance of **ego boundaries** where internal experiences are felt to be externally imposed or controlled. *Delusion of reference* - A **delusion of reference** involves the false belief that certain **neutral events or objects** in the environment carry specific, personal meaning or messages for the individual. - While the patient's thoughts are 'broadcast on television', the core belief is about her thoughts being *known* or *sent out*, not merely interpreting an existing television program as referring to her. *Thought disorder* - This term refers to **disturbances in the form or stream of thought**, affecting how thoughts are expressed, such as **thought blocking**, loosening of associations, or tangentiality. - Although the patient exhibits **thought blocking**, "thought broadcasting" is a **delusion** (a disturbance in content of thought) specifically categorized under passivity phenomena, not primarily a disorder of thought *form*. *Overvalued idea* - An **overvalued idea** is an understandable, albeit unreasonable, belief that is pursued with conviction but is not held with the same **absolute certainty** as a delusion and does not involve external imposition. - Unlike thought broadcasting, overvalued ideas do not involve the perception of one's thoughts being **controlled or accessible** by external forces. *Grandiose delusion* - A **grandiose delusion** is a false belief in one's **exaggerated importance, power, or identity**, such as believing one can **control the weather**, which the patient also exhibits. - While the patient has a grandiose delusion, this is a separate and distinct type of delusion from **thought broadcasting**, which specifically concerns the boundaries of one's mind and the privacy of thoughts.

Question 167: A 40-year-old man with chronic paranoid schizophrenia has been treated with various oral antipsychotics over 8 years with poor adherence. He has had four hospital admissions in the past 2 years. His care coordinator reports he forgets to take medications and becomes suspicious of tablets. He currently takes olanzapine 20mg daily but admits taking it only 2-3 times weekly. What is the most appropriate management strategy to improve adherence?

A. Increase olanzapine to 30mg daily
B. Change to paliperidone long-acting injection (Correct Answer)
C. Initiate clozapine treatment
D. Add lithium augmentation
E. Arrange supervised daily dispensing by pharmacy

Explanation: ***Change to paliperidone long-acting injection*** - **Long-acting injectable (LAI)** antipsychotics are the treatment of choice for patients with chronic schizophrenia who exhibit **poor adherence** and frequent hospital readmissions. - This strategy ensures reliable delivery of medication and allows the clinical team to immediately identify **non-compliance** if the patient misses an injection appointment. *Increase olanzapine to 30mg daily* - Increasing the dose is ineffective when the primary issue is **medication non-adherence** rather than a lack of clinical response to the molecules. - Higher doses may lead to increased **metabolic side effects**, which could further discourage the patient from taking the medication. *Initiate clozapine treatment* - **Clozapine** is indicated for **treatment-resistant schizophrenia**, defined as failure of two different antipsychotics despite adequate adherence. - This patient's relapse is clearly linked to **poor compliance** rather than resistance, and clozapine requires strict adherence to blood monitoring and daily dosing. *Add lithium augmentation* - **Lithium augmentation** is typically used to manage mood symptoms or treatment-resistant cases, not as a primary strategy to manage **medication forgetfulness**. - Adding more medications increases the **pill burden**, which likely worsens the patient's existing suspicion and poor adherence. *Arrange supervised daily dispensing by pharmacy* - While this ensures ingestion, it is more intrusive and burdensome than an **LAI**, requiring the patient to travel to a pharmacy every single day. - For a patient with **suspiciousness** and a history of forgetting pills, a once-monthly or fortnightly injection provides a more sustainable and less stigmatizing long-term solution.

Question 168: A 31-year-old woman with bipolar affective disorder type I is admitted to the psychiatric ward during her first trimester of pregnancy. She presents with pressured speech, grandiose delusions, reduced need for sleep, and irritability. She has been non-compliant with lithium for 3 months. She has no past history of violent behaviour. Her physical examination and routine blood tests are normal. What is the most appropriate acute pharmacological management?

A. Restart lithium carbonate
B. Commence haloperidol (Correct Answer)
C. Commence sodium valproate
D. Commence lamotrigine
E. Commence carbamazepine

Explanation: ***Commence haloperidol*** - **Haloperidol** is a first-line agent for **acute mania** in pregnancy due to its established safety profile and extensive data regarding fetal safety, particularly in the **first trimester**. - It effectively manages severe **psychotic symptoms** and irritability, making it a suitable choice for rapid control of acute manic episodes during pregnancy. *Restart lithium carbonate* - **Lithium** use during the **first trimester** is associated with an increased risk of **Ebstein's anomaly**, a congenital cardiac malformation. - While it may be considered in later trimesters with careful monitoring, the immediate risks in early pregnancy make it an inappropriate acute management choice. *Commence sodium valproate* - **Sodium valproate** is strongly **contraindicated** in pregnancy, especially in the first trimester, due to a high risk of **neural tube defects** and long-term neurodevelopmental problems. - Its teratogenicity makes it an unsuitable option for managing acute mania in a pregnant woman. *Commence lamotrigine* - **Lamotrigine** is primarily used for the management of **bipolar depression** or as maintenance therapy, rather than for the acute treatment of severe manic symptoms. - Its slow **titration** schedule and limited efficacy for rapid mood stabilization make it inappropriate for an acute manic episode. *Commence carbamazepine* - **Carbamazepine** is a known **teratogen** associated with risks of **neural tube defects** and craniofacial anomalies when used in the first trimester of pregnancy. - Given these risks and the availability of safer alternatives like haloperidol, it is not the appropriate acute pharmacological choice.

Question 169: A 34-year-old man with a 6-year history of paranoid schizophrenia is reviewed in the community mental health team. He has been stable on risperidone long-acting injection 50mg fortnightly for the past 2 years. He now wishes to start a family with his partner. On examination, he has mild gynaecomastia and reports reduced libido. Blood tests show a prolactin level of 2800 mU/L (normal range: 86-324 mU/L). His mental state remains stable with no active psychotic symptoms. What is the most appropriate next step in management?

A. Switch to aripiprazole long-acting injection (Correct Answer)
B. Add cabergoline to current medication
C. Switch to clozapine
D. Reduce risperidone dose to 25mg fortnightly
E. Continue current medication and reassure

Explanation: ***Switch to aripiprazole long-acting injection***- **Risperidone** is a potent **D2 antagonist** that frequently cause **hyperprolactinaemia**; switching to **aripiprazole**, a **partial dopamine agonist**, helps lower prolactin levels while maintaining antipsychotic control.- Using the **long-acting injection (LAI)** formulation ensures continued **medication adherence** and stability in a patient who has been well-managed on a depot.*Add cabergoline to current medication*- **Cabergoline** is a dopamine agonist used for prolactinomas but is generally avoided in **schizophrenia** as it can potentially **exacerbate psychotic symptoms**.- This approach introduces unnecessary **polypharmacy** rather than addressing the primary cause, which is the risperidone therapy.*Switch to clozapine*- **Clozapine** is typically reserved for cases of **treatment-resistant schizophrenia**, defined by failing two other antipsychotics, which does not apply to this stable patient.- It requires intensive **haematological monitoring** due to the risk of **agranulocytosis**, making it a disproportionate intervention for managing side effects.*Reduce risperidone dose to 25mg fortnightly*- A dose reduction carries a significant **risk of relapse** of psychotic symptoms in a patient who has been stable for two years.- Lowering the dose may not be sufficient to resolve **symptomatic hyperprolactinaemia** (gynaecomastia and reduced libido) if the D2 blockade remains high enough.*Continue current medication and reassure*- Clinical symptoms such as **gynaecomastia** and **reduced libido** are significant side effects that impair **quality of life** and the patient's desire to start a family.- **Hyperprolactinaemia** can have long-term health consequences, including **reduced bone mineral density** and osteoporosis, necessitating active management.

Question 170: A 27-year-old woman with bipolar affective disorder presents for medication review. She has had three manic episodes and two severe depressive episodes over the past 4 years. She has previously taken lithium (stopped due to tremor and polyuria) and sodium valproate (stopped due to significant weight gain and hair loss). She is currently on lamotrigine 200mg daily but had a hypomanic episode 3 months ago. In comparing the neuroprotective and neurocognitive effects of long-term mood stabilizer therapy, which statement represents the most accurate interpretation of current evidence?

A. Lithium demonstrates unique neuroprotective properties by increasing grey matter volume and reducing progression of cognitive decline in bipolar disorder (Correct Answer)
B. Sodium valproate provides superior cognitive preservation compared to lithium due to its anti-inflammatory mechanisms in the central nervous system
C. All mood stabilizers equally prevent cognitive decline through stabilization of mood episodes alone with no direct neuroprotective effects
D. Lamotrigine has the strongest evidence for neuroprotection through glutamate modulation preventing excitotoxic neuronal damage
E. Atypical antipsychotics demonstrate greater neuroprotective effects than traditional mood stabilizers through BDNF upregulation

Explanation: ***Lithium demonstrates unique neuroprotective properties by increasing grey matter volume and reducing progression of cognitive decline in bipolar disorder***- **Lithium** is the most robustly associated mood stabilizer with neuroprotection, evidenced by increased **grey matter volume** in the hippocampus and prefrontal cortex.- It acts through multiple mechanisms, including inhibition of **GSK-3β**, increasing **BDNF** levels, and enhancing **anti-apoptotic** factors like bcl-2.*Sodium valproate provides superior cognitive preservation compared to lithium due to its anti-inflammatory mechanisms in the central nervous system*- While **sodium valproate** has some neuroprotective properties, current clinical evidence does not support its superiority over lithium for **cognitive preservation**.- High-dose valproate therapy may actually be associated with **cognitive impairment** and is not as thoroughly linked to brain volume increases as lithium.*All mood stabilizers equally prevent cognitive decline through stabilization of mood episodes alone with no direct neuroprotective effects*- Although preventing **mood episodes** reduces excitotoxic neurotoxicity, evidence shows that **lithium** has direct cellular neuroprotective effects that exceed simple mood stabilization.- Different mood stabilizers have distinct **molecular targets**, leading to varying levels of biochemical and structural neuroprotection.*Lamotrigine has the strongest evidence for neuroprotection through glutamate modulation preventing excitotoxic neuronal damage*- **Lamotrigine** modulates **glutamate release**, which may offer theoretical neuroprotection, but large-scale structural neuroimaging evidence remains less substantial than that of lithium.- It is primarily effective for preventing **bipolar depression** and lacks the robust evidence for increasing cortical thickness seen with lithium.*Atypical antipsychotics demonstrate greater neuroprotective effects than traditional mood stabilizers through BDNF upregulation*- While some studies show **atypical antipsychotics** might increase BDNF, long-term use has also been paradoxically linked to **brain volume reductions** in some populations.- **Lithium** remains the gold standard for neuroprotective evidence in bipolar disorder compared to antipsychotics which have more **heterogeneous results**.

Question 171: A 36-year-old man with schizophrenia on clozapine 450mg daily attends A&E with 2-day history of severe constipation, abdominal distension, vomiting, and no bowel movements for 4 days. Examination reveals tachycardia (110/min), abdominal distension with reduced bowel sounds, and tympanic percussion. Abdominal X-ray shows grossly dilated large bowel (caecal diameter 11cm) with no evidence of mechanical obstruction. What is the most appropriate immediate management of this life-threatening complication?

A. Continue clozapine, commence regular laxatives, and arrange routine surgical outpatient review
B. Stop clozapine, insert nasogastric tube for decompression, commence IV fluids, and request urgent surgical review (Correct Answer)
C. Reduce clozapine dose by 50%, give high-dose lactulose and bisacodyl, and observe for 24 hours
D. Continue clozapine, give phosphate enema and oral polyethylene glycol, and arrange colonoscopy
E. Stop clozapine temporarily, give IV metoclopramide for prokinetic effect, and arrange CT abdomen

Explanation: ***Stop clozapine, insert nasogastric tube for decompression, commence IV fluids, and request urgent surgical review*** - The patient presents with **clozapine-induced paralytic ileus** or **toxic megacolon**, a surgical emergency due to severe constipation and bowel dilation (caecal diameter **11cm**, indicating high perforation risk). - Immediate management involves **stopping the offending agent** (clozapine), **resuscitation with IV fluids**, **bowel decompression** via a nasogastric tube, and **urgent surgical consultation** to prevent bowel ischemia, perforation, or death. *Continue clozapine, commence regular laxatives, and arrange routine surgical outpatient review* - Continuing **clozapine** is contraindicated as its potent **antimuscarinic effects** are the cause of the severe gut hypomotility and will exacerbate the condition, increasing perforation risk. - A **routine outpatient review** is entirely inappropriate for a patient presenting with an acute abdomen, significant bowel dilation, and **systemic tachycardia**, indicating a medical emergency. *Reduce clozapine dose by 50%, give high-dose lactulose and bisacodyl, and observe for 24 hours* - Merely **reducing the clozapine dose** is insufficient when the patient has established **life-threatening intestinal obstruction** with features of systemic distress. - Osmotic and stimulant laxatives like **lactulose** and **bisacodyl** can worsen intestinal distension and intraluminal pressure in a dilated, paralytic bowel, potentially increasing the risk of **bowel perforation**. *Continue clozapine, give phosphate enema and oral polyethylene glycol, and arrange colonoscopy* - Continuing **clozapine** is incorrect. **Enemas and oral polyethylene glycol (PEG)** are appropriate for simple constipation but are ineffective and potentially harmful in severe **paralytic ileus** with significant bowel dilation. - **Colonoscopy** is generally contraindicated in cases of acute megacolon due to the substantial risk of **iatrogenic perforation** from air insufflation and instrumentation of a compromised bowel wall. *Stop clozapine temporarily, give IV metoclopramide for prokinetic effect, and arrange CT abdomen* - While stopping clozapine is correct, **metoclopramide** is a dopamine receptor antagonist and its use in patients on antipsychotics, particularly clozapine, carries an increased risk of **extrapyramidal side effects**. - Prokinetics like metoclopramide are typically ineffective and may even be harmful in severe **clozapine-induced paralytic ileus** where anticholinergic effects cause widespread gut paralysis, and are not indicated for immediate management of acute megacolon.

Question 172: A 41-year-old woman with bipolar affective disorder type I has been stable on lithium carbonate 800mg twice daily for 2 years. She presents to her GP with a 6-week history of polyuria, polydipsia (drinking 5-6 litres daily), and nocturia (waking 4-5 times per night). Urine dipstick shows no glucose, blood tests reveal: sodium 148 mmol/L, serum osmolality 298 mOsm/kg, urine osmolality 120 mOsm/kg, lithium level 0.8 mmol/L, creatinine 98 μmol/L. What is the most likely underlying diagnosis?

A. Lithium-induced nephrogenic diabetes insipidus due to impaired aquaporin-2 expression in collecting ducts (Correct Answer)
B. Lithium-induced primary polydipsia due to direct stimulation of hypothalamic thirst centres
C. Lithium-induced chronic interstitial nephritis causing osmotic diuresis
D. Central diabetes insipidus due to lithium toxicity affecting posterior pituitary ADH release
E. Lithium-induced hyperparathyroidism causing hypercalcaemia and polyuria

Explanation: ***Lithium-induced nephrogenic diabetes insipidus due to impaired aquaporin-2 expression in collecting ducts***- The patient presents with **polyuria**, **polydipsia**, and **nocturia** alongside **hypernatremia** (148 mmol/L) and **high serum osmolality** (298 mOsm/kg).- Crucially, the **urine osmolality is low** (120 mOsm/kg), indicating an inability of the kidneys to concentrate urine despite the body's dehydrated state, a classic sign of **nephrogenic diabetes insipidus (NDI)**, a known side effect of long-term lithium that impairs **aquaporin-2 (AQP2)** channel function in the **collecting ducts**.*Lithium-induced primary polydipsia due to direct stimulation of hypothalamic thirst centres*- **Primary polydipsia** is characterized by excessive fluid intake leading to **hyponatremia** and **low serum osmolality** due to water intoxication, which contradicts this patient's **hypernatremia** and elevated serum osmolality.- In primary polydipsia, the kidneys are typically able to concentrate urine if dehydrated; this patient's **dilute urine** despite hypernatremia points to a **renal concentrating defect**, not just increased thirst.*Lithium-induced chronic interstitial nephritis causing osmotic diuresis*- **Osmotic diuresis** occurs when unreabsorbed solutes (like glucose or mannitol) in the renal tubules draw water, leading to polyuria with a **relatively high urine osmolality** (e.g., >250-300 mOsm/kg), which is not consistent with this patient's **very dilute urine** (120 mOsm/kg).- While lithium can cause chronic interstitial nephritis, leading to impaired concentrating ability, the primary mechanism of **osmotic diuresis** is different, and the patient's **normal creatinine** makes severe interstitial nephritis less likely as the primary driver of polyuria.*Central diabetes insipidus due to lithium toxicity affecting posterior pituitary ADH release*- **Central diabetes insipidus (CDI)** is caused by a deficiency in **ADH (vasopressin)** production or release from the posterior pituitary, which is not a typical direct effect of lithium.- Lithium primarily causes **nephrogenic diabetes insipidus (NDI)** by making the kidney's collecting ducts resistant to ADH, rather than affecting ADH synthesis or release from the pituitary.*Lithium-induced hyperparathyroidism causing hypercalcaemia and polyuria*- While long-term lithium therapy can induce **hyperparathyroidism** and subsequent **hypercalcaemia**, and **hypercalcaemia** itself can impair renal concentrating ability (leading to nephrogenic DI), there are no data provided in the case for serum calcium or PTH levels.- The most direct and common mechanism of polyuria in stable lithium therapy, with the given lab findings, is direct lithium toxicity on the collecting duct's response to ADH, rather than secondary effects via calcium.

Question 173: A 29-year-old man with a 5-year history of schizophrenia presents to his GP requesting medication review. He has been taking risperidone depot 25mg fortnightly with good symptom control but complains of gynaecomastia, galactorrhoea, reduced libido, and erectile dysfunction for 8 months. Blood tests show prolactin level 2,850 mU/L (normal range 86-324 mU/L). His psychotic symptoms are well-controlled and he has good treatment adherence. What underlying mechanism best explains his symptoms?

A. Risperidone's strong 5-HT2A receptor antagonism causing disruption of the hypothalamic-pituitary axis
B. Risperidone's potent D2 receptor blockade in the tuberoinfundibular pathway removing dopamine's inhibitory effect on prolactin (Correct Answer)
C. Risperidone's anti-muscarinic properties causing indirect stimulation of lactotroph cells in the anterior pituitary
D. Risperidone's alpha-1 adrenergic blockade leading to increased prolactin synthesis and release
E. Risperidone's effect on histamine H1 receptors causing downstream stimulation of prolactin-releasing hormone

Explanation: ***Risperidone's potent D2 receptor blockade in the tuberoinfundibular pathway removing dopamine's inhibitory effect on prolactin***- **Dopamine** normally acts via the **tuberoinfundibular pathway** to provide tonic inhibition of prolactin release from the **anterior pituitary** lactotrophs.- **Risperidone** has a high affinity for **D2 receptors**; by blocking these receptors, it removes the inhibitory signal, leading to **hyperprolactinaemia** and clinical symptoms like **gynaecomastia** and **galactorrhoea**.*Risperidone's strong 5-HT2A receptor antagonism causing disruption of the hypothalamic-pituitary axis*- While risperidone is a potent **5-HT2A antagonist**, this specific mechanism is associated with a reduction in **extrapyramidal side effects** rather than causing prolactin elevation.- **Serotonin** typically stimulates prolactin release, so **antagonism** at these receptors would actually tend to **lower** prolactin levels rather than increase them.*Risperidone's anti-muscarinic properties causing indirect stimulation of lactotroph cells in the anterior pituitary*- Risperidone possesses very **low affinity** for **muscarinic receptors**, unlike low-potency typical antipsychotics or clozapine.- Even in drugs with strong **anticholinergic** effects, this mechanism does not directly influence the secretion of **prolactin** from the pituitary gland.*Risperidone's alpha-1 adrenergic blockade leading to increased prolactin synthesis and release*- **Alpha-1 adrenergic blockade** by antipsychotics is primarily responsible for side effects such as **orthostatic hypotension** and reflex tachycardia.- There is no clinical or physiological evidence linking **alpha-1 blockade** to the synthesis or pathological release of **prolactin**.*Risperidone's effect on histamine H1 receptors causing downstream stimulation of prolactin-releasing hormone*- Blockade of **H1 receptors** is a common feature of many antipsychotics that primarily leads to **sedation** and **weight gain**.- **Histaminergic activity** is not a primary regulator of the **tuberoinfundibular pathway**, and its blockade does not explain the significant **prolactin elevation** seen with risperidone.

Question 174: A 33-year-old man with paranoid schizophrenia has been treated with multiple antipsychotics over 6 years with persistent positive symptoms despite adequate trials of risperidone, olanzapine, and quetiapine at therapeutic doses for appropriate durations. He has adherence confirmed by depot medication and plasma levels. Which criterion must be met before defining his condition as treatment-resistant schizophrenia and initiating clozapine?

A. Failure to respond to at least two different antipsychotics, one of which should be a second-generation agent, each tried for 6-8 weeks at therapeutic doses
B. Failure to respond to at least two different antipsychotics from different classes, each tried for at least 4-6 weeks at minimum effective doses
C. Failure to respond to at least two different antipsychotics, each tried sequentially for 6-8 weeks at adequate doses, with one being an atypical agent (Correct Answer)
D. Failure to respond to trials of both typical and atypical antipsychotics for at least 3 months each at maximum licensed doses
E. Failure to respond to adequate trials of at least three different antipsychotics, each for at least 6 weeks at therapeutic doses

Explanation: ***Failure to respond to at least two different antipsychotics, each tried sequentially for 6-8 weeks at adequate doses, with one being an atypical agent***- **Treatment-resistant schizophrenia (TRS)** is formally defined by the failure of at least **two different antipsychotic medications** at adequate therapeutic doses for a duration of **6-8 weeks** each.- At least one of these trials must involve a **second-generation (atypical) antipsychotic**, and **medication adherence** must be confirmed (as seen with this patient's depot and plasma levels).*Failure to respond to at least two different antipsychotics, one of which should be a second-generation agent, each tried for 6-8 weeks at therapeutic doses*- While very similar, the standard clinical definition emphasizes the **sequential nature** of these trials to ensure individual efficacy is assessed.- This option is technically less precise than the correct answer regarding the **sequential trial requirement** established by international consensus.*Failure to respond to at least two different antipsychotics from different classes, each tried for at least 4-6 weeks at minimum effective doses*- A trial duration of **4-6 weeks** is considered too short to definitively establish treatment resistance, as full clinical response can take longer.- Using only the **minimum effective dose** may not provide a sufficient challenge to the symptoms before labeling the patient as treatment-resistant.*Failure to respond to trials of both typical and atypical antipsychotics for at least 3 months each at maximum licensed doses*- Requiring **3 months** for each trial exceeds the standard guideline of **6-8 weeks**, potentially delaying the initiation of Clozapine.- **Maximum licensed doses** are not strictly required; the medications only need to be at a **therapeutic dose** within the standard licensed range.*Failure to respond to adequate trials of at least three different antipsychotics, each for at least 6 weeks at therapeutic doses*- Although the patient in this scenario has failed three agents, the formal definition of TRS only requires the failure of **two different antipsychotics**.- Requiring **three trials** would unnecessarily delay the use of **Clozapine**, which is the gold-standard treatment for resistant cases.

Question 175: A 52-year-old woman with bipolar disorder type II is reviewed in outpatient clinic. She has had four episodes of major depression in the past 3 years and two hypomanic episodes. Her current mood is euthymic on lamotrigine 200mg daily. She reports the depressive episodes are severely debilitating and seeks optimization of her treatment to reduce future episodes. What is the most appropriate evidence-based modification to her medication regimen?

A. Add lithium carbonate as combination therapy is superior for preventing depressive episodes (Correct Answer)
B. Switch from lamotrigine to quetiapine as monotherapy for better depression prophylaxis
C. Continue lamotrigine alone as it provides optimal prophylaxis for bipolar II disorder
D. Add sodium valproate as it has specific efficacy for rapid cycling bipolar disorder
E. Switch to high-dose lamotrigine 400mg daily to maximize antidepressant effect

Explanation: ***Add lithium carbonate as combination therapy is superior for preventing depressive episodes*** - For patients with **Bipolar II disorder** experiencing breakthrough depressive episodes on monotherapy, adding **Lithium** is the most evidence-based strategy to enhance **prophylaxis**. - Studies show the combination of **Lithium and Lamotrigine** is more effective at preventing depressive relapses and reducing **suicidal ideation** than either agent alone. *Switch from lamotrigine to quetiapine as monotherapy for better depression prophylaxis* - While **Quetiapine** is effective for bipolar depression, switching agents risks losing the partial stability the patient has already achieved on **Lamotrigine**. - Evidence generally supports **combination therapy** over switching to a different monotherapy when a patient remains symptomatic despite a standard therapeutic dose. *Continue lamotrigine alone as it provides optimal prophylaxis for bipolar II disorder* - Although **Lamotrigine** is useful for preventing depression, four major depressive episodes in three years indicate that **monotherapy** is insufficient for this patient. - Maintenance treatment must be optimized when there is a high frequency of **breakthrough episodes** to reduce long-term morbidity. *Add sodium valproate as it has specific efficacy for rapid cycling bipolar disorder* - **Sodium Valproate** is primarily effective for preventing **manic episodes** and has less robust evidence for the prevention of the depressive phase of Bipolar II. - It is generally not the first-choice adjunct for someone whose primary burden is **recurrent depression** rather than mania or mixed states. *Switch to high-dose lamotrigine 400mg daily to maximize antidepressant effect* - The standard daily maintenance dose for **Lamotrigine** is typically **200mg**; titrating to 400mg offers marginal benefit while increasing the risk of adverse effects. - Dose escalation does not address the need for a **mechanistically different** mood stabilizer to achieve better therapeutic coverage.

Question 176: A 26-year-old woman presents with a 4-month history of social withdrawal, hearing her dead grandmother's voice telling her she is worthless, and believing that strangers can read her thoughts. She meets criteria for schizophrenia and agrees to start antipsychotic medication. Her BMI is 32 kg/m², fasting glucose 5.8 mmol/L, and she has a family history of type 2 diabetes. Which atypical antipsychotic would be the most appropriate first-line choice given her metabolic risk profile?

A. Olanzapine 10mg daily due to superior efficacy in first episode psychosis
B. Quetiapine 300mg daily due to lower risk of extrapyramidal side effects
C. Aripiprazole 10mg daily due to favorable metabolic profile (Correct Answer)
D. Risperidone 4mg daily due to established efficacy and NHS cost-effectiveness
E. Amisulpride 400mg daily due to specific efficacy for negative symptoms

Explanation: ***Aripiprazole 10mg daily due to favorable metabolic profile*** - **Aripiprazole** is a **partial dopamine agonist** known for having the most favorable metabolic profile with minimal risk of **weight gain**, dyslipidemia, or hyperglycemia. - This makes it the ideal choice for a patient with a **BMI of 32**, elevated fasting glucose (pre-diabetic range), and a significant family history of **Type 2 Diabetes**, mitigating her metabolic risk. *Olanzapine 10mg daily due to superior efficacy in first episode psychosis* - **Olanzapine** is associated with the highest risk of **metabolic syndrome**, leading to significant **weight gain** and worsening of lipid/glucose profiles. - Its use is generally avoided as a first-line option in patients who already possess multiple **metabolic risk factors** like obesity and pre-diabetes. *Quetiapine 300mg daily due to lower risk of extrapyramidal side effects* - While **Quetiapine** has a low risk of **Extrapyramidal Side Effects (EPSE)**, it carries a moderate-to-high risk of **weight gain** and metabolic disturbances. - In this clinical scenario, the patient's existing **obesity** makes Quetiapine a less suitable choice compared to more metabolically neutral agents. *Risperidone 4mg daily due to established efficacy and NHS cost-effectiveness* - **Risperidone** carries an intermediate metabolic risk and is frequently associated with significant **hyperprolactinemia** and moderate weight gain. - Although effective, it is less desirable than Aripiprazole for a patient at high risk for **cardiovascular and metabolic complications** given her profile. *Amisulpride 400mg daily due to specific efficacy for negative symptoms* - **Amisulpride** is effective for negative symptoms but is notorious for causing marked elevations in **prolactin levels**. - While it has a lower metabolic impact than Olanzapine, it still lacks the **weight-neutral** benefits provided by **Aripiprazole** in the context of a patient with a high BMI and other metabolic risk factors.

Question 177: A 45-year-old man with chronic schizophrenia presents with 3-day history of fever (39.2°C), confusion, muscle rigidity, and profuse sweating. He was started on haloperidol 15mg daily 10 days ago after non-compliance with depot medication. Observations show: BP 168/102 mmHg, pulse 118/min, temperature 39.2°C. Blood tests reveal: WCC 16.5 × 10⁹/L, creatine kinase 8,500 U/L, creatinine 185 μmol/L. What is the most critical immediate management priority?

A. Stop haloperidol, commence dantrolene 1mg/kg IV, and arrange urgent ICU admission (Correct Answer)
B. Commence broad-spectrum antibiotics for suspected sepsis and arrange lumbar puncture
C. Stop haloperidol, give benzodiazepines for muscle rigidity, and arrange urgent CT head
D. Administer procyclidine for acute dystonia and continue haloperidol at reduced dose
E. Stop haloperidol, provide supportive care with IV fluids and cooling measures only

Explanation: ***Stop haloperidol, commence dantrolene 1mg/kg IV, and arrange urgent ICU admission*** - The patient's presentation with **fever**, **confusion**, severe **muscle rigidity**, profuse sweating, **autonomic instability**, and extremely elevated **creatine kinase (CK 8,500 U/L)** after starting haloperidol is highly consistent with **Neuroleptic Malignant Syndrome (NMS)**. - Immediate management for NMS includes **discontinuation of the causative antipsychotic**, administration of specific agents like **dantrolene** (a direct muscle relaxant) or bromocriptine, and **urgent ICU admission** for comprehensive supportive care due to the high risk of complications like **rhabdomyolysis** and **acute kidney injury**. *Commence broad-spectrum antibiotics for suspected sepsis and arrange lumbar puncture* - While fever and confusion are present, the extreme **muscle rigidity** and significantly elevated **CK levels** are not typical for uncomplicated sepsis or meningitis; these findings strongly point towards a neuromuscular disorder like NMS. - Delaying specific NMS treatment by solely pursuing a sepsis workup would be detrimental given the rapid progression and life-threatening nature of the syndrome. *Stop haloperidol, give benzodiazepines for muscle rigidity, and arrange urgent CT head* - While stopping haloperidol is correct, **benzodiazepines** are generally insufficient for the severe, generalized "lead-pipe" **muscle rigidity** characteristic of NMS and do not address the underlying pathophysiology or prevent complications like rhabdomyolysis. - An **urgent CT head** is not the primary diagnostic or management priority in a patient with a clear history of antipsychotic use and laboratory evidence (elevated CK) strongly suggesting NMS. *Administer procyclidine for acute dystonia and continue haloperidol at reduced dose* - **Procyclidine** is indicated for **acute dystonic reactions**, which are typically localized and self-limiting muscle spasms, not the diffuse rigidity, hyperthermia, and systemic features of NMS. - **Continuing haloperidol**, even at a reduced dose, is strictly contraindicated as it is the precipitating agent for NMS and would exacerbate the syndrome, increasing morbidity and mortality. *Stop haloperidol, provide supportive care with IV fluids and cooling measures only* - **Stopping haloperidol** and providing **aggressive supportive care** with intravenous fluids and cooling measures are essential components of NMS management to prevent complications like dehydration and hyperthermia. - However, in severe cases with marked muscle rigidity and significant CK elevation, **supportive care alone is often inadequate**; specific pharmacological interventions such as **dantrolene** are critical to reverse the muscle rigidity and mitigate the systemic effects of NMS.

Question 178: A 38-year-old woman with bipolar affective disorder has been stable on lithium for 3 years. She attends for pre-conception counselling as she and her partner are planning pregnancy. Her current lithium level is 0.7 mmol/L with normal renal and thyroid function. She is particularly concerned about risks to the fetus and maintaining her mood stability. What is the most evidence-based recommendation regarding her lithium therapy during pregnancy?

A. Continue lithium throughout pregnancy as the risk of relapse outweighs fetal risks, with careful monitoring (Correct Answer)
B. Stop lithium and remain medication-free during first trimester, then restart in second trimester
C. Switch to sodium valproate before conception as it has a better safety profile in pregnancy
D. Gradually discontinue lithium over 4 weeks before conception and remain medication-free throughout pregnancy
E. Stop lithium immediately and switch to lamotrigine for pregnancy and breastfeeding

Explanation: ***Continue lithium throughout pregnancy as the risk of relapse outweighs fetal risks, with careful monitoring*** - Stopping **lithium** in stable patients with **bipolar disorder** carries a high **relapse risk** (up to 70%), which can lead to severe manic or depressive episodes and poor self-care during pregnancy. - While lithium is associated with **Ebstein's anomaly**, the absolute risk is much lower than previously thought (0.05-0.1%), making the **benefit-risk ratio** favor continuation with **fetal echocardiography** and frequent **serum level monitoring**. *Stop lithium and remain medication-free during first trimester, then restart in second trimester* - Discontinuing medication during the first trimester significantly increases the risk of **maternal relapse**, which poses a greater threat to the pregnancy than the low risk of **teratogenicity**. - Abrupt or temporary cessation is often followed by a high rate of **recurrence**, making it difficult to regain **mood stability** later in the pregnancy. *Switch to sodium valproate before conception as it has a better safety profile in pregnancy* - **Sodium valproate** is strictly contraindicated in pregnancy due to its high risk of major **malformations** (like **neural tube defects**) and significant **neurodevelopmental delay**. - It has the worst safety profile among mood stabilizers for fetal outcomes, whereas lithium's risks are manageable through **prenatal screening**. *Gradually discontinue lithium over 4 weeks before conception and remain medication-free throughout pregnancy* - Remaining medication-free throughout pregnancy carries a dangerously high risk of **postpartum psychosis** and relapse, which are medical emergencies. - Clinical guidelines recommend maintaining effective treatment for patients with a history of **severe mental illness** rather than attempting drug-free pregnancies. *Stop lithium immediately and switch to lamotrigine for pregnancy and breastfeeding* - **Lamotrigine** is primarily effective against **bipolar depression** but is significantly less effective than lithium at preventing **mania**. - Switching a patient who is stable on lithium to a different agent just before pregnancy risks **breakthrough symptoms** during a vulnerable physiological period.

Question 179: A 30-year-old woman with treatment-resistant schizophrenia has been taking clozapine 400mg daily for 8 weeks. She attends for routine blood monitoring. Her full blood count shows: Hb 125 g/L, WCC 2.8 × 10⁹/L, neutrophils 1.2 × 10⁹/L, platelets 245 × 10⁹/L. She is asymptomatic with no signs of infection. Previous FBC 4 weeks ago showed WCC 4.5 × 10⁹/L and neutrophils 2.5 × 10⁹/L. What is the most appropriate immediate management according to clozapine monitoring guidelines?

A. Continue clozapine, repeat FBC in 1 week, and provide patient with infection warning advice
B. Stop clozapine immediately, admit for urgent haematology review, and start broad-spectrum antibiotics
C. Stop clozapine immediately, repeat FBC daily, and do not rechallenge with clozapine (Correct Answer)
D. Reduce clozapine dose to 200mg daily, repeat FBC in 3 days, and monitor for signs of infection
E. Continue clozapine, repeat FBC in 3 days, and advise patient to report fever or sore throat immediately

Explanation: ***Stop clozapine immediately, repeat FBC daily, and do not rechallenge with clozapine*** - The patient's **absolute neutrophil count (ANC)** is **1.2 × 10⁹/L**, which falls below the critical threshold of **1.5 × 10⁹/L** for clozapine monitoring, placing her in the **RED zone**. - According to clozapine monitoring guidelines, an ANC in the RED zone necessitates **immediate cessation of clozapine**, daily FBC monitoring until recovery, and a **permanent contraindication** to rechallenge due to the high risk of severe agranulocytosis. *Continue clozapine, repeat FBC in 1 week, and provide patient with infection warning advice* - Continuing clozapine is inappropriate for a **RED zone** result; this level of neutropenia requires immediate cessation to prevent further bone marrow suppression. - Repeating FBC in **one week** is too infrequent for such a significant drop in neutrophil count, as rapid deterioration can occur. *Stop clozapine immediately, admit for urgent haematology review, and start broad-spectrum antibiotics* - While stopping clozapine is correct, **admission and broad-spectrum antibiotics** are typically reserved for patients with **febrile neutropenia** or clear signs of infection, which are not present as the patient is asymptomatic. - Urgent haematology review is important, but the immediate priority is stopping the drug and **daily monitoring** to track recovery, rather than proactive septic management for an asymptomatic patient. *Reduce clozapine dose to 200mg daily, repeat FBC in 3 days, and monitor for signs of infection* - **Dose reduction** is not an appropriate measure for clozapine-induced neutropenia; the drug must be stopped due to the idiosyncratic nature of the adverse reaction. - Continuing clozapine, even at a reduced dose, when the patient is in the **RED zone** for neutropenia poses an unacceptable risk of progressing to **agranulocytosis**. *Continue clozapine, repeat FBC in 3 days, and advise patient to report fever or sore throat immediately* - This management strategy is typically for **AMBER zone** results (ANC between 1.5 and 2.0 × 10⁹/L), where clozapine may be continued with increased monitoring. - Given the ANC of **1.2 × 10⁹/L**, the patient is in the **RED zone**, making continued clozapine therapy clinically unsafe and contrary to safety protocols.

Question 180: A 24-year-old student is brought to A&E by police after being found naked in the street, shouting that he is 'the chosen one' who will save humanity. His friends report he has not slept for 5 days, has been spending excessive amounts of money, and initiated multiple sexual relationships. He has no past psychiatric history but his mother has bipolar disorder. Mental state examination reveals pressured speech, flight of ideas, and grandiose delusions. What is the most appropriate initial pharmacological management?

A. Oral olanzapine and lorazepam (Correct Answer)
B. Oral sodium valproate and risperidone
C. Oral lithium carbonate as monotherapy
D. Intramuscular haloperidol and oral lithium
E. Intramuscular lorazepam and oral lamotrigine

Explanation: ***Oral olanzapine and lorazepam*** - This patient is presenting with **acute mania with psychotic features**; NICE guidelines recommend **atypical antipsychotics** (like olanzapine, risperidone, or quetiapine) as first-line treatment for rapid symptom control. - The addition of a **benzodiazepine** such as **lorazepam** is appropriate for managing acute agitation, behavioral disturbance, and severe insomnia associated with the manic episode. *Oral sodium valproate and risperidone* - While risperidone is a first-line agent, **sodium valproate** is generally considered a second-line option for acute mania if antipsychotics are ineffective or not tolerated. - Combination therapy with a mood stabilizer and an antipsychotic is usually reserved for cases that fail to respond to monotherapy, rather than as the **initial pharmacological management**. *Oral lithium carbonate as monotherapy* - **Lithium** has a **slow onset of action** (typically 5-7 days for full effect), making it unsuitable as a sole agent for acute, severe mania where rapid tranquilization is required. - It is highly effective for long-term prophylaxis but requires titration and **blood level monitoring**, making it secondary to antipsychotics in an emergency setting. *Intramuscular haloperidol and oral lithium* - **Intramuscular (IM)** administration should be reserved for patients who refuse oral medication or pose an immediate danger, which is not clearly indicated before attempting oral route first. - Starting **lithium** during an acute psychotic manic episode without a sedative or faster-acting antipsychotic does not address the patient's immediate safety and behavioral needs. *Intramuscular lorazepam and oral lamotrigine* - **Lamotrigine** is effective for **bipolar depression** and maintenance therapy but has no clinical efficacy in the treatment of **acute mania**. - Use of **intramuscular lorazepam** is unnecessary if the patient is willing and able to take medications orally, as oral routes are preferred for initial stabilization.

Question 181: A 42-year-old man with bipolar affective disorder type I presents to his psychiatrist for routine follow-up. He has been taking lithium carbonate for 18 months with good mood stability. Recent blood tests show: lithium level 0.9 mmol/L, creatinine 145 μmol/L (baseline 95 μmol/L), eGFR 52 ml/min/1.73m² (previously 78), and TSH 6.2 mU/L (normal range 0.5-5.0). Which parameter represents the most concerning long-term complication requiring immediate action?

A. The lithium level indicating potential toxicity
B. The elevated TSH suggesting hypothyroidism
C. The significantly reduced eGFR indicating chronic kidney disease (Correct Answer)
D. The combination of elevated creatinine and reduced eGFR
E. The duration of lithium therapy exceeding 12 months

Explanation: ***The significantly reduced eGFR indicating chronic kidney disease*** - The patient's **eGFR has significantly dropped** from 78 to 52 ml/min/1.73m², indicating a progression to **Stage 3a Chronic Kidney Disease (CKD)**. - This substantial decline in kidney function due to chronic lithium use (known to cause **chronic tubulointerstitial nephritis**) is a **major long-term complication** requiring urgent assessment and potential adjustment of lithium therapy to prevent irreversible damage. *The lithium level indicating potential toxicity* - A lithium level of **0.9 mmol/L** is within the generally accepted **therapeutic range** for maintenance therapy (0.6–1.0 mmol/L). - This level does not indicate **acute lithium toxicity**, which typically occurs at levels >1.5 mmol/L, and the patient is reported to have good mood stability, suggesting no acute toxic symptoms. *The elevated TSH suggesting hypothyroidism* - An elevated TSH (6.2 mU/L) is indicative of **lithium-induced hypothyroidism**, a common side effect of long-term lithium therapy. - While it requires management, usually with **levothyroxine**, it is generally **less acutely life-threatening** or organ-damaging compared to a significant decline in renal function. *The combination of elevated creatinine and reduced eGFR* - While both an **elevated creatinine (145 µmol/L from 95 µmol/L)** and **reduced eGFR** are concerning indicators of renal impairment, the eGFR provides a more standardized measure of **kidney function stage**. - The specific *reduction* in eGFR from baseline (78 to 52 ml/min/1.73m²) represents the direct evidence of **progressive chronic kidney disease**, making it the most precise and alarming parameter for long-term complications requiring action. *The duration of lithium therapy exceeding 12 months* - The **duration of lithium therapy (18 months)** itself is not a complication, but rather a risk factor for developing long-term side effects like renal and thyroid dysfunction. - Many patients safely take lithium for **decades**, but regular monitoring is crucial; the actual *physiological changes* (like declining eGFR) are the concerning complications, not the time on medication.

Question 182: A 35-year-old woman with established schizophrenia has been taking haloperidol 10mg daily for 6 months. She attends her GP reporting involuntary writhing movements of her tongue and grimacing that started 2 weeks ago. These movements persist throughout the day and are causing significant distress. Her psychotic symptoms remain well-controlled. Examination confirms oro-buccal dyskinesia. What is the most appropriate immediate management?

A. Stop haloperidol and switch to clozapine
B. Add procyclidine to counteract the extrapyramidal side effects
C. Stop haloperidol and switch to an atypical antipsychotic such as olanzapine (Correct Answer)
D. Continue haloperidol and reassure that symptoms will resolve
E. Reduce haloperidol dose by 50% and review in 2 weeks

Explanation: ***Stop haloperidol and switch to an atypical antipsychotic such as olanzapine*** - The patient's involuntary writhing movements of the tongue and grimacing, after 6 months of haloperidol, are characteristic of **tardive dyskinesia (TD)**, a late-onset extrapyramidal side effect. - The most appropriate immediate management is to discontinue the offending typical antipsychotic (**haloperidol**) and switch to a **second-generation (atypical) antipsychotic** like olanzapine, which has a lower risk of TD. *Stop haloperidol and switch to clozapine* - While **clozapine** has the lowest risk of extrapyramidal symptoms, it is typically reserved for **treatment-resistant schizophrenia** due to its significant side effect profile and need for intensive monitoring. - It is not usually the first-line switch for TD when other safer atypical antipsychotics have not been tried. *Add procyclidine to counteract the extrapyramidal side effects* - **Anticholinergic medications** like procyclidine are effective for **acute dystonia** and **parkinsonism**, but they are **contraindicated** in tardive dyskinesia. - These drugs can paradoxically worsen TD by further disturbing the dopamine-acetylcholine balance in the basal ganglia. *Continue haloperidol and reassure that symptoms will resolve* - **Tardive dyskinesia** is often irreversible, and continuing the causative drug (haloperidol) significantly increases the risk of permanent symptoms. - Reassurance alone is inappropriate and can lead to chronic, debilitating movements. *Reduce haloperidol dose by 50% and review in 2 weeks* - While dose reduction can be a strategy for some side effects, TD typically requires **complete cessation of the typical antipsychotic** to prevent further progression and potentially allow some resolution. - A 50% reduction may not be sufficient to halt the underlying neurological changes causing these involuntary movements.

Question 183: A 28-year-old man presents to A&E with a 3-week history of hearing voices commenting on his actions and believing that his thoughts are being broadcast on the radio. He has become socially withdrawn and neglects his personal hygiene. His family reports no previous psychiatric history. On examination, he appears dishevelled and displays blunted affect. Urine drug screen is negative. Which first-rank symptom of schizophrenia is he demonstrating?

A. Thought broadcast and third-person auditory hallucinations (Correct Answer)
B. Thought insertion and second-person auditory hallucinations
C. Delusional perception and thought withdrawal
D. Passivity phenomena and thought echo
E. Somatic passivity and running commentary

Explanation: ***Thought broadcast and third-person auditory hallucinations*** - The patient's belief that his thoughts are being transmitted via the radio is a classic example of **thought broadcast**, a core first-rank symptom of schizophrenia. - Hearing voices **commenting on his actions** directly points to **third-person auditory hallucinations**, where voices discuss the patient or his actions. *Thought insertion and second-person auditory hallucinations* - **Thought insertion** is the belief that external thoughts are being *put into* one's mind, which is not described in the patient's symptoms. - **Second-person auditory hallucinations** involve voices talking *directly to* the patient, whereas the patient hears voices *commenting on* his actions (third-person). *Delusional perception and thought withdrawal* - **Delusional perception** occurs when a normal perception is given a sudden, abnormal, delusional meaning, a feature not present in this scenario. - **Thought withdrawal** refers to the belief that thoughts are being *removed* from one's mind by an external force, which is distinct from thoughts being broadcast. *Passivity phenomena and thought echo* - **Passivity phenomena** involve the belief that one's actions, feelings, or impulses are *controlled* by an external agency, which is not the primary symptom described. - **Thought echo** is the experience of hearing one's own thoughts spoken aloud immediately after they occur, not voices commenting on actions. *Somatic passivity and running commentary* - **Somatic passivity** involves the belief that bodily sensations are being *imposed* by an external agency, a symptom not evidenced in this patient's presentation. - While **running commentary** (voices commenting on actions) is a first-rank symptom described, the presence of **somatic passivity** in this option makes it incorrect for the overall clinical picture.

Practice by Chapter

Bipolar disorder

Practice Questions

Schizophrenia

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Severe Mental Illness — MCQs

Severe Mental Illness — MCQs

On this page